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Abstract
Multiple myeloma is a cancer of plasma cells. In multiple myeloma, a clone of plasma cells
in the bone marrow secretes a unique, monoclonal immunoglobulin (Ig), whose biological
properties depend on its type and structure. The monoclonal Ig offers a convenient
opportunity for clinicians to monitor the response of the tumour to therapy via the
secreted protein, which is readily quantified in a blood sample. Responses to treatment
are assigned based on the percentage reduction in monoclonal Ig; however, response
criteria do not take into account the different metabolic half-lives of the proteins.
70% of multiple myeloma patients have either monoclonal IgA- or monoclonal IgG-
producing clones. IgA and IgG have metabolic half-lives of 6 days and 23 days, at
normal concentrations, respectively. The large difference in their metabolic half-lives
suggests that they would respond at different rates during therapy. The elimination rate
of IgG is concentration-dependent due to saturable recycling by a receptor. This could
further impact upon its response during therapy, with the possibility that IgG is elimi-
nated from the body at different rates at the beginning of therapy, when its concentration
is high, and at the end of therapy, when its concentration has decreased.
In this thesis compartmental models of IgG metabolism from the literature are analysed
and parameter values are estimated from available data. A model of IgA metabolism is
sourced in the literature. These models are used to predict the responses of monoclonal
IgA and IgG during therapy. The simulations are able to replicate typical monoclonal
IgA and IgG responses seen in a clinical trial of patients with relapsed and refractory
multiple myeloma.
Importantly, the plasma cell clone is not directly accessible to measurement and therefore
not available to validate model-based predictions. However, monoclonal Ig responses are
not evaluated by their ability to predict the tumour burden, but by the strength of
their association with patient survival. In this thesis, a prediction is made of how the
different metabolic properties of IgA and IgG may influence their association with survival
outcomes. Evidence for this effect is then evaluated in data from a clinical trial using the
methods of survival analysis.
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1Introduction
Multiple myeloma is a cancer of plasma cells located in the bone marrow. It is charac-
terised as a disease of the elderly, with symptoms including bone pain, fractures, anaemia
and frequent infections. Multiple myeloma is considered incurable, with less than half
of patients surviving beyond five years from diagnosis; however, treatment extends life
expectancy and maintains quality of life. In recent years the introduction of novel agents
has substantially improved responses to treatment and survival rates and as such greater
emphasis is now being placed on markers of response [1; 2].
Plasma cells normally produce antibodies as part of a healthy, functioning immune sys-
tem. Antibodies are also known as immunoglobulins, with the two terms often considered
synonymous; however, there is a subtle difference in their meanings. ‘Antibody’, directly
translated from the German Antiko¨rper, is defined by the Oxford English Dictionary as ‘a
blood protein produced in response to and counteracting a specific antigen’. The mean-
ing of ‘antibody’ thus incorporates its function, whereas ‘immunoglobulin’ refers purely
to the protein itself, as a γ-globulin of the immune system. In multiple myeloma, clonal
plasma cells usually secrete a unique, monoclonal immunoglobulin into the blood. The
monoclonal immunoglobulin serves no immune function and is therefore only referred to
as an immunoglobulin, or Ig, and not an antibody throughout this thesis.
There are five classes of Ig – IgA, IgD, IgE, IgG and IgM – which have different biological
properties depending on their role in the normal immune response. In myeloma, clonal
cells produce a unique monoclonal Ig of a single type. This thesis is only concerned with
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patients producing monoclonal IgA and IgG; such patients are said to have IgA or IgG
myeloma and comprise 70% of all multiple myeloma patients [3]. For the remainder of
this chapter discussion will be restricted to IgA and IgG myeloma.
The monoclonal Ig produced in multiple myeloma serves no useful purpose; however, it
does offer a convenient opportunity for physicians to monitor changes in the size of the
plasma cell clone via the secreted protein, which can be readily quantified in a blood
sample. The cancer itself is only accessible by bone marrow biopsy or aspirate, both of
which are unpleasant, invasive procedures. The concentration of monoclonal Ig in the
blood is the preferred measure by which the cancer is monitored; patient monitoring
in clinical trials and the non-trial setting alike is heavily reliant on measurements of
monoclonal Ig concentration in the blood [4; 5].
During therapy, it is important for the physician to know how well the cancer is re-
sponding to the treatment, and at the end of therapy, they would also like to make an
assessment of the overall success of the treatment in order to give the patient an accurate
prognosis. Ideally, the physician would like to know what proportion of the cancer has
been eradicated by the therapy; however, rather than accessing the cancer directly, the
physician evaluates the percentage reduction in the monoclonal Ig present in the blood.
The percentage reduction in the monoclonal Ig is thus a marker for the response of the
cancer, and throughout this thesis will be referred to as the monoclonal Ig response.
According to international guidelines for response assignment, a 50% reduction in mono-
clonal Ig is a criterion that must be met in order for partial response (PR) to be assigned
at a particular time during or after treatment; likewise a 90% reduction is a criterion for
very good partial response (VGPR) assignment [5; 6]. However, a 50%, say, monoclonal
Ig response does not necessarily mean that 50% of the cancer cells have been eradicated:
the concentration of monoclonal Ig in the blood at any time depends both on the rate
of production, which is assumed proportional to the tumour burden, and also the rate at
which it is eliminated. Herein lies the motivation for the work presented in this thesis.
IgA and IgG are known to have metabolic half-lives of 6 days and 23 days, at normal
concentrations, respectively. This suggests that, for the same tumour response, mon-
oclonal IgG may respond more slowly compared to IgA. Interestingly, the elimination
rate of IgG is concentration-dependent due to saturable recycling by the neonatal Fc
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receptor (FcRn). This could complexify its relationship with the tumour response, with
the possibility that IgG is eliminated from the body at a faster rate at the beginning of
therapy, when its concentration is high, and at a slower rate at the end of therapy, when
its concentration has decreased [7; 8].
Presently it is not clear how the different elimination mechanisms of IgA and IgG affect
their responses in multiple myeloma. In particular, we would like to ask, for an IgA
patient and an IgG patient whose tumours respond at the same rate, whether monoclonal
IgG responds more slowly than monoclonal IgA. We would also like to ascertain whether
the elimination mechanisms of IgA and IgG influence their final responses at the end
of therapy, when a maximal proportion of the tumour has been killed. At the end of
therapy, is monoclonal IgG remaining in the system because the therapy has failed to
eradicate the cancer, or are the IgG molecules simply being recirculated by the FcRn
receptor? These questions could have implications for how monoclonal Ig measurements
are interpreted in patients and possibly for response assignment criteria.
To answer these questions, mathematical models of IgA and IgG metabolism are required,
describing the elimination of IgA and IgG from the body. Mathematical models of the
myeloma cell population during therapy are also required; assuming that the production
rate of the monoclonal protein is proportional to the tumour burden, these models will
dictate the production rates of monoclonal IgA and IgG. Together, parameterised models
of the tumour response and IgA and IgG metabolism will allow for predictions of how
monoclonal IgA and IgG respond during therapy.
Due to the systemic distribution of malignant plasma cells in multiple myeloma and the
invasiveness of bone marrow examination, physicians are unable to routinely assess the
size of the plasma cell clone. Therefore the myeloma cell population is unavailable for
validation of model-based predictions of responses. However, the motivation for this
research is to consider the possible effects of the metabolic properties of Igs on their
prognostic utility. Response markers are evaluated by the strength of their association
with patient survival; therefore the aim of this thesis is to qualitatively predict how the
different metabolic properties of IgA and IgG may influence their association with survival
outcomes. Evidence for these effects can then be assessed in available survival data.
As multiple myeloma is an incurable disease, maintaining and prolonging quality of life is
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a primary goal of patient care. It is hugely important that physicians can meaningfully
assess response to therapy so that they can provide patients with accurate information
about their prognosis and also offer the best care. This thesis aims to improve our under-
standing of the importance of marker metabolism; it is hoped that further developments
in this area will aid physicians in their work.
1.1 Thesis aims
 Select from the literature mathematical models of IgA and IgG metabolism in hu-
mans that can be used to simulate IgA and IgG responses in multiple myeloma.
Estimate from experimental data, or source in the literature, parameter values for
the models.
 Simulate responses to therapy of the myeloma cell population and corresponding
monoclonal IgA and IgG responses. Investigate assumptions and hypotheses relat-
ing to IgA and IgG responses in multiple myeloma.
 Consider how the respective modes of metabolism of IgA and IgG may impact upon
their utility as markers for survival and assess the evidence for any such impact in
a dataset of newly diagnosed multiple myeloma patients.
1.2 Thesis outline
 Chapter 2 reviews the relevant literature. The biology of Ig metabolism and how
Igs are currently used to monitor patients are discussed in this chapter.
 In chapter 3 the methods used to mathematically model the metabolism of Igs
are described. These include compartmental modelling, parameter estimation and
structural identifiability analysis.
 The survival analysis methods used to evaluate the prognostic ability of Igs in multi-
ple myeloma are introduced in chapter 4. The Kaplan-Meier survival estimator, the
proportional hazards class of survival models and methods for comparing survival
models are described.
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 In chapter 5 a two-compartment model of IgG metabolism is analysed. Parameter
values for humans are estimated from limited experimental data available in the
literature.
 In chapter 6 a four-compartment model of IgG metabolism is analysed and param-
eter values estimated, again using the data available in the literature.
 In chapter 7 the two-compartment and four-compartment models of IgG metabolism
are compared.
 In chapter 8 the two-compartment model of IgG metabolism and a two-compartment
model of IgA metabolism are used to predict blood monoclonal Ig responses during
therapy.
 In chapter 9, the final results chapter, the impact of the different metabolic proper-
ties of IgA and IgG upon their association with patient survival is considered; the
evidence for this effect is then evaluated in a dataset from a clinical trial.
 Chapter 10 summarises the conclusions that can be drawn from the work presented
in this thesis and recommendations for future work are made.
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2Background
This chapter provides the background to the work and a brief summary of previous
research that this work builds upon. It is divided into four sections. The first section
deals with metabolism of immunoglobulins, in particular immunoglobulin G. The second
section introduces the disease multiple myeloma. The third section discusses how multiple
myeloma is monitored using blood monoclonal immunoglobulins, and how the prognostic
utility of response markers is assessed using survival analysis. Finally these elements are
brought together to formulate the problem that is the subject of this thesis.
2.1 Metabolism of immunoglobulins
2.1.1 Immunoglobulins
Immunoglobulins (Igs), or antibodies, are proteins of the immune system whose role is
to identify and neutralise foreign objects, or antigens. Antibodies work by binding to
antigens and generating an attack from other parts of the immune system. They are
produced by white blood cells called plasma cells. They exist in two forms, membrane-
bound as cell-surface receptors and secreted in the blood plasma and other body fluids.
The monomeric Ig consists of two identical heavy chains and two identical light chains
connected by disulphide bonds to form a Y-shaped molecule (see figure 2-1). At the ends
of the arms of the Y-shape are two identical antigen binding sites; hence this part of the
7
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Fab
Fc
Antigen
Fc receptor
Figure 2-1 Immunoglobulin monomer. Heavy chains are shown in green,
with the constant regions in light green and the variable regions in dark
green. Light chains are shown in blue, with the constant regions in light
blue and the variable regions in dark blue. The Fab region is shown to be
binding an antigen and the Fc region is bound by an Fc receptor.
molecule is called the fragment antigen-binding (Fab) region. The base of the Y, known as
the fragment crystallisable (Fc) region, is responsible for eliciting an appropriate response
from other parts of the immune system, for example by binding to cell-surface receptors on
phagocytic or cytotoxic white blood cells, inciting them to destroy the invading pathogen.
Receptors which bind the Fc region of Igs are known as Fc receptors.
Humans (and most mammals) have five Ig isotypes – IgA, IgD, IgE, IgG and IgM – each
having α, δ, , γ or µ heavy chains, respectively. There are two classes of light chain, κ
and λ. An Ig has a pair of identical heavy chains and a pair of identical light chains; thus
an individual molecule belongs to one heavy chain class and one light chain class only.
An Ig with γ heavy chains and κ light chains for example is referred to as IgGκ. Each
heavy chain has a constant region, identical within each isotype, and a variable region.
Light chains also have a constant region, identical within their light chain class, and a
variable region. Both heavy and light chains contribute to the variable region situated
in the Fab portion of the Ig that enables an individual to produce an enormous range of
Igs, specific to a wide variety of different antigens [1].
The five Ig isotypes all share the basic function of identifying and neutralising pathogens,
but their roles differ in terms of their location in the body and the types of antigens
against which they protect, mediated by the Fc region. The antibody isotypes also have
slightly different structures and can form complexes: secreted IgA forms a dimer and
IgM forms a pentamer. The Fc region of an Ig consists only of the constant region
of two identical heavy chains; thus the immune response generated by the antibody is
8
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Table 2-1 Antibody isotypes [1]
Name Role % of total
Ig in serum
Half-life
(days)
IgA Protects against pathogens in mucosal locations
including gastronintestinal tract and respiratory tract
5–15 6
IgD Mostly exists as a B-cell receptor with barely detectable
amounts in plasma
<1 2–3
IgE Protects against parasitic worms and involved in allergy <1 2–3
IgG Found in plasma and extracellular spaces; responsible for
most antibody-based immunity
75–85 23
IgM Exists as a B-cell receptor and secreted in plasma;
operates in the first instance of infection
5–10 5
determined by its isotype. The roles of the isotypes and their respective percentages of
total Ig in adult serum are summarised in table 2-1 [1].
In this thesis interest lies primarily with IgA and IgG as they are most frequently im-
plicated in multiple myeloma and we are concerned with their use as biomarkers for this
disease. IgG is of particular interest as its concentration-dependent metabolic half-life in
large part motivates this work. IgA and IgG both have subclasses: IgA1 and IgA2, and
IgG1, IgG2, IgG3 and IgG4. The subclasses have small differences in the structure of
their heavy chains that affect their properties. IgG is also special in that it is the only Ig
isotype to be transferred across the placenta, offering protection to the newborn before
its own immune system has developed [1].
2.1.2 Metabolism of immunoglobulin G
IgG is the most abundant Ig isotype in the circulation, having a plasma concentration of
10–16 g l−1 [2]. Its high concentration is enabled by its unusually long metabolic half-life
(see table 2-1). Interestingly the half-life of IgG is not constant, but varies with its plasma
concentration, as depicted in figure 2-2A. Figure 2-2B shows the fractional catabolic rate
(FCR), that is the proportion of the IgG in plasma that is catabolised per day. The
relationship between the concentration and half-life of IgG can be explained by its route
of catabolism, mediated by the neonatal Fc receptor (FcRn). The receptor derives its
name from its role in transporting IgG across the placenta from mother to foetus.
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Figure 2-2 Plasma concentration-dependence of (A) metabolic half-life
and (B) fractional catabolic rate of IgG; data from Waldmann et al. [3].
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Endothelial cell
Plasma
Figure 2-3 FcRn-mediated recycling of IgG. (1) IgG molecules are inter-
nalised into endosomes by nonspecific pinocytosis. (2) Endosomes acidify
allowing FcRn to bind IgG. Bound and unbound proteins are sorted, with
(3) unbound proteins degraded in lysosomes and (4) bound IgG trafficked to
the cell surface. (5) Bound IgG is exocytosed back into the circulation.
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IgG is catabolised by endocytosis, whereby molecules are internalised into cells in vesi-
cles called endosomes in order to be degraded. FcRn expressed within these cells binds
IgG inside the acidic environment of endosomes with a pH-dependent affinity. FcRn
then sequesters the bound IgG away from the degradation pathway and back to the cell
membrane, releasing it once again into the circulation. Those IgG molecules that are
not bound to FcRn continue to follow the pathway to be degraded in lysosomes [4]. The
scenario is illustrated in figure 2-3.
In this way, FcRn protects IgG from degradation in a recycling process. The variable
half-life can be explained by the saturability of the recycling receptors. At increasing
plasma concentrations of IgG the receptors become increasingly saturated and a greater
proportion of IgG is degraded. Conversely at very low IgG concentrations a greater
proportion is recycled and the half-life is increased. In the absence of FcRn the half-life
of IgG is only three days, as has been observed in patients with a condition where FcRn
is not expressed. At normal concentrations the half-life is approximately 23 days. The
recycling system enables healthy humans to maintain high plasma concentrations of IgG
[5; 6].
The relationship between production and concentration of IgG is therefore not entirely
straightforward. Many mathematical models of IgG metabolism have been published in
the literature (more than 20 at the time of writing), usually with the aim of describing the
pharmacokinetics of therapeutic monoclonal antibodies (mAbs) that are similarly regu-
lated by FcRn [7]. Many of the models are therefore pharmacokinetic in nature: their
parameter values are obtained from animal experiments and they may be physiologically
based, with up to around ten organs explicitly represented in the model [7–17]. Physio-
logically based pharmacokinetic models typically include the lymphatic system as well as
the circulation [7; 9–12; 17]. Models describing mAb disposition may not be suitable for
describing endogenous IgG dynamics, as whilst mAbs also benefit from FcRn-mediated
recycling, they may be treated differently by the body in other ways, for example due
to binding of the mAb to its target. In addition, mAb disposition may be adequately
described by linear models in many cases, where the plasma concentration of therapeutic
mAb is substantially smaller than the plasma concentration of endogenous IgG and the
latter is constant [17].
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For investigating the role of IgG as a cancer marker, physiologically based models may be
more complex than necessary. Where models are more complex than the data they seek
to represent, more sophisticated assumptions are required. Whilst it may be possible to
reconcile the outputs of more complex models with human data, this does not imply that
the model parameters or model assumptions are accurate, due to the inherent flexibility
of such models [13]. In this thesis two comparatively simple models [3; 18; 19] are used.
Both models are compartmental (lumped-parameter) models wherein the quantities or
concentrations of IgG in discrete compartments are described by ordinary differential
equations. The models are based upon the underlying biology of IgG and FcRn, which
has been well characterised, and mass-balance principles.
2.1.3 Metabolism of immunoglobulin A
IgA is considered primarily as the antibody of the mucosal surfaces, such as within the
gut and respiratory tract, and external secretions, including breast milk, saliva and tears.
In mucosal areas, IgA primarily exists as a dimer with an additional secretory component,
and is thus known as secretory IgA. IgA in the circulation is predominately monomeric
and is known as systemic or serum IgA. Secretory and systemic IgA are synthesised in
different physiological spaces. Secretory IgA is synthesised locally in large quantities in
the mucosal tissues [20].
Plasma cells located in the bone marrow synthesise mainly monomeric IgA into the cir-
culation [20]. In multiple myeloma monoclonal Igs are synthesised by clonal plasma
cells located in the bone marrow and secreted into the plasma [21]; therefore it is the
metabolism of systemic IgA that is important to this thesis and that needs to be repre-
sented by a mathematical model.
Unlike IgG, the rate at which systemic IgA is catabolised is independent of its plasma
concentration, with a constant half-life of 6 days [3]. For this reason, and because most
therapeutic monoclonal antibodies are rather based on IgG [22], there are not many
mathematical models of systemic IgA metabolism in the literature. Fortunately, the
experimental data on IgA metabolism indicate that a simple, linear, two-compartment
model will suffice [3].
12
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2.2 Multiple myeloma
Multiple myeloma accounts for 1% of all new cancer diagnoses in the UK. It is the 17th
most common cancer in the UK and affects men more than women with 55% of UK
diagnoses in men. The incidence rate increases with age, with 70% of cases occurring in
people over 65. 77%, 47% and 33% of patients survive more than one, five and ten years
with the disease, respectively [23].
Multiple myeloma is the cancer of Ig-producing, long-lived plasma cells. In healthy
humans, long-lived plasma cells survive in the bone marrow for months or years following
infection or vaccination, continuing to produce Igs against the original antigen in order to
maintain serological memory. Multiple myeloma occurs when one of these cells becomes
malignant [24]. Malignant plasma cells accumulate in the bone marrow, causing bone
disease and hypercalcaemia and interfering with the bone marrow microenvironment,
such that other blood cells are not produced in normal quantities. Thus patients develop
anaemia and low counts of other white blood cells, rendering them more susceptible to
infection.
The preferred treatment course for young (up to 65–70 years), fit patients consists of
induction therapy based around novel agents, high dose chemotherapy, autologous stem
cell transplantation (ASCT), consolidation therapy and maintenance therapy. The goal
of induction therapy is to decrease the tumour burden in order to improve the over-
all response, and to improve the quality of bone marrow that is harvested before high
dose chemotherapy and transplanted afterwards. Induction regimens based around novel
agents, particularly proteasome inhibitors, such as bortezomib, and immunomodulatory
agents, such as thalidomide and its derivatives, have contributed to the significant im-
provement in patient outcomes that have been seen in the last decade [21; 25]. Consoli-
dation therapy is optional and short-term. Maintenance therapy is a long-term, ‘gentler’
therapy, intended to maintain the response achieved by induction therapy and ASCT.
Those patients for whom stem cell transplantation is not possible are treated with com-
binations of chemotherapy, steroids and biological therapies [21; 26].
Malignant plasma cells usually produce a large quantity of a monoclonal Ig and/or Ig
light chain (with the exception of oligosecretory and nonsecretory multiple myeloma). As
13
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they are derived from a single clone, myeloma cells produce monoclonal Igs. Thus Igs of
a single heavy chain isotype (α, δ, , γ or µ) and a single light chain isotype (κ or λ) are
produced in an individual patient, for example IgGκ (γ heavy chain and κ light chain)
[27]. IgG multiple myeloma is the most common form (50%), followed by IgA (20%),
whilst IgD, IgE and IgM myelomas are rare [28]. Patients producing a monoclonal Ig are
said to have intact Ig multiple myeloma (IIMM). Monoclonal Igs do not fulfil any useful
function. In addition, patients’ normal, polyclonal, functioning antibodies are usually
suppressed [29].
Around 20% of patients do not produce an intact monoclonal Ig, but produce a mono-
clonal Ig free light chain (κ or λ). These patients are said to have light chain multiple
myeloma. Free light chains (FLC) are cleared by the kidneys, which in large quanti-
ties can lead to renal failure [30]. Around 3% of patients produce little (oligosecretory
myeloma) or no monoclonal protein at all (nonsecretory myeloma) [23].
The initial investigation of a patient with suspected multiple myeloma involves a range of
laboratory tests along with physical examination and examination of medical and family
history. Symptomatic multiple myeloma is diagnosed by confirmation of all three of the
following criteria [31]:
 clonal bone marrow plasma cells ≥10%, measured by bone marrow aspirate/biopsy;
 presence of serum and/or urinary monoclonal protein, identified by electrophoresis
and immunofixation (except in nonsecretory multiple myeloma);
 evidence of end-organ damage, that is hypercalcaemia, renal insufficiency, anemia
and/or bone lesions.
2.2.1 International uniform response and disease progression
criteria
During therapy, both serum protein electrophoresis and nephelometric quantification of
Igs (see section 2.4) are recommended for the assessment of tumour response. For light
chain multiple myeloma patients FLC should be measured in urine. Serum FLC should
also be monitored in all patients, particularly in those with nonsecretory or oligosecretory
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Table 2-2 IMWG international uniform response criteria. See Kumar et
al. [33] for the full version.
Response Criteria
sCR CR with normal FLC ratio and absence of clonal cells in bone marrow
CR Negative immunofixation on serum and urine, disappearance of soft tissue plas-
macytomas and ≤5% plasma cells in bone marrow
VGPR Monoclonal protein detectable by immunofixation but not on electrophoresis or
≥90% reduction in serum monoclonal protein and urine monoclonal protein <100
mg per 24 h
PR ≥50% reduction in serum monoclonal protein and≥90% reduction in 24 h urinary
monoclonal protein or to <200 mg per 24 h
SD Not meeting criteria for CR, VGPR, PR or PD
multiple myeloma. A multitude of other tests are used in the investigation, diagnosis and
monitoring of multiple myeloma, however they are not studied in this thesis [31; 32].
Observations of decreasing blood monoclonal Ig concentration can be used to assess the re-
sponse to treatment. In order that responses can be assigned that have universal meaning,
the International Myeloma Working Group (IMWG) has developed international uniform
response criteria. The IMWG responses are stringent complete response (sCR), complete
response (CR), very good partial response (VGPR), partial response (PR) and stable
disease (SD), as summarised in table 2-2. The criteria have been somewhat simplified;
for the full version see Kumar et al. [33].
The involvement of malignant plasma cells in the bone marrow is assessed by the bone
marrow plasma cell percentage (BMPC%) in order to confirm diagnosis. The BMPC%
is estimated on the bone marrow aspirate and biopsy. These procedures are invasive
and unpleasant for the patient and are in practice restricted to diagnosis (more than
10% BMPC required) and when a complete response is suspected (less than 5% BMPC
required for CR). Notably physicians do not consider the response in the BMPC% in
terms of its proportional decrease during therapy. For response assessment, specifically
the assignment of CR, only the absolute value of BMPC% is used. This is in contrast
to serum monoclonal protein concentration, which is always considered in terms of its
proportional decrease (see table 2-2) [33; 34].
Relapse can be assigned as either progressive disease (PD), clinical relapse or relapse from
complete response. PD criteria are important because the assignment of PD is used for
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the calculation of progression-free survival (PFS). PD assignment requires an increase of
25% from the lowest value in at least one of the following [33]:
 serum monoclonal protein (absolute increase ≥0.5 g/dl) or ≥1 g dl−1, if the lowest
value was ≥5 g dl−1;
 urine monoclonal protein (absolute increase ≥200 mg/24 h);
 the difference between involved and uninvolved FLC (absolute increase≥10 mg dl−1);
 bone marrow plasma cell percentage (absolute value ≥10%);
 New bone lesions or increase in size of those pre-existing;
 ≥50% increase in circulating plasma cells (minimum of 200 cells per µl).
2.3 Early studies linking tumour burden with mon-
oclonal protein
Response assessment and patient monitoring using blood monoclonal proteins are based
upon the fundamental assumption that a growing tumour burden causes an increase in
blood monoclonal protein and that a shrinking tumour burden causes a decrease. Thus
from increases and decreases in monoclonal protein concentrations, clinicians can infer
tumour growth or regression, respectively. The earliest studies linking myeloma cell
number with monoclonal protein were performed in mice using transplantable mouse
plasmacytomas – discrete plasma cell tumours which closely resemble multiple myeloma
in human [35; 36]. Plasmacytomas in mice are convenient for study because the animal
can be sacrificed and the tumour excised and weighed. Multiple myeloma on the other
hand presents with a systemic infiltration of cells in the marrow rather than a discrete
mass; estimation of the extent of the infiltration is therefore not as simple. Sacrifice of
the animal prior to tumour mass assessment has meant that the author has had difficulty
finding studies with serial measurements of tumour size in mouse.
Nathans et al. [35] authored one of the earliest papers to provide conclusive evidence
that the monoclonal Ig often present in multiple myeloma is produced by the cancerous
cells themselves and not by another tissue in response to the tumour. Nathans et al.
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[35] studied mice bearing transplanted plasmacytomas, sacrificing individuals at intervals
in order to obtain measurements from the tumours. Using biosynthetic labelling with
amino acid (glycine), they showed that monoclonal Igs in the tumour tissue are the
immediate precursors of circulating plasma monoclonal Igs, leading to the conclusion that
monoclonal IgG is synthesised by the plasma cells of the tumour. They also correlated
the mass of excised tumours against the total quantity of plasma monoclonal Ig, finding
a strong positive relationship.
Humphrey et al. [36] also studied mice with transplanted IgG-producing plasmacytomas.
They injected radiolabelled monoclonal IgG and normal (polyclonal) IgG into mice with
plasmacytomas and found that the proportional rate of catabolism of either protein was
positively associated with both the tumour burden and the quantity of serum mono-
clonal IgG. In normal mice, monoclonal and polyclonal IgG had the same half-life; in
the mice with IgG-producing plasmacytomas the half-life was the same for both proteins,
but dramatically shortened. In general, mice with the highest blood concentrations of
monoclonal IgG demonstrated the fastest catabolism of both monoclonal and polyclonal
administered IgG. It is now known that this is due to saturation of FcRn receptors;
however Brambell et al. [37] first postulated a saturable recycling receptor for IgG three
years later and the receptor itself was not discovered until the 1990s. Humphrey et al.
[36] excised the plasmacytomas from the recipient mice at the end of the experiment and
weighed the tumours; however little analysis was performed on these data, possibly due
to the relatively small number of individuals studied. Similarly to Nathans et al. [35], no
serial assessment of tumour size was made.
Solomon et al. [38] extended the work of Humphrey et al. [36] to the human case. For
a range of human subjects, including IgG- and IgA-myeloma patients, the investigators
performed a study of the metabolism of radiolabelled normal IgG. They correlated the
half-life of normal IgG against the serum IgG concentration, finding a strong relationship,
with those subjects having an elevated IgG concentration having a shorter half-life and
vice versa. They concluded that the presence of IgA- or FLC-producing myeloma cells
does not accelerate IgG catabolism – nor does the presence of the proteins produced by
these cells – therefore the class of the monoclonal protein is important in determining the
cause of increased IgG catabolism. Of course it is now known that it is the presence of a
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large quantity of IgG that causes FcRn receptor saturation [4].
Salmon et al. [39] provide an early study linking tumour burden with plasma monoclonal
Ig in humans. Salmon et al. [39] performed an in vivo turnover study of radiolabelled
IgG and calculated the FCR for each patient from the radioactivity data. Using the
calculated FCR, along with measurements of serum monoclonal IgG concentration and
plasma volume, they calculated the absolute rate of IgG catabolism, assuming steady
state conditions. They also measured the in vitro rate of IgG synthesis per myeloma
cell. The total number of myeloma cells was estimated from the in vivo monoclonal
IgG production rate divided by the in vitro synthesis rate per cell. The authors found
that measurements of cellular IgG synthesis varied between patients, but within patients
were reproducible; in one patient the cellular IgG synthesis rate was consistent over eight
months, both before and after chemotherapy. Receiving chemotherapy prior to the study
did not seem to have an effect on the cellular IgG synthesis rate. Estimates of the total
myeloma cell population correlated with the extent of skeletal disease; however neither
the total IgG synthesis rate nor the cellular IgG synthesis rate correlated with skeletal
damage independently. The variability in cellular Ig synthesis rates could contribute to
the unreliability of absolute values of plasma monoclonal Ig for prognosis: only percentage
changes and not absolute values are used in response criteria (see section 2.2.1).
The study by Sullivan et al. [40] is conceptually similar to that of Salmon et al. [39];
however now serial assessments of serum monoclonal IgG were made, from which growth
and regression curves of the myeloma cell population were predicted. Hiramoto et al. [41]
performed a similar study but in mice. IgM-producing plasmacytomas were transplanted
in mice which were treated with chemotherapy. The actual tumour size was not assessed;
however the tumour cell number was calculated based on measurements of plasma IgM,
the metabolic half-life of IgM and a model for tumour growth and tumour kill. Hiramoto
et al. [41] observed the total quantity of monoclonal IgM per mouse increase between
injection of the tumour cells and administration of cyclophosphamide (chemotherapy),
and subsequently decrease following the treatment.
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2.4 The role of serum monoclonal immunoglobulin
in response assessment
Serum monoclonal Ig plays an important part in monitoring and response assessment in
multiple myeloma. Firstly it should be clarified that Igs are assayed in patient serum,
which simply refers to a blood sample that has been removed of blood cells and clotting
factors. They can also be measured in urine, however in this thesis we are only interested
in serum monoclonal Ig. Here the laboratory tests used to measure monoclonal Ig in a
serum sample are briefly introduced.
2.4.1 Laboratory tests
Serum protein electrophoresis
Serum protein electrophoresis (SPEP) is a gel-based technique in which proteins are sep-
arated by their electrophoretic mobility (dependent on size, charge, shape, etc.) on a
gel. Staining the proteins with a dye then results in distinct bands representing different
proteins in the sample. One such band represents the γ-globulins. A myeloma patient
will typically have a dense band in this region, known as an M-spike. The gel is then
analysed by densitometry, whereby the stained gel is scanned to produce a line drawing,
or ‘electrophoretogram’, representing the density of stain along the gel, with peaks rep-
resenting the proteins in different regions. The monoclonal protein typically appears as
a large, sharp peak in the γ-globulin region, hence the term ‘M-spike’. By quantifying
the total protein concentration by an alternative assay and determining the area under
the M-spike relative to the area under the whole curve, the analyst can quantify the
concentration of monoclonal Ig in the sample [42; 43].
After separation on a gel it is possible to identify the heavy and light chain types of
the M-spike by immunofixation. In this technique antibodies are applied to the gel that
are specific to IgG, IgA, IgM, κ light chains and λ light chains, respectively. Now the
monoclonal band will appear only in one heavy chain lane and one light chain lane,
enabling the clinician to identify the monoclonal Ig as, for example, IgAκ.
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Nephelometric quantification of immunoglobulins
Nephelometric quantification of Igs uses antibodies specific to the Ig under study, for
example IgA. IgA in the serum sample reacts with anti-IgA antibodies to form large
complexes. The analyst then measures the light scatter from the sample and compares
this with reference curves to obtain the concentration of IgA in the sample. Nephelometric
assays are particularly useful for patients with very small amounts of monoclonal Ig in
the blood that may not be detected by SPEP [31].
Heavy/light chain assay
More recently it has become possible to measure different light chain types of intact Igs
by targeting an epitope between the heavy and light chain, with the heavy/light chain
(HLC) assay [44]. It is thus now possible to separately quantify IgAκ, IgAλ, IgGκ, IgGλ,
IgMκ and IgMλ in patient sera. The HLC assay also relies on nephelometry; however
throughout this thesis HLC is used to refer to the quantification of Igs by both heavy
and light chain type, and nephelometry is used to refer to the quantification of Igs by
heavy chain type only. In an IgGκ patient, for example, the HLC measurement of IgGκ
can be considered to represent the monoclonal Ig. We refer to the IgGκ measurement in
an IgGκ patient as the involved HLC.
2.4.2 Limitations of techniques for serum monoclonal im-
munoglobulin quantification
It is of course not possible to ascertain the ‘true’ monoclonal Ig concentration as all
measurements taken from patients are subject to error. More significantly, it is also
difficult to separate the monoclonal Ig from polyclonal Ig in the sample. SPEP can in some
sense be considered as quantifying only the monoclonal Ig because it typically presents
as a prominent spike on the electrophoretogram. The polyclonal γ-globulin fraction is
diffuse and therefore an M-spike present in the γ region is believed to pertain mainly to
the monoclonal Ig. Generally SPEP is the preferred technique for M-spike quantification
for this reason [45]. There is of course polyclonal Ig present in the background between
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the limits of the M-spike and there is also the issue that these limits are set by the
interpreter, usually as vertical lines, which can be seen as subjective [43].
Another limitation of SPEP is that monoclonal Igs, particularly IgA, of relatively low
concentration migrate in the β-region and are obscured by other proteins in this region,
such as transferrin and C3. The aforementioned issues represent a more significant prob-
lem when the concentration of monoclonal Ig is comparatively small. Indeed at small
concentrations, less than 10 g l−1, SPEP is acknowledged to be unreliable. At large con-
centrations there is the possibility of dye saturation leading to an underestimation of the
monoclonal Ig concentration [43; 46; 47].
The HLC assay does not suffer from issues associated with gel-based techniques. The
assay is also more sensitive than SPEP and can quantify concentrations less than 1 g l−1,
presenting a significant advantage over SPEP. One limitation of HLC is that the assay
measures both monoclonal and polyclonal Ig of the same heavy- and light-chain type as
the monoclonal Ig. This presents a similar problem to background polyclonal Ig in the
same region of the gel as the M-spike, and similarly becomes significant when the HLC
is in the normal reference range. Fortunately the HLC assay provides the concentration
of the polyclonal Ig of the same heavy chain type but alternative light chain type as
the paraprotein, e.g. IgAκ in an IgAλ patient. Therefore HLC measurements are often
considered as Ig’κ/Ig’λ ratios.
2.4.3 Interpretation of serum monoclonal immunoglobulins in
practice
In patient monitoring, monoclonal Igs have two roles as markers: response assessment
and follow-up. In this thesis we are primarily interested in monoclonal Igs as response
markers. Response assessment is particularly important because it is believed that the
better the response to therapy, the better the prognosis of the patient.
In multiple myeloma, the fall in serum monoclonal Ig concentration in the months fol-
lowing initiation of therapy is used as an indication that the tumour is responding. An
example of how the monoclonal Ig (in this case involved HLC) for an individual patient
changes during the course of therapy is shown in figure 2-4. The data in figure 2-4 is
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Figure 2-4 Plot of involved HLC concentration during treatment for a
patient with IgGλ myeloma. The data is taken from the IFM 2009/01 clinical
trial, which is analysed in chapter 9.
from the IFM (Intergroupe Francophone du Mye´lome) 2009/01 clinical trial [48; 49]. At
screening, highlighted in pink, the patient presents with an elevated concentration of the
involved HLC. Following induction therapy, the concentration has decreased from 28.09
g l−1 at screening to 2.63 g l−1 at pre-maintenance (highlighted in light blue), a decrease of
90.6%. At this point the physician can use the proportional decrease in the involved HLC
concentration to assess the quality of the response to treatment. Responses are assigned
using the decrease in serum monoclonal Ig concentration as a proportion of its baseline
value, along with other clinical indicators. A decrease of 90.6% in the monoclonal protein
corresponds to VGPR (see table 2-2).
Patient responses are often discussed in terms of their quality or depth. The proportional
or percentage decrease in the monoclonal Ig concentration is often referred to as the
‘depth’ of response, with larger decreases representing deeper, or higher quality, responses.
When referring to the IMWG responses given in table 2-2, sCR represents a deeper
response than CR, CR represents a deeper response than VGPR, and so on.
At pre-maintenance, the patient shown in figure 2-4 begins a year-long course of mainte-
nance therapy. By this stage, the serum monoclonal Ig has reached a plateau phase. After
maintenance therapy, the involved HLC is monitored approximately every two months
for 22 months of follow-up. During this time serum monoclonal Ig is monitored for any
increase that may indicate regrowth of the tumour [32].
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2.4.4 Evaluation of response markers in multiple myeloma
The prognostic ability of response markers is evaluated by the strength of their association
with long-term outcomes, specifically event time outcomes. The most widely used event
time outcomes in multiple myeloma are overall survival (OS) and progression-free survival
(PFS) [50]. These outcomes are used to assess the efficacy of treatment regimens in clinical
trials. OS is given by the date of death. PFS is calculated as the time when the criteria
for PD are met (see section 2.2.1), or the time of death, when death occurs first. PFS is
ultimately decided by the physician and so is somewhat susceptible to investigator bias.
OS is less ambiguous, however its use is limited by several factors, outlined by Durie et al.
[50]. In chapter 9, the association between monoclonal Ig response during therapy and
PFS is analysed.
The multiple myeloma literature has focused on the association between depth of re-
sponse, as defined by the criteria in table 2-2, and PFS or OS. In order to analyse this
association, patients are grouped according to the response achieved at a clinically signif-
icant time point, and the subsequent survival times compared between the groups. The
survival times, such as PFS, can be compared using the log-rank test or proportional
hazards regression [51–54].
The prognostic utility of the currently recommended response criteria, given in table 2-2,
has been debated [55; 56]. The strength of the association between response to treatment
and survival outcomes depends on the particular therapy administered, at what time
the response is evaluated, and the survival endpoint used. In recent years, with the
introduction of novel agents, more and more patients have been achieving CR and the
importance of accurate response markers has been emphasized [51; 57].
2.5 The research problem
The ultimate goal of therapy is cure; however, given that multiple myeloma is currently
considered incurable, preserving and prolonging quality of life is a primary goal of patient
care. The means to achieving improved OS and PFS is to eradicate as large a proportion
of the tumour burden as possible [57].
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Figure 2-5 Illustration of how different aspects of the research problem
are connected to one another. Arrows represent causal relationships. See
section 2.5 for details.
Rather than assess the proportion of the tumour that has been eradicated, physicians
instead monitor the proportional decrease in the serum monoclonal Ig, as described in
section 2.4. Throughout this thesis, the term ‘tumour response’ is used to refer to either
the proportion of the tumour burden eradicated, or the proportion of the tumour burden
still remaining, at a certain time during treatment. Similarly, ‘monoclonal Ig response’ is
used to refer to the decrease in serum monoclonal Ig concentration as a proportion of its
baseline value, at any time during treatment, or alternatively the proportion remaining.
Of course, a monoclonal Ig response of, say, 90% does not necessarily mean that 90% of
the tumour cells have been eradicated: the concentration of monoclonal Ig in the blood
at any time depends both on its rate of production, which is assumed proportional to the
tumour burden, and also the rate at which the Ig is eliminated.
As described in section 2.1, IgA and IgG are known to have metabolic half-lives of 6
days and 23 days, at normal concentrations, respectively, while the elimination rate of
IgG is concentration-dependent due to saturable recycling by FcRn. The purpose of this
thesis is to investigate possible differences between monoclonal IgA and monoclonal IgG
responses, in terms of their relationship with tumour response. Monoclonal Ig responses
of 90% in an IgA patient and in an IgG patient do not necessarily correspond to the same
tumour response. The long metabolic half-life of IgG suggests that monoclonal IgG would
respond more slowly than monoclonal IgA, for the same tumour response. In addition,
the concentration-dependent half-life of IgG implies that, at the beginning of treatment,
IgG is eliminated at a faster than normal rate, due to saturation of recycling receptors.
Figure 2-5 depicts the different elements of the research problem and how they are related.
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The arrows represent links between two elements where one is seen to be driving the
other. The dashed line connecting survival outcomes with measured serum monoclonal
Ig response represents the associative link between these two measurable outcomes. This
association is studied using the methods of survival analysis, which are introduced in
chapter 4. The aim of this project is to consider the left hand side of the diagram – the
metabolic processes that link tumour response and serum monoclonal Ig response – and
how this might impact upon the association between measured monoclonal Ig responses
and survival endpoints. Throughout this thesis, and as indicated in figure 2-5, it is
assumed that the quality of the tumour response ultimately drives survival outcomes.
2.5.1 Previous contributions to the research problem
The effect of the metabolism of Igs on their application as biomarkers in multiple myeloma
has been little studied, perhaps because the importance of accurate response markers has
been highlighted only in recent years with the adoption of novel agents and ASCT. Salmon
et al. [39] and Sullivan et al. [40] first directed attention to the issue of IgG metabolism
in multiple myeloma in the early 1970s. Salmon et al. [39] stated: ‘Because of metabolic
considerations, serial paraprotein measurements in IgG myeloma may not reflect total
paraprotein synthesis or tumor cell mass in a linear fashion. Despite this limitation,
determinations of paraprotein concentrations remain the most valuable parameter for
objective follow-up of such patients. In IgA myeloma, because of the relatively fixed
IgA catabolic rate, changes in the serum concentration would be anticipated to reflect
the changes in cell mass more directly’. Sullivan et al. [40] recognised that ‘changes in
IgG metabolism, which occur as a concentration-dependent phenomenon, could lead to
significant underestimation of the degree of change in total body M-component synthesis
(and tumor mass)’, noting that this would particularly affect patients presenting with low
concentrations of IgG and could adversely influence the management of such patients.
A more recent contribution to the problem of IgG metabolism in multiple myeloma has
been made by Hattersley [19]. Hattersley derived a reduced model of IgG metabolism and
estimated parameter values using HLC data from an IgG myeloma patient, assuming a
delayed logistic form for the production rate of monoclonal IgG. Hattersley then evaluated
the use of different response markers using mathematical analysis, concluding that the
25
Chapter 2. Background
ratio of monoclonal to polyclonal IgG may be the best response marker.
In spite of the relatively little research in this area, potential issues arising from IgG
metabolism are acknowledged in the multiple myeloma community. Bradwell et al. [58]
and Koulieris et al. [59] cite the concentration-dependent metabolism of IgG as a pos-
sible explanation for why monoclonal IgG can be seen as unreliable and its utility as a
biomarker still debated in the literature. Durie et al. [50] also advise that metabolic prop-
erties of Igs are a potential problem. Bradwell [60] discusses in detail several aspects of
the problem, stating that, due to the concentration-dependent metabolism of IgG, serum
IgG concentrations ‘do not accurately relate to tumour production rates’.
2.5.2 Contributions of this thesis
In this thesis the effects of IgG metabolism on monoclonal Ig responses in IgG myeloma
are investigated, with a focus on the potential differences between monoclonal Ig responses
in IgA and IgG myeloma patients, respectively. The different metabolisms of IgA and
IgG could have a real impact in patient monitoring and response assessment, which is
also investigated in this thesis using survival data from a recent clinical trial.
In this thesis two compartmental models of IgG metabolism, which have previously been
published by Waldmann et al. [3], Kim et al. [18] and Hattersley et al. [61], are analysed
with respect to parameter identification. In chapters 5 and 6 model parameter values are
estimated using data available in the literature from tracer experiments, specifically de-
signed to demonstrate the steady state metabolic behaviour of Igs. The two models of IgG
metabolism are compared using simulations in chapter 7. The behaviour of monoclonal
Ig responses in IgA and IgG patients is predicted using simulations that qualitatively
agree with patient data. The implications of IgA and IgG metabolism for the association
between the monoclonal Ig response and survival outcomes is analysed in a dataset from
a recent clinical trial.
It is important that physicians can meaningfully assess tumour responses during therapy.
With the introduction of novel agents and ASCT, patients are achieving deeper responses
to treatment, and, in particular, the achievement of CR is treated as an important ther-
apeutic goal [21; 57]. Therefore assigned responses must be strongly correlated with
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long-term outcomes. Whilst the outlook for patients has improved over the last 20 years,
still the majority of patients will go on to relapse or develop refractory disease [62]. For
this reason it is all the more important to be able to provide patients, who will likely live
with the disease until death, with as much information as possible about their response
to treatment and prognosis.
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3Compartmental modelling of
physiological systems
The theory and methods of compartmental modelling are used in chapters 5–8. The
aim of the thesis is to investigate the impact of immunoglobulin (Ig) metabolism on the
association between plasma monoclonal Ig responses and survival, in multiple myeloma.
Achieving this aim requires predictions to be generated from compartmental models.
In this chapter compartmental models and their use in pharmacokinetic and physiological
applications are introduced. The methods of parameter estimation, structural identifia-
bility analysis and simulation are briefly discussed, along with the computational tools
for their application.
3.1 Compartmental modelling
A compartmental model is a mathematical model consisting of a finite number of discrete
‘compartments’, each representing a homogeneous, well-mixed amount of substance (or
other physical quantity). Compartments are connected to one another and the environ-
ment by flows of material, which is assumed to mix uniformly and instantaneously on
entering a compartment. Given a physical system which can be reasonably approximated
by a collection of compartments, the modeller applies the principle of conservation of
mass to obtain a mathematical model described by ordinary differential equations. For a
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comprehensive overview of compartmental modelling theory see Jacquez [1] and Godfrey
[2].
Compartmental models are used widely, particularly in the field of pharmacokinetics. Of-
ten the concentration of a drug (or protein, or metabolite) in plasma is homogeneous and
can be assumed to behave as a compartment. Pharmacokinetic compartmental models
commonly consist of a central compartment (also called the plasma or vascular compart-
ment) and a peripheral compartment (also called the extravascular compartment), rep-
resenting those tissues which are less rapidly perfused by the drug. Other compartments
specific to the drug administration or elimination mechanism may be incorporated, such
as the gastrointestinal tract and urine. Similarly, compartmental models can be used
to describe the kinetics of substances endogenous to the subject such as proteins and
metabolites. Application of the principle of conservation of mass yields a mathematical
description of the model, usually in the form of coupled ordinary differential equations
with a number of unknown parameters [1–3].
The general conceptual form of a compartmental model is illustrated in figure 3-1. The
general compartmental model is described mathematically by
dxi
dt
= fi0 +
p∑
j=1
j 6=i
fij −
p∑
j=1
j 6=i
fji − f0i, i = 1, 2, ..., p, (3-1)
where xi(t) is the quantity or concentration of material in compartment i and fij is the
material flow from compartment j to compartment i. The flows between compartments
are positive. In physiological models the material flow fij is often directly proportional to
the quantity of material in compartment j. In linear models, the constant of proportion-
ality is denoted by kij, has dimension 1/time and is referred to as a rate constant. The
state variables xi(t) have initial conditions xi(0) that may be unknown. The experimenter
may observe one or more of the state variables themselves or some linear combinations of
the state variables, possibly involving unknown parameters. Observation functions, also
called outputs, in this thesis are denoted by y(t).
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fji
fij
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to/from other 
compartments
to/from other 
compartments
Figure 3-1 Schematic of the general form of a compartmental model, re-
produced from Godfrey [2]
3.2 Data generation
Having derived a compartmental model of a biomedical system, parameter values must
be determined in order for the model to be used for prediction. The process of inferring
model structure and determining parameter values is often referred to as the ‘inverse
problem’ [1].
In the pharmacokinetic context, experiments for determining parameter values usually in-
volve administration of the drug (the ‘input’) and subsequent observations of the amount
or concentration of substance in one or more compartments at selected time intervals (the
‘output’). For example, the experimenter may administer a bolus intravenous injection
of a drug and then take blood samples at time intervals after administration. Where the
substance under investigation is also produced endogenously, for example Igs, labelling
with radioactive isotopes allows the experimenter to distinguish between the endogenous
substance and the administered dose [4–6]. The data collected from an individual subject
typically consist of measurements of drug (or other substance) concentration in the blood
(or other physiological compartment) at known time points. The data may also include
known inputs at known time points, typically administered doses of drug. Multiple out-
puts can be observed for an individual, but for clarity a single output will be considered
here.
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3.3 Modelling the data of an individual subject
The solution of the compartmental model ordinary differential equations for the observa-
tion function, y(t), gives the theoretical evolution of the quantity of interest in time. In
practice, however, experimental data believed to arise from an underlying compartmental
model are always observed with error. The observational error comprises both measure-
ment error and the error caused by approximating a complex physiological system with
a highly simplified model.
Taking into account inevitable errors, one observation for one individual can be expressed
as Yj = y(tj,ψ) + ej, 1 ≤ j ≤ J , where J data points, Yj, are measured at times
tj. y(tj,ψ) is the quantity predicted by the compartmental model, also known as the
structural model, where ψ is the vector of parameter values. ej is the residual error,
representing the difference between the value predicted by the structural model, y(tj,ψ),
and the value measured in practice, Yj, at time tj.
The residual errors themselves require a model to describe them. The simplest and
most common models are the constant error model and the proportional error model.
In the constant error model, ej = aj, where j is the normalised residual error and a
is a constant. The normalised residual errors are usually assumed to be independently
and identically distributed random variables drawn from a centred distribution, typically
the normal distribution: j ∼ N(0, 1). In the proportional error model, ej = ay(tj,ψ)j.
Now the residual error is assumed to be proportional to the value predicted by the model,
y(tj,ψ) [7].
Distributional assumptions regarding the residual errors of the measured data are im-
portant when deciding upon the parameter estimation procedure to use. Pharmacoki-
netic data from individual subjects are typically analysed using nonlinear least squares,
weighted least squares, or maximum likelihood (ML) approaches [7]. Where residual er-
rors are assumed constant, least squares is appropriate; where the errors are assumed
proportional to the model prediction, it is necessary to use weighted least squares or ML
estimation. Depending upon the complexity of the structural model, a numerical ordi-
nary differential equation solver may need to be employed if the model cannot be solved
analytically [3].
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3.4 Population approaches
Applying the approach in section 3.3 to the data generated by an individual subject, say
subject i, yields an estimate for a vector of parameter values, ψi, describing the evolution
of their observation function, y(t,ψi), in time. If the same approach is applied to a second
subject, it is unlikely that their parameter estimates will take the same values as those
for subject i.
In a population approach, each individual is assumed to have a unique parameter vector,
ψi, that comes from a probability distribution. The ‘typical’ behaviour in the population
is represented by y(t,ψpop), where ψpop is the vector of so-called population parameters.
Depending upon the distribution from which the individual parameters are assumed to
be drawn, ψpop may be the mean or median of the distribution. The predicted behaviour
of the individual subject i, y(t,ψi), deviates somewhat from the expected population
behaviour due to deviation in their parameters, ψi, from the population parameters,
ψpop [8].
In pharmacokinetics, individual parameters are typically assumed to be drawn from a
log-normal distribution, ensuring non-negative parameter values. For example, consider
a rate constant, k. It is assumed that the individual parameters, ki, are log-normally
distributed, that is log(ki) ∼ N(log
(
kpop
)
, σ2k), where kpop is the population parameter
and σk is the standard deviation of the parameter k. In this way, the individual param-
eter ki can be decomposed into a fixed (population average) effect, kpop, and random
(individual) effect, ηi: ki = kpop exp(ηi), with ηi ∼ N(0, σ2k). The parameter vector of
the individual i, ψi, now has a fixed component ψpop and a random component ηi, with
ηi ∼ N(0,Ω). Ω is the variance-covariance matrix of the random effects [7].
The population approach enables the measurement data from a sample of subjects to
be described simultaneously by a single, nonlinear, mixed effects model. ‘Mixed effects’
refer to the population average parameters, considered as non-random or fixed variables,
and subject specific effects, considered as random variables drawn from probability dis-
tributions. Parameter estimation uses the data from all of the subjects in the sample to
estimate both population parameters and individual parameters, using ML estimation.
There are a number of well-known software packages used in academia and industry for
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this purpose, such as Monolix [9], Nonmem [10] and Phoenix NLME [11]; in this thesis
Monolix is used.
The population approach is particularly useful in that it describes the average behaviour
of a population and the variability within that population. When interest lies in the
expected population behaviour of a system, estimated population parameters can be
used to predict such behaviour. When interest lies in the variability within a population,
the estimated standard deviations of the individual parameters provide a summary of the
variability. A further advantage of population models is that they allow for dependence
of individual parameters on relevant covariates such as body weight, however this is not
considered in this thesis.
3.5 Structural identifiability of compartmental mod-
els
In some situations it may not be possible to uniquely estimate the model parameters
from the available observations. Structural identifiability analysis addresses this ques-
tion, under the assumption of the availability of ideal (i.e. noise-free) and continuous
observational data [2]. The structural identifiability problem is first considered in terms
of models describing the data from one individual, as in section 3.3.
A parameter is said to be globally identifiable if it can be uniquely determined from
the given input-output structure of an experiment, locally identifiable if it takes one
of a countable set of values, and unidentifiable if it can take any of an uncountable
set (continuum) of values. A compartmental model is said to be structurally globally
identifiable if all parameters are globally identifiable, locally identifiable if all parameters
are locally identifiable and at least one is not globally identifiable, and unidentifiable if
at least one parameter is not identifiable.
Consider the generic parameter vector of an individual, ψ, which belongs to a space of
feasible parameter vectors, Ψ; that is ψ ∈ Ψ. Now consider a second parameter vector,
ψ, that generates the same observation function as ψ, such that y(t,ψ) = y(t,ψ) for
all t. If this equality requires that ψ = ψ in a neighbourhood N of the vector ψ, then
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the parameter vector ψ is locally structurally identifiable. If this is also true for N = Ψ
then the parameter vector is globally structurally identifiable. If there are infinitely many
values of ψ 6= ψ producing the same output y(t,ψ) = y(t,ψ) then the parameter vector
ψ is structurally unidentifiable [12].
Methods for assessing structural identifiability include the Laplace transform, Taylor
series, similarity transformation, differential algebra, and observable normal form ap-
proaches [2; 13–16]. The Laplace transform approach can only be applied to linear
systems. It is important to note that structural identifiability analysis only addresses the
question of whether the input-output structure of the experiment allows for the param-
eter values to be uniquely determined or otherwise. Structural identifiability does not
imply that model parameters can be estimated with an acceptable level of confidence in
practice – that is the issue of practical, or numerical, identifiability.
In chapters 5 and 6 the Laplace transform approach is applied [17]. This approach is
applicable to linear models that can be described in the form
x˙(t,ψ) = A(ψ)x(t,ψ) +B(ψ)u(t,ψ)
x(t0,ψ) = 0
y(t,ψ) = C(ψ)x(t,ψ),
(3-2)
where x(t,ψ) is the state of the system, u(t,ψ) is the input vector, y(t,ψ) is the obser-
vation function, and A(ψ), B(ψ) and C(ψ) are matrices with functions of the system
parameters as their elements.
The input-output relationship of the system can be described in the form of Y (s) =
G(s)U(s), where Y (s) is the Laplace transform of the observation y(t), U(s) is the
Laplace transform of the input vector u(t) and G(s) is the transfer function, given by
G(s) = C(ψ)
(
sI −A(ψ))−1B(ψ). The coefficients of s in G(s), denoted by Φ(ψ) =
(φ1, φ2, ..., φF ) are functions of the system parameters, ψ. Introducing a second parameter
vector ψ, capable of generating the same output as ψ, that is y(t,ψ) = y(t,ψ), then
Φ(ψ) = Φ(ψ). If the only solution to Φ(ψ) = Φ(ψ) is given by ψ = ψ, then there is a
unique parameter vector ψ and the system is structurally globally identifiable.
Structural identifiability is an a priori analysis, that is the analysis is performed before
data are introduced. It is therefore also a generic, symbolic exercise, in general requir-
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ing the computation of symbolic expressions and the solution of potentially nonlinear
simultaneous algebraic equations. Symbolic computing packages are therefore extremely
important when the model being analysed is large, in terms of its dimension and number
of parameters, and can speed up the process of analysing small models. In chapters 5
and 6 structural identifiability analyses are performed in Mathematica [18].
3.5.1 Structural identifiability of mixed effects models
Recently methods have been developed that enable the structural identifiability of pop-
ulation models, as described in section 3.4, to be analysed [12; 19]. Previously structural
identifiability analysis has only dealt with deterministic models describing the observation
of an individual and was unable to handle the scenario in which individual parameters
are assumed to be drawn from a distribution.
One of the new methods designed for mixed effects models is the Laplace transform
mixed effects extension approach [12; 19]. As in the Laplace transform method for linear
deterministic systems the input-output relationship is described by the transfer function,
G(s). The Laplace transform mixed effects extension approach is based on the same
principle, but now the parameters have both fixed and random effects, ψpop and η,
where η ∼ N(0,Ω). Now the coefficients of s in the transfer function are functions of
both the fixed and random effects and are thus random variables, given by Z(ψpop,η) =
(Z1, Z2, ..., ZF ). The structural identifiability problem amounts to determining whether
the distributions of Z(ψpop,η) are uniquely determined by the population parameter
vector ψpop and the variance-covariance matrix Ω [12].
An alternative population parameter vector ψpop and an alternative variance-covariance
matrix Ω are introduced. Statistical moments of the distributions are evaluated for both
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{ψpop,Ω} and {ψpop,Ω}, yielding a set of (nonlinear) algebraic equations
E
(
Z l1
(
ψpop,η
))
= E
(
Z l1
(
ψpop,η
))
...
E
(
Z lF
(
ψpop,η
))
= E
(
Z lF
(
ψpop,η
))
η ∼ N(0,Ω)
η ∼ N(0,Ω),
(3-3)
where E(Z l) denotes the lth statistical moment of the distribution Z. If the solution of
equations (3-3) requires that ψpop = ψpop and Ω = Ω, then the mixed effects model is
structurally globally identifiable [12].
3.6 Simulation and analysis
Using the methods thus far described, it is possible to derive a mathematical represen-
tation of the system under study, use data from human or animal subjects to estimate
parameter values, and verify that the parameters are uniquely structurally identifiable.
Once a model has been generated, it can be used for prediction and the system dynamics
can be analysed in a realistic context.
Simulation of compartmental models more often than not involves numerical solution of
ordinary differential equations. There are many specialist computer software packages
that allow for simulation of compartmental models. In this thesis Berkeley Madonna
[20] and Mathematica [18] are used to perform model simulations. Symbolic analyses,
such as analyses of steady states, can be readily performed for generic parameters using
Mathematica.
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4Survival analysis
In this chapter the basic concepts and definitions of survival analysis are introduced. The
proportional hazards class of survival models [1] is introduced; these models are used
in chapter 9 to describe the association between response markers and progression-free
survival in multiple myeloma patients.
4.1 Survival data
Therapeutic strategies are frequently assessed by their effect on patient survival, that is
the time until death, or the time until some other outcome of clinical importance such as,
for example, disease progression. Event time outcomes also occur in other fields, such as
failure times of engineering systems or components, but the following discussion will be
restricted to the context of clinical research. Even though clinical events are not restricted
to deaths, the terms ‘event time’ and ‘survival time’ are often used interchangeably and
this will be the case throughout this thesis.
Event times have certain properties that must be considered in their analysis, for example
they are always positive and are not appropriately described by normal distributions.
Statistical methods also need to be able to handle patients for whom the event of interest
does not occur before the end of the study. Such observations are called ‘censored’ and
clearly cannot be disregarded.
Consider a patient who is recruited into a study at time t0. In this hypothetical study
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the endpoint of interest is death. This patient does not die during the study duration;
however they die later at time t0 + t. If the last contact with the patient is made at the
end of the study, at time t0 + c, then this time is called the censoring time. This type
of censoring is known as right-censoring because the event is known to occur after the
censoring time: t > c. Events can also, less commonly, be left-censored; however this
type of censoring does not apply to the data used in this thesis. Survival data for a cohort
of individuals usually consist of an event time and a binary variable indicating whether
the event occurred or was censored at the given time, for each individual.
Subjects are frequently recruited into a study over a period of time, such that the study
start date is different between individuals across the cohort. The time origin t0 from
which survival times are calculated is then different for each individual. The time origin
may be the time at which the patient is recruited or begins treatment, for example.
At the time origin, by definition, no events have yet occurred and thus every subject is
considered ‘at risk’. At risk individuals are those individuals for whom the event has
not yet occurred, assuming that the event can only occur once per subject, for example
death. Models in which multiple events can occur are not considered in this thesis. At
any time t there is a set of individuals who are at risk. When an event occurs for an
individual they are removed from the set of at risk individuals at the event time. Similarly
if an observation is censored then the individual is removed from the at risk set at the
censoring time.
In clinical trials and in patient monitoring, clinicians desire a marker that is strongly cor-
related with patient survival. In this case the biomarker is considered as an explanatory
variable and survival as the response variable, as in regression analysis. Due to the distri-
bution of the survival times and censoring of observations, usual regression methods are
not suitable [2]. Fortunately statistical models for survival times have been developed;
but first, several functions need to be defined.
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4.2 The survival function, hazard function and cu-
mulative hazard function
In order to perform statistical analysis on survival data, the survival time of an individ-
ual is considered as a random variable, T , with probability density function f(t). The
cumulative distribution function F (t), representing the probability that the survival time
T takes a value less than t, is given by
F (t) = P (T ≤ t) =
∫ t
0
f(u) du. (4-1)
The survival function, S(t), is defined as the probability that the survival time, T , is
greater than some time, t, and is thus given by
S(t) = P (T > t) = 1− F (t). (4-2)
The survival function therefore represents the probability that an individual will survive
beyond time t and is necessarily a nonincreasing function [3].
The hazard function is defined as the probability that an event occurs at time t, condi-
tional on the event not having already occurred by that time. It can also be considered
as the instantaneous rate of events at time t. It is defined by
h(t) = lim
δt→0
P (t ≤ T < t+ δt|T ≥ t)
δt
. (4-3)
The hazard function is particularly important as it expresses the level of risk of the
occurrence of an event over time. It is natural then to think of events occurring at
certain times due to an underlying stochastic process with an associated hazard function.
Unlike the survival function, the hazard function can increase or decrease over time. It is
also possible that certain factors may influence the hazard rate, such as the patient’s sex
or treatment arm in a randomised clinical trial. This idea paves the way for proportional
hazards models, also known as Cox models, introduced in section 4.3 [3].
Another function that is used in survival analysis is the cumulative hazard function,
defined as the cumulative risk of an event occurring up to time t. It can also be interpreted
as the expected number of events up to time t. It is defined by
H(t) =
∫ t
0
h(u) du, (4-4)
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Figure 4-1 Plot of the Kaplan-Meier estimator of the survival function of
discontinuation of intrauterine device use. Data from Collett [2, p. 5].
where h(·) is the hazard function as before.
The following relationships link the hazard function, h(t), survival function, S(t), and
the probability density function, f(t), of the event times [2]:
h(t) =
f(t)
S(t)
H(t) = − logS(t).
(4-5)
4.2.1 The Kaplan-Meier survival estimator
A useful visualisation of event time data is the Kaplan-Meier survival estimator plot,
which is frequently reported in the results of clinical trials [4]. The plot illustrates a
non-parametric estimator of the survival function of a sample of individuals. An example
survival plot is shown in figure 4-1. The survival plot is particularly useful as it is easy
to interpret, with each step change representing the proportion of patients for whom
the event has occurred at that time. The tick marks (+) represent the times at which
individuals are censored.
The estimator is a step function, the value of which is assumed to be constant between
observed events. The estimator takes into account right-censored observations by remov-
ing them from the ‘at risk’ subjects immediately prior to an observed event time in its
calculation.
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The Kaplan-Meier estimator over the time interval tk ≤ t < tk+1 is given by
Sˆ(t) =
k∏
j=1
(
nj − dj
nj
)
, (4-6)
for k = 1, 2, ..., r, where r is the total number of observed events, nj is the number of at
risk individuals immediately prior to the event time tj, having removed any individuals
that were censored during the preceding interval tj−1 ≤ t < tj, and dj is the number of
individuals for whom the event occurs at time tj. Prior to time t1 the value of Sˆ(t) is 1.
tr+1 is ‘infinity’, such that after the final event has been observed the value of Sˆ(t) is zero
for the rest of time. In the example plot shown in figure 4-1, two patients are censored
at the final event time; in this case the survival estimator is undefined for t > tr = 107
weeks.
The survival plot can also be stratified by a factor of interest, in order to compare
the survival functions of the respective groups. For example in chapter 9 the survival
functions of myeloma patients with immunoglobulin A (IgA) and immunoglobulin G
(IgG) paraproteins are compared via survival plots.
It is also possible to test whether the survival functions of the two groups are significantly
different using a hypothesis test. The log-rank test and the Wilcoxon test both test the
null hypothesis that there is no difference between the survival functions of two groups
[5; 6]. Rejection or non-rejection of the null hypothesis is not the most informative way
to analyse the data; it only states whether or not there is sufficient evidence to reject
the null hypothesis at a pre-specified significance level. A more informative approach
would be to estimate the size of the difference between the two groups [2]. This requires
a model-based approach which is introduced in the following section.
4.3 The proportional hazards model
The proportional hazards model, or Cox regression model, describes the relationship
between the survival of patients and explanatory variables, such as the age of the patient
and biomarkers measured at the time origin [1]. The model allows for comparison between
groups, for example it may be that males have a worse prognosis than females. It may be
possible to identify a biomarker cut-off value, such that patients with baseline biomarker
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values larger than the cut-off have a worse prognosis than those with smaller values. There
may also be a continuous relationship, where larger biomarker values are associated with
a worse prognosis, for example.
The proportional hazards model postulates that the explanatory variables have a direct
effect on the hazard rate h(t), defined in section 4.2. Intuitively, the explanatory variable
can be thought of as influencing the rate at which events happen. The rate of events,
that is the hazard function h(t), then determines the distribution of the survival times.
For example, having a particular genetic risk factor could be seen as increasing the death
rate, which in turn would mean that patients with the risk factor on average have shorter
survival times.
According to the proportional hazards model the hazard function hi(t) of patient i, with
p explanatory variables x1i, . . . , xpi, is given by
hi(t) = exp
(
β1x1i + β2x2i + · · ·+ βpxpi
)
h0(t), (4-7)
where h0(t) is the baseline hazard rate. The baseline hazard rate h0(t) is the hazard rate
of a (possibly theoretical) patient for whom the term in parentheses in equation (4-7)
evaluates to zero. This could represent for example a male whose biomarker levels are all
zero. β1, . . . , βp are the coefficients of the explanatory variables, reflecting the size of their
respective effects on the hazard function. From equation (4-7) it is clear why the model
is called ‘proportional hazards’, as the hazard function for any patient i is proportional
to the baseline hazard h0(t) and thus to every other patient represented by the model.
The model is usually fitted using a maximum likelihood method, such that the maximum
likelihood estimator of the coefficients β1, . . . , βp and their standard errors are found.
This approach allows for the estimation of confidence intervals and hypothesis tests on
the values of the coefficients [2].
Equation (4-7) can be rearranged to give
log
(
hi(t)
h0(t)
)
= β1x1i + β2x2i + ...+ βpxpi. (4-8)
Hazard functions and thus their ratios are necessarily positive. For a patient whose linear
predictor (the right hand side of equation (4-8)) is zero, the ratio of hi(t) to h0(t) is equal
to 1 and the patient’s individual hazard rate is thus equal to the baseline hazard rate.
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Likewise, if the patient’s linear predictor is positive, then the ratio is greater than 1 and
their hazard rate is greater than the baseline hazard rate. When the linear predictor
is negative, then the ratio is between 0 and 1 and the hazard rate is smaller than the
baseline hazard rate. The log of the ratio lies within the range (−∞,+∞) and is linearly
dependent on the explanatory variables.
Now in order to compare two groups of patients, rather than performing a hypothesis
test with the null hypothesis that there is no difference between their survival functions,
it is possible to estimate the size of the difference by fitting the proportional hazards
model. For example, the survival of myeloma patients with IgA and IgG paraproteins,
respectively, can be compared by considering the isotype of the monoclonal immunoglob-
ulin as a factor with two levels, for IgA and IgG paraproteins, respectively. Then the
proportional hazards model is expressed as
hi(t) = exp
(
βIgGxisotype,i
)
h0(t), (4-9)
where hi(t) is the hazard function of patient i, h0(t) is the baseline hazard function for
all subjects, xisotype,i is the value of an indicator variable Xisotype that takes the value 1
when the patient has an IgG paraprotein and 0 when the patient has an IgA paraprotein,
and βIgG is the effect on the hazard function of having an IgG paraprotein.
The model is parameterised such that the hazard function of a patient with an IgA
paraprotein is given by h0(t) and the hazard function of an IgG patient is given by
exp
(
βIgG
)
h0(t). exp
(
βIgG
)
is thus the hazard ratio of IgG patients relative to IgA patients.
Now, by estimating the coefficient βIgG, it is possible to estimate the size of the difference
between the survival of the two groups, rather than simply determining whether there is
a difference at all.
The hazard functions of all individuals are assumed proportional to one another, but
the hazard functions are not necessarily constant in time. The relationship between any
two hazard functions is however constant in time, and fixed from the outset, depending
only on those covariates that are measured at the defined time origin. There is a clear
limitation here in that the hazard function of a patient cannot change, that is to say their
outlook cannot improve or worsen after the pre-defined time origin [2].
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4.3.1 Comparing alternative models
The methods that can be used to compare two models depend on whether one model is a
nested form of the other, that is, whether one model is equivalent to setting one or more
of the parameters in the second model equal to zero. Where models are nested, they can
be compared using the likelihood ratio test.
Consider two models, M1 and M2, where M1 is nested in M2. The models can be compared
using the statistic −2 log Lˆ, where Lˆ is the maximised value of the likelihood function
for each model, respectively. Let M2 contain k additional parameters compared to M1;
therefore Lˆ2 is always greater than Lˆ1 and −2 log Lˆ2 is always smaller than −2 log Lˆ1,
indicating that M2 improves the goodness-of-fit of the model to the observed data. The
question is whether the improvement is great enough to justify the inclusion of the k
additional parameters that are present in M2, but not in M1.
This question can be addressed by the likelihood ratio test, with the test statistic
D = −2 log
(
Lˆ1
Lˆ2
)
= −2 log Lˆ1 + 2 log Lˆ2. (4-10)
The larger the value of D, the greater the difference in adequacy between the two models.
D has a chi-squared distribution under the null hypothesis that the additional parameters
are all zero, with the degrees of freedom given by the number of additional parameters
in M2 compared to M1, that is k. Therefore a hypothesis test can be performed to assess
whether there is strong evidence to reject the simpler model M1 [2].
The likelihood ratio test can only be performed when one model is nested in the other.
Non-nested models can be compared using the Akaike Information Criterion (AIC), given
by −2 log Lˆ+2k. When comparing alternative models, the model with the smallest value
of the AIC is considered to be the preferred model [7].
4.3.2 Time-varying covariates
An important quantity that is often reported in clinical trials is the number of patients
achieving a certain level of response. In multiple myeloma there are several levels of
response with corresponding criteria, given in section 2.2.1 of chapter 2. The criteria
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for response are often reliant on measurements of some physiological quantity, or disease
marker, representing the size of the effect of the treatment on the body. It is clear though
that the response in itself can be achieved at different times for different patients.
Previously it was stated that the proportional hazards model is used to assess the effect
on survival of explanatory variables known at the time origin of the survival times. If the
survival times are calculated from the study entry date for each patient, then the values
of explanatory variables must be known at the beginning of the study; such variables are
called baseline covariates. However it is possible to incorporate a marker measured later
in the study, as long as the survival times are then calculated from this new time point
and the time point used is consistent across all patients. This is the simplest way to
incorporate biomarkers that are strictly time-varying into a survival model and is known
as landmark analysis [8; 9].
To give an example, it is possible to assess the influence of response on survival by
determining whether or not response has occurred at a specific time point, such as six
months after the beginning of treatment for each patient, and calculating survival times
from this newly defined time origin. Those patients who have already died before six
months are excluded from the analysis. It would not be legitimate to use survival times
calculated from the beginning of the study and make a comparison between patients for
whom response has or has not occurred at all [9].
Several methods have been developed specifically for the incorporation of time-varying
covariates. These are time-varying Cox models and joint models for longitudinal and
survival data [2; 3]. The assumption behind these models is fundamentally different from
the standard proportional hazards model, in that the hazard function of an event at time
t is associated with the values of explanatory variables at time t, not some earlier time
from which survival times are calculated.
Time-varying Cox and joint models can be used to investigate, for example, whether
a larger value of a biomarker at time t is associated with an increased risk of event
at time t – this can provide information about which markers should be monitored in
patient follow-up. A proportional hazards model however can be used to represent the
association between the response to treatment at a given time and the risk of event at any
time afterwards, where response to treatment is evaluated within a clinically relevant time
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frame of therapy. Given that response assessment is the focus of this work, proportional
hazards models, and not time-varying Cox or joint models, will be used in this thesis.
4.4 Computational tools
The methods discussed in this chapter can be implemented in many statistical software
packages. In this thesis all survival analysis is performed using the R language and
environment for statistical computing version 3.0.1 [10] and the Survival package version
2.37-4 [11]. Examples of the code used to perform the analyses in chapter 9 are provided
in appendix A.
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5Parameter identification for a
two-compartment model of
immunoglobulin G metabolism
A mathematical model of immunoglobulin G (IgG) metabolism, with parameter values
suitable for humans, is required in order to simulate plasma IgG responses during multiple
myeloma treatment and relapse. In this chapter a previously published two-compartment
model of IgG metabolism is analysed with respect to parameter identification. The model
is nonlinear, employing Michaelis-Menten kinetics to describe the rate of recycling of IgG
by neonatal Fc receptors (FcRn). Model parameters are estimated using data from
radioactive tracer experiments in humans, also taken from the literature. The model has
been previously presented by Waldmann et al. [1], Kim et al. [2] and Hattersley [3].
Several authors have suggested that the concentration-dependent metabolism of IgG
means that monoclonal IgG responses in IgG myeloma patients may underestimate tu-
mour responses to treatment [4; 5]. It is also possible that IgG patients may show slower
monoclonal immunoglobulin (Ig) responses than immunoglobulin A (IgA) patients when
the tumour response is comparable, due to the slower metabolism of IgG compared to
IgA. However, these claims have not been investigated using simulations of IgA and IgG
responses in patients. Based on a qualitative understanding of the biology these propo-
sitions have merit; however it is not known whether the differences in metabolic rates
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between patients are so large as to cause meaningful differences in monoclonal Ig response
rates.
Mathematical models of both IgA and IgG metabolism are available in the literature. The
metabolism of systemic IgA is simple and can be described by a linear two-compartment
model [6]. There is little data in the literature to support parameter estimation for the IgA
model; however certain parameter values are available [1; 6]. In contrast, the literature
provides data suitable for parameterising the model of IgG metabolism from several
subjects. Ideally it would be useful to obtain a parameterised distribution of individual
parameter values within the population, which would facilitate simulations of expected
IgG responses to different tumour responses. This would also allow for simulations of a
cohort of patients, as in a clinical trial, all with unique parameter vectors arising from a
distribution.
In the following section the work of previous authors on which this chapter builds is briefly
outlined. In section 5.2 the two-compartment model of IgG metabolism of Waldmann
et al. [1], Kim et al. [2] and Hattersley [3] is described. In section 5.3 the data taken from
the literature for parameter estimation are described. In section 5.4 the relationship
between the experimental observations and the system model is described. In section
5.5 the data generation process and how errors manifest in the data are considered. A
population approach to parameter identification using timecourse data is taken in section
5.6. In section 5.7 a naive pooled approach to parameter identification is taken, using
fractional catabolic rate and half-life data. Parts of the work in this chapter have been
published by the author [7].
5.1 Overview of the work of previous authors
The work presented in this chapter builds upon the work of previous authors, particularly
Waldmann et al. [1], Kim et al. [2] and Hattersley [3]. Some descriptions of the work
performed by previous authors are interspersed with original work within this chapter
so that the text proceeds logically from one section to the next. In this section a brief
description of the work drawn from previous authors is provided for clarity.
The model described in section 5.2 has been previously published by Kim et al. [2] and
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Figure 5-1 Schematic of the two-compartment model of IgG metabolism
described in section 5.2
Hattersley et al. [6] and is based upon an expression for the fractional catabolic rate
(equation (5-13)) first suggested by Waldmann et al. [1]. Section 5.2 (except for the
equilibrium point and stability analysis) is therefore a description of the work of previous
authors. No original data have been collected as part of this work; the data described
in section 5.3 have been sourced by the author from the literature. In section 5.4.2 a
linear model is derived from the nonlinear coupled model of unlabelled and labelled IgG
dynamics. Authors Kim et al. [2] and Hattersley [3] have used this linear model of tracer
dynamics ((5-10)–(5-12)) for parameter estimation; however previous authors have not
considered the relationship between the linear and nonlinear models nor compared the
two using simulations. Kim et al. [2] and Hattersley [3] have estimated parameters for
individual subjects from timecourse data; their results are discussed and compared with
the results presented in this chapter in section 5.8. Waldmann et al. [1] and Kim et al. [2]
have used the expression for the fractional catabolic rate to estimate model parameters;
again these results are discussed and compared with the results presented in this chapter
in section 5.8.
5.2 System model
The two-compartment model of endogenous IgG metabolism, with the rate of recycling
by FcRn receptors described by Michaelis-Menten kinetics [1; 2; 6], is given by
x˙1(t) = −
(
k21 + k31 − Vmax
KM + x1(t)
)
x1(t) + k12x2(t) + I(t)
x˙2(t) = k21x1(t)− k12x2(t),
(5-1)
where x1(t) and x2(t) represent the quantities in µmol of IgG in plasma and in a pe-
ripheral compartment, respectively. I(t) represents the synthesis of IgG into plasma in
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Table 5-1 States and parameters of two-compartment model of IgG
metabolism
Name Units Physiological interpretation
x1 µmol Quantity of IgG in the central (plasma) compartment
x2 µmol Quantity of IgG in the peripheral (tissue) compartment
k21 day
−1 Rate constant of flow of IgG from plasma to peripheral compartment
k31 day
−1 Rate constant of flow of IgG from plasma into endosomes by pinocytosis
k12 day
−1 Rate constant of flow of IgG from peripheral compartment to plasma
Vmax µmol day
−1 Maximum absolute recycling rate
KM µmol Michaelis constant; the quantity of IgG in plasma at which the absolute
recycling rate is half Vmax
µmol day−1. The rate constants kij represent material flow from compartment j to com-
partment i. The rate constant for the removal of IgG from the plasma compartment into
intracellular endosomes for degradation is given by k31, with the indices denoting the
transfer from plasma to a third compartment representing intracellular endosomes. The
endosome compartment is omitted from the model, as it is assumed that the rates of elimi-
nation and recycling of IgG can be expressed in terms of x1(t). The rate of FcRn-mediated
recycling, as a fraction of the quantity of IgG in plasma, is given by Vmax/(KM + x1(t)).
The parameters Vmax and KM are the maximum absolute rate of FcRn-mediated recycling
in µmol day−1 and the Michaelis constant, representing the quantity of IgG in plasma in
µmol at which the absolute recycling rate is half Vmax. Those IgG molecules which are
removed from the plasma compartment into intracellular endosomes and which are not
recycled by FcRn are degraded in lysosomes. A schematic of the system model is shown
in figure 5-1. Table 5-1 summarises the model states and parameters.
All states and parameters can only take non-negative values. The rate at which IgG is
recycled cannot exceed the rate at which it leaves the plasma compartment; equivalently,
the net elimination rate must be positive for all states and input rates, such that k31 −
Vmax
KM
> 0.
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5.2.1 Stability anaysis
When the production rate of IgG is constant, I(t) = I0, solving x˙1(t) = 0 and x˙2(t) = 0
simultaneously yields a single equilibrium point:
xˆ1 =
−k31KM + I0 + Vmax +
√
4k31KMI0 + (−k31KM + I0 + Vmax)2
2k31
xˆ2 =
k21
k12
xˆ1.
(5-2)
Note the positive sign before the square root to ensure that xˆ1 and thus xˆ2 are positive
for all positive values of I0.
Linearising the system about the equilibrium point givesx˙1(t)
x˙2(t)
 =
−k21 − k31 − Vmaxxˆ1(KM+xˆ1)2 k12
k21 −k12

x1(t)
x2(t)
 . (5-3)
According to the Routh-Hurwitz stability criterion [8], the two-state system is stable
provided the coefficients of the characteristic polynomial of the linearised system are
positive. The coefficients of the characteristic polynomial are given by
a2 = 1
a1 =
k31K
2
M −KMVmax + 2k31KMxˆ1 + k31xˆ21 + k12(KM + xˆ1)2 + k21(KM + xˆ1)2
(KM + xˆ1)2
a0 =
k12
(
k31 (KM + xˆ1)
2 −KMVmax
)
(KM + xˆ1)
2 .
(5-4)
The denominator in the expressions for a0 and a1 is always positive. All parame-
ters and the steady state xˆ1 are positive. The sign of a0 is thus given by the sign of(
k31 (KM + xˆ1)
2 −KMVmax
)
. For stability of the equilibrium point it is necessary that(
k31 (KM + xˆ1)
2 −KMVmax
)
> 0. This condition is met when k31K
2
M −KMVmax > 0, or
equivalently k31 − VmaxKM > 0.
The sign of a1 is given by the sign of its numerator, k31K
2
M − KMVmax + 2k31KMxˆ1 +
k31xˆ
2
1 + k12(KM + xˆ1)
2 + k21(KM + xˆ1)
2. Once again, the sign of a1 is positive provided
that k31 − VmaxKM > 0.
Both of the coefficients a0 and a1 are positive provided that all parameter values are
positive and k31 − VmaxKM > 0, which is the condition ensuring a positive IgG elimination
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Figure 5-2 (A) Proportion of administered IgG remaining in plasma (blue
circles) and the body (red triangles) in a typical normal subject; data
from Solomon et al. [9]. Plasma concentration dependence of (B) fractional
catabolic rate (FCR) and (C) half-life (T1/2) of IgG; data from Waldmann
et al. [1].
rate for all x1 > 0. A negative elimination rate does not make sense physiologically and
as such parameter values are not permitted which violate this condition. The equilibrium
point is thus stable for all permitted parameter values.
5.3 Experimental data from the literature
Data for parameter estimation were obtained from tracer experiments reported in the lit-
erature. These studies entail intravenous administration of a bolus dose of radiolabelled
IgG (the tracer) and monitoring the proportion of the dose remaining in the blood and in
the body over time. In this way the administered dose is distinguishable (by the experi-
menter) from the subject’s own endogenous IgG. The quantity of administered tracer is
small, so as not to perturb the steady state of the endogenous IgG. The purpose of tracer
experiments is to enable observation of the processes such as distribution and elimination
undergone by the endogenous protein, whilst it is in steady state. The radioactive label
(usually iodine) remains bound to the protein until the protein is degraded, at which
point the label is released and rapidly excreted in urine. Several tracer studies were per-
formed for IgG in humans in the middle of the last century and the results collated by
Waldmann et al. [1], who also describe the methods in detail.
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5.3.1 Timecourse data
The data from an individual subject consist of the timecourse of the proportion of an
administered dose of radiolabelled IgG remaining in plasma and the proportion remaining
in the whole body. An example is shown in figure 5-2A. The data have been extracted
from a plot by Solomon et al. [9] using OriginPro [10]. Seven plots of this type have
been found by the author in the literature. The data in these plots are assumed to arise
from seven individuals to whom we refer as subjects A–G. The data for subjects A–D
are taken from Solomon et al. [9], for subjects E and F from Waldmann et al. [11] and
for subject G from Waldmann et al. [1]. Subjects A and C have IgG myeloma, subject
D has macroglobulinemia and subject E has familial hypercatabolic hypoproteinemia.
Subjects B, F and G are referred to as ‘normal’ subjects. No information is provided by
the authors regarding the errors on these data; in section 5.5 expressions for measurement
errors are derived based on assumptions about the experiment.
5.3.2 Fractional catabolic rate and half-life
In compartmental analysis, parameters are often considered as either micro constants
or macro constants. The micro constants are dependent upon the assumed structure
of the compartmental model, whereas the macro constants can be determined directly
from the profile of concentration or radioactivity over time, such as the exponents of a
multi-exponential profile, and do not assume a particular model structure [12]. Plots of
the fractional catabolic rate (FCR) and half-life (T1/2), respectively, vs. subjects’ plasma
concentrations of endogenous IgG, obtained from a group of individuals with a range
of plasma IgG concentrations, are available in the literature [1]. Macro parameters are
functions of the micro parameters of the assumed compartmental structure – therefore in
this chapter the FCR and T1/2 data are used in the estimation of the parameters of the
underlying compartmental model.
The FCR is defined as the fraction of IgG in plasma that is degraded per day. In practice
the FCR is calculated from the rate at which the tracer dose leaves the body at time t
divided by the quantity of tracer in plasma at time t. The rate at which the dose leaves
the body is given by the slope of the timecourse of the dose remaining in the whole body.
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A plot of the FCR vs. the plasma concentration of endogenous IgG for 41 individuals
provided by Waldmann et al. [1] is shown in figure 5-2B.
The half-life (T1/2) is defined as the time taken for the quantity of tracer to halve, after
the distribution phase is complete. The parameter T1/2 is obtained from a plot of the
timecourse of radioactivity remaining in plasma and in the body on a log scale. The
slope of the curves is obtained for the latter part of the experiment, when distribution
between the compartments is assumed to be complete, and the dynamics dominated by
elimination and recycling. A plot of T1/2 vs. the plasma concentration of endogenous IgG
for 44 individuals provided by Waldmann et al. [1] is shown in figure 5-2C. All of the data
described in this section were extracted from plots in the literature using the Digitizer
tool in OriginPro [10]. Mathematical expressions for both the FCR and T1/2 are provided
in section 5.4.
5.4 Mathematical description of observations
In this section we consider how the experimental observations (timecourse of radioactiv-
ity, FCR and T1/2) are defined in terms of the underlying system model. Tracer experi-
ments are designed specifically so that the tracer-labelled protein observes linear kinetics,
whether or not the underlying model is linear or nonlinear [13]. A linear model describing
the timecourse observations is derived from the nonlinear model of coupled tracer and
endogenous IgG dynamics. The linear model has been used by other authors for pa-
rameter estimation [1–3], however its use has not been previously validated by a formal
consideration of its relationship with the full nonlinear model. The derivation of a new
expression for the half-life makes data available that have previously not been used for
parameter estimation.
5.4.1 Nonlinear structural model of coupled tracer and endoge-
nous IgG dynamics
Assuming that the radiolabelled IgG dose and unlabelled endogenous IgG are indistin-
guishable by the system, both are described by the model given in equations (5-1). The in-
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jected and endogenous IgG can be explicitly represented by letting xi(t) = xi,T(t)+xi,E(t)
for i = 1, 2, with ‘T’ denoting tracer and ‘E’ denoting endogenous IgG. Then, from equa-
tions (5-1), the dynamics of labelled and unlabelled IgG are given by
x˙1,T(t) = −
(
k21 + k31 − Vmax
KM + x1,E(t) + x1,T(t)
)
x1,T(t) + k12x2,T(t)
x˙2,T(t) = k21x1,T(t)− k12x2,T(t)
x˙1,E(t) = −
(
k21 + k31 − Vmax
KM + x1,E(t) + x1,T(t)
)
x1,E(t) + k12x2,E(t) + IE
x˙2,E(t) = k21x1,E(t)− k12x2,E(t),
(5-5)
where xi,T(t) and xi,E(t) represent the quantities in µmol of radiolabelled and endogenous
IgG in compartment i, respectively, and IE (µmol day
−1) represents the production rate
of endogenous IgG, which is assumed constant.
The intravenous bolus injection of tracer can be treated as a non-zero initial condition
for x1,T(t); thus the initial conditions for the tracer are given by
x1,T(0) = D
x2,T(0) = 0,
(5-6)
where D is the dose of tracer in µmol. The endogenous IgG is assumed to be in steady
state at the beginning of the experiment and remain in steady state throughout, as
verifiable by the experimenter. Waldmann et al. [11] state that ‘serum immunoglobulin
. . . concentrations were obtained at intervals throughout the study period to verify that
each patient was in a steady state.’ Solomon et al. [9] do not make such a statement;
however, they assume steady state when calculating the absolute synthetic rate of IgG
from the fractional catabolic rate and the quantity of unlabelled IgG in plasma. Given
that most methods for analysing tracer experiment data rest on the assumption that the
endogenous protein is in steady state throughout the experiment [1], it is assumed that
this was the case for each subject whose data are analysed in this chapter. The initial
conditions for the endogenous IgG are therefore given by the equilibrium point in section
5.2, with I0 = IE.
The experimenter observes the proportion of the initially injected radioactivity in plasma
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and in the whole body. The observation functions are thus given by
y1(t) = x1,T(t)/D
y2(t) =
(
x1,T(t) + x2,T(t)
)
/D.
(5-7)
5.4.2 Linearised structural model of tracer dynamics
A sufficiently small quantity of radiolabelled IgG, typically 0.5–1 mg (3.33× 10−3–
6.67× 10−3 µmol) [9], is administered into plasma such that the tracer-labelled protein
obeys approximately linear kinetics. The dose is small enough so as not to perturb the
steady state of the endogenous protein; thus x1,E and x2,E can be assumed constant. Then
the equations describing the tracer dynamics are no longer coupled with those describing
the endogenous IgG dynamics, giving
x˙1,T(t) = −
(
k21 + k31 − Vmax
KM + x1,E + x1,T(t)
)
x1,T(t) + k12x2,T(t)
x˙2,T(t) = k21x1,T(t)− k12x2,T(t).
(5-8)
A second assumption is required in order to derive a linear model: the quantity of tracer,
x1,T(t), is assumed to be much smaller than the quantity of the subject’s endogenous
IgG, x1,E. Thus the term
Vmax
KM+x1,E+x1,T(t)
can be approximated by Vmax
KM+x1,E
. In this way,
the elimination rate of the tracer is determined by the subject’s endogenous IgG only.
The equations describing the tracer kinetics are now given by
x˙1,T(t) = −
(
k21 + k31 − Vmax
KM + x1,E
)
x1,T(t) + k12x2,T(t)
x˙2,T(t) = k21x1,T(t)− k12x2,T(t),
(5-9)
where x1,T(t) and x2,T(t) represent the quantities in µmol of radiolabelled IgG in the
central and peripheral compartments, respectively. x1,E represents the quantity of the
subject’s endogenous IgG in the central compartment, which is assumed to remain in
steady state. All other parameters are defined as in section 5.2. The initial conditions
and observation functions are given by equations (5-6) and (5-7), respectively.
We note that the parameters k31, Vmax and KM only appear in the expression(
k31 − VmaxKM+x1,E
)
; therefore we can set this expression equal to a new constant and sim-
plify the equations, effectively reparameterising the model. We also note that for the
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Figure 5-3 Simulations of timecourse responses y1(t) and y2(t) as de-
scribed by equations (5-5)–(5-7) (nonlinear model – solid line) and equations
(5-10)–(5-12) (linearised model – dashed line). The quantity of endogenous
IgG in plasma at t = 0, x1,E(0), is 5 µmol. The tracer dose D is (A) 0.01
µmol and (B) 10 µmol.
linear model, the initial conditions and observation gain cancel out; the tracer kinetics
can therefore be described by
x˙1,P(t) = − (k21 + FCR)x1,P(t) + k12x2,P(t)
x˙2,P(t) = k21x1,P(t)− k12x2,P(t),
(5-10)
where x1,P(t) and x2,P(t) represent the proportion of the radiolabelled IgG dose D in the
central and peripheral compartments, respectively, at time t. The parameter FCR is the
fractional catabolic rate (see section 5.4.3), equal to the expression noted in the preceding
paragraph. All other parameters are defined as in section 5.2.
The initial conditions for the model are now given by
x1,P(0) = 1
x2,P(0) = 0.
(5-11)
The corresponding observation functions are given by
y1(t) = x1,P(t)
y2(t) = x1,P(t) + x2,P(t).
(5-12)
The approximation of the nonlinear model (equations (5-5)–(5-7)) by the linearised model
(equations (5-10)–(5-12)) relies on two assumptions:
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 that the endogenous IgG can be considered in steady state,
 that the quantity x1,T(t) can be neglected in the denominator of the Michaelis-
Menten term.
Both assumptions require that the administered dose of tracer, D, is sufficiently smaller
than the quantity of endogenous IgG in plasma, x1,E(t). In figure 5-3 simulations of the
nonlinear model and the linearised model are compared. The parameter values used in the
simulations are estimated in this chapter and summarised in table 5-11. The production
rate of endogenous IgG is set to IE = 0.0727 µmol day
−1 to give x1,E(0) = 5 µmol for the
nonlinear model and x1,E = 5 µmol for the linearised model, representing the lower limit
of the quantities of endogenous IgG in plasma seen in the data. In figure 5-3A the tracer
dose D = 0.01 µmol, representing the upper limit of administered tracer doses [9]. The
nonlinear and linearised model responses are visually indistinguishable, illustrating that
for typical tracer doses the linearised model is a valid approximation of the nonlinear
model. In figure 5-3B the tracer dose D = 10 µmol, 1000 times larger; at this point the
assumptions weaken and there is a small but noticeable difference between the responses
of the two models.
5.4.3 Fractional catabolic rate and half-life
The fractional catabolic rate (FCR) is defined as the proportion of the radiolabelled IgG
in plasma that is catabolised per day. From equation (5-9) this is equal to
FCR = k31 − Vmax
KM + x1,E
, (5-13)
defined for non-negative values of x1,E. The maximal value of the FCR, as x1,E tends
to infinity, is equal to k31 day
−1; that is, the IgG cannot be catabolised faster than it
is internalised into endosomes. The minimal value of the FCR, when x1,E = 0, is given
by
(
k31 − Vmax/KM
)
day−1, where Vmax/KM day−1 is the value to which the fractional
recycling rate tends for small values of x1,E.
The terminal half-life, T1/2, is related with the elimination phase of the kinetics, after
the distribution phase is complete. The model described by equations (5-10)–(5-12) is
a linear two-compartment model with the solutions of x1,P(t) and x2,P(t) given by the
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bi-exponential functions
x1,P(t) = A11 exp(λ1t) + A12 exp(λ2t)
x2,P(t) = A21 exp(λ1t) + A22 exp(λ2t),
(5-14)
where Aij and λj are macro constants, with |λ1| > |λ2|. By definition, the terminal
half-life is given by
T1/2 = − log 2
λ2
. (5-15)
Solving equations (5-10)–(5-12) for λ2 and substituting into equation (5-15) gives the
following expression for T1/2:
T1/2 =
2 log 2
k12 + k21 + FCR−
√
−4k12FCR + (k12 + k21 + FCR)2
. (5-16)
Substituting in the expression for FCR from (5-13) gives
T1/2 =2 log 2
/(
k12 + k21 + k31 − Vmax
KM + x1,E
−
√√√√−4k12(k31 − Vmax
KM + x1,E
)
+
(
k12 + k21 + k31 − Vmax
KM + x1,E
)2)
.
(5-17)
The maximal value of T1/2, when x1,E = 0 and FCR = k31 − Vmax/KM, is given by
2 log 2
k12 + k21 + k31 − VmaxKM −
√
−4k12
(
k31 − VmaxKM
)
+
(
k12 + k21 + k31 − VmaxKM
)2 . (5-18)
The minimal value to which T1/2 tends, when x1,E tends to infinity and FCR tends to k31,
is given by
2 log 2
k12 + k21 + k31 −
√
−4k12k31 + (k12 + k21 + k31)2
. (5-19)
5.5 Errors and the data generating process
In this section we consider how the timecourse data described in section 5.3 were calcu-
lated from measurements of radioactivity. We then consider where errors are likely to
arise in data collection and calculation. It is assumed that y1(t) is observed with error
at measurement times t
(1)
1 , . . . , t
(1)
N1
and y2(t) is observed with error at measurement times
t
(2)
1 , . . . , t
(2)
N2
, with t
(1)
1 = t
(2)
1 = 0. The superscripts (1) and (2) are used to allow for
different sampling times between the two outputs.
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5.5.1 Calculation of y1(t) from radioactivity measurements
The first timecourse observation, y1(t), represents the quantity of labelled IgG in plasma
as a proportion of the administered IgG dose. In practice, the experimenters measure
the radioactivity APS(t) (microcurie; µCi) in a plasma sample of known volume VPS(t)
(l), giving the resulting plasma radioactivity concentration Cplasma(t) (µCi l
−1):
Cplasma(t) =
APS(t)
VPS(t)
. (5-20)
Values of Cplasma(t) for blood samples taken within the first 30 minutes [9; 11] are extrap-
olated to time t = 0 to find the plasma radioactivity concentration at t = 0, Cplasma(0).
It is assumed that the plasma volume Vplasma is constant and is thus given by
Vplasma =
Adose
Cplasma(0)
, (5-21)
where Adose is the radioactivity in µCi in the injected dose. Then the proportion of the
dose of radioactivity in plasma at time t is given by
Aplasma(t)
Adose
=
Cplasma(t)
Adose
Adose
Cplasma(0)
=
Cplasma(t)
Cplasma(0)
, (5-22)
where Aplasma(t) (µCi) is the total radioactivity in plasma at time t. The quantity of
radioactivity is assumed to be directly proportional to the quantity of labelled IgG, with
proportionality constant α (µCi µmol−1),
Aplasma(t) = αx1,T(t), (5-23)
such that
y1(t) =
αx1,T(t)
αD
=
Aplasma(t)
Adose
, (5-24)
where x1,T(t) (µmol) is the quantity of tracer in plasma at time t and D (µmol) is the
tracer dose. The relationship between the model output y1(t) and the measurements
taken at discrete sampling times is thus given by
y1(t
(1)
j ) =

1 j = 1
Cplasma(t
(1)
j )
Cplasma(0)
j = 2, . . . , N1.
(5-25)
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5.5.2 Measurement errors relating to y1(t)
The model output y1(t) is calculated from measurements of plasma radioactivity concen-
tration, Cplasma(t) (µCi l
−1). Measurements of plasma radioactivity concentration have
been assumed by other authors to have normally distributed, additive errors [14]. The
errors have also been assumed or found (by taking replicate measurements) to be pro-
portional to the size of the measurement, i.e. the coefficient of variation (CV) is constant
[14; 15, p. 233–235]. From equations (5-23),
Cplasma(t) =
Aplasma(t)
Vplasma
=
αx1,T(t)
Vplasma
. (5-26)
We now use tilde (˜·) notation to denote quantities observed with error, as opposed to
‘true’ quantities. The plasma radioactivity concentration, measured with noise, is given
by
C˜plasma(t
(1)
j ) =
αx1,T(t
(1)
j )
Vplasma
+ 
(P)
j , (5-27)
where 
(P)
j are independent, normally distributed residual errors, with superscript (P)
referring to ‘plasma’. The errors 
(P)
j are assumed to have zero mean and standard
deviation proportional to the size of the true value of Cplasma(t
(1)
j ).
The measured (with noise) values of the model output y1(t) are now given by
y˜1(t
(1)
j ) =

1 j = 1
C˜plasma(t
(1)
j )
C˜plasma(0)
j = 2, . . . , N1.
(5-28)
For j = 2, . . . , N1, y˜1(t
(1)
j ) is given by a random variable with a constant CV (C˜plasma(t
(1)
j ))
divided by a random variable with a constant CV (C˜plasma(0)). From the standard formu-
lae for calculating propagation of errors [16], this means that the squared CV of y˜1(t
(1)
j )
is approximately equal to sum of the squared CV of C˜plasma(t
(1)
j ) and the squared CV of
C˜plasma(0). The CV of y˜1(t
(1)
j ) is therefore constant. The division by a random variable,
C˜plasma(0), means that the measured values of y˜1(t
(1)
j ) have a ratio distribution; however
Q-Q (quantile-quantile) plots of simulated data show that the distribution is close to the
normal distribution.
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From equations (5-27) and (5-28), we have
y˜1(t
(1)
j ) =
αx1,T(t
(1)
j )
Vplasma
+ 
(P)
j
αx1,T(0)
Vplasma
+ 
(P)
1
j = 2, . . . , N1. (5-29)
Unfortunately, due to the error 
(P)
1 in the denominator of (5-29), a systematic error is
introduced into every measured value of y˜1(t
(1)
j ), j = 2, . . . , N1; therefore the mean of the
measured y˜1(t
(1)
j ) is not equal to the true value y1(t
(1)
j ), for j = 2, . . . , N1.
5.5.3 Calculation of y2(t) from radioactivity measurements
The second timecourse observation, y2(t), represents the quantity of labelled IgG in the
body as a proportion of the administered IgG dose. The proportion of the dose of
radioactivity remaining in the body can be obtained either by using a whole body counter
or by subtracting the cumulative radioactivity in urine from the radioactivity in the
administered dose [1]; Waldmann et al. [1], Waldmann et al. [11] and Solomon et al. [9]
all state that urine collections were used. The experimenters measure the radioactivity,
AUC(t) (µCi), in urine collections and the total radioactivity in the injected dose, Adose
(µCi). The cumulative excreted radioactivity is calculated as the sum of the radioactivity
in all urine collections up to the current time:
Aurine(t
(2)
j ) =

0 j = 1∑k=j
k=2AUC(t
(2)
k ) j = 2, . . . , N2.
(5-30)
The radioactivity in the body, Abody(t
(2)
j ), is calculated as the dose minus the cumulative
excreted radioactivity:
Abody(t
(2)
j ) = Adose − Aurine(t(2)j ), j = 1, . . . , N2. (5-31)
The radioactivity in the body is divided by the radioactivity in the dose to give the
proportion of the radioactivity dose in the body:
Abody(t
(2)
j )
Adose
=
Adose − Aurine(t(2)j )
Adose
, j = 1, . . . , N2. (5-32)
Again the radioactivity is assumed to be directly proportional to the quantity of labelled
IgG, with proportionality constant α (µCi µmol−1), such that
y2(t
(2)
j ) =
α
(
x1,T(t
(2)
j ) + x2,T(t
(2)
j )
)
αD
=
Abody(t
(2)
j )
Adose
. (5-33)
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The relationship between the model output y2(t) and the measurements taken at discrete
sampling times is thus given by
y2(t
(2)
j ) =

1 j = 1
Adose−
∑k=j
k=2 AUC(t
(2)
k )
Adose
j = 2, . . . , N2.
(5-34)
5.5.4 Measurement errors relating to y2(t)
The model output y2(t) is calculated from measurements of radioactivity in urine collec-
tions, AUC(t) (µCi), and the radioactivity in the administered tracer dose, Adose (µCi).
Chen et al. [14] state that measurement noise primarily due to radioactive counting can
be assumed to be normally distributed. It is assumed that, similar to measurements
of plasma radioactivity concentration, the CVs of the measurements of A˜UC(t
(2)
k ), j =
2, . . . , N2, and A˜dose are constant. The activity in the dose is given by
Adose = αD. (5-35)
It is assumed that the measured radioactivity in the tracer dose is given by
A˜dose = αD + 
(D)
j , (5-36)
where 
(D)
j is the normally distributed residual error, having zero mean and standard
deviation proportional to the size of the true value of Adose. Superscript (D) refers to
‘dose’. We denote the standard deviation of 
(D)
j by σD and the CV by CVD.
From (5-31), the cumulative excreted activity is given by
Aurine(t
(2)
j ) = Adose − Abody(t(2)j ) = α
(
D − x1,T(t(2)j )− x2,T(t(2)j )
)
,
j = 1, . . . , N2.
(5-37)
The activity in each urine collection is given by
AUC(t
(2)
j ) = Aurine(t
(2)
j )− Aurine(t(2)j−1), j = 2, . . . , N2. (5-38)
Substituting from equation (5-37) into equation (5-38) gives
AUC(t
(2)
j ) = α
(
−x1,T(t(2)j )− x2,T(t(2)j ) + x1,T(t(2)j−1) + x2,T(t(2)j−1)
)
. (5-39)
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Again using tilde (˜·) notation to denote quantities observed with error, as opposed to
‘true’ quantities, the measured radioactivity in a urine collection is given by
A˜UC(t
(2)
j ) = α
(
−x1,T(t(2)j )− x2,T(t(2)j ) + x1,T(t(2)j−1) + x2,T(t(2)j−1)
)
+ 
(UC)
j ,
j = 2, . . . , N2,
(5-40)
where 
(UC)
j are independent, normally distributed residual errors, with superscript (UC)
referring to ‘urine collection’. The errors 
(UC)
j are assumed to have zero mean and
standard deviation proportional to the size of the true value of AUC(t
(2)
j ). We denote the
standard deviation of 
(UC)
j by σUC(t
(2)
j ) and the CV by CVUC. The measured cumulative
excreted activity is now given by
A˜urine(t
(2)
j ) =

0 j = 1∑k=j
k=2AUC(t
(2)
k ) + 
(UC)
k j = 2, . . . , N2.
(5-41)
For j = 2, . . . , N2, measurements of A˜urine(t
(2)
j ) are now given by sums of random variables,
each having a constant CV, denoted by CVUC. From standard propagation of error
formulae, the variance of the sum of random variables is equal to the sum of variances of
the summed variables [16]. The greater the value of j, that is the later the point in time,
the more random variables are summed to obtain A˜urine(t
(2)
j ); therefore the variance of
A˜urine(t
(2)
j ) increases with increasing j, and thus with increasing Aurine(t
(2)
j ). The CV of
A˜urine(t
(2)
j ), CVurine(t
(2)
j ), however is not constant. By definition,
CVurine(t
(2)
j ) =
σurine(t
(2)
j )
µurine(t
(2)
j )
, (5-42)
where σurine(t
(2)
j ) is the standard deviation of A˜urine(t
(2)
j ) and µurine(t
(2)
j ) is the mean value
of A˜urine(t
(2)
j ). From the propagation of error formula,
σ2urine(t
(2)
j ) ≈
j∑
k=2
σ2UC(t
(2)
k ), j = 2, . . . , N2. (5-43)
Again, by definition,
σUC(t
(2)
k ) = CVUCAUC(t
(2)
k ), (5-44)
where AUC(t
(2)
k ) is the mean of A˜UC(t
(2)
k ). A˜urine(t
(2)
j ) is the sum of normally distributed
variables; therefore A˜urine(t
(2)
j ) is normally distributed and its mean is equal to the sum
of the means of A˜UC(t
(2)
k ). The mean of A˜urine(t
(2)
j ) is therefore equal to its true value
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Aurine(t
(2)
j ), given by equation (5-30). Substituting from equations (5-30), (5-43) and
(5-44) into equation (5-42) gives
CVurine(t
(2)
j ) ≈ CVUC
√∑j
k=2A
2
UC(t
(2)
k )∑j
k=2AUC(t
(2)
k )
, j = 2, . . . , N2. (5-45)
Equation (5-45) shows that for increasing j, the magnitude of CVurine(t
(2)
j ) decreases.
From (5-34), the measured (with noise) values of the model output y2(t) are given by
y˜2(t
(2)
j ) =

1 j = 1
1− A˜urine(t
(2)
j )
A˜dose
j = 2, . . . , N2.
(5-46)
The division by a random variable, A˜dose, means that the measured values of y˜2(t
(2)
j ) have
a ratio distribution; however Q-Q (quantile-quantile) plots of simulated data show that
the distribution is close to the normal distribution. The variance of y˜2(t
(2)
j ) is equal to
the variance of
A˜urine(t
(2)
j )
A˜dose
, for j = 2, . . . , N2. From the propagation of error formula,
σ2y2(t
(2)
j ) ≈
µ2urine(t
(2)
j )
A2dose
σ2urine(t(2)j )
µ2urine(t
(2)
j )
+
σ2dose
A2dose
 , (5-47)
which is equivalent to
σ2y2(t
(2)
j ) ≈
σ2urine(t
(2)
j )
A2dose
+
µ2urine(t
(2)
j )σ
2
dose
A4dose
. (5-48)
Both σ2urine(t
(2)
j ) and µ
2
urine(t
(2)
j ) increase with increasing t
(2)
j ; thus σ
2
y2
(t
(2)
j ) increases with
increasing t
(2)
j . The mean of y˜2(t
(2)
j ) decreases with time and therefore its CV must also
increase with time.
From (5-47), the CV of y˜2(t
(2)
j ) is given by
CVy2(t
(2)
j ) =
σy2(t
(2)
j )
µy2(t
(2)
j )
≈
µurine(t
(2)
j )
Adose
√
CV2urine(t
(2)
j ) + CV
2
D
1− µurine(t
(2)
j )
Adose
(5-49)
or
CVy2(t
(2)
j ) ≈
(
1− µy2(t(2)j )
)√
CV2urine(t
(2)
j ) + CV
2
D
µy2(t
(2)
j )
. (5-50)
Consideration of the distribution and size of the errors in the data is important for
selecting the most appropriate parameter estimation methods. This will be discussed in
section 5.6.3.
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5.6 Population approach to parameter identification
using timecourse data
In this section model parameters are estimated using the timecourse data taken from
the literature and described in section 5.3. It is assumed that the unique parameter
vector of the ith subject in the sample, ψi =
(
FCRi, k12,i, k21,i
)
, is drawn from a proba-
bility distribution. The parameters of this distribution are estimated by fitting the data
from the seven available subjects simultaneously. The outputs y1(t) and y2(t) of the
structural model described by equations (5-10)–(5-12) are fitted to the timecourse data.
The population approach is implemented in the software package Monolix [17]. Mono-
lix is a specialist software for estimating parameters of nonlinear mixed effects models.
In Monolix an implementation of the stochastic approximation expectation maximiza-
tion (SAEM) algorithm is used to maximise the likelihood function and thus generate
maximum likelihoood (ML) parameter estimates.
5.6.1 The distribution of parameters in the population
The parameters for the individual subjects, or ‘individual parameters’, FCRi, k12,i and
k21,i, are assumed to be log-normally distributed in the population to ensure positivity:
log(FCRi) ∼ N(log
(
FCRpop
)
, σ2FCR)
log
(
k12,i
) ∼ N(log(k12,pop), σ2k12)
log
(
k21,i
) ∼ N(log(k21,pop), σ2k21),
(5-51)
where log
(
FCRpop
)
, log
(
k12,pop
)
, and log
(
k21,pop
)
are the means of the natural logarithms
of the individual parameters and σFCR, σk12 and σk21 are the standard deviations of the
natural logarithms of the individual parameters. FCRpop, k12,pop, and k21,pop are thus
the medians of the log-normally distributed individual parameters. It is also assumed
that the individual parameters are correlated with one another, with coefficients ρFCRk12 ,
ρFCRk21 and ρk12k21 for the correlations between FCRi and k12,i, FCRi and k21,i, and k12,i
and k21,i, respectively. This general approach also allows for individual parameters to be
uncorrelated when the relevant correlation coefficients are equal to zero.
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The individual parameters can also be expressed as
FCRi = FCRpop exp(ηFCR)
k12,i = k12,pop exp(ηk12)
k21,i = k21,pop exp(ηk21),
(5-52)
where now the individual parameters are decomposed into their fixed or population effects
(FCRpop, k12,pop and k21,pop) and random or individual effects (ηFCR, ηk12 and ηk21). The
random effects η = (ηFCR, ηk12 , ηk21) are normally distributed:
η ∼ N(0,Ω), (5-53)
where Ω is the variance-covariance matrix,
Ω =

σ2FCR ρFCRk12σFCRσk12 ρFCRk21σFCRσk21
ρFCRk12σk12σFCR σ
2
k12
ρk12k21σk12σk21
ρFCRk21σk21σFCR ρk12k21σk21σk12 σ
2
k21
 . (5-54)
We refer to the parameter θ =
(
ψpop,Ω
)
, where ψpop =
(
FCRpop, k12,pop, k21,pop
)
, as the
population parameter, describing the distribution of the individuals’ parameter values
in the population. The parameter ψpop represents the value of ψi in the absence of
randomness. It is also considered to be the ‘predicted’ or typical value of the parameter
ψi within the population.
5.6.2 Structural identifiability analysis
Before attempting to estimate the population parameter vector θ, it is necessary to estab-
lish whether the parameter vector is structurally identifiable given the available model
outputs. The parameter ψpop, representing the fixed effect of the individual parame-
ters, can be analysed using standard structural identifiability methods for deterministic
systems. Standard methods do not however address whether the parameter Ω is also
structurally identifiable. Methods for analysing structural identifiability of mixed effects
models have only recently been developed [18; 19]. Here the Laplace transform mixed
effects extension approach of Janze´n et al. [19] is applied.
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Deterministic problem
In this section we confirm that the parameter ψ = (FCR, k12, k21) is structurally uniquely
identifiable from the timecourse outputs, y1(t) and y2(t), using the transfer function
method [20]. Note that in this analysis the parameter ψ is considered to be a constant
and not a random variable. The system described by equations (5-10)–(5-12) is re-written
in vector-matrix notation as
x˙(t,ψ) = A(ψ)x(t,ψ) +Bu(t)
x(0,ψ) = 0
y(t,ψ) = Cx(t,ψ),
(5-55)
where x(t,ψ) =
(
x1,P(t), x2,P(t)
)
and y(t,ψ) =
(
y1(t), y2(t)
)
are column vectors repre-
senting the state and the observation, respectively. u(t) represents the single input to
the system, a unit impulse applied at time t = 0, given by u(t) = δ(t). A(ψ) and C are
2× 2 matrices and B is a column vector. A(ψ), B and C are given by
A(ψ) =
− (k21 + FCR) k12
k21 −k12
 ,B =
1
0
 ,C =
1 0
1 1
 . (5-56)
Note that the administration of a bolus dose is now represented as an impulse at time
t = 0, rather than a non-zero initial condition, such that x(0,ψ) = 0.
Taking Laplace transforms of equations (5-55), the input-output relation is described by
Y (s) = G(s)U(s), where G(s) is the transfer function matrix, given by G(s) = C(sI −
A(ψ))−1B, where I is the 2× 2 identity matrix. G(s) has two elements, corresponding
to the two measured outputs, which are given by
G1(s) =
s+ k12
s2 + (FCR + k12 + k21) s+ FCRk12
G2(s) =
s+ k12 + k21
s2 + (FCR + k12 + k21) s+ FCRk12
.
(5-57)
Let Φ(ψ) = (φ1(ψ), ..., φ4(ψ)) denote the (distinct) coefficients of s in equations (5-57).
The coefficients Φ(ψ) are unique with respect to the input-output relationship of the
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system and are given by
φ1(ψ) = k12
φ2(ψ) = k12 + k21
φ3(ψ) = FCRk12
φ4(ψ) = FCR + k12 + k21.
(5-58)
Introducing an alternative parameter vector ψ = (FCR, k12, k21) and equating Φ(ψ) =
Φ(ψ) gives the following set of simultaneous equations:
k12 = k12
k12 + k21 = k12 + k21
FCRk12 = FCRk12
FCR + k12 + k21 = FCR + k12 + k21.
(5-59)
Now equations (5-59) are solved for ψ. Immediately it can be seen from the first of
equations (5-59) that the only solution for k12 is k12 = k12. Then from any pair of
the remaining equations it can be seen that FCR = FCR and k21 = k21. It has thus
been shown that Φ(ψ) = Φ(ψ) requires ψ = ψ and therefore the parameter vector ψ is
structurally globally identifiable. This analysis also proves that the population parameter
ψpop =
(
FCRpop, k12,pop, k21,pop
)
is structurally globally identifiable [19].
Mixed effects problem
To extend the analysis to the mixed effects model, both the fixed and random effects of
the parameters are now considered. The moment invariants of the system, Z(ψpop,η),
where ψpop = (FCRpop, k12,pop, k21,pop) and η = (ηFCR, ηk12 , ηk21), are now given by
Z1(ψpop,η) = k12,pop exp(ηk12)
Z2(ψpop,η) = k12,pop exp(ηk12) + k21,pop exp(ηk21)
Z3(ψpop,η) = FCRpop exp(ηFCR)k12,pop exp(ηk12)
Z4(ψpop,η) = FCRpop exp(ηFCR) + k12,pop exp(ηk12) + k21,pop exp(ηk21).
(5-60)
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The first order statistical moments are given by
E(Z1) = k12,pop exp
(
σ2k12
2
)
E(Z2) = k12,pop exp
(
σ2k12
2
)
+ k21,pop exp
(
σ2k21
2
)
E(Z3) = FCRpopk12,pop exp
(
1
2
(
σ2FCR + σ
2
k12
+ 2σFCRσk12ρFCRk12
))
E(Z4) = FCRpop exp
(
σ2FCR
2
)
+ k12,pop exp
(
σ2k12
2
)
+ k21,pop exp
(
σ2k21
2
)
.
(5-61)
Whereas in the deterministic problem the availability of noise-free continuous data is
assumed, in the mixed-effects case we also assume the availability of an infinite number
of subjects, such that full knowledge of the random variables Z(ψpop,η) is obtained.
Introducing an alternative parameter vector ψpop and an alternative variance-covariance
matrix Ω of the random effects η, the mixed effects structural identifiability analysis
amounts to solving the system of equations given by
E(Z l1(ψpop,η)) = E(Z l1(ψpop,η))
...
E(Z l4(ψpop,η)) = E(Z l4(ψpop,η))
η ∼ N(0,Ω)
η ∼ N(0,Ω),
(5-62)
where E(Z l) denotes the lth statistical moment of the distribution Z, for the parameters
in the vector ψpop and the matrix Ω.
Equating the first order statistical moments evaluated for ψpop and Ω with the first order
moments evaluated for ψpop and Ω gives
k12,pop exp
(
σ2k12
2
)
= k12,pop exp
(
σ2k12
2
)
, (5-63)
k12,pop exp
(
σ2k12
2
)
+ k21,pop exp
(
σ2k21
2
)
= k12,pop exp
(
σ2k12
2
)
+ k21,pop exp
(
σ2k21
2
)
, (5-64)
76
Chapter 5. Two-compartment model of IgG metabolism
FCRpopk12,pop exp
(
1
2
(
σ2FCR + σ
2
k12
+ 2σFCRσk12ρFCRk12
))
= FCRpopk12,pop exp
(
1
2
(
σ2FCR + σ
2
k12
+ 2σFCRσk12ρFCRk12
))
, (5-65)
and
FCRpop exp
(
σ2FCR
2
)
+ k12,pop exp
(
σ2k12
2
)
+ k21,pop exp
(
σ2k21
2
)
= FCRpop exp
(
σ2FCR
2
)
+ k12,pop exp
(
σ2k12
2
)
+ k21,pop exp
(
σ2k21
2
)
. (5-66)
Now equations (5-63) to (5-66) are solved for ψpop and Ω. It is already known from
the deterministic structural identifiability analysis that the population parameters are
structurally identifiable, that is FCRpop = FCRpop, k12,pop = k12,pop and k21,pop = k21,pop.
From equation (5-63), given k12,pop = k12,pop, it can be seen that σk12 must be equal
to σk12 . σk12 = −σk12 is also a solution of (5-63), but σk12 is a standard deviation
and therefore can only be positive. Then from equation (5-64), with k12,pop = k12,pop,
σk12 = σk12 and k21,pop = k21,pop known, the solution for σk21 is given by σk21 = σk21 . Now
solving equation (5-66) gives σFCR = σFCR. Finally solving equation (5-65) for ρFCRk12
gives ρFCRk12 = ρFCRk12 .
The remaining parameters ρk12k21 and ρFCRk21 do not feature in the first order statistical
moments given in equations (5-61); therefore the second order moments of the moment
invariants Z2(ψpop,η) and Z4(ψpop,η) are required in order to assess whether the system
is structurally globally identifiable. These are given by
E(Z22) = k212,pop exp
(
2σ2k12
)
+ k221,pop exp
(
2σ2k21
)
+ 2k12,popk21,pop exp
(
1
2
(
σ2k12 + σ
2
k21
+ 2σk12σk21ρk12k21
))
(5-67)
and
E(Z24) = FCR2pop exp
(
2σ2FCR
)
+ k212,pop exp
(
2σ2k12
)
+ k221,pop exp
(
2σ2k21
)
+ 2FCRpopk12,pop exp
(
1
2
(
σ2FCR + σ
2
k12
+ 2σFCRσk12ρFCRk12
))
+ 2k12,popk21,pop exp
(
1
2
(
σ2k12 + σ
2
k21
+ 2σk12σk21ρk12k21
))
+ 2k21,popFCRpop exp
(
1
2
(
σ2k21 + σ
2
FCR + 2σk21σFCRρFCRk21
))
. (5-68)
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Equating E
(
Z22(ψpop,η)
)
with E
(
Z22(ψpop,η)
)
gives
k212,pop exp
(
2σ2k12
)
+ k221,pop exp
(
2σ2k21
)
+ 2k12,popk21,pop exp
(
1
2
(
σ2k12 + σ
2
k21
+ 2σk12σk21ρk12k21
))
= k212,pop exp
(
2σ2k12
)
+ k221,pop exp
(
2σ2k21
)
+ 2k12,popk21,pop exp
(
1
2
(
σ2k12 + σ
2
k21
+ 2σk12σk21ρk12k21
))
. (5-69)
With k12,pop, k21,pop, σk12 and σk21 already shown to be structurally identifiable, solving
equation (5-69) for ρk12k21 gives ρk12k21 = ρk12k21 . Last of all, equating E
(
Z24(ψpop,η)
)
with E
(
Z24(ψpop,η)
)
and solving for ρk21FCR gives ρk21FCR = ρFCRk21 .
It has thus been shown that the system of equations in (5-62) requires Ω = Ω; therefore
both population parameters ψpop and Ω are structurally globally identifiable. The Math-
ematica [21] code used to perform the mixed effects structural identifiability analysis is
provided in appendix B.
5.6.3 Error models
The structural identifiability analysis shows that in the absence of errors on the obser-
vations, a set of continuous trajectories of y1(t,ψi) and y2(t,ψi), i = 1, . . . , n, for some
n subjects, must arise from a unique parameter θ. In reality, however, model outputs
are observed with error at discrete timepoints. The measured quantities with error are
denoted by y˜k(t
(k)
ij ,ψi), k = 1, 2, for subjects i = 1, . . . , n. It is assumed that y˜k(t
(k)
ij ,ψi)
is measured at discrete timepoints t
(k)
ij , j = 1, . . . , Nik, with t
(k)
i1 = t
(k)
i1 = 0.
From section 5.5, there are several features of the data that may cause problems when
attempting to estimate parameters. Firstly, systematic errors are introduced in the cal-
culation of y˜1(t
(1)
ij ,ψi) and y˜2(t
(2)
ij ,ψi) due to division by quantities measured with error at
time t = 0. This means that the observations are not symmetric about their predicted or
‘true’ value. Secondly, it is assumed that y˜2(t
(2)
ij ,ψi) is calculated by summing daily urine
collections, such that the errors on individual measurements of y˜2(t
(2)
ij ,ψi) are no longer
independent. Finally, the calculation of y˜2(t
(2)
ij ,ψi) leads to a non-standard relationship
between variance of y˜2(t
(2)
ij ,ψi) and its mean, as shown in the expression for the CV in
equation (5-50).
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In order to estimate model parameters, it is necessary to make assumptions regarding
the data that are in actuality violated, as described above. The importance of violating
these assumptions will be assessed in section 5.6.5 by using the estimation method on
synthetic data for which the true parameter values are known. It is therefore assumed
that the observed measurements for the ith subject are given by
y˜k(t
(k)
ij ,ψi) = yk(t
(k)
ij ,ψi) + gk(t
(k)
ij ,ψi, ξ)
(k)
ij ,
j = 1, . . . , Nik, k = 1, 2,
(5-70)
where 
(k)
ij are independent and identically distributed random variables following the
normal distribution: 
(k)
ij ∼ N(0, 1). The error model is represented by gk(t(k)ij ,ψi, ξ),
allowing for possible dependence of the residual errors on time, the individual’s true
parameter vector, and an additional error model parameter ξ.
The population parameters are estimated by ML estimation. In order to use ML esti-
mation it is necessary to specify the error model for the observations, the most common
being normally distributed errors with constant variance (constant error model) and nor-
mally distributed errors with standard deviation proportional to the size of the predicted
value (proportional error model). The constant error model is given by
gk(t
(k)
ij ,ψi, ξ) = ak. (5-71)
The proportional error model is given by
gk(t
(k)
ij ,ψi, ξ) = bkyk(t
(k)
ij ,ψi). (5-72)
The two model outputs y˜k(t
(k)
ij ,ψi), k = 1, 2, need not have the same error model; however
the error model for each output (k = 1 or 2) is assumed to apply to all individuals in the
population.
These models assume that the observations are symmetrically distributed around their
predicted value, which is not strictly true for the data used here due to the systematic
error described above. They also assume that the errors are independent, whereas we
believe the errors on the calculated y˜2(t
(2)
ij ,ψi) to be autocorrelated. It is assumed, based
on information about the data collection, that y˜1(t
(1)
ij ,ψi) has a constant CV and that
y˜2(t
(2)
ij ,ψi) has a more complex relationship between its variance and its mean that may
not be possible to specify in a standard form; we are therefore consigned to misspecify the
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error model for y˜2(t
(2)
ij ,ψi). The problems identified here mean that several assumptions
underlying the estimation method will be violated by these data and the estimation may
yield biased parameter estimates.
The suitability of different assumed error models can be compared by estimating the
population parameters from multiple synthetic datasets and assessing the performance of
each method in recovering the true parameter values, which in this scenario are known.
Bonate states that, ‘before undertaking anything, the question of whether it is worth
the effort to find a residual variance model must be answered’, and offers the rule of
thumb that a correct error model is required when the ratio of the largest to the smallest
standard deviation of the errors exceeds 3 [22, p. 133].
Given the issues discussed in this section, synthetic data will be used to compare two
methods:
 Method 1, in which a proportional error model is assumed to apply to both
y˜1(t
(1)
ij ,ψi) and y˜2(t
(2)
ij ,ψi);
 Method 2, in which a proportional error model is assumed to apply to y˜1(t
(1)
ij ,ψi)
and a constant error model to y˜2(t
(2)
ij ,ψi).
Firstly Method 1 is applied to the real data in order to estimate the population parameters
in section 5.6.4; these parameter estimates are then used to simulate data in section 5.6.5.
The population parameters are then estimated from the synthetic data using both Method
1 and Method 2 in section 5.6.6.
5.6.4 Parameter estimation
The population parameter vector θ =
(
ψpop,Ω
)
is estimated by maximising the observed
likelihood of θ given the data for the seven subjects. The data for the ith individual are
assumed to be described by equation (5-70), with the proportional error model for both
outputs, given by equation (5-72). For brevity, the data for an individual are denoted by
yi and the data for the sample of individuals are denoted by y. The measurement times
for all observations are denoted by t, where t = t
(k)
ij , i = 1, . . . , n; k = 1, 2; j = 1, . . . , Nik.
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Table 5-2 Initial values for SAEM algorithm
Parameter Units Initial value
FCRpop day
−1 1
k12,pop day
−1 1
k21,pop day
−1 1
σFCR day
−1 1
σk12 day
−1 1
σk21 day
−1 1
b1 – 0.3
b2 – 0.3
Table 5-3 Maximum likelihood (ML) parameter estimates, standard errors
(S.E.) and relative standard error (R.S.E.) as a % of the value of the estimate
Parameter Units ML estimate S.E. R.S.E. (%)
FCRpop day
−1 0.0778 0.02 26
k12,pop day
−1 0.422 0.12 27
k21,pop day
−1 0.441 0.083 19
σFCR day
−1 0.685 0.18 27
σk12 day
−1 0.713 0.19 27
σk21 day
−1 0.498 0.13 27
ρFCRk12 – 0.872 0.092 11
ρFCRk21 – 0.608 0.24 39
ρk12k21 – 0.739 0.17 23
b1 – 0.0814 0.0065 8
b2 – 0.0222 0.0016 7
The likelihood of θ given y is given by
L(θ;y, t) = f(y;θ, t), (5-73)
where f(y;θ, t) is the probability density function of y, parameterised by θ and t.
The population parameters were estimated by fitting the timecourse data from seven
subjects (see section 5.3) using the software package Monolix [17]. Initial values for the
parameters provided to the SAEM algorithm are given in table 5-2. The population
parameter ML estimates and their standard errors are summarised in table 5-3.
The individual parameters are estimated by estimating the distribution of the individual
parameter vector ψi, conditional on the individual data yi and parameterised by the ML
estimate of the population parameter vector, θˆ, for each individual, using the Metropolis-
Hastings algorithm. The modes of the conditional distributions are found by numerical
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Figure 5-4 Timecourse fits: model described by equations (5-10)–(5-12)
fitted to timecourse data for (A–D) subjects A–D (data from [9]), (E–F)
subjects E–F (data from [11]), and (G) subject G (data from [1]), by the
population approach described in section 5.6
Table 5-4 Individual parameter estimates
Subject FCRi (day
−1) k12,i (day−1) k21,i (day−1)
A 0.03589 0.11643 0.21413
B 0.077272 0.40364 0.46188
C 0.13218 0.62103 0.62127
D 0.030666 0.27822 0.2388
E 0.27073 1.6953 0.66285
F 0.074878 0.43395 0.57506
G 0.077297 0.52945 0.80139
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maximisation. These conditional modes represent the estimated individual parameter
vectors and are provided in table 5-4. The model outputs are plotted for the estimated
individual parameter vectors alongside the data in figure 5-4.
As stated in section 5.3, several subjects have IgG myeloma, macroglobulinemia or familial
hypercatabolic hypoproteinemia. Patients with familial hypercatabolic hypoproteinemia
do not express FcRn, explaining the large value of the FCR (0.27 day−1) for subject E.
The parameter Vmax (not estimated here) for subject E should be equal to zero, reflecting
the absence of recycling receptors. Subjects A and C have IgG myeloma and subject D has
macroglobulinemia. The high or low values of the FCR in these patients may be explained
by the concentration-dependent catabolism of IgG, as described by equation (5-13), with
abnormally high or low plasma IgG concentrations likely occurring as symptoms of the
respective disease.
5.6.5 Synthetic data simulation
In this section it is assumed that the parameter estimates for ψpop and Ω in table 5-3
are the true population parameters for seven hypothetical subjects. Data were simulated
with these population parameters in order to test how well the true parameter values can
be recovered in Monolix, taking into account the errors in the data and the small sample
of subjects available. Population parameters are estimated from the synthetic data in
section 5.6.6.
Seven individual parameter vectors ψi, i = 1, . . . , 7, were drawn from the parameterised
lognormal distribution. The experimental data for each individual parameter vector ψi
were simulated 10 times, yielding 10 unique datasets for the same sample of seven in-
dividuals. Since the sample size of n = 7 may be small for estimating the population
parameters, the process was repeated for five different samples of seven individual pa-
rameter vectors ψi, i = 1, . . . , 7. The individual parameter vectors are tabulated in table
5-5. In total 5× 10 = 50 datasets to be fitted by a population approach were simulated,
each of seven subjects.
Data were simulated according to the equations and assumptions given in section 5.5.
Data for y˜1(t
(1)
ij ,ψi) were generated by first simulating the plasma radioactivity concen-
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Table 5-5 True individual parameter values for the seven subjects in each of five samples, for whom data were simulated
Subject number, i
1 2 3 4 5 6 7
Sample 1
FCRi 0.110984975 0.179022118 0.416445474 0.140046278 0.042490161 0.297597056 0.091545732
k12,i 0.577924426 0.680583598 3.632129902 0.561378088 0.207230189 0.90208813 0.619241405
k21,i 0.53221047 0.332086484 0.92700592 0.302140328 0.261303137 0.783250661 0.561366815
Sample 2
FCRi 0.038102176 0.041663693 0.084583507 0.126985597 0.073098181 0.028028037 0.0340121
k12,i 0.09330052 0.264287512 0.182981488 0.864572255 0.475266716 0.123687218 0.232631827
k21,i 0.139111835 0.366803897 0.278437758 0.729767545 0.8231428 0.379733231 0.621086268
Sample 3
FCRi 0.075505969 0.225431461 0.07190829 0.083094083 0.038178905 0.049781932 0.056795114
k12,i 1.32718538 1.910523519 0.285251404 0.947762901 0.192667415 0.220377271 0.169079559
k21,i 1.266685187 1.053054063 0.195643213 0.748559935 0.133500771 0.410446241 0.238353978
Sample 4
FCRi 0.065701025 0.102613006 0.029847141 0.073268156 0.151423804 0.027887747 0.101710455
k12,i 0.314681321 0.487770168 0.194480467 0.610676399 0.562160173 0.285784722 0.66122055
k21,i 0.386736952 0.432089394 0.17667979 0.583309366 0.388046681 0.345315908 0.746369857
Sample 5
FCRi 0.083260871 0.066260186 0.058434785 0.037116266 0.089870319 0.014216423 0.041865056
k12,i 0.474629657 0.444656782 0.267908687 0.107578224 0.331561656 0.052473962 0.194705474
k21,i 0.945166455 0.364942643 0.415110773 0.093591273 0.292122172 0.174690329 0.368286271
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Table 5-6 Experiment parameters used for simulating tracer experiment
data
Parameter Units Value Reference
D µmol 0.005 Solomon et al. [9]
Vplasma l 3 Solomon et al. [9]
α µCi µmol−1 45 Solomon et al. [9]
tration C˜plasma(t
(1)
ij ,ψi) with constant CV, denoted by CVplasma, from which y˜1(t
(1)
ij ,ψi)
was calculated. Data for y˜2(t
(2)
ij ,ψi) were generated by simulating the radioactivity in
urine collections, A˜UC(t
(2)
k ), k = 2, . . . , N2, with constant CV, denoted by CVUC, and the
radioactivity in the administered tracer dose, A˜dose, with constant CV, denoted by CVD.
The data were simulated in Mathematica [21] using the script provided in appendix C.
In order to simulate the data it is necessary to assign values to the tracer dose D (µmol),
plasma volume Vplasma (l), and proportionality constant α (µCi µmol
−1). The values
used, for all simulations, are provided in table 5-6. Three coefficients of variation must
be specified, which determine the magnitudes of the errors. These are CVplasma, CVUC
and CVD. Cobelli et al. [15, p. 233–235] provide a value of 0.02 for the CV of plasma
radioactivity concentrations. The variability in the activity in the dose is assumed to be
similar to that of the activity in plasma; thus it is assumed that CVD = CVplasma.
The summation of radioactivity measurements in urine collections in the calculation
of y˜2(t
(2)
ij ,ψi) results in autocorrelated errors and thus very smooth trajectories of the
measured values of y˜2(t
(2)
ij ,ψi). Therefore larger values of CVUC are required in order to
achieve similar variability to that seen in the real data. By a process of trial and error,
values of CVD = CVplasma = 0.07 and CVUC = 0.3 were chosen.
It is assumed that measurements of both model outputs were taken daily. It is also
assumed that subjects showing faster metabolism would be observed over a shorter time
period. The following simple linear relationship between the individual values of FCRi
and the final observation time was used:
f = −70× FCRi + 24. (5-74)
The relationship was obtained by fitting a straight line to the final observation times for
the real subjects and their estimated values of FCR, obtained by an individual approach.
The obtained value of f was rounded to the next whole number and, if smaller than 7,
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Figure 5-5 Example of synthetic data for seven individuals. Simulation
process described in section 5.6.5.
replaced by 7, giving the value of Tmax,i (days) that was used for the i
th subject:
Tmax,i = max
(df(FCRi)e, 7) . (5-75)
An example of one simulated dataset for one sample of seven individuals is shown in
figure 5-5. The true trajectories are also shown in the plots.
5.6.6 Parameter estimation using synthetic data
In this section the population parameters are estimated from the synthetic data simulated
in section 5.6.5. The aim of this exercise is to find out how well the population parameters
are estimated in Monolix, by looking at properties of the parameter estimates, such as
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the mean, standard deviation and bias. We also wish to ascertain the importance of
the error model that is assumed for y2(t) when estimating the population parameters;
therefore the estimation is performed, firstly, assuming a proportional error model for
both y1(t
(1)
ij ,ψi) and y2(t
(2)
ij ,ψi) (Method 1) and, secondly, assuming a proportional error
model for y1(t
(1)
ij ,ψi) and a constant error model for y2(t
(2)
ij ,ψi) (Method 2). Aside from
the choice of error model, each of the 50 datasets were estimated by the same approach
as in section 5.6.4. When the constant error model is assumed, an initial value of 0.0251
for the error model parameter a2 is used. This is the default value provided by Monolix
for the first dataset analysed.
Four properties of the parameter estimates of the kth parameter are calculated: sample
mean (µk), sample standard deviation (S.D.k), bias (bk) and variability (vk). The bias is
given by
bk = µk − p0k, (5-76)
where µk is the mean of the estimates and p
(0)
k is the true value of the parameter. The
variability of the kth parameter is given by
vk =
√
S.D.2k + b
2
k
p
(0)
k
. (5-77)
Variability as defined here has been used by Chen et al. [14] to evaluate the performance
of estimation methods when the assumptions relied upon by the methods, in particular
relating to noise, are violated. A larger value of vk represents a worse performance of an
estimation method. Chen et al. [14] also define the overall variability of a method V as
V =
∑Np
k=1 vk
Np
, (5-78)
where Np is the total number of parameters estimated. The properties of the parameter
estimates are calculated for each sample of seven subjects. Since the sample size n = 7
is small, the parameter estimates might vary significantly depending on which sample is
used.
Method 1: proportional error models assumed for both y1(t) and y2(t)
The sample mean, sample standard deviation, bias and variability of the parameter es-
timates are tabulated in table 5-7. The population parameter estimates as a proportion
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Figure 5-6 Plots illustrating the distributions of population parameter
estimates relative to their true values for (A–E) samples 1 to 5 of seven
individual parameters ψi, when estimated by Method 1. Details in section
5.6.6.
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Table 5-7 Mean, standard deviation (S.D.), bias and variability of the parameter estimates for five samples of seven individual
parameter vectors. Data were simulated 10 times for each sample and population parameters estimated from each of the 10
datasets. A proportional error model was assumed for both y1(t) and y2(t) (Method 1).
Population parameter
FCRpop k12,pop k21,pop σFCR σk12 σk21 ρFCRk12 ρFCRk21 ρk12k21
Sample 1
Mean 0.1411 0.6531 0.4517 0.6661 0.8556 0.5157 0.61202 0.54441 0.7974
S.D. 0.0075638 0.177309 0.0784518 0.044725 0.320203 0.202313 0.353596 0.292445 0.23481
Bias 0.0633 0.2311 0.0107 -0.0189 0.1426 0.0177 -0.25998 -0.06359 0.0584
Variability 0.819413 0.690244 0.179542 0.0708824 0.491614 0.407802 0.503308 0.492234 0.32742
Sample 2
Mean 0.05334 0.2487 0.4262 0.5375 0.7554 0.6355 0.7339 0.3808 0.8286
S.D. 0.0019665 0.0292842 0.0464107 0.0285939 0.172537 0.102896 0.0775148 0.232178 0.0720111
Bias -0.02446 -0.1733 -0.0148 -0.1475 0.0424 0.1375 -0.1381 -0.2272 0.0896
Variability 0.31541 0.416485 0.110461 0.219337 0.249188 0.344855 0.181614 0.534291 0.15555
Sample 3
Mean 0.07125 0.4487 0.4048 0.5097 0.9353 0.7943 0.7302 0.5149 0.8093
S.D. 0.00397639 0.104905 0.0805437 0.041414 0.311434 0.157657 0.169444 0.322123 0.186995
Bias -0.00655 0.0267 -0.0362 -0.1753 0.2223 0.2963 -0.1418 -0.0931 0.0703
Variability 0.0984899 0.256516 0.200238 0.262957 0.536653 0.673962 0.253382 0.551491 0.270329
Sample 4
Mean 0.0667 0.4367 0.4202 0.5779 0.5268 0.513 0.7973 0.6625 0.8973
S.D. 0.00217715 0.057219 0.0506443 0.0538526 0.153113 0.0863147 0.104402 0.112183 0.0626206
Bias -0.0111 0.0147 -0.0208 -0.1071 -0.1862 0.015 -0.0747 0.0545 0.1583
Variability 0.145392 0.139993 0.124148 0.175003 0.338105 0.17592 0.147218 0.205132 0.23036
Sample 5
Mean 0.04845 0.2273 0.3238 0.6096 0.8034 0.6963 0.9397 0.6587 0.7668
S.D. 0.0031135 0.0256993 0.0328458 0.0502531 0.106104 0.0851914 0.0299149 0.0954033 0.105973
Bias -0.02935 -0.1947 -0.1172 -0.0754 0.0904 0.1983 0.0677 0.0507 0.0278
Variability 0.379366 0.465376 0.275999 0.13228 0.195501 0.433384 0.0848794 0.177695 0.148252
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Figure 5-7 Plots illustrating the distributions of population parameter
estimates relative to their true values for (A–E) samples 1 to 5 of seven
individual parameters ψi, when estimated by Method 2. Details in section
5.6.6.
such as systematic errors and other issues discussed in section 5.6.3.
Method 2: proportional error model assumed for y1(t) and constant error
model for y2(t)
The sample mean, sample standard deviation, bias and variability of the parameter esti-
mates are tabulated in table 5-9. The population parameter estimates as a proportion of
the true population parameter values are plotted in figure 5-7. Comparing tables 5-7 and
5-9 and figures 5-6 and 5-7, overall the results of the parameter estimation are similar
whether a proportional or constant error model is assumed for model output y˜2(t
(2)
ij ,ψi).
Table 5-8 Overall variability of Method 1 and Method 2 for samples 1–5
Sample
1 2 3 4 5
Method 1 0.442 0.288 0.345 0.187 0.255
Method 2 0.705 0.272 0.443 0.284 0.283
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Figure 5-8 Variability of population parameter estimates when estimated
by Method 1 (blue solid lines) and Method 2 (red dashed lines), for (A–E)
samples 1 to 5 of seven individual parameter vectors
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Table 5-9 Mean, standard deviation (S.D.), bias and variability of the parameter estimates for five samples of seven individual
parameter vectors. Data were simulated 10 times for each sample and population parameters estimated from each of the 10
datasets. A proportional error model was assumed for y1(t) and a constant error model for y2(t) (Method 2).
Population parameter
FCRpop k12,pop k21,pop σFCR σk12 σk21 ρFCRk12 ρFCRk21 ρk12k21
Sample 1
Mean 0.1413 0.8878 0.6106 0.6761 1.09 0.856 0.6337 0.4521 0.656092
S.D. 0.00569698 0.387486 0.251132 0.0420673 0.325055 0.325865 0.331798 0.280094 0.488291
Bias 0.0635 0.4658 0.1696 -0.0089 0.377 0.358 -0.2383 -0.1559 -0.082908
Variability 0.819474 1.43578 0.687159 0.0627714 0.698155 0.972086 0.46847 0.527233 0.670202
Sample 2
Mean 0.05341 0.25 0.4295 0.5388 0.7538 0.6305 0.7405 0.39066 0.8259
S.D. 0.00197678 0.0250333 0.04287 0.0275834 0.166625 0.0922078 0.0686444 0.213858 0.0863423
Bias -0.02439 -0.172 -0.0115 -0.1462 0.0408 0.1325 -0.1315 -0.21734 0.0869
Variability 0.314524 0.411877 0.100648 0.217196 0.240599 0.32415 0.170113 0.501502 0.165766
Sample 3
Mean 0.07152 0.5101 0.4668 0.5129 1.0841 0.9746 0.6715 0.5076 0.8765
S.D. 0.00410983 0.130705 0.111839 0.0426209 0.34115 0.226613 0.215252 0.38352 0.110987
Bias -0.00628 0.0881 0.0258 -0.1721 0.3711 0.4766 -0.2005 -0.1004 0.1375
Variability 0.0964688 0.373518 0.260264 0.258831 0.706987 1.0597 0.337347 0.652046 0.239112
Sample 4
Mean 0.06683 0.4946 0.4768 0.5806 0.686 0.6949 0.7086 0.5943 0.9399
S.D. 0.00211977 0.126096 0.110904 0.0538789 0.215703 0.186224 0.14712 0.156045 0.0345365
Bias -0.01097 0.0726 0.0358 -0.1044 -0.027 0.1969 -0.1634 -0.0137 0.2009
Variability 0.143611 0.344793 0.264261 0.171508 0.30489 0.544207 0.252147 0.25764 0.275842
Sample 5
Mean 0.04925 0.2391 0.338 0.6084 0.8537 0.737 0.9013 0.6369 0.7757
S.D. 0.00243139 0.0259463 0.0381372 0.0497576 0.152958 0.166705 0.0905134 0.1047 0.138956
Bias -0.02855 -0.1829 -0.103 -0.0766 0.1407 0.239 0.0293 0.0289 0.0367
Variability 0.368295 0.437752 0.249056 0.133346 0.291484 0.585132 0.109103 0.178644 0.194481
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The variability vk of the estimates of the k
th population parameter combines both the
bias and the spread of the estimates. The variability vk is plotted in figure 5-8. Figures
5-8A to 5-8E represent samples 1–5, each of seven individual parameter vectors. Blue
solid lines represent the variability of the population parameter estimates when they are
estimated by Method 1; red dashed lines represent the variability when the parameters
are estimated by Method 2. The variabilities of the parameter estimates for samples B, C
and E follow the same trend regardless of the error model assumed for y˜2(t
(2)
ij ,ψi), with the
peak in the red line in figure 5-8C showing a particularly large variability in the estimates
for σk21 , when the constant error model is assumed for y˜2(t
(2)
ij ,ψi). For samples A and
D, the difference between the two methods is more apparent, with Method 2 resulting in
substantially greater variability for several population parameters. The overall variability
V , defined in equation 5-78, is tabulated for each sample and for both methods in table
5-8. The overall variability is greater for Method 2 for each sample, except for sample B,
for which the variabilities are close for both methods.
5.7 Naive pooled approach to parameter identifica-
tion using fractional catabolic rate and half-life
data
The parameters k31, Vmax and KM are structurally unidentifiable from an individual sub-
ject’s timecourse data, assuming the linearised model given by equations (5-10)–(5-12)
(see section 5.4.2). It is therefore necessary to make use of the relationships between
FCR and T1/2, respectively, and the quantity of endogenous IgG in plasma, x1,E. Un-
fortunately, these relationships are not known for an individual subject; obtaining them
would require performing the tracer experiment over a range of different plasma concen-
trations of endogenous IgG within an individual subject, which is not practically feasible.
Parameter values are therefore estimated from the FCR and T1/2 measurements taken
from a sample of patients with a wide range of endogenous IgG plasma concentrations,
as though the data arose from an individual subject, in what may be described as a naive
pooled approach [23]. By this approach it is not however possible to gain a sense of the
distribution of the parameters k31, Vmax and KM within the population.
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5.7.1 Structural identifiability analysis
Fractional catabolic rate
The relationship between the FCR and x1,E is given by equation (5-13). The SolveAl-
ways function was used in Mathematica [21] to determine whether the parameter vector
φ = (k31, Vmax, KM) is uniquely identifiable given the relationship in equation (5-13). In-
troducing an alternative parameter vector φ =
(
k31, V max, KM
)
and solving the equation
k31 − Vmax
KM + x1,E
= k31 − V max
KM + x1,E
, (5-79)
over all values of x1,E, gives
(
k31, V max, KM
)
= (k31, Vmax, KM) as the only solution for
the unknown parameters. FCR(x1,E,φ) = FCR(x1,E,φ) requires φ = φ; therefore the
parameters k31, Vmax and KM are structurally globally identifiable given the relationship
between FCR and x1,E.
Half-life
The relationship between T1/2 and x1,E is given by equation (5-17). We now wish to know
whether the parameter vector φ = (k12, k21, k31, Vmax, KM) is structurally identifiable with
respect to the relationship in equation (5-17). From equation (5-15), this is equivalent to
asking whether φ is structurally identifiable with respect to the relationship between λ2
and x1,E, given by
λ2 =
1
2
(
− k12 − k21 − k31 + Vmax
KM + x1,E
+
√√√√−4k12(k31 − Vmax
KM + x1,E
)
+
(
k12 + k21 + k31 − Vmax
KM + x1,E
)2)
.
(5-80)
The structural identifiability problem amounts to determining whether there exists an
alternative parameter vector φ such that λ2(x1,E,φ) = λ2(x1,E,φ) with φ 6= φ. λ2 is one
of the roots of the characteristic polynomial equation, given by
λ2 +
(
k12 + k21 + k31 − Vmax
KM + x1,E
)
λ+ k12
(
k31 − Vmax
KM + x1,E
)
= 0. (5-81)
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We wish to know whether there exists an alternative parameter vector φ 6= φ, such that
λ2+
(
k12 + k21 + k31 − Vmax
KM + x1,E
)
λ+ k12
(
k31 − Vmax
KM + x1,E
)
= λ2 +
(
k12 + k21 + k31 − V max
KM + x1,E
)
λ+ k12
(
k31 − V max
KM + x1,E
)
.
(5-82)
From the uniqueness of interpolating polynomials [24, p. 98], the coefficients of the
quadratic are unique, therefore
k12 + k21 + k31 − Vmax
KM + x1,E
= k12 + k21 + k31 − V max
KM + x1,E
k12
(
k31 − Vmax
KM + x1,E
)
= k12
(
k31 − V max
KM + x1,E
)
.
(5-83)
The only solution to equations (5-83), over all values of x1,E and for generic positive
parameter values, is φ = φ. Therefore the parameters k12, k21, k31, Vmax and KM are
structurally globally identifiable given the relationship between T1/2 and x1,E.
5.7.2 Parameter estimation
The parameters k12, k21, k31, Vmax and KM were estimated from FCR vs. x1,E and T1/2 vs.
x1,E data, simultaneously. Waldmann et al. [1] provide plots of FCR and T1/2 vs. plasma
endogenous IgG concentration in g l−1. The data were extracted using the Digitizer tool
in OriginPro [10]. The plasma IgG concentration in g l−1 was converted to µmol l−1 by
dividing by the molar mass of IgG, 0.15 g µmol−1. The concentration was then multiplied
by an average plasma volume of 3 l [9] to obtain the quantity x1,E in µmol.
The FCR and T1/2 data were fitted simultaneously by the model outputs described in
equations (5-13) and (5-17). The parameter values were estimated by minimising the
sum of squared residual errors between the model outputs and the measured values,
using the function NonlinearModelFit in Mathematica [21]. Due to the different scales
for the parameters (0.02 < FCR < 0.17 day−1; 10 < T1/2 < 72 days) the T1/2 data points
were assigned different weights to the FCR data points. It is assumed that the residual
errors on the FCR measurements have a constant standard deviation, σF, and that the
residual errors on the T1/2 measurements have a constant standard deviation, σT1/2 . It is
assumed that the ratio of the two standard deviations is equal to the ratio of the means
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Figure 5-9 Expressions for (A) FCR (equation (5-13)) and (B) T1/2 (equa-
tion (5-17)) fitted to data from [1]
Table 5-10 Parameter estimates and standard errors estimated from FCR
and T1/2 data
Parameter Units Estimate Standard error (SE) 95% confidence interval
k31 day
−1 0.159 0.0111 (0.137, 0.181)
Vmax µmol day
−1 40.0 10.5 (19.1, 60.9)
KM µmol 272 55.4 (162, 382)
k12 day
−1 0.158 0.155 (−0.150, 0.467)
k21 day
−1 0.187 0.231 (−0.273, 0.647)
of the measured values, as follows:
σT1/2
σF
=
T1/2
FCR
, (5-84)
where FCR and T1/2 are the sample means of the measured values of FCR and T1/2, respec-
tively. The relative weighting of each data point is assumed to be inversely proportional
to its error variance, therefore
wF
wT1/2
=
σ2T1/2
σ2F
=
T1/2
2
FCR2
= 1.08× 105, (5-85)
where wF and wT1/2 are the weights assigned to the FCR data points and the T1/2 data
points, respectively. The weights given to the FCR data points were set to 1.08× 105
and the weights given to the T1/2 data points were set to 1.
The data and model fits are shown in figure 5-9. The parameter estimates and their
standard errors are given in table 5-10. The standard errors are almost as large as, or
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Table 5-11 Comparison with published parameter values
Parameter Units
Previously published values This
thesis
Waldmann et al.
[1]
Kim et al. [2] Hattersley et al.
[6]
k12 day
−1 – 0.158 0.41 0.422
k21 day
−1 – 0.156 0.51 0.441
k31 day
−1 0.18 0.18† 0.13 0.159
Vmax µmol day
−1 68.6* 68.6*† 103 40.0
KM µmol – 420** 530 272
*Assuming 70 kg human. **Assuming 3 l plasma volume. †Taken from Waldmann et al. [1].
larger than, the estimates themselves for the parameters k12 and k21, indicating that these
parameters cannot be estimated with a reasonable level of precision.
The correlation matrix of the parameter estimates is given by
k31 Vmax KM k12 k21

k31 1 0.928 0.839 −0.290 −0.300
Vmax 0.928 1 0.976 −0.228 −0.253
KM 0.839 0.976 1 −0.0890 −0.115
k12 −0.290 −0.228 −0.0890 1 0.996
k21 −0.300 −0.253 −0.115 0.996 1
.
The parameters k31, Vmax and KM are highly correlated pairwise, with the strongest
correlation between KM and Vmax. k12 and k21 are highly correlated with one another
(correlation coefficient of 0.996) and not with the other parameters, explaining why they
cannot be estimated with a reasonable level of precision from these data.
5.8 Comparison with previously published parame-
ter values
Table 5-11 compares previously published parameter values alongside the parameter val-
ues estimated in this chapter. For the parameters k12 and k21 the estimated population
parameters k12,pop and k21,pop are provided; for the parameters k31, Vmax and KM the
values estimated from FCR and T1/2 vs. x1,E data from many subjects are taken to rep-
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resent the population average. At first glance the newly estimated parameter values are
reasonably similar to the previously published values.
Waldmann et al. [1] give values of k31 = 0.18 day
−1 and Vmax/w = 147 mg day−1 kg−1,
where w is body weight in kg. Assuming a 70 kg human, this is equivalent to Vmax = 68.6
µmol day−1. The value of k31 was obtained ‘from the asymptotic value of the plot of
the IgG fractional catabolic rate versus its concentration’ [1]. These are the same data
that were utilised in this paper as described in section 5.3. The authors subtracted the
value of the FCR for each individual from 0.18 to find the fractional recycling rate. The
fractional recycling rate is thus given by
FRR = k31 − FCR = k31 −
(
k31 − Vmax
KM + x1,E
)
=
Vmax
KM + x1,E
. (5-86)
They then multiplied the plasma concentration of endogenous IgG by the plasma volume
per kg of body weight for each individual to get the quantity of endogenous IgG in plasma
per kg of body weight, x1,E/w. Finally the authors multiplied the fractional recycling rate
by x1,E/w to obtain the absolute recycling rate per kg of body weight, which is denoted
here by ARR. They then plotted the reciprocal of the ARR against the reciprocal of
x1,E/w to obtain a straight line relationship, given by
1
ARR
=
KM
Vmax
w
x1,E
+
w
Vmax
. (5-87)
From the intercept the authors obtained the value of Vmax/w = 147 mg kg
−1 day−1.
Kim et al. [2] provide values for all model parameters. Again using the FCR vs. endoge-
nous IgG concentration data first published by Waldmann et al. [1] and described here
in section 5.3, Kim et al. [2] estimate KM/w using a least-squares fitting. The equation
fitted to the data is
FCR = k31 − Vmax/w
v1
w
(
KM
v1
+
x1,E
v1
) , (5-88)
where v1 is the plasma volume. The authors fit equation (5-88) to FCR vs. x1,E/v1 to
obtain KM/v1 whilst fixing the remaining parameters as follows: k31 = 0.18 day
−1 [1],
Vmax/w = 0.98 µmol kg
−1 [1], and v1/w = 0.042 l kg−1 [11]. By this approach the authors
obtain a value of KM/v1 = 140 µmol l
−1. Assuming a plasma volume of 3 l this equates to
KM = 420 µmol. The authors also estimate the parameters k12 and k21 by curve fitting
to tracer experiment data from Waldmann et al. [11].
98
Chapter 5. Two-compartment model of IgG metabolism
The parameter values provided by Hattersley et al. [6] were obtained by methods de-
scribed in Hattersley [3], which involved estimating the parameters k12 and k21 by fitting
the model to tracer experiment data in [1]. For the remaining model parameters, k31,
Vmax and KM, the author takes a completely different approach, fitting the model directly
to serum IgG data from an IgG myeloma patient, assuming a delayed logistic function to
describe the production of tumour-produced IgG. For this approach, the parameters k12,
k21 and v1 were fixed.
The values provided by Hattersley et al. [6] and Kim et al. [2] for k12 and k21 are similar
to the individual parameter values estimated in this chapter, given in table 5-4. The
value for parameter k31 estimated here is between previously estimated values. The esti-
mated values for parameters Vmax and KM are both significantly smaller than previously
published values, although the value of Vmax = 68.6 µmol day
−1 assumes a body weight
of 70 kg, which may be too high for multiple myeloma patients.
5.9 Conclusions
The aim of this chapter was to analyse a previously published model of endogenous IgG
metabolism and available measurements in humans with respect to parameter identifi-
cation. The model was linearised to replicate experimental conditions in which small
doses of administered IgG exhibit linear timecourse responses and a new expression for
the half-life of the tracer was derived. The linearised model was then analysed in terms
of parameter structural identifiability, both for individual parameters and population
parameters. Certain important parameters are not structurally identifiable from an indi-
vidual’s timecourse response, namely, k31, Vmax, and KM; however they are structurally
identifiable using the relationships between the FCR and T1/2, respectively, and the quan-
tity of endogenous IgG in plasma, which is assumed to remain in steady state.
It is not known whether the parameters k31, Vmax and KM are structurally identifiable
in the nonlinear model of coupled radiolabelled and endogenous IgG responses given
by equations (6-7)–(5-7). There are two reasons this approach was not pursued here:
firstly, structural identifiability analysis of a four-state nonlinear model with rational
terms presents a more challenging problem; secondly, if the nonlinear model were found to
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be structurally identifiable, then the responses available nonetheless do not demonstrate
nonlinear behaviour due to the small doses of radiolabelled IgG administered (see figure
5-3) – therefore the parameters representing nonlinear behaviour may not be practically
identifiable by fitting the nonlinear model and there would be an increased risk of fitting
the noise in the data with the increased model complexity.
The parameters estimated using Monolix were validated by estimating the same parame-
ters from synthetic data. The sources of experimental errors were considered in order to
simulate the data. This simulation study showed how the population parameter estimates
may be biased, dependent largely on the sample of individual parameter values. This re-
sult suggests that whilst the population parameter estimates may represent the studied
sample, future experiments would benefit from a larger sample of individuals in order
to more accurately estimate the population parameters. A future analysis may involve
estimating parameters directly from the simulated data for the radioactivity in plasma,
urine collections and the tracer dose, to explore the impact of misspecification of the error
model in estimating the parameters. If future experiments were permitted, the distribu-
tions of errors on these observations could be validated by taking replicate measurements.
By performing a simulation study it would be possible to make recommendations for fu-
ture experiments, by determining whether the correct specification of the error model or
an increase in the sample size would produce more accurate parameters; the benefit of
these measures could then be weighed up against their respective costs. Using a naive
pooled approach to parameter estimation, the parameter k31 was estimated with higher
precision than Vmax and KM, possibly due to the very high correlation between Vmax and
KM. A recommendation for future work is to estimate these parameters from synthetic
data for FCR and T1/2 to assess the stability of their parameter estimates.
In this chapter population parameters have been estimated, which will be used in chapter
8 for predicting cancer marker responses in patients with IgG multiple myeloma. In
section 5.8, the parameter values obtained in this chapter are compared with previously
published values and the parameter estimation methods used by previous authors are
briefly described. Parameter values obtained from individual subjects’ data can be quite
different, for example the values for k21 and k12 obtained by Hattersley et al. [6] and Kim et
al. [2], respectively. The population approach taken in this chapter has provided estimates
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of the average parameter values in the population, which can be used to predict average
responses. The simulation study performed in this chapter also provides an indication of
the level of variability within population parameter estimates for the FCR, k21 and k12.
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6Parameter identification for a
four-compartment model of
immunoglobulin G metabolism
In this chapter a four-compartment model of immunoglobulin G (IgG) metabolism is
analysed with respect to parameter identification using data from radioactive tracer ex-
periments. The previously published model [1; 2] is semi-mechanistic, with binding of
neonatal Fc receptor (FcRn) and IgG in endosomes represented by nonlinear receptor-
ligand binding kinetics. The model has been previously presented by Kim et al. [1] and
Hattersley [2]. The principles of this model have been extended to physiologically based
pharmacokinetic models of IgG-based monoclonal antibodies by a number of authors
[3–6]. The four-compartment model represents a compromise between complex, physi-
ologically based models and the two-compartment model [1; 2; 7] analysed in chapter
5.
The purpose of modelling IgG metabolism in this thesis is to be able to predict responses
of plasma IgG in multiple myeloma patients; mechanistic models are desirable when the
purpose is prediction beyond readily available datasets. Mechanistic models can also be
used to explain why certain behaviours arise in terms of underlying biological processes.
With accurate parameter values, it may be possible to draw meaningful interpretations
regarding FcRn-mediated recycling based upon binding kinetics. In addition, using a
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Figure 6-1 Schematic of the four-compartment model of IgG metabolism.
Arrows represent material flow between compartments and hooked arrows
represent nonlinear receptor-ligand binding.
simpler, descriptive or phenomenological model to describe data can result in biased
parameter estimates [8].
The aim of this chapter is to determine whether parameter values can be estimated
using the limited in vivo human data available in the literature. In section 6.1 the four-
compartment model is described. In section 6.2 the model is linearised and relationships
between available experimental observations and the system model are described. In
section 6.3 parameters are estimated from the timecourse data of six individuals from
tracer experiments reported in the literature. In section 6.4 a naive-pooled approach is
used to estimate parameters for a reparameterised model. All of the data used in this
chapter are taken from Solomon et al. [9], Waldmann et al. [7] and Waldmann et al. [10].
The four-compartment model presented in section 6.1 has been previously published by
Kim et al. [1] and Hattersley [2]. The remainder of the work presented in this chapter
represents original work by the author.
6.1 System model
The four-compartment model of IgG metabolism [1; 2] has four state variables (x1(t),
x2(t), x3(t) and x4(t)), nine parameters and an input function, I(t), representing the
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Table 6-1 States and parameters of four-compartment model of IgG
metabolism, with parameter values sourced in the literature
Name Units Literature
value
Physiological interpretation
x1 µmol – Quantity of IgG in the central (plasma) compartment
x2 µmol – Quantity of IgG in the peripheral compartment
x3 µmol – Quantity of unbound IgG in intracellular endosomes
x4 µmol – Quantity of IgG-FcRn complexes in intracellular en-
dosomes
v1 l 2.9
∗ Plasma volume
v2 l – Volume of peripheral compartment
v3 l 0.34
† Total volume of endosomes
k21 day
−1 0.51‡ Rate constant of flow of IgG from plasma to peripheral
compartment
k31 day
−1 0.18§ Rate constant of flow of IgG from plasma into endo-
somes by pinocytosis
k12 day
−1 0.41‡ Rate constant of flow of IgG from peripheral compart-
ment to plasma
k14 day
−1 5.0¶ Rate constant of flow of recycled IgG from endosomes
back into plasma
k03 day
−1 3.0‖ Rate constant of degradation of unbound IgG in en-
dosomes
kon l µmol
−1 day−1 1000∗∗ Association rate constant of IgG-FcRn binding
Rtot µmol 14
¶ Total quantity of FcRn receptors, bound and unbound
koff day
−1 100∗∗ Dissociation rate constant of IgG-FcRn binding
∗Solomon et al. [9], †Shah et al. [5], ‡Hattersley et al. [11], §Waldmann et al. [7], ¶Ferl et al.
[3], ‖Hansen et al. [12], ∗∗Chen et al. [13]
synthesis rate of IgG. The model equations are given by
x˙1(t) = −(k21 + k31)x1(t) + k12x2(t) + k14x4(t) + I(t)
x˙2(t) = k21x1(t)− k12x2(t)
x˙3(t) = k31x1(t)− k03x3(t)− kon
v3
x3(t)(Rtot − x4(t)) + koffx4(t)
x˙4(t) =
kon
v3
x3(t)(Rtot − x4(t))− (k14 + koff)x4(t),
(6-1)
where x1(t), x2(t), x3(t) and x4(t) represent the quantities in micromoles (µmol) of IgG
in plasma, IgG in a peripheral compartment, unbound IgG in endosomes and IgG bound
to FcRn in endosomes, respectively. I(t) represents the synthesis rate of IgG in plasma in
micromoles per day (µmol day−1). The rate constants, kij, represent material flow from
compartment j to compartment i, with the convention that 0 represents the environment
outside the system. The parameters kon and koff are the receptor-ligand binding con-
stants of IgG and FcRn. The volumes of plasma, the peripheral compartment and the
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endosomes are denoted by v1, v2 and v3, respectively. We notice that the parameters kon
and v3 appear in the equations only as the fraction kon/v3; therefore we immediately can
conclude that these two parameters are not uniquely structurally identifiable. We assume
a constant total (bound and unbound) quantity of FcRn, Rtot, as other authors have done
[3]. This means that the quantity of unbound FcRn is represented by (Rtot−x4(t)). The
model states and physiological interpretations of the parameters are summarised in table
6-1. Note that all states and parameters can only take non-negative values. We refer to
figure 6-1 for a schematic of the model.
6.1.1 Stability analysis
When the production rate of IgG is constant, I(t) = I0, the system has an equilibrium
point given by
xˆ1 =
I0 (k03k14v3 + k03koffv3 + konI0 + k14konRtot)
k31
(
k03v3(k14 + koff) + konI0
)
xˆ2 =
k21
k12
xˆ1
xˆ3 =
I0
k03
xˆ4 =
konI0Rtot
k03v3(k14 + koff) + konI0
.
(6-2)
Linearising the system about the equilibrium point gives
x˙1(t)
x˙2(t)
x˙3(t)
x˙4(t)

=

−k21 − k31 k12 0 k14
k21 −k12 0 0
k31 0 a33 koff +
konI0
k03v3
0 0 a43 −k14 − koff − konI0k03v3


x1(t)
x2(t)
x3(t)
x4(t)

, (6-3)
where
a33 = −k03(kon(I0 + (k14 + koff)Rtot) + k03v3 (k14 + koff)
konI0 + k03v3 (k14 + koff)
a43 =
k03konRtot (k14 + koff)
konI0 + k03v3 (k14 + koff)
.
(6-4)
The coefficients of the characteristic polynomial for this matrix are given by
c1 =
1
k03v3
(
konI0 + k03v3(k14 + koff)
)(I20k2on + I0k03(k03 + k12 + 2k14 + k21 + k31
+ 2koff)konv3 + k
2
03(k14 + koff)v3
(
konRtot + (k03 + k12 + k14 + k21 + k31 + koff)v3
))
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c2 =
1
k03v3
(
konI0 + k03v3(k14 + koff)
)(I20 (k03 + k12 + k21 + k31)k2on
+ I0k03
(
2(k21 + k31)(k14 + koff) + k12(2k14 + k31 + 2koff) + k03(k12 + 2k14 + k21 + k31
+ 2koff)
)
konv3 + k
2
03(k14 + koff)v3
(
k21konRtot + k31konRtot + k03k21v3 + k03k31v3
+ k03koffv3 + k21koffv3 + k31koffv3 + k14
(
konRtot + (k03 + k21 + k31)v3
)
+ k12
(
konRtot + (k03 + k14 + k31 + koff)v3
)))
c3 =
1
k03v3
(
konI0 + k03v3(k14 + koff)
)(I20(k12k31 + k03(k12 + k21 + k31))k2on
+ I0k03
(
2k12k31(k14 + koff) + k03
(
2(k21 + k31)(k14 + koff)
+ k12(2k14 + k31 + 2koff)
))
konv3 + k
2
03(k14 + koff)v3
(
k03(k21 + k31)koffv3
+ k14(k21konRtot + k03k21v3 + k03k31v3) + k12
(
k03koffv3 + k14
(
konRtot + (k03
+ k31)v3
)
+ k31
(
konRtot + (k03 + koff)v3
))))
c4 =
k12k31
(
k03v3 (k14 + koff) + konI0
)
v3
. (6-5)
According to the Routh-Hurwitz stability criterion [14], the four-state system is stable
provided the coefficients of the characteristic polynomial of the linearised system satisfy
the conditions:
c1, c3, c4 > 0
c1c2c3 > c
2
3 + c
2
1c4.
(6-6)
All parameters, including the input I0, can only take positive values. The conditions
given by the first inequality in 6-6 can easily be checked by noticing that none of the
terms in equations 6-5 are preceded by a minus sign. The second inequality was tested
in Mathematica [15] using the code:
Assuming[Table[parameters[[i]] > 0, {i, 10}], FullSimplify[c1*c2*c3 > c3^2 +
c4*c1^2]
Both conditions are found to be met, showing that the equilibrium point of the system
is stable.
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6.2 Mathematical description of observations
The data available in the literature that may be used for parameter estimation are de-
scribed in section 5.3 of chapter 5. The data for subject E, who has familial hyper-
catabolic hypoproteinemia, are unsuitable for estimating all of the parameters of the
four-compartment model: subjects with familial hypercatabolic hypoproteinemia do not
express FcRn receptors and therefore the compartments for IgG-FcRn complexes and
unbound FcRn receptors can be eliminated from the model described in section 6.1, leav-
ing a three-compartment model with parameters k21, k12, k31 and k03. This sub-model
could potentially be used to estimate some of the model parameters; however this is not
investigated in this thesis.
In this section we consider how the available experimental observations are defined in
terms of the underlying system model. A linear model describing the timecourse observa-
tions is derived from the nonlinear model of coupled tracer and endogenous IgG dynamics.
Expressions for the fractional catabolic rate (FCR) and half-life (T1/2) are then derived
from the linear model of the timecourse observations.
6.2.1 Nonlinear structural model of coupled tracer and endoge-
nous IgG dynamics
The administered tracer and the endogenous IgG are assumed to be indistinguishable by
the system, that is they exhibit identical kinetic behaviour – a standard assumption in
tracer studies [16]. It is thus assumed that the kinetics of both tracer and endogenous
IgG are described by the model in (6-1). From (6-1), letting xi(t) = xi,T(t) + xi,E(t),
i = 1, . . . , 4, where subscript ‘T’ denotes tracer, and subscript ‘E’ denotes endogenous
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IgG, respectively, gives
x˙1,T(t) = −(k21 + k31)x1,T(t) + k12x2,T(t) + k14x4,T(t)
x˙2,T(t) = k21x1,T(t)− k12x2,T(t)
x˙3,T(t) = k31x1,T(t)− k03x3,T(t)− kon
v3
x3,T(t)(Rtot − x4,E(t)− x4,T(t)) + koffx4,T(t)
x˙4,T(t) =
kon
v3
x3,T(t)(Rtot − x4,E(t)− x4,T(t))− (k14 + koff)x4,T(t)
x˙1,E(t) = −(k21 + k31)x1,E(t) + k12x2,E(t) + k14x4,E(t) + IE
x˙2,E(t) = k21x1,E(t)− k12x2,E(t)
x˙3,E(t) = k31x1,E(t)− k03x3,E(t)− kon
v3
x3,E(t)(Rtot − x4,E(t)− x4,T(t)) + koffx4,E(t)
x˙4,E(t) =
kon
v3
x3,E(t)(Rtot − x4,E(t)− x4,T(t))− (k14 + koff)x4,E(t),
(6-7)
where xi,T(t) and xi,E(t) represent the quantities in µmol of radiolabelled and endogenous
IgG in compartment i, respectively, and IE (µmol day
−1) represents the production rate
of endogenous IgG, which is assumed constant. All other parameters are as defined in
section 6.1.
The dose of tracer administered at time t = 0 is treated as a non-zero initial condition
for x1,T(t). Tracer is administered to the plasma compartment (i = 1) only, therefore the
initial conditions for the remaining tracer compartments are zero. The endogenous IgG
is assumed to be in steady state at the beginning of the experiment and remain in steady
state throughout, as verifiable by the experimenter, such that the initial conditions of
the endogenous IgG are given by the steady states in equation (6-2), with I0 = IE. In
summary, the initial conditions are given by
x1,T(0) = D
x2,T(0) = x3,T(0) = x4,T(0) = 0
x1,E(0) = xˆ1
x2,E(0) = xˆ2
x3,E(0) = xˆ3
x4,E(0) = xˆ4,
(6-8)
where D (µmol) is the administered dose of tracer.
The experimenter observes the proportion of the dose remaining in plasma and in the
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body during the experiment. The observation functions are thus given by
y1(t) =
x1,T(t)
D
y2(t) =
x1,T(t) + x2,T(t) + x3,T(t) + x4,T(t)
D
.
(6-9)
6.2.2 Linearised structural model of tracer dynamics
Provided that the administered dose of tracer is sufficiently small, the tracer kinetics can
be approximated using a Taylor series expansion of the model state about the equilibrium
point [17]. In this way a linear model of the experiment is derived. The derivation of a
linearised model for tracer dynamics from a general compartmental model is provided by
Anderson [18].
The dynamics of endogenous IgG and FcRn receptors are described by
x˙1,E(t) = −(k21 + k31)x1,E(t) + k12x2,E(t) + k14x4,E(t) + IE
x˙2,E(t) = k21x1,E(t)− k12x2,E(t)
x˙3,E(t) = k31x1,E(t)− k03x3,E(t)− kon
v3
x3,E(t)x5,E(t) + koffx4,E(t)
x˙4,E(t) =
kon
v3
x3,E(t)x5,E(t)− (k14 + koff)x4,E(t)
x˙5,E(t) = −kon
v3
x3,E(t)x5,E(t) + (k14 + koff)x4,E(t),
(6-10)
where xi,E(t), i = 1, . . . , 4, is the quantity of unlabelled IgG in compartment i (for details
see section 6.1) and x5,E(t) is the quantity of unbound FcRn receptors in intracellular
endosomes. The total quantity of FcRn, x4,E(t) + x5,E(t), is constant and given by Rtot,
therefore the equation for the rate of change of x5,E(t) is not actually required in equations
(6-10). However, in order to linearise the model, all endogenous quantities are assumed
to be in steady state, including the endogenous FcRn receptors. Including the equation
for x5,E(t) makes this assumption more straightforward later. Prior to administration of
the tracer dose, the system is assumed to be in steady state, where xˆi, i = 1, . . . , 4, is
the quantity of IgG in compartment i in steady state, as given by (6-2) with I0 set to IE.
The steady state of unbound FcRn is given by xˆ5 = Rtot− xˆ4. For convenience equations
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(6-10) are re-written as follows:
x˙1,E(t) = F1(x1,E(t), x2,E(t), x3,E(t), x4,E(t), x5,E(t)) + IE
x˙2,E(t) = F2(x1,E(t), x2,E(t), x3,E(t), x4,E(t), x5,E(t))
x˙3,E(t) = F3(x1,E(t), x2,E(t), x3,E(t), x4,E(t), x5,E(t))
x˙4,E(t) = F4(x1,E(t), x2,E(t), x3,E(t), x4,E(t), x5,E(t))
x˙5,E(t) = F5(x1,E(t), x2,E(t), x3,E(t), x4,E(t), x5,E(t)).
(6-11)
The administration of a small bolus dose of labelled IgG is treated as a perturbation of
the steady state at time t = 0. The input of tracer is denoted by u(t). Now the dynamics
of the total quantity of both labelled and unlabelled IgG are described by
q˙1(t) = −(k21 + k31)q1(t) + k12q2(t) + k14q4(t) + IE + u(t)
q˙2(t) = k21q1(t)− k12q2(t)
q˙3(t) = k31q1(t)− k03q3(t)− kon
v3
q3(t)x5,E(t) + koffq4(t)
q˙4(t) =
kon
v3
q3(t)x5,E(t)− (k14 + koff)q4(t)
x˙5,E(t) = −kon
v3
q3(t)x5,E(t) + (k14 + koff)q4(t),
(6-12)
where qi(t) = xi,E(t) +xi,T(t), i = 1, . . . , 4 is the total quantity of labelled and unlabelled
IgG in compartment i.
Assuming that the tracer dose is sufficiently small, we have xi,T(t) = qi(t)−xˆi, i = 1, . . . , 4,
where xi,T(t) is the quantity of tracer, qi(t) is the total quantity of tracer and endogenous
IgG, and xˆi is the quantity of IgG in steady state, in compartment i, respectively. Since
the FcRn receptors are endogenous to the system they are assumed to be in steady state,
such that x5,E(t) = xˆ5, where xˆ5 = Rtot − xˆ4 is the quantity of unbound FcRn receptors
in equilibrium. The rate of change of the total quantity of IgG in compartment i is given
by
q˙i(t) =
d
dt
(
xi,T(t) + xˆi
)
= x˙i,T(t), i = 1, . . . , 4. (6-13)
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From (6-12) and (6-13) we have that
x˙1,T(t) = −(k21 + k31)(x1,T(t) + xˆ1) + k12(x2,T(t) + xˆ2) + k14(x4,T(t) + xˆ4) + IE
+ u(t)
x˙2,T(t) = k21(x1,T(t) + xˆ1)− k12(x2,T(t) + xˆ2)
x˙3,T(t) = k31(x1,T(t) + xˆ1)− k03(x3,T(t) + xˆ3)− kon
v3
(x3,T(t) + xˆ3)xˆ5
+ koff(x4,T(t) + xˆ4)
x˙4,T(t) =
kon
v3
(x3,T(t) + xˆ3)xˆ5 − (k14 + koff)(x4,T(t) + xˆ4).
(6-14)
It is now possible to approximate the right hand sides of (6-14) using the Taylor series
expansion. Equations (6-14) are re-written to give
x˙1,T(t) = F1(xˆ1 + x1,T(t), xˆ2 + x2,T(t), xˆ3 + x3,T(t), xˆ4 + x4,T(t), xˆ5) + IE + u(t)
x˙2,T(t) = F2(xˆ1 + x1,T(t), xˆ2 + x2,T(t), xˆ3 + x3,T(t), xˆ4 + x4,T(t), xˆ5)
x˙3,T(t) = F3(xˆ1 + x1,T(t), xˆ2 + x2,T(t), xˆ3 + x3,T(t), xˆ4 + x4,T(t), xˆ5)
x˙4,T(t) = F4(xˆ1 + x1,T(t), xˆ2 + x2,T(t), xˆ3 + x3,T(t), xˆ4 + x4,T(t), xˆ5).
(6-15)
The Taylor series expansion of the right hand side of (6-15) is given by
Fi(xˆ1 + x1,T(t), xˆ2 + x2,T(t), xˆ3 + x3,T(t), xˆ4 + x4,T(t), xˆ5)
= Fi(xˆ1, xˆ2, xˆ3, xˆ4, xˆ5) + x1,T(t)
∂Fi
∂x1,E
(xˆ1, xˆ2, xˆ3, xˆ4, xˆ5)
+ x2,T(t)
∂Fi
∂x2,E
(xˆ1, xˆ2, xˆ3, xˆ4, xˆ5) + x3,T(t)
∂Fi
∂x3,E
(xˆ1, xˆ2, xˆ3, xˆ4, xˆ5)
+ x4,T(t)
∂Fi
∂x4,E
(xˆ1, xˆ2, xˆ3, xˆ4, xˆ5) + H.O.T,
(6-16)
where H.O.T are higher order terms. Expanding (6-15) using (6-16) gives
x˙1,T(t) ≈ −(k21 + k31)x1,T(t) + k12x2,T(t) + k14x4,T(t) + u(t)
x˙2,T(t) ≈ k21x1,T(t)− k12x2,T(t)
x˙3,T(t) ≈ k31x1,T(t)− k03x3,T(t)− kon
v3
xˆ5x3,T(t) + koffx4,T(t)
x˙4,T(t) ≈ kon
v3
xˆ5x3,T(t)− (k14 + koff)x4,T(t).
(6-17)
It is assumed that the tracer dose is small enough so that higher order terms in the Taylor
series expansion can be neglected. We also recall that xˆ5 = Rtot − xˆ4. Finally a linear
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model for the tracer dynamics is obtained, given by
x˙1,T(t) = −(k21 + k31)x1,T(t) + k12x2,T(t) + k14x4,T(t) + u(t)
x˙2,T(t) = k21x1,T(t)− k12x2,T(t)
x˙3,T(t) = k31x1,T(t)− k03x3,T(t)− k43x3,T(t) + k34x4,T(t)
x˙4,T(t) = k43x3,T(t)− (k14 + k34)x4,T(t),
(6-18)
where k34 and k43 are given by
k34 = koff
k43 =
kon(Rtot − xˆ4)
v3
=
konRtotk03(k14 + koff)
IEkon + k03v3(k14 + koff)
.
(6-19)
The input u(t) can be treated as a non-zero initial condition for x1,T(t). The linear
equations describing the tracer kinetics are then given by
x˙1,T(t) = −(k21 + k31)x1,T(t) + k12x2,T(t) + k14x4,T(t)
x˙2,T(t) = k21x1,T(t)− k12x2,T(t)
x˙3,T(t) = k31x1,T(t)− k03x3,T(t)− k43x3,T(t) + k34x4,T(t)
x˙4,T(t) = k43x3,T(t)− (k14 + k34)x4,T(t),
(6-20)
where x1,T(t), x2,T(t), x3,T(t) and x4,T(t) represent the quantities of radiolabelled IgG in
the central compartment, in the peripheral compartment, unbound in intracellular endo-
somes, and bound to FcRn in intracellular endosomes, respectively. The new parameters
k34 and k43 are given by equation (6-19) and all other parameters are defined as in section
6.1.
The initial conditions are given by
x1,T(0) = D
x2,T(0) = x3,T(0) = x4,T(0) = 0.
(6-21)
The observation functions are given by
y1(t) =
x1,T(t)
D
y2(t) =
x1,T(t) + x2,T(t) + x3,T(t) + x3,T(t)
D
.
(6-22)
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Figure 6-2 Simulations of the quantities of tracer in each compartment
after administration at t = 0 days, for a tracer dose of (A) 1 µmol and (B)
100 µmol. The nonlinear model is represented by solid lines and the linearised
model by dashed lines (‘lin.’). In (A) the dashed lines overlay the solid lines;
hence the linearised model is valid for the smaller dose (A) but not for the
larger dose (B). Note the different scales for x1,T(t) and x2,T(t) (left axis),
and x3,T(t) and x4,T(t) (right axis), respectively.
6.2.3 Comparison of the nonlinear and linearised models for
large tracer doses
The linearisation of the model of tracer and endogenous IgG dynamics relies on the
assumption of a sufficiently small dose of tracer, such that the endogenous IgG can be
assumed to remain in steady state. A typical tracer dose is 3× 10−3 µmol – 7× 10−3 µmol
[9]. Simulations of the quantity of tracer in each compartment are shown in figure 6-2.
The nonlinear model, described by equations (6-7)–(6-8), is represented by solid lines and
the linearised model, described by equations (6-20)–(6-21), is represented by dashed lines.
In figure 6-2A a dose of D = 1 µmol is assumed and in figure 6-2B a dose of D = 100 µmol
is assumed. The parameter values in table 6-1 are used. A normal IgG synthesis rate
of IE = 15 µmol day
−1 was used; however the conclusion drawn was the same when very
small values of IE were used. The simulations illustrate that, for a dose of 1 µmol and
the particular parameter values used, the linearised model is a valid approximation of the
full nonlinear model over a 25-day simulated time course. When the dose is increased to
100µmol, the assumption that the steady state is not perturbed by the administered dose
no longer holds, and the two models give different simulation results for the quantities of
tracer. For D = 1 µmol, which is more than 100 times typical tracer doses, the maximal
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Figure 6-3 (A) Simulation of FCRT(t) given by equations (6-23) and
(6-24), for the parameter values in table 6-1 and dose D = 0.01 µmol. (B)
Simulations of T1/2,T(t) given by equation (6-30), for the parameter values in
table 6-1 with normal endogenous IgG production rate IE = 15 µmol day
−1
[7].
difference between the linear model and nonlinear model simulations is less than 0.7%.
The extremely large dose of D = 100 µmol was chosen specifically to show the dynamics
of the linearised model when it is not a valid approximation of the nonlinear model.
6.2.4 Fractional catabolic rate
The fractional catabolic rate (FCR) is defined as the elimination rate of IgG as a fraction
of the quantity of IgG in plasma. The FCR can be defined with respect to the tracer,
denoted here by FCRT, or with respect to the endogenous IgG, denoted here by FCRE.
FCRT and FCRE have units of µmol day
−1.
As there is only elimination from the system and no input after time t = 0, FCRT is given
by the rate of change of radiolabelled IgG in all compartments, divided by the quantity
of radiolabelled IgG in plasma:
FCRT(t) =
− (x˙1,T(t) + x˙2,T(t) + x˙3,T(t) + x˙4,T(t))
x1,T(t)
=
−y˙2(t)
y1(t)
. (6-23)
From equation (6-23), it can be seen that in practice FCRT is obtained from the slope of
the observation y2(t) divided by y1(t). Substituting equations (6-20) into equation (6-23)
gives
FCRT(t) =
k03x3,T(t)
x1,T(t)
, (6-24)
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where x3,T(t) and x1,T(t) are given by the solution of equations (6-20)–(6-21).
Whilst a single value of FCRT is measured for an individual subject (see section 5.3 in
chapter 5), in actuality FCRT is not constant, as shown by the dependence on time in
equations (6-23) and (6-24). A simulation of FCRT(t) during the experiment is shown
in figure 6-3A. After around day 5 (for the particular parameter values used) FCRT(t)
approaches a steady state value, which is denoted here by FCRT,∞:
FCRT,∞ = lim
t→∞
k03x3,T(t)
x1,T(t)
. (6-25)
Solving equations (6-20)–(6-21) gives
xi,T(t) = Ai1 exp(λ1t) + Ai2 exp(λ2t) + Ai3 exp(λ3t) + Ai4 exp(λ4t), (6-26)
assuming, without loss of generality, |λ1| > |λ2| > |λ3| > |λ4|. After sufficient time,
xi,T(t) can be approximated by Ai4 exp(λ4t); thus, FCRT,∞ is given by
FCRT,∞ = k03
A34 exp(λ4t)
A14 exp(λ4t)
= k03
A34
A14
, (6-27)
where A34 and A14 are expressions in terms of the model parameters. The expressions for
A34 and A14 are extremely long. The Mathematica [15] code for generating the expressions
is provided in appendix D.
It is also possible to derive an expression for the FCR with respect to the endogenous
IgG, FCRE. If the endogenous IgG is assumed to remain in steady state, then from the
definition of the FCR,
FCRE =
k03xˆ3
xˆ1
, (6-28)
where xˆ1 and xˆ3 are the quantities of IgG in compartments 1 and 3 in steady state,
given by (6-2). Substituting the expression for xˆ3 from (6-2) into (6-28), eliminating I0
in favour of xˆ1 using the first equation of (6-2), and setting xˆ1 = x1,E, gives the following
expression for the FCRE in terms of the quantity of IgG in plasma, x1,E:
FCRE =
1
2konx1,E
(
k31konx1,E − k14konRtot − k03k14v3 − k03koffv3
+
{
4k03k31(k14 + koff)konx1,Ev3
+ (−k31konx1,E + k14konRtot + k03k14v3 + k03koffv3)2
}1/2)
.
(6-29)
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6.2.5 Half-life
The half-life is obtained from the slope of either timecourse observation, y1(t) or y2(t),
plotted on a log scale. The half-life is thus given by
T1/2,i(t) =
− log(2)
d(log yi(t)) / dt
, (6-30)
for i = 1 or i = 2, depending on whether y1(t) or y2(t) is used. Simulations of T1/2,1(t)
and T1/2,2(t) are plotted in figure 6-3B. After sufficient time, the slopes of log
(
y1(t)
)
and
log
(
y2(t)
)
approach the same value and therefore so do T1/2,1(t) and T1/2,2(t). Experi-
menters measure the value towards which T1/2,1(t) and T1/2,2(t) tend for increasing values
of t, which we will call T1/2,∞:
T1/2,∞ = lim
t→∞
− log 2
d(log yi(t)) / dt
, i = 1, 2. (6-31)
For the linear model described by equations (6-20)–(6-22), T1/2,∞ is given by
T1/2,∞ = lim
t→∞
− log 2
d(log yi(t)) / dt
=
− log 2
λ4
, (6-32)
where λ4 is the negative terminal slope of the timecourse observations plotted on a log
scale. The expression for λ4 is large and omitted for brevity. The Mathematica [15] code
for generating the expression is provided in appendix D. Henceforth FCRT,∞ and T1/2,∞
will be referred to simply as FCRT and T1/2,T.
6.3 Individual approach to parameter identification
using timecourse data
In this section we investigate parameterisation of the model by fitting the linearised
model outputs described in section 6.2.2 to the timecourse data described in section 5.3 of
chapter 5. Firstly, a structural identifiability analysis is performed in order to determine
which, if any, of the model parameters are structurally identifiable. The parameters
are then estimated from the data by fitting the linearised model described by equations
(6-20)–(6-22). The simulation in figure 6-2 illustrates that, for typical doses, the solution
to the linear approximation is practically indistinguishable from the solution to the full
nonlinear model. It is therefore sufficient to perform the fitting on the linear model.
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6.3.1 Structural identifiability analysis
Structural identifiability addresses the question of whether model parameters can be
uniquely identified from available observations, under the assumption of the availability
of ideal (i.e. noise-free) and continuous observational data. Here we determine which of
the model parameters are structurally uniquely identifiable from the observations y1(t)
and y2(t) for an individual subject, given by equations (6-20)–(6-22). The parameter
vector is given by θ = (k21, k31, k12, k14, k03, k43, k34)
T.
Here the transfer function method is used [19]. To apply this approach the system
described by equations (6-20)–(6-22) is re-written in vector-matrix notation as
x˙T(t,θ) = A(θ)xT(t) +B(θ)u(t)
xT(0,θ) = 0
y(t,θ) = C(θ)xT(t),
(6-33)
where xT(t) =
(
x1,T(t), x2,T(t), x3,T(t), x4,T(t)
)T
and y(t,θ) =
(
y1(t,θ), y2(t,θ)
)T
are
column vectors representing the state and the observation, respectively. u(t) represents
the single input to the system, an impulse at time t = 0, given by u(t) = δ(t). A(θ) is
a 4 × 4 matrix, C(θ) is a 2 × 4 matrix and B(θ) is a column vector. A(θ), B(θ) and
C(θ) are given by
A(θ) =

− (k21 + k31) k12 0 k14
k21 −k12 0 0
k31 0 − (k03 + k43) k34
0 0 k43 − (k14 + k34)

,
B(θ) =

D
0
0
0

,C(θ) =
 1D 0 0 0
1
D
1
D
1
D
1
D
 .
(6-34)
Note that the administration of a bolus dose is now represented as an impulse at time
t = 0, rather than a non-zero initial condition, such that xT(0,θ) = (0, 0, 0, 0)
T.
Taking Laplace transforms of equations (6-33), the input-output relation is given by
Y (s) = G(s)U(s), whereG(s) is the transfer function matrix, given byG(s) = C(θ)(sI−
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A(θ))−1B(θ), where I is the 4×4 identity matrix. G(s) has two elements, corresponding
to the two observed outputs, which are given by
G1(s) =
φ1 + φ2s+ φ3s
2 + s3
φ4 + φ5s+ φ6s2 + φ7s3 + s4
G2(s) =
φ8 + φ9s+ φ10s
2 + s3
φ11 + φ12s+ φ13s2 + φ14s3 + s4
,
(6-35)
where the coefficients of s, Φ(θ) = (φ1(θ), φ2(θ), ..., φ14(θ))
T, are nonlinear expressions
in the parameters. The coefficients of s, Φ(θ), are given by
φ1(θ) = k12
(
k03 (k14 + k34) + k14k43
)
φ2(θ) = k03 (k12 + k14 + k34) + k14k43 + k12 (k14 + k34 + k43)
φ3(θ) = k03 + k12 + k14 + k34 + k43
φ4(θ) = φ11(θ) = k03k12k31(k14 + k34)
φ5(θ) = φ12(θ) = k03((k21 + k31)(k14 + k34) + k12(k14 + k31 + k34)) + k14k21k43
+ k12(k14(k31 + k43) + k31(k34 + k43))
φ6(θ) = φ13(θ) = k14k21 + k14k31 + k21k34 + k31k34 + k03(k12 + k14 + k21 + k31
+ k34) + k14k43 + k21k43 + k31k43 + k12(k14 + k31 + k34 + k43)
φ7(θ) = φ10(θ) = φ14(θ) = k03 + k12 + k14 + k21 + k31 + k34 + k43
φ8(θ) = k03(k12 + k21)(k14 + k34) + k14k21k43 + k12(k14(k31 + k43) + k31(k34
+ k43))
φ9(θ) = k14k21 + k14k31 + k21k34 + k31k34 + k03(k12 + k14 + k21 + k34) + k14k43
+ k21k43 + k31k43 + k12(k14 + k31 + k34 + k43).
(6-36)
The coefficients Φ(θ) are unique with respect to the input-output relationship rep-
resented by the transfer function. Introducing an alternative parameter vector θ =
(k21, k31, k12, k14, k03, k43, k34)
T and equating Φ(θ) = Φ(θ), the resulting set of simul-
taneous equations is solved for θ using the Solve function in Mathematica [15]. The
only solution is θ = θ; therefore all of the parameters in θ are structurally uniquely
identifiable.
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6.3.2 The parameter estimation problem
The ‘true’ parameter vector for an individual is denoted by θ0. For an individual
subject it is assumed that yi(t,θ0), i = 1, 2, is observed with error at measurement
times t
(i)
1 , . . . , t
(i)
Ni
, i = 1, 2, where t
(1)
1 = t
(2)
1 = 0. The observed (with error) values of
yi(t,θ0), i = 1, 2, are now denoted by y˜i(t
(i)
j ,θ0) for i = 1, 2 and j = 1, . . . , Ni.
Assumptions regarding data generation and collection and the resulting errors are out-
lined in section 5.5 of chapter 5. The assumptions that applied to the two-compartment
model also apply to the four-compartment model; however now y1(t), y2(t) and x1,T(t)
are defined by equations (6-20)–(6-22). Where x2,T(t) appears in sections 5.5.3 and 5.5.4,
it is replaced by x2,T(t) + x3,T(t) + x4,T(t) for the four-compartment model.
From section 5.5, it is assumed that observation y˜1(t
(1)
j ,θ0) has standard deviation pro-
portional to its mean, or a constant coefficient of variation. The standard deviation of
y˜2(t
(2)
j ,θ0) however has a more complex relationship with its mean. It is also assumed
that there are systematic errors and autocorrelation between errors present as a result of
calculations from raw measurements. Any of the standard estimation methods is strictly
not valid due to the presence of systematic errors; therefore when estimating parameter
values from the data by any method, it will be necessary to validate the method against
synthetic data with known true parameter values.
In section 6.3.3 the parameter vector θ is estimated for each subject using unweighted
least squares, by fitting the timecourse data described in section 5.3 of chapter 5. Un-
weighted least squares is used initially because it is the simplest method and can be used
to investigate whether it is possible to fit the data before refining the error model.
In order to estimate the parameters, it is assumed that the observed measurements for
an individual are given by
y˜i(t
(i)
j ,θ0) = yi(t
(i)
j ,θ0) + bi(t
(i)
j ), j = 1, . . . , Ni, i = 1, 2, (6-37)
where i(t
(i)
j ) are independent and identically distributed random variables following the
normal distribution, (x1,E,j) ∼ N(0, 1). The standard deviation of the errors is denoted
by b. It is assumed that b does not depend on time or on i.
Both outputs y1 and y2 were fitted simultaneously, therefore the cost functional for θ is
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Table 6-2 Parameters for differential evolution
Subject
A B C D F G
Scaling factor (F ) 0.5 0.5 0.7 0.5 0.5 0.7
Crossover probability (CR) 0.9 0.9 0.95 0.9 0.9 0.95
given by
J(θ0,θ) =
2∑
i=1
Ji(θ0,θ), (6-38)
where
Ji(θ0,θ) =
Ni∑
j=1
(
y˜i(t
(i)
j ,θ0)− yi(t(i)j ,θ)
)2
. (6-39)
Since the model parameters can only take positive values it is assumed that θ0,θ ∈ R7+.
6.3.3 Parameter estimation
Differential evolution was implemented using the NonlinearModelFit function in Mathe-
matica [15] to minimise of the cost functional in equation (6-38). The differential evolution
algorithm was chosen because there is little information available about the parameters, in
particular k14, k03, k43 and k34. Differential evolution is a stochastic, global minimisation
algorithm that does not require the user to specify initial guesses for the parameter val-
ues [20]. All parameters were constrained to be positive, by providing the constraints to
NonlinearModelFit. The maximum number of iterations was increased up to a maximum
of 5000, which was sufficient for the algorithm to converge in all cases. In differential
evolution an initial population of parameter vectors is generated randomly. The algo-
rithm was run for each subject’s data with integer seeds for the pseudorandom number
generator between 1 and 10; thus ten estimates for each parameter were obtained for each
subject.
Differential evolution maintains a population of parameter vectors which evolves itera-
tively. For each new generation of the algorithm, a mutant and trial vector are produced
from the current generation and the trial vector is compared with a target vector from
the current generation. Either the target or trial vector is selected to move forward to
the new generation based on which has the smallest value of the cost function to be
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minimised. The scaling factor (F ) is used to produce the mutant vector and generally a
larger value of F means a broader search of the parameter space. The crossover probabil-
ity (CR) is the probability that each element of the mutant vector is used to produce the
trial vector, rather than the corresponding element of the target vector. F and CR were
tuned by trial and error for each subject. The parameters were initially set to F = 0.5,
as recommended by Storn et al. [20], and CR = 0.9, as recommended by Storn et al.
[20] for faster convergence. For subjects C and G the algorithm either took a very long
time to converge or gave larger residual sums of squares than local methods that were
previously tried; therefore the parameters were adjusted to F = 0.7, for a broader search
of the parameter space, and CR = 0.95, to speed convergence.
Differential evolution is a stochastic minimisation method: each run with a unique seed
for the pseudorandom number generator can produce unique parameter estimates; it is
therefore recommended to perform multiple runs with unique, randomly chosen starting
populations of parameter vectors [20]. The parameter estimates and root mean square
error (RMSE) for each run and each subject are tabulated in tables 6-3 to 6-5. The
parameter estimates from multiple runs should be close to one another so that they
can be averaged [20; 21]; however, for the data fitted here, the different runs give very
different parameter estimates, implying that the algorithm has difficulty finding the global
minimum and that there may be many local minima. It is therefore not certain that the
global minimum has been found for each subject. It is also likely that certain parameters
are highly correlated, such that different parameter vectors produce very similar model
outputs. This is reflected in the diversity of parameter vectors obtained within subjects
using differential evolution.
In some cases parameters are estimated to be zero, or very close to zero, for example k34
for subject B, k12 and k14 for subject C, k34 for subject D, and k21 and k14 for subject F.
For each of these subjects the data can be well represented by a reduced model in which
either IgG-FcRn binding is irreversible (k34 = 0), there is no transfer from the peripheral
compartment to plasma (k12 = 0) or vice versa (k21 = 0), or bound IgG molecules are not
recycled into plasma (k14 = 0). None of these scenarios is consistent with the biology.
The data and the model outputs using the parameter estimates in tables 6-3 to 6-5 are
plotted in figure 6-4. In each panel of figure 6-4, the model outputs y1(t) and y2(t) are
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Figure 6-4 Tracer experiment data (y1(t) blue circles; y2(t) red circles)
and model fits (y1(t) blue line; y2(t) red line) for (A–F) subjects A–D, F and
G
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Table 6-3 Estimated parameter values from multiple runs; subjects A and B
Run
Parameter
RMSE
k21 (day
−1) k31 (day−1) k12 (day−1) k14 (day−1) k03 (day−1) k43 (day−1) k34 (day−1)
S
u
b
j
e
c
t
A
1 0.39119 0.157878 1.28693 0.0627919 0.260824 1.88308 0.206295 0.0123609
2 0.390745 0.158698 1.29161 0.0623367 0.29449 2.22981 0.216064 0.01236
3 0.390487 0.159263 1.29333 0.0616348 0.341147 2.6961 0.224638 0.0123598
4 0.38958 0.159262 1.28763 0.0612125 0.363375 2.90857 0.227123 0.0123599
5 0.388328 0.139006 1.10777 0.0698655 0.0880881 0.208648 0.0279417 0.0122732
6 0.391029 0.159866 1.29897 0.0611406 0.395192 3.24859 0.232921 0.0123601
7 0.391508 0.159861 1.30286 0.0616297 0.364982 2.95008 0.229264 0.01236
8 0.386326 0.158598 1.26971 0.0614646 0.327351 2.54105 0.221117 0.0123603
9 0.390512 0.159204 1.29311 0.0616972 0.336033 2.64455 0.22378 0.0123598
10 0.389696 0.158633 1.28534 0.0619406 0.307191 2.34694 0.217706 0.0123599
S
u
b
j
e
c
t
B
1 1.71644 0.174093 2.95564 0.151315 1.04088 1.22565 1.0875× 10−16 0.00858265
2 0.100606 0.731658 0.14714 3.18125 0.208244 1.7168 0. 0.00858943
3 0.0986298 1.09096 0.146438 2.48661 0.408062 20.1932 7.16228 0.00864507
4 1.734 0.174091 2.98353 0.151317 1.04436 1.22956 0. 0.00858265
5 1.71644 0.174093 2.95564 0.151315 1.04088 1.22565 0. 0.00858265
6 1.71644 0.174093 2.95564 0.151315 1.04088 1.22565 0. 0.00858265
7 1.71644 0.174093 2.95564 0.151315 1.04088 1.22565 0. 0.00858265
8 1.71644 0.174093 2.95564 0.151315 1.04088 1.22565 3.688 03× 10−15 0.00858265
9 0.100606 0.731658 0.14714 3.18125 0.208244 1.7168 0. 0.00858943
10 1.71619 0.174078 2.95504 0.151295 1.04094 1.22553 0. 0.00858265
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Table 6-4 Estimated parameter values from multiple runs; subjects C and D
Run
Parameter
RMSE
k21 (day
−1) k31 (day−1) k12 (day−1) k14 (day−1) k03 (day−1) k43 (day−1) k34 (day−1)
S
u
b
j
e
c
t
C
1 0.0217371 0.438343 6.4685× 10−16 0.527361 0.580325 2.10374 0.331603 0.00681915
2 0.346192 0.159615 0.536837 0. 1.3126 0.446687 0.0880231 0.00552995
3 0.0217371 0.438343 9.748 08× 10−15 0.527361 0.580325 2.10374 0.331603 0.00681915
4 1104.9 0.349394 8586.71 0.2537 0.764531 1.72415 0.140787 0.00780007
5 0.346192 0.159615 0.536837 2.807 85× 10−16 1.3126 0.446687 0.0880231 0.00552995
6 202.854 0.349347 1576.2 0.253697 0.764203 1.72264 0.140666 0.00780007
7 0.0217371 0.438343 1.509 99× 10−16 0.527361 0.580325 2.10374 0.331603 0.00681915
8 0.0217371 0.438343 4.653 98× 10−15 0.527361 0.580325 2.10374 0.331603 0.00681915
9 284.447 0.349385 2210.37 0.253656 0.765017 1.72557 0.140863 0.00780007
10 0.0217371 0.438343 2.747 36× 10−15 0.527361 0.580325 2.10374 0.331603 0.00681915
S
u
b
j
e
c
t
D
1 0.346344 0.153825 0.432311 2.732 79× 107 20.3408 80.1561 0.0549054 0.0136333
2 0.346115 1.50133 0.432278 1.4454× 109 15.3493 725.205 68.6663 0.0136105
3 0.345524 0.15922 0.432213 4.845 87× 1016 9.08349 37.3264 94575.2 0.0136749
4 0.345826 0.172752 0.432204 1.985 65× 107 11.5164 52.3632 1183.85 0.0136546
5 0.346178 0.102262 0.431988 2.121 37× 1017 22.1847 50.6702 0. 0.0136437
6 0.343936 1.94633 0.432605 1.157 36× 107 3.89904 239.768 207.839 0.0136425
7 0.345699 0.0999169 0.431651 1.2234× 106 15.4357 34.0737 3.06844 0.0136652
8 0.345878 0.950743 0.432202 2.160 62× 1011 12.8357 379.272 1705.63 0.0136156
9 0.133928 0.241859 0.428493 0.434878 5.48696 37.1081 0. 0.0136694
10 0.34689 0.141799 0.432315 4.140 53× 108 163.322 581.028 0. 0.0136031
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Table 6-5 Estimated parameter values from multiple runs; subjects F and G
Run
Parameter
RMSE
k21 (day
−1) k31 (day−1) k12 (day−1) k14 (day−1) k03 (day−1) k43 (day−1) k34 (day−1)
S
u
b
j
e
c
t
F
1 0.412129 0.116792 0.361135 0.272648 0.994852 1.01853 0.326048 0.00550167
2 1.402 57× 10−6 0.444537 141.642 0.452248 0.148064 0.69255 0.00603218 0.00378963
3 2.195 54× 10−13 0.444528 8.71379 0.452283 0.148045 0.692391 0.00600534 0.00378963
4 0.454367 0.0795007 0.362001 7.119 19× 10−8 4.51354 5.30071 1.10612 0.00549635
5 0.454351 0.0794952 0.361966 2.965 81× 10−12 5.39512 6.75573 1.14185 0.0054954
6 0.454415 0.07951 0.362082 0.000022722 3.41001 3.51726 1.03978 0.00549893
7 0. 0.454276 6.907 69× 107 0.418849 0.175345 0.94755 0.0586333 0.00402419
8 0.454348 0.0795006 0.361985 0. 4.11203 4.66027 1.08929 0.00549701
9 0.454432 0.0795174 0.362085 0.0000416412 3.21347 3.20078 1.02184 0.00549978
10 0.45423 0.0794697 0.36176 5.405 78× 10−7 51.2404 83.9639 1.30387 0.0054928
S
u
b
j
e
c
t
G
1 0.455651 4.21715 0.372039 19.2778 0.956271 1.445 75× 107 5.368 35× 106 0.00686157
2 1.234 56× 1010 0.531781 4.2902× 1010 0.359708 1692.03 15306.6 0.213966 0.00286239
3 0.455565 4.21228 0.371993 14.6467 6.23104 1.205 04× 108 5.223 45× 106 0.00686157
4 0.455598 4.21346 0.372012 17.0521 1.46728 1.700 37× 107 3.643 04× 106 0.00686157
5 0.455584 4.21184 0.372002 15.4307 2.86613 1.402 61× 108 1.392 69× 107 0.00686157
6 0.455577 4.2128 0.371991 17.5851 1.28423 1.538 39× 107 3.884 15× 106 0.00686157
7 0.455807 4.15569 0.372092 47.9845 0.364451 184.906 407.172 0.00686531
8 0.455568 4.21544 0.371981 16.1167 2.01938 1.415 04× 107 1.415 04× 107 0.00686157
9 4.969 67× 108 0.531465 1.726 38× 109 0.359917 33602.9 303849. 0.21395 0.00286184
10 0.455544 4.21255 0.371978 15.6524 2.51039 1.435 87× 108 1.650 85× 107 0.00686157
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Table 6-6 Relative standard deviations of parameter estimates obtained
from ten runs using differential evolution, for each of the subjects A–D, F
and G
Parameter
Relative standard deviation
A B C D F G
k21 0.00404 0.634 2.18 0.206 0.691 3.03
k31 0.0405 0.905 0.312 1.24 0.907 0.446
k12 0.0458 0.642 2.18 0.00277 3.16 3.03
k14 0.0417 1.38 0.643 2.58 1.33 0.792
k03 0.280 0.461 0.373 1.71 2.12 3.00
k43 0.360 1.85 0.399 1.15 2.32 1.14
k34 0.305 3.16 0.502 3.05 0.758 1.01
plotted for each of the estimated parameter vectors from ten runs. The model outputs
are very similar for all of the estimated parameter vectors for an individual. For some
subjects there are noticeably different trajectories within the fits, for example: in the first
and last five days of y2(t) for subject A; in the first two days of y1(t) for subject B; for
all of y1(t) and the latter part of y2(t) for subject C; between days 2 and 6 for y1(t) and
the initial two days of y2(t) for subject F; and the first twelve days and final five days
of y2(t) for subject G. The similarity between the outputs for the parameter estimates
obtained in different runs is shown by the similar values of RMSE within each subject.
The model appears to fit the data reasonably well and in some subjects extremely well.
The results of the multiple runs of differential evolution show that in many cases, highly
different parameter vectors can produce very similar model outputs. The spread of the
parameter estimates from multiple runs is conveyed using the relative standard deviation,
that is, the standard deviation of the estimates of a parameter from ten runs, divided by
the mean of those estimates. The relative standard deviations are tabulated in table 6-6.
For some parameters and subjects, the estimates for the parameters have a small relative
standard deviation, for example the first four parameters for subject A and parameter k12
for subject D. In other instances however the relative standard deviation is much larger,
reflecting the highly different estimates obtained for these parameters. The similarly high
quality fits produced by diverse parameter vectors implies that, whilst the parameters
are structurally identifiable, they are not practically identifiable for the quality of data
that are available.
128
Chapter 6. Four-compartment model of IgG metabolism
It must be noted again that, based on assumptions about the data collection and sub-
sequent calculations, the data do not meet the assumptions on which the parameter
estimation method is based. Violation of the assumptions of the estimation method
leads to biased parameter estimates with decreased precision [8]. However, if the param-
eter estimators are insensitive to true parameter values or are highly correlated, this will
cause problems in estimating true parameter values regardless of the true error model. It
is possible to assess the degree of bias and variability in parameter estimates for various
estimation methods based on different assumptions about the error model, by simulating
data with plausible parameter values and estimating the parameters from those data;
however, given the practical identifiability issue, this approach was not taken.
6.4 Naive pooled approach to parameter identifica-
tion using fractional catabolic rate data
Authors who have studied a two-compartment model of IgG metabolism have esti-
mated parameters from FCR vs. plasma IgG concentration data [1; 7]. The purpose
of this section is to investigate whether it is possible to estimate parameters of the four-
compartment model from these data. The data are described in section 5.3 of chapter
5. In section 6.2.4 two expressions for the FCR were introduced: the FCR of the tracer,
FCRT (6-27), and the FCR of the endogenous IgG in steady state, FCRE (6-29). In
practice FCRT is measured, however it is difficult to obtain a closed form expression for
FCRT. In contrast, we can easily obtain an expression for FCRE in terms of the model
parameters and the quantity of endogenous IgG in plasma, x1,E, as given by equation
(6-29).
FCRT and FCRE are not equal for this model. FCRT vs. x1,E and FCRE vs. x1,E are
plotted alongside one another in figure 6-5A. The difference between FCRT and FCRE as
a proportion of FCRT is plotted in figure 6-5B. Both FCRE and FCRT are evaluated for
the parameter values from the literature, given in table 6-1. Since in practice subjects
were observed for up to around 25 days, the FCRT was calculated at time t = 10 days,
using
FCRT =
k03x3,T(10)
x1,T(10)
, (6-40)
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Figure 6-5 (A) Comparison of FCRE and FCRT. (B) The difference be-
tween FCRT and FCRE as a proportion of FCRT. Both simulations were
produced using the literature parameter values in table 6-1.
where x3,T(10) and x1,T(10) were obtained by numerically solving the system of equa-
tions given by (6-20)–(6-21). The simulation was performed multiple times for values
of IE between 0 and 295 µmol day
−1, giving different values of FCRT. The quantity of
endogenous IgG in plasma, x1,E, was calculated from equation (6-2) for each value of
IE. For the particular parameter values used, the difference between FCRT and FCRE
is within 2% of the true value of FCRT. In this section model parameters are estimated
by fitting the expression for FCRE vs. x1,E (6-29) to the FCRT vs. x1,E data. FCRT is
simulated for the estimated parameter values, in order to assess the difference between
FCRT and FCRE.
6.4.1 Structural identifiability analysis
The relationship between FCRE and x1,E is given by equation (6-29). Given that the
parameters kon and v3 only appear in the model equations (6-7) as the ratio kon/v3, we
re-write equation (6-29), defining φ1 = kon/v3, giving
FCRE =
1
2φ1x1,E
(
k31φ1x1,E − k14φ1Rtot − k03k14 − k03koff
+
√
4k03k31 (k14 + koff)φ1x1,E +
(−k31φ1x1,E + k14φ1Rtot + k03 (k14 + koff))2). (6-41)
We wish to know whether the parameter vector φ = (φ1, k31, k14, Rtot, k03, koff) is struc-
turally identifiable with respect to the relationship in equation (6-41). The structural
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identifiability problem amounts to determining whether there exists an alternative param-
eter vector φ =
(
φ1, k31, k14, Rtot, k03, koff
)
such that FCRE(x1,E,φ) = FCRE(x1,E,φ).
From equations (6-28) and (6-2)
FCRE =
I0
xˆ1
. (6-42)
I0 is given in terms of xˆ1 by the solution of the following quadratic equation, obtained
by rearranging the first equation of (6-2) and setting φ1 = kon/v3:
− φ1I20 +
(−k03(k14 + koff) + φ1(k31xˆ1 − k14Rtot)) I0 + k03k31(k14 + koff)xˆ1 = 0. (6-43)
Substituting FCRExˆ1 in place of I0 and setting xˆ1 = x1,E gives the following quadratic
equation in FCRE:
−φ1x21,EFCR2E +
(−k03(k14 + koff) + φ1(k31x1,E − k14Rtot))x1,EFCRE
+k03k31(k14 + koff)x1,E = 0.
(6-44)
Dividing (6-44) throughout by the coefficient of FCR2E gives
FCR2E +
(
k03 (k14 + koff)− k31φ1x1,E + k14φ1Rtot
φ1x1,E
)
FCRE − k03k31 (k14 + koff)
φ1x1,E
= 0.
(6-45)
The expression for FCRE given by equation (6-41) is one of the two solutions of equation
(6-45). We therefore wish to know whether there exists an alternative parameter vector
φ such that:
FCR2E +
(
k03 (k14 + koff)− k31φ1x1,E + k14φ1Rtot
φ1x1,E
)
FCRE − k03k31 (k14 + koff)
φ1x1,E
= FCR2E +
k03
(
k14 + koff
)
− k31φ1x1,E + k14φ1Rtot
φ1x1,E
FCRE − k03k31
(
k14 + koff
)
φ1x1,E
.
(6-46)
The coefficients of the quadratic in (6-45) are unique, therefore the problem amounts to
solving the simultaneous equations:
k03 (k14 + koff)− k31φ1x1,E + k14φ1Rtot
φ1x1,E
=
k03
(
k14 + koff
)
− k31φ1x1,E + k14φ1Rtot
φ1x1,E
−k03k31 (k14 + koff)
φ1x1,E
= −
k03k31
(
k14 + koff
)
φ1x1,E
.
(6-47)
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The solution was found using the SolveAlways function in Mathematica. The only solu-
tion to equation (6-47), for all values of x1,E, is given by
k31 = k31
k14Rtot = k14Rtot
k03
(
k14 + koff
)
φ1
=
k03 (k14 + koff)
φ1
.
(6-48)
Therefore the parameter k31 and the expressions k14Rtot and k03 (k14 + koff) /φ1 are struc-
turally identifiable with respect to the relationship between FCRE and x1,E.
6.4.2 Parameter estimation
Having analysed the structural identifiability of the expression for FCRE vs. x1,E, it be-
comes clear that we can rewrite the expression by combining parameters into structurally
identifiable parameter combinations, as follows:
FCRE(x1,E,ψ) =
1
2x1,E
(
k31x1,E − ψ1 − ψ2
+
√
k231x
2
1,E + 2k31x1,E (ψ1 − ψ2) + (ψ1 + ψ2)2
)
,
(6-49)
where
ψ1 =
k03v3 (k14 + koff)
kon
ψ2 = k14Rtot
(6-50)
are uniquely identifiable parameter combinations. ψ1 and ψ2 have units of µmol day
−1.
The parameter vector to be estimated is now ψ = (k31, ψ1, ψ2).
It is assumed that (6-49) is a close approximation to the relationship between the mea-
sured FCRT and x1,E. The ‘true’ or ‘nominal’ parameter vector is denoted by ψ0.
It is assumed that FCRE(x1,E,ψ0) is observed with error for values of x1,E given by
x1,E,0, . . . , x1,E,N . It is thus assumed that the observed measurements are given by
YFCR(x1,E,j,ψ0) = FCRE(x1,E,j,ψ0) + b(x1,E,j), j = 1, . . . , N, (6-51)
where (x1,E,j) are independent and identically distributed random variables following the
normal distribution, (x1,E,j) ∼ N(0, 1). The standard deviation of the errors is denoted
by b. It is assumed that b does not depend on x1,E.
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Table 6-7 Parameter estimates from fitting FCRE expression to FCRT vs.
x1,E data
Parameter Units Estimate Standard error 95% confidence interval
ψ1 µmol day
−1 7.46556 2.73608 (1.92666, 13.0045)
ψ2 µmol day
−1 25.729 6.65578 (12.255, 39.2029)
k31 day
−1 0.15419 0.00969072 (0.134572, 0.173808)
Parameters values were estimated using unweighted least squares, by numerically min-
imising the cost functional
J(ψ0,ψ) =
N∑
j=1
(
YFCR(x1,E,j,ψ0)− FCRE(x1,E,j,ψ)
)2
. (6-52)
The estimated parameters were constrained to be positive: ψ0,ψ ∈ R3+.
Waldmann et al. [7] provide FCRT vs. plasma IgG concentration data. The plasma
concentrations of endogenous IgG were multiplied by the average plasma volume v1, from
table 6-1, in order to obtain the quantity of endogenous IgG in plasma, x1,E. The data for
FCRT vs. x1,E were then fitted using the interior point algorithm implemented within the
NonlinearModelFit function in Mathematica. The starting value for the minimisation was
set to 1 for each parameter. To verify that the estimates were insensitive to the starting
values, the parameters were also estimated using the differential evolution algorithm,
with ten different seeds for the random number generator, to find the global minimum of
the residual sum of squares. The parameter estimates for each method were equal to at
least four significant figures and the residual sums of squares were equal to six significant
figures.
The parameter estimates and their standard errors are provided in table 6-7. The fitted
expression given by (6-49) is plotted alongside the data in figure 6-6A. The residuals
vs. the fitted values are plotted in figure 6-6B. On inspection, the model appears to fit
the data well. The residuals appear reasonably homoscedastic and there is no obvious
autocorrelation. The parameter correlation matrix is given by
ψ1 ψ2 k31

ψ1 1. 0.886758 0.626202
ψ2 0.886758 1. 0.868569
k31 0.626202 0.868569 1.
.
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Figure 6-6 (A) Expression for FCRE vs. x1,E, given by equation (6-49),
fitted to FCRT vs. x1,E data from Waldmann et al. [7]. (B) Residuals vs.
fitted values.
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Figure 6-7 (A) Scaled traditional sensitivity functions (TSFs) and (B)
generalised sensitivity functions for FCRE vs. x1,E, evaluated for the param-
eter values estimated in section 6.4.2 and provided in table 6-7
6.4.3 Sensitivity analysis
We now consider a hypothetical problem in which we know the true parameter vector ψ0
and investigate the sensitivity of the output FCRE(x1,E,ψ) to the elements of ψ, when
ψ = ψ0. It is assumed that the true parameter vector is given by those values estimated
in the previous section, such that ψ0 = (7.46556, 25.729, 0.15419). It is assumed that
measurements are available on the interval
[
x1,E,1, x1,E,N
]
= [10, 1826], reflecting the
range of values of x1,E that are available in the real data.
The traditional sensitivity function (TSF) of FCRE(x1,E,ψ0) with respect to a parameter
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ψk, is given by
sFCR,ψk(x1,E,ψ0) =
∂FCRE(x1,E,ψ0)
∂ψk
, (6-53)
where ψk, k = 1, . . . , 3, are the elements of ψ. Due to the different orders of magnitude of
the TSFs with respect to the parameters ψ1, ψ2 and k31, respectively, each TSF is scaled
by the true value of the parameter, giving
s˜FCR,ψk(x1,E,ψ0) =
∂FCRE(x1,E,ψ0)
∂ψk
× ψk,0, (6-54)
where ψk,0 is the true value of the parameter ψk.
The scaled TSFs, s˜FCR,ψk(x1,E,ψ0), of FCRE(x1,E,ψ0) are plotted in figure 6-7A. The
scaled TSFs show that the output FCRE(x1,E,ψ0) is only sensitive to the parameter ψ1
for small values of x1,E, implying that measurements on a subinterval of x1,E close to zero
are important for estimating this parameter. FCRE(x1,E,ψ0) is also more sensitive to the
parameter ψ2 for small values of x1,E, but is less sensitive to k31 for small values of x1,E.
Generalised sensitivity functions (GSFs), which better represent correlations between
parameters, are plotted in figure 6-7B. In order to plot smooth GSFs which are more
easily interpreted, it is assumed that measurements are taken on a uniform sampling grid
given by
x1,E,j = j + 9, j = 1, . . . , N = 1817 (6-55)
on the interval
[
x1,E,1, x1,E,N
]
= [10, 1826]. The N ×N diagonal matrix D is given by
D = diag
(
1
σ2
, . . . ,
1
σ2
)
, (6-56)
where σ2 = 0.000281693 is the variance of the residuals obtained by fitting the real data.
The Fisher information matrix FFCR(ψ0) for the model output is given by
FFCR(ψ0) = (DψFFCR(ψ0))TDDψFFCR(ψ0), (6-57)
where FFCR(ψ0) = (FCRE(x1,E,1,ψ0), . . . ,FCRE(x1,E,N ,ψ0))
T is the column vector of
model outputs.
The generalised sensitivity matrix for one observation function [22] is given by
G (x1,E,j,ψ0) = F (ψ0)
−1F (j)(ψ0), j = 1, . . . , N, (6-58)
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where F (ψ0) is the Fisher information matrix for the parameter estimation problem and
F (j)(ψ0) is the Fisher information matrix for the parameter estimation problem where
only measurements up to x1,E,j are available. The diagonal elements of G (x1,E,j,ψ0) are
the GSFs with respect to each parameter ψk in ψ, which are denoted by
gψk(x1,E,j,ψ0) = G (x1,E,j,ψ0)(k,k), k = 1, . . . , 3. (6-59)
The GSFs as defined by equations (6-55)–(6-59) are plotted in figure 6-7B. The GSFs
show that the interval on which measurements are available can be divided into three
subintervals corresponding to each parameter. The information on the parameters ψ1, ψ2
and k31, respectively, is available on the approximate subintervals [10, 200], [200, 800] and
[800, 1826]. The GSFs suggest that it should be possible to estimate the true parameter
values, provided that valid assumptions were made and that sufficient data points were
available on the subintervals identified.
6.4.4 Comparison of endogenous IgG and tracer fractional
catabolic rates for estimated parameter values
It is important to recall that the FCRE as defined by equations (6-29) and (6-49) is not
measured in practice. By definition, measuring FCRE requires measurement of the quan-
tities of IgG in plasma and unbound in endosomes in steady state, along with knowledge
of the value of the parameter k03 (see equation (6-28)). Assuming the endogenous IgG is
in steady state, it is possible to measure the steady state quantity of IgG in plasma, xˆ1,
however to the author’s knowledge it is not practically feasible to obtain xˆ3 as intracel-
lular endosomes are not easily accessible to measurement. Since it is difficult to obtain a
closed form expression for FCRT, the FCRE expression was fitted to the FCRT vs. x1,E
data.
In figure 6-5, FCRE and FCRT are plotted using the parameter values from the literature;
however, having fitted the real FCRT data, it is clear that the parameter values from the
literature do not fit the data well. It is possible that, for the parameter values estimated
in section 6.4.2, the difference between FCRE and FCRT is large; therefore in this section
the plot in figure 6-5B is reproduced for the parameter values estimated in section 6.4.2.
FCRE was calculated from equation (6-29). FCRT was calculated from equation (6-40),
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as described at the beginning of section 6.4. FCRT cannot be defined by the parameters
k31, ψ1 and ψ2 alone: firstly, the solution of equations (6-20)–(6-22) requires the additional
parameters k21 and k12; secondly, ψ1 and ψ2 do not provide values for the individual
parameters k03, Rtot, koff, k14 and kon/v3.
Parameter vectors which satisfy ψ1 = 7.46556 µmol day
−1 and ψ2 = 25.729 µmol day−1
can be found by fixing three parameters (not including both Rtot and k14) out of k03,
Rtot, koff, k14 and kon/v3, yielding a linear system of two equations and two unknowns.
Equation (6-50) is then solved for the remaining two parameters. Three parameters of
k03, Rtot, koff, k14 and kon/v3 were fixed to randomly generated values and the remaining
two calculated. Each value was generated by assuming a lognormal distribution, in
order to ensure positivity, with median given by the parameter value from the literature,
given in table 6-1, and variance 1. Random values for k21 and k12 were also generated
in this way. k31 was set to the estimated value in table 6-7. There are seven sets of
three parameters from k03, Rtot, koff, k14 and kon/v3, which can be fixed to give the
remaining two parameters. Parameters were generated ten times for each of these seven
sets, giving seventy parameter vectors in total, which are tabulated in tables 6-8 to 6-11.
The parameters which were not randomly generated are labelled with an asterisk (∗).
For each of the parameter vectors, the parameters estimated in section 6.4.2 are equal to
their estimated values: (ψ1, ψ2, k31) = (7.46556, 25.729, 0.15419).
In figure 6-8, both FCRE and FCRT are plotted for the parameter vectors in tables 6-8
to 6-11. In each of the seven plots, a different set of parameters was randomly generated
and the remaining parameters calculated. The difference between FCRT and FCRE is
highly dependent on the parameter values. Whilst it may be possible to estimate the
parameters ψ1 = k03v3 (k14 + koff) /kon, ψ2 = k14Rtot and k31 by fitting the FCRE vs. x1,E
relationship to FCRT vs. x1,E data, individual model parameter values would also need
to be known in order to validate the approximation of FCRT by FCRE.
6.5 Conclusions
In this chapter parameter identification for a four-compartment model of IgG metabolism
has been investigated, using in vivo human data obtained from tracer experiments and
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Figure 6-8 FCRE and FCRT evaluated for the parameter vectors in (A–B)
table 6-8, (C–D) table 6-9, (E–F) table 6-10, and (G) 6-11. The parameter
vectors used in panel (A) are labelled A1–A10, and likewise for the other
panels.
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Table 6-8 Parameters used for comparing FCRE and FCRT
k21 (day
−1) k31 (day−1)* k12 (day−1) k14 (day−1) k03 (day−1) kon/v3
(µmol−1 day−1)*
Rtot (µmol)* koff (day
−1)
A1 0.1856345921 0.1541900000 0.1097537128 14.95919855 30.82311663 751.3749429 1.719945084 167.0287161
A2 0.4895880322 0.1541900000 1.074255468 19.82491140 3.102060329 18.14343259 1.297811601 23.83990173
A3 0.1435674005 0.1541900000 0.4010150060 2.400327761 16.54449597 2485.765410 10.71895281 1119.279707
A4 0.3864796452 0.1541900000 0.09962847246 3.499839508 0.6765305842 6.474389427 7.351479958 67.94547850
A5 1.716833969 0.1541900000 0.04939591400 1.384847410 4.377473729 26.41884511 18.57894221 43.67115647
A6 0.6758131115 0.1541900000 0.1278125097 9.667682902 3.824106865 101.3775527 2.661340909 188.2452493
A7 0.3206851069 0.1541900000 0.1033674177 3.980573768 1.798150222 11.88590563 6.463641047 45.36732860
A8 2.341018666 0.1541900000 0.8801037899 4.570220219 7.673700016 116.8162923 5.629706835 109.0775687
A9 0.09830406964 0.1541900000 0.1619128974 12.38998997 3.485032976 32.21972227 2.076595709 56.63038129
A10 0.1343257412 0.1541900000 0.3989146114 15.04220163 0.3610727119 2.926553736 1.710454403 45.46739046
k21 (day
−1) k31 (day−1)* k12 (day−1) k14 (day−1) k03 (day−1) kon/v3
(µmol−1 day−1)
Rtot (µmol)* koff (day
−1)*
B1 0.6943884374 0.1541900000 0.6209714527 1.613456446 2.895702089 4330.950116 15.94651040 11164.23405
B2 0.4208673089 0.1541900000 0.2467496600 12.86710689 5.270940166 1654.590347 1.999594798 2330.631988
B3 0.6869401743 0.1541900000 0.01468724713 3.773131082 1.742624869 3189.540769 6.819005076 13660.50333
B4 0.3595315002 0.1541900000 0.1535438196 3.170010552 11.62314125 1040.487125 8.116376769 665.1363356
B5 0.4518490717 0.1541900000 0.8449208561 4.991633460 4.417643647 17567.29327 5.154424941 29682.70897
B6 0.1932362745 0.1541900000 0.09794711818 1.964934988 1.888215170 930.8187838 13.09407189 3678.274261
B7 0.5642193322 0.1541900000 0.1850012768 5.507296574 0.9493875002 14421.76604 4.671802155 113400.8306
B8 0.2090607604 0.1541900000 0.7380873774 8.931821715 5.739142103 7772.132214 2.880599369 10101.17145
B9 1.103987485 0.1541900000 0.3118039830 1.734556175 0.9084503385 632.2258592 14.83318925 5193.838482
B10 0.6467637266 0.1541900000 0.1707292613 2.943052822 1.532151189 1356.577960 8.742282778 6607.118821
139
C
h
ap
ter
6.
F
ou
r-com
p
artm
en
t
m
o
d
el
of
IgG
m
etab
olism
Table 6-9 Parameters used for comparing FCRE and FCRT
k21 (day
−1) k31 (day−1)* k12 (day−1) k14 (day−1)* k03 (day−1) kon/v3
(µmol−1 day−1)
Rtot (µmol)* koff (day
−1)
C1 0.1004069159 0.1541900000 0.2135941627 1460.336688 15.05177191 3089.824705 0.01761853977 72.19196518
C2 0.5873451339 0.1541900000 0.1615523506 328.4497418 14.65187750 1195.450685 0.07833466350 280.6673365
C3 0.2829075719 0.1541900000 0.1345545947 1078.454692 4.767150876 933.2375554 0.02385728412 383.0348106
C4 1.975178924 0.1541900000 0.5464299446 10922.21534 1.581068051 2328.372728 0.002355657638 72.00232291
C5 4.652530259 0.1541900000 0.2634046016 122000.4134 2.373034683 38799.33400 0.0002108927281 62.17510883
C6 0.4202074295 0.1541900000 1.391932462 406.3499633 8.628225540 541.1454798 0.06331734299 61.87540110
C7 0.5095934759 0.1541900000 0.2944506661 17240.81092 1.444834913 3465.426860 0.001492331197 665.2847338
C8 0.3740153789 0.1541900000 0.08552095699 6287.928030 4.857029137 4342.562308 0.004091808920 386.8640192
C9 2.955511860 0.1541900000 0.7179231654 67788.99191 0.7877116273 7159.027302 0.0003795453993 60.89886058
C10 1.411376086 0.1541900000 0.5862088346 862.8750460 2.516207642 604.3192635 0.02981775880 930.1334661
k21 (day
−1) k31 (day−1)* k12 (day−1) k14 (day−1)* k03 (day−1) kon/v3
(µmol−1 day−1)*
Rtot (µmol) koff (day
−1)
D1 0.6953416343 0.1541900000 0.1480967541 14.57172812 4.138551492 53.65851124 1.765679388 82.22320989
D2 0.1921416066 0.1541900000 0.2766639527 0.9544293027 7.544456560 47.54254062 26.95747074 46.09093265
D3 0.1261409549 0.1541900000 0.05368335660 1.506888773 2.024864366 29.76850170 17.07425289 108.2478875
D4 0.08498647642 0.1541900000 0.2147443285 4.483863783 0.6727814283 4.674721754 5.738131497 47.38947021
D5 0.06372162209 0.1541900000 0.1775017503 0.9455567461 0.3895396600 4.284423911 27.21042402 81.16578403
D6 0.2248886645 0.1541900000 0.1135637469 0.9252852626 3.544196371 53.62932028 27.80655982 112.0404950
D7 1.606231307 0.1541900000 0.7093851811 1.795263795 10.38304041 77.54470049 14.33159855 53.96052559
D8 0.3554974363 0.1541900000 0.5934760799 2.807590666 6.591148559 15.05829607 9.164085176 14.24840675
D9 0.1910162739 0.1541900000 0.08664274150 3.137066577 3.851953137 35.21908301 8.201611082 65.12185766
D10 0.4402451744 0.1541900000 0.3459107874 1.189812915 1.797917569 8.593572477 21.62440807 34.49359773
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Table 6-10 Parameters used for comparing FCRE and FCRT
k21 (day
−1) k31 (day−1)* k12 (day−1) k14 (day−1)* k03 (day−1) kon/v3
(µmol−1 day−1)
Rtot (µmol) koff (day
−1)*
E1 0.3138078505 0.1541900000 1.175442511 1.748916629 0.5413273486 1607.857406 14.71139309 22172.55276
E2 0.1993513894 0.1541900000 2.039783388 1.990790155 0.8608245468 2810.638211 12.92401409 24373.46212
E3 1.479692405 0.1541900000 0.9421116766 0.7721965104 0.7137028436 10405.82200 33.31923889 108847.4539
E4 0.6036061886 0.1541900000 0.8710609460 0.7261548338 15.18549936 14039.52211 35.43183740 6901.443619
E5 1.271117171 0.1541900000 2.789337774 5.492748273 12.61318112 1888.315982 4.684176067 1112.174249
E6 0.3650575250 0.1541900000 0.3086189409 0.4954434537 5.651685939 9954.484398 51.93125433 13148.81988
E7 1.178608732 0.1541900000 24.48785817 6.265789430 4.583971770 9282.806225 4.106266303 15111.92217
E8 0.05137643134 0.1541900000 1.284805476 10.64866561 2.055590318 8028.505703 2.416171278 29147.54035
E9 1.024144690 0.1541900000 0.7682659939 3.470167911 10.04658341 4541.245229 7.414338631 3371.103788
E10 1.237277457 0.1541900000 0.04668542959 2.336393286 16.29472491 777.4977702 11.01227270 353.8804981
k21 (day
−1) k31 (day−1)* k12 (day−1) k14 (day−1) k03 (day−1)* kon/v3
(µmol−1 day−1)
Rtot (µmol)* koff (day
−1)
F1 0.4227979497 0.1541900000 0.5847978719 2.175288467 590.0174200 3196.129134 11.82785658 38.26571041
F2 0.4881123798 0.1541900000 1.652660655 67.04644452 100.0399314 2528.777345 0.3837489099 121.6655901
F3 0.7637183865 0.1541900000 1.724180793 2.314080011 4.673562055 478.5463675 11.11845739 762.1171135
F4 0.2176901897 0.1541900000 0.6355392693 1.163775383 220.7883037 5766.184777 22.10821811 193.8094080
F5 2.369273527 0.1541900000 0.4811737286 2.695987864 69.82344860 933.5275171 9.543440585 97.11726729
F6 0.7728110410 0.1541900000 0.1313636229 18.93111429 405.4594059 4289.925975 1.359085345 60.05755708
F7 0.3962002241 0.1541900000 1.511500544 0.5936060006 50.03634540 2357.717632 43.34356454 351.1843327
F8 0.6423813098 0.1541900000 0.09057099241 11.16852970 924.1355728 10491.09504 2.303705205 73.58299573
F9 2.049426746 0.1541900000 1.896558855 2.649676358 87.12501574 1400.131731 9.710242506 117.3246772
F10 0.5225569819 0.1541900000 0.4813453981 2.497344610 137.3366784 6286.402084 10.30254291 339.2286421
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Table 6-11 Parameters used for comparing FCRE and FCRT
k21 (day
−1) k31 (day−1)* k12 (day−1) k14 (day−1)* k03 (day−1)* kon/v3 (µmol−1 day−1) Rtot (µmol) koff (day−1)
G1 0.6858589725 0.1541900000 0.7755310870 0.4899032028 58.59066140 2136.674363 52.51853805 271.7628804
G2 0.08521829759 0.1541900000 1.156906451 2.815779948 27.89464102 518.4547255 9.137432780 135.9404370
G3 0.4302125295 0.1541900000 0.5491562190 0.5205815942 1871.149288 8390.147288 49.42356834 32.95464585
G4 0.9412978335 0.1541900000 0.7717423546 4.815221139 181.1848430 1909.147373 5.343264464 73.84949510
G5 0.9133212014 0.1541900000 0.2738199714 0.6612078409 454.6407214 18974.98671 38.91212174 310.9230720
G6 0.2135381053 0.1541900000 0.1857331628 0.7805893660 84.14355890 3767.588162 32.96099220 333.4952107
G7 0.2697199607 0.1541900000 0.5450843786 1.313670204 33.69332961 1189.674114 19.58558542 262.2869766
G8 0.6924590204 0.1541900000 2.208729760 0.7601887407 229.4283338 5541.378783 33.84554206 179.5553595
G9 3.081751624 0.1541900000 0.2649774411 2.122118852 221.4273895 2754.264912 12.12420311 90.73960888
G10 0.5113141025 0.1541900000 0.7624342094 1.868746436 152.6193438 1384.804507 13.76805301 65.87064280
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available in the literature. Two observed model outputs were considered: the timecourse
of the proportion of a dose of IgG remaining in plasma and in the body of an individual
subject; and the FCR vs. the quantity of endogenous IgG in plasma, measured in a cohort
of subjects with a range of plasma IgG concentrations. The stability of the model steady
state has also been analysed.
In section 6.3 parameters were estimated using data for the timecourse of an administered
dose of radiolabelled IgG in plasma and in the body. All parameters of the linearised
model were found to be structurally globally identifiable. Whilst the model is capable
of fitting the data well, the results of ten runs of differential evolution suggest that the
parameter estimates are unstable. Highly different parameter vectors, as illustrated by
the relative standard deviations of parameter estimates from ten runs, produce simi-
larly excellent fits to the data. These results suggest that certain parameters are highly
correlated and that the available data do not support the complexity of the model.
The structural identifiability of the relationship between FCRE and the quantity of en-
dogenous IgG in plasma, x1,E, was analysed. It was found that the parameter k31 and
parameter combinations ψ1 = (k03v3 (k14 + koff))/kon and ψ2 = k14Rtot are structurally
globally identifiable. These parameters were estimated using unweighted least squares.
Sensitivity analysis, assuming that the estimated parameter values were the known, true
parameter values, using TSFs and GSFs, shows that the parameter estimators are sen-
sitive to the true parameter values. The GSFs also highlighted sub-intervals of x1,E on
which additional data points would improve the precision of individual parameter esti-
mates. The parameters k31 and ψ2 have physiological meaning, with k31 being the rate at
which plasma IgG is internalised into intracellular endosomes, and ψ2 being the maximal
rate of recycling of IgG from endosomes into plasma. The 95% confidence interval for
k31 (0.135–0.174 day
−1) is similar to other values reported in the literature (0.13 day−1
[2]; 0.18 day−1 [7]) and overlaps with the 95% confidence interval (0.137–0.181 day−1)
estimated with respect to the two-compartment model in chapter 5. The 95% confidence
interval for ψ2 (12.3–39.2 µmol day
−1) is considerably smaller than previously reported
values (68.6 µmol day−1 [1]; 103 µmol day−1 [2]); however it overlaps with the 95% confi-
dence interval (19.1–60.9 day−1) estimated with respect to the two-compartment model
in chapter 5.
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In applications in which the behaviour of the variables x3(t) and x4(t), representing
unbound and bound IgG in intracellular endosomes, respectively, are of great importance,
clearly parameter values are required which determine this behaviour, including receptor-
ligand binding (kon/v3, koff and Rtot), recycling of bound IgGs into plasma (k14) and
degradation of unbound IgGs (k03). Unfortunately, the results presented in this chapter
suggest that it may not be possible to estimate these parameters from the available data.
For example, the data for subject D are fitted well by the model when k34 = koff =
5.49× 10−2 day−1 and 9.46× 104 day−1. Similarly, in section 6.4.4, it is shown that the
parameters listed above can be varied enormously whilst having a minimal effect on the
relationship between the FCRT and x1,E. For investigations limited to behaviour of IgG
in plasma, the two-compartment model analysed in chapter 5 may be sufficient. However,
the relationship between the four-compartment model and the two-compartment model
is not clear and it is not known whether the two models produce equivalent responses in
relevant simulations; this will be the subject of chapter 7.
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7Comparison of two- and
four-compartment models of
immunoglobulin G metabolism
The aim of this chapter is to clarify the relationship between the two models of im-
munoglobulin G (IgG) metabolism studied in chapters 5 and 6. A derivation of the
two-compartment model from the four-compartment model is taken from Hattersley [1]
and the assumptions for the derivation are investigated with simulations. Simulations
of IgG responses during multiple myeloma are compared for the two respective models,
using the parameter values estimated in chapters 5 and 6.
The derivation presented in section 7.1 is reproduced from Hattersley [1]. Section 7.3
summarises the classical Michaelis-Menten approximation for an enzyme reaction, first
presented by Michaelis et al. [2]. A similar summary can be found in many biochemistry
and mathematical biology texts; an extended mathematical introduction can be found in
Murray [3, ch. 6]. The remainder of this chapter comprises original work by the author.
7.1 Derivation of two-compartment model
A derivation of the two-compartment model of IgG metabolism (chapter 5) from the
four-compartment model (chapter 6) is provided by Hattersley [1]. Hattersley [1] states:
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‘if a quasi-steady state assumption is made regarding the bound IgG, namely that the
bound IgG dynamics are much faster than the free IgG in the endosome, the IgG bound
in the endosome can be considered in steady state’.
The four-compartment model equations are given by
x˙1(t) = −(k21 + k31)x1(t) + k12x2(t) + k14x4(t) + I(t)
x˙2(t) = k21x1(t)− k12x2(t)
x˙3(t) = k31x1(t)− k03x3(t)− kon
v3
x3(t)(Rtot − x4(t)) + koffx4(t)
x˙4(t) =
kon
v3
x3(t)(Rtot − x4(t))− (k14 + koff)x4(t).
(7-1)
Details including physiological interpretations of states and parameters are provided in
section 6.1 of chapter 6.
The steady state is given by
xˆ1 =
I0 (k03k14v3 + k03koffv3 + konI0 + k14konRtot)
k31
(
k03v3(k14 + koff) + konI0
)
xˆ2 =
k21
k12
xˆ1
xˆ3 =
I0
k03
xˆ4 =
konI0Rtot
k03v3(k14 + koff) + konI0
,
(7-2)
where xˆi is the equilibrium point for xi(t).
By setting x˙4(t) = 0, Hattersley [1] rearranges the ordinary differential equation for x4(t)
in order to obtain an expression for the quantity x4(t):
x4(t) =
kon
v3
Rtotx3(t)
koff + k14 +
kon
v3
x3(t)
. (7-3)
Hattersley [1] then assumes that the concentrations of unbound IgG in plasma and in
endosomes are equal, such that x1(t)/v1 = x3(t)/v3, where v1 is the plasma volume and
v3 is the total volume of the endosomes, then
x4(t) =
kon
v3
Rtot
v3
v1
x1(t)
koff + k14 +
kon
v3
v3
v1
x1(t)
. (7-4)
The expression for the rate at which IgG is recycled into plasma is then given by
k14x4(t) =
k14konRtot
1
v1
x1(t)
koff + k14 + kon
1
v1
x1(t)
. (7-5)
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Several parameters are then lumped together to give
k14x4(t) =
Vmaxx1(t)
KM + x1(t)
, (7-6)
where
Vmax = k14Rtot (7-7)
and
KM =
v1(k14 + koff)
kon
. (7-8)
Substituting equation (7-6) into the first equation of (7-1) gives the reduced two-
compartment model:
x˙1(t) = −
(
k21 + k31 − Vmax
KM + x1(t)
)
x1(t) + k12x2(t) + I(t)
x˙2(t) = k21x1(t)− k12x2(t).
(7-9)
The equilibrium point for the two-compartment model is given by
xˆ1 =
−k31KM + I0 + Vmax +
√
4k31KMI0 + (−k31KM + I0 + Vmax)2
2k31
xˆ2 =
k21
k12
xˆ1.
(7-10)
7.2 Four-compartment model non-dimensional anal-
ysis
In the following non-dimensional analysis, the following assumptions are made, based
upon the general relations between estimated parameter values found in chapter 6:
Rtot
x1(0)
 1
kon
v3
> koff
kon, koff > k12, k31, k14, k21.
(7-11)
The four-compartment model given by equations (7-1) can be non-dimensionalised [4] by
making the following substitutions,
tˆ =
konRtott
v3
, xˆ1 =
x1
x1(0)
, xˆ2 =
x2
x1(0)
, xˆ3 =
x3
x1(0)
, xˆ4 =
x4
Rtot
,
β =
Rtot
x1(0)
, γ =
v3
konRtotx1(0)
,
(7-12)
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and defining the following parameters,
K =
k21v3
konRtot
, L =
kon
v3x1(0)
, M =
k14v3
x1(0)kon
, N =
koffv3
x1(0)kon
,
P =
k31v3
konRtot
, Q =
k12v3
konRtot
, R =
k03v3
konRtot
.
(7-13)
The non-dimensional system is obtained by using
dx1
dt
=
dx1
dtˆ
dtˆ
dt
=
konRtot
v3
x1(0)
dxˆ1
dtˆ
. (7-14)
Similarly for x2, x3 and x4, we have
dx2
dt
=
konRtotx1(0)
v3
dxˆ2
dtˆ
dx3
dt
=
konRtotx1(0)
v3
dxˆ3
dtˆ
dx4
dt
=
konR
2
tot
v3
dxˆ4
dtˆ
.
(7-15)
Using equations (7-14) and (7-15), and making the substitutions in equations (7-12) and
(7-13), gives the following non-dimensional system equations,
dxˆ1
dtˆ
= −(K + P )xˆ1 +Qxˆ2 +Mxˆ4 + γI(t)
dxˆ2
dtˆ
= Kxˆ1 −Qxˆ2
dxˆ3
dtˆ
= Pxˆ1 −Rxˆ3 − xˆ3 (1− xˆ4) +Nxˆ4
β
dxˆ4
dtˆ
= xˆ3 (1− xˆ4)− (M +N)xˆ4.
(7-16)
A series solution is assumed, such that
xˆ1 =
∞∑
n=0
xˆ
(n)
1 β
n, xˆ2 =
∞∑
n=0
xˆ
(n)
2 β
n, xˆ3 =
∞∑
n=0
xˆ
(n)
3 β
n, xˆ4 =
∞∑
n=0
xˆ
(n)
4 β
n, (7-17)
where superscript (n) indicates the nth derivative. Substituting (7-17) into the ordinary
differential equation for xˆ4 in (7-16) gives
β
∞∑
n=0
xˆ
(n+1)
4 β
n =
∞∑
n=0
xˆ
(n)
3 β
n
(
1−
∞∑
n=0
xˆ
(n)
4 β
n
)
− (M +N)
∞∑
n=0
xˆ
(n)
4 β
n. (7-18)
Assuming β  1, higher order terms (n ≥ 1) can be neglected, giving
0 = xˆ3 (1− xˆ4)− (M +N) xˆ4. (7-19)
By reverting back to the original dimensional variables, equation (7-19) gives x˙4(t) = 0
and thus allows for the algebraic approximation for x4(t) in equation (7-3), provided that
β  1.
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7.3 Classical Michaelis-Menten kinetics
The model reduction provided by Hattersley [1] and re-produced in section 7.1 depends
on two simplifying assumptions. Firstly, Hattersley [1] states that a quasi-steady state
(QSS) assumption enables the setting of the rate of change of bound IgG in endosomes
(x4(t) in equations (7-1)) to zero. In order to investigate the validity of this assumption
under different conditions, the four-compartment model of IgG kinetics is compared with
the classical model of Michaelis-Menten kinetics, which is briefly summarised here.
Classical Michaelis-Menten kinetics deals with a reaction scheme in which an enzyme (E)
and substrate (S) bind reversibly to form a complex (C), which irreversibly goes on to
form a product (P), within a closed system, as given by
E + S
k1

k−1
C →
k2
P. (7-20)
The reaction is described by the following ordinary differential equations and initial con-
ditions
e˙(t) = −k1e(t)s(t) + k−1c(t) + k2c(t)
s˙(t) = −k1e(t)s(t) + k−1c(t)
c˙(t) = k1e(t)s(t)− k−1c(t)− k2c(t)
p˙(t) = k2c(t)
e(0) = e0
s(0) = s0
c(0) = 0
p(0) = 0,
(7-21)
where lower case denotes concentration and e0 and s0 are the initial concentrations of
the enzyme and substrate, respectively. The total quantity of enzyme, in both free and
bound form, is constant, that is e(t) + c(t) = e0. This allows e(t) to be eliminated from
the equations, giving
s˙(t) = −k1(e0 − c(t))s(t) + k−1c(t)
c˙(t) = k1(e0 − c(t))s(t)− k−1c(t)− k2c(t)
p˙(t) = k2c(t).
(7-22)
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Table 7-1 Parameters for simulations of enzyme reaction
k1 k−1 k2 e0 s0 
Good approximation 1 1 1 0.05 50 0.001
Poor approximation 1 1 1 25 50 0.5
When the ratio e0/s0  1, it can be assumed that the initial formation of complex is
fast, after which the complex is approximately in equilibrium, i.e. c˙(t) ≈ 0. This provides
the following approximation for c(t),
c(t) =
e0s(t)
s(t) +KM
, (7-23)
where
KM =
k−1 + k2
k1
. (7-24)
The rate of product formation is then given by
p˙(t) = k2c(t) =
k2e0s(t)
s(t) +KM
. (7-25)
This is known as the quasi-steady state (QSS) approximation and is valid for   1,
where
 =
e0
s0 +KM
. (7-26)
Simulations of the reaction are shown in figure 7-1. The parameters for the simulations
in panels (A) and (C) (good approximation) and (B) and (D) (poor approximation),
respectively, are provided in table 7-1. In figure 7-1A the initial enzyme concentration is
0.001 times the initial substrate concentration. There is an initial stage in which enzyme
and substrate rapidly bind to form complexes, after which point the complexes can be
considered to be in approximate equilibrium. During the second stage the rate at which
substrate is ‘used up’ effectively equals the rate of product formation. In figure 7-1B the
initial enzyme concentration is now half the initial substrate concentration and  = 0.5
is no longer much smaller than 1. Whilst there are still two timescales at play, the
initial binding is slower and takes up a larger proportion (half) of the substrate. Figures
7-1C and 7-1D show simulations of c(t) and the QSS approximation to c(t), given by
equation (7-23). In the initial fast binding stage the approximation is poor for both sets
of parameter values, but in the second stage it is good for  = 0.001 (figure 7-1C) and
poor for  = 0.5 (figure 7-1D).
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Figure 7-1 (A, B) Simulations of e(t), c(t), s(t) and p(t). (C, D) Simula-
tions of c(t) and the approximation to c(t) based on a QSS assumption. In
panels (A) and (C) the QSS approximation is good and in panels (B) and
(D) it is poor. Parameter values for the simulations are given in table 7-1.
Note the two different scales used for e(t) and c(t) (left axis) and s(t) and
p(t) (right axis) in (A).
7.4 Quasi-steady state assumption in the four-
compartment model of IgG kinetics
In this section the QSS assumption with respect to the four-compartment model of IgG
metabolism is investigated, by comparing the four-compartment model with the enzyme
reaction model discussed in 7.3. Figure 7-2 shows how the classical Michaelis-Menten
model is a sub-model within the four-compartment model. The parameters k1, k−1 and
k2 in the enzyme reaction model are equivalent to the parameters kon, koff and k14,
respectively, in the IgG model. The quantities E, S, C and P correspond to x5, x3,
x4 and x1, respectively. Concentrations e, s, c and p correspond to x5/v3, x3/v3, x4/v3
and x1/v1, respectively, where v1 is the plasma volume and v3 is the total volume of
the endosomes. x5 represents the quantity of unbound neonatal Fc receptors (FcRn) in
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Figure 7-2 Schematic showing the relationship between the four-
compartment model of IgG kinetics and the original enzyme reaction model
that can be simplified using Michaelis-Menten kinetics. The original enzyme
reaction model is shown in black and the additional compartments and flows
required for the four-compartment model are shown in red.
intracellular endosomes; it is eliminated from the IgG metabolism model in the same
way that e is eliminated from the enzyme reaction equations in (7-22), leaving a four-
compartment rather than five-compartment model.
When simulating the four-compartment model with feasible parameter values, steady
state initial conditions and realistic models (developed in chapter 8) for the IgG pro-
duction rate, it is difficult to violate the QSS assumption. We therefore attempt to find
conditions under which the QSS assumption is not valid for the four-compartment model,
by drawing comparison with the original enzyme reaction model. In section 7.3, it was
shown that the QSS is not valid for the ‘poor approximation’ parameter values given in
table 7-1, for which  = 0.5. We now consider the four-compartment model in which the
equivalent parameter values and initial conditions are set to the ‘poor approximation’
parameter values in table 7-1. The initial condition for x4(t) is set to zero, as in the
enzyme reaction model.
The main differences between the enzyme reaction model and the four-compartment
model are the elimination from the ‘substrate’ compartment (x3(t)) with rate constant
k03, the flow from the ‘product’ compartment (x1(t)) to the ‘substrate’ compartment
(x3(t)) with rate constant k31, the interaction between x1(t) and x2(t), and the input of
new product, I(t). The QSS assumption for x4(t) can therefore be violated in a trivial
sense, by choosing parameter values and initial conditions which violate the condition
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Table 7-2 Parameter values and initial conditions for simulations of the
four-compartment model in which the QSS assumption is violated by setting
the parameter k31 to be small
Parameter Units Value
k21 day
−1 0.51 Value from the literature [5]
k31 day
−1 1× 10−6 Chosen to be small
k12 day
−1 0.41 Value from the literature [5]
k14 day
−1 1 Fixed for large 
k03 day
−1 1× 10−6 Chosen to be small
kon l µmol
−1 day−1 1 Fixed for large 
Rtot µmol 25 Fixed for large 
koff day
−1 1 Fixed for large 
v1 l 2.9 Value from the literature [6]
v3 l 0.34 Value from the literature [7]
x1(0) µmol 500 Chosen to be large
x2(0) µmol 621.951 In steady state with respect to x1(0)
x3(0) µmol 50 Fixed for large 
x4(0) µmol 0 Fixed for large 
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Figure 7-3 (A) Simulation of x4(t) given by equations (7-1) (actual) and
the approximation given by equation (7-3) (approx.), for the parameter val-
ues in table 7-2. (B) The same simulation as in (A), but now varying the
parameter k31.
 1 and then setting the parameters k03 and k31, the initial conditions x1(0) and x2(0),
and the IgG production rate I(t) close to zero, such that there is little interaction between
the Michaelis-Menten sub-model and the additional compartments or the environment.
Figure 7-3A shows a simulation of x4(t) given by solving equations (7-1) (actual) and given
by the approximation in equation (7-3) (approx.). The production rate of IgG, I(t), is
assumed to be zero. All parameter values and initial conditions for the simulation are
provided in table 7-2. The values of k14, kon, Rtot, koff, x3(0) and x4(0) are fixed in order to
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replicate the dynamics of the simulation shown in figures 7-1B and 7-1D, in which  = 0.5.
The values for parameters k31 and k03 were chosen, by trial and error, to be sufficiently
small such that the interaction between the Michaelis-Menten sub-model and additional
compartments is minimal and the QSS assumption remains violated. Parameters k21, k12,
v1 and v3 are fixed to values from the literature. The initial condition for x1(t) is set to
x1(0) = 500 µmol; this value is chosen somewhat arbitrarily and the importance of x1(0)
will be investigated later. The initial condition for x2(t) is given by its steady state with
respect to x1(t), xˆ2 = k21x1(0)/k12, with values for x1(0), k21 and k12 given in table 7-2.
As expected, the dynamics shown by x4(t) and its approximation in figure 7-3A are
similar to those shown by c(t) and its approximation in figure 7-1D. Even though there is
a large pool of IgG in the system (1122 µmol initially between x1(0) and x2(0)), it is not
made available to the ‘substrate’ compartment, due to the ‘small’ value of k31 = 1× 10−6
day−1. The effect of increasing the value of k31 is shown in figure 7-3B. The parameter k31
is varied between the simulations and is labelled next to each pair of curves on the plot.
As the value of k31 is increased between 0.0001 day
−1 and 0.1 day−1, the approximation
to x4(t) given by equation (7-3) becomes closer to the true value of x4(t), until the two
outputs are indistinguishable, by inspection, for the second phase of the simulation. The
initial, fast binding stage of the reaction lasts less than 0.1 days. Increasing k31 has the
effect of slowing down the dynamics of the second stage, after initial fast binding has
occurred; the two models are still indistinguishable by inspection when simulated over a
longer timecourse, for example from 0.1 to 8000 days.
In the classical enzyme reaction model, the QSS assumption is valid for  1 (for example
 = 0.001), where  is given by equation (7-26). Therefore the QSS assumption is valid
when the total quantity of enzyme is much smaller than the initial quantity of substrate.
For the simulation shown in figure 7-3A, the QSS is violated by having an initial quantity
of x3(t) (substrate) that is only twice the total quantity of receptors (enzyme). This is
still the case for the simulations shown in figure 7-3B; now however there is a constant
flow of ‘substrate’ from the first compartment to the third compartment due to k31. In the
classical enzyme reaction, the substrate is used up such that a steady state concentration
of complexes cannot be maintained indefinitely: the complex concentration falls during
the reaction until it eventually reaches zero, when all of the substrate has been converted
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Table 7-3 Parameters and initial conditions for simulations of the four-
compartment model in which the QSS assumption is violated by setting
initial conditions x1(0) and x2(0) to be small
Parameter Units Value
k21 day
−1 0.51 Value from the literature [5]
k31 day
−1 0.1 Value for which QSS is valid, with large x1(0)
k12 day
−1 0.41 Value from the literature [5]
k14 day
−1 1 Fixed for large 
k03 day
−1 1× 10−6 Chosen to be small
kon l µmol
−1 day−1 1 Fixed for large 
Rtot µmol 25 Fixed for large 
koff day
−1 1 Fixed for large 
v1 l 2.9 Value from the literature [6]
v3 l 0.34 Value from the literature [7]
x1(0) µmol 1 Chosen to be small
x2(0) µmol 1.2439 In steady state with respect to x1(0)
x3(0) µmol 50 Fixed for large 
x4(0) µmol 0 Fixed for large 
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Figure 7-4 (A) Simulation of x4(t) given by equations (7-1) (actual) and
the approximation given by equation (7-3) (approx.), for the parameter val-
ues in table 7-3. (B) The same simulation as in (A), but now varying the
initial conditions for x1(0) and x2(0).
to product (see figure 7-1). At the same time, having rapidly bound to substrate in
the initial fast stage, the enzyme recovers its initial concentration by the end of the
experiment. In the four-compartment model however, there is a positive flow from x1(t)
to x3(t) (the ‘substrate’ compartment); as such the substrate is not used up and there
is enough unbound substrate to maintain a QSS quantity of complexes. Likewise the
receptors remain in a bound state and do not recover their initial unbound concentration
during the simulation.
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The effect of the initial conditions for x1(t) and x2(t) on the validity of the QSS assumption
is now investigated. In figure 7-3B, the QSS assumption was valid for k31 = 0.1 day
−1.
Despite the small ratio of ‘substrate’ to ‘enzyme’ initially, violating the condition  1,
the transfer of IgG from x1(t) to x3(t) meant that there was a constant supply of IgG
to bind to receptors. This implies that, if k31 = 0.1 day
−1 but there is little IgG in
the plasma and peripheral compartments initially, relative to the size of k31, the QSS
assumption will be similarly invalidated. This scenario is simulated in figure 7-4A, in
which the parameter k31 is 0.1 day
−1 and the initial condition for x1(t) is small, with
x1(0) = 1 µmol; all other parameters and initial conditions are given in table 7-3. In
figure 7-4A, the QSS assumption is poor due to the ‘small’ values of x1(0) = 1 µmol and
x2(0) = 1.24 µmol, relative to the size of k31. The effect of increasing x1(0) and x2(0) is
shown in figure 7-4B. As x1(0) is increased from 10 µmol to 250 µmol, the validity of the
QSS approximation improves.
The effect of including the elimination of substrate, parameterised by k03, in the model
is to speed up the dynamics of the second stage of the simulation (after the fast binding
stage), since ‘substrate’ that would have been converted to ‘product’ is now removed
from the system. The inclusion of this flow has the opposite effect, qualitatively, to the
inclusion of a pool of IgG (x1(t)) which flows to the ‘substrate’ compartment (x3(t)). If
the model is simulated instead with parameter values that give a small value of  = 0.001,
such that the QSS approximation ought to be valid, increasing the value of k03 makes the
approximation progressively worse.
The simulations in this section show that additions to the classical enzyme reaction model
which serve to feed the substrate compartment (x3(t)) will have the effect of improving
the approximation to x4(t), given by equation (7-3). Additions which serve to remove
substrate from x3(t) will have the effect of worsening the approximation of x4(t). In the
simulations seen in this section, parameter values and initial conditions have been set to
certain values in order to give  = 0.5, to purposely violate the QSS assumption. However,
when simulating responses in IgG multiple myeloma, the system is assumed to be in steady
state, or at least near to steady state, prior to any intervention. This is fundamentally
different to the classical enzyme reaction scheme, in which the concentration of complex
is initially zero and substrate and enzyme rapidly bind at the onset of the reaction. The
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Table 7-4 Parameter values and initial conditions for the simulations of
the four-compartment model and the two-compartment reduced model in
section 7.5
Parameter Units Value
k21 day
−1 0.441 Estimated for two-compartment model in chapter 5
k31 day
−1 0.15419 Estimated for four-compartment model in chapter 6
k12 day
−1 0.422 Estimated for two-compartment model in chapter 5
k14 day
−1 14.9592 See section 6.4.4 in chapter 6
k03 day
−1 30.8231 See section 6.4.4 in chapter 6
kon l µmol
−1 day−1 255.467 See section 6.4.4 in chapter 6
Rtot µmol 1.71994 See section 6.4.4 in chapter 6
koff day
−1 167.029 See section 6.4.4 in chapter 6
v1 l 2.9 Value from the literature [6]
v3 l 0.34 Value from the literature [7]
kkill day
−1 0.055 Chosen for realistic tumour response
I0 µmol day
−1 76 Chosen for realistic tumour response
I∞ µmol day−1 26.5 Chosen for realistic tumour response
simulations in this section show that it is possible to violate the QSS assumption, however
the conditions required to achieve this are unlikely to occur in practice.
7.5 The relationship between plasma and endosomal
concentrations of IgG
The second assumption used by Hattersley [1] to derive the two-compartment model from
the four-compartment model is that the concentration of unbound IgG in endosomes is
equal to the concentration of IgG in plasma. Hattersley [1] states that ‘pinocytosis
is assumed to be a constant extraction and recycling process, which ensures that the
concentrations of IgG in the endosome and plasma are constant’. In this section the
four-compartment model is simulated with feasible parameter values to see whether this
assumption is likely to hold in practice. The two-compartment model is then simulated
using the parameter values calculated from the four-compartment parameter values.
The four-compartment model, given by equations (7-1), was simulated with feasible pa-
rameter values (see table 7-4) and a model for the IgG production rate that produces
IgG responses that are typically observed in patients. The IgG production rate, I(t), is
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Figure 7-5 (A) Plasma and endosomal concentrations of unbound IgG.
(B) Quantity of bound IgG in endosomes and an approximation, assum-
ing both QSS and equality of plasma and endosomal concentrations of IgG.
(C) Quantities of IgG in the plasma and peripheral compartments, for the
four-compartment model and the two-compartment model, parameterised
according to Hattersley’s [1] derivation.
assumed to be given by
I(t) = (I0 − I∞) exp(−kkillt) + I∞. (7-27)
This model is discussed in section 8.2 of chapter 8. At the beginning of the simulation,
when t = 0 days, the system is assumed to be in steady state. The initial conditions for
the model states are therefore given by the equilibrium point in equation (7-2).
The parameter values used to produce the simulation are given in table 7-4. The values for
k21 and k12 were estimated for the two-compartment model in chapter 5. The parameter
k31 was estimated for the four-compartment model in chapter 6. The values for k14, k03,
kon, Rtot and koff are taken from row A1 of table 6-8 in chapter 6 and their generation is
discussed in section 6.4.4 of that chapter.
Figure 7-5A shows the plasma and endosomal concentrations of IgG, given by x1(t)/v1
and x3(t)/v3, respectively, for the simulation described. According to the derivation of
the two-compartment model in section 7.1, these two quantities are required to be equal,
however this is clearly not the case for the current simulation. This means that the
approximation of x4(t), based on this assumption and given by equation (7-4), is a poor
one, as shown in figure 7-5B.
Figure 7-5C shows the quantities of IgG in plasma (x1(t)) and in the peripheral compart-
ment (x2(t)), simulated from the four-compartment model and from the reduced model.
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The reduced model, given by equations (7-9), was simulated assuming the same model
for IgG production, given by equation (7-27). Again the system was assumed to be in
steady state at t = 0 days; therefore the initial conditions for the reduced model are given
by equation (7-10). The parameters Vmax and KM were calculated using equations (7-7)
and (7-8); all other parameter values are given in table 7-4. Figure 7-5C shows that there
is a small difference in x1(t) and x2(t) between the two models at t = 0 days, around 2%,
which increases to around 12% by the end of the simulation. This difference is due to the
poor approximation of x4(t) shown in figure 7-5B, based upon an assumption that is not
supported by the model, with feasible parameter values.
The simulations shown in figure 7-5 show that the dynamics of x1(t) and x3(t) are not the
same and therefore, assuming a constant total volume of endosomes, the concentrations
are not equal. However, if we are to assume that the concentrations are equal based on
the biological process of pinocytosis, then clearly the total volume of the endosomes must
vary with time. Pinocytosis is nonspecific, that is, the cell internalises a small quantity of
the surrounding fluid and its contents, without targeting certain molecules. It is therefore
not unreasonable to suggest that the concentration of IgG within endosomes would equal
that of the environment outside the cell. From the point of view of the model, this would
mean that the total volume of the endosomes must become a variable which changes such
that x1(t)/v1 = x3(t)/v3(t).
The suggestion that the total volume of the endosomes containing IgG may vary is not
unreasonable: the total volume is made up of many individual endosomes, some of which
may not manage to capture IgG molecules when there is less IgG available in the system.
This modification to the model is easy to achieve by including an additional ordinary
differential equation for v3(t), which satisfies the second assumption of Hattersley’s [1]
derivation. However, this assumption requires us to consider endosomes as separate
entities. A simplified diagram of FcRn-mediated recycling is provided in figure 2-3 in
chapter 2. This diagram shows the transit of IgG through a cell within an endosome.
When the IgG is first internalised, the endosomal concentration of unbound IgG may
be assumed to be equal to its concentration in plasma; however once the endosome
has acidified, IgG-FcRn binding takes place and as such the concentration of unbound
IgG within that particular endosome must decrease. The concentration of unbound IgG
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within an individual endosome therefore changes during its transit through the cell. Due
to the difficulty in validating this assumption, a model in which v3 is time-varying is not
presented here, but may be the subject of future work.
7.6 Simulations of IgG responses in multiple
myeloma
As discussed in section 7.5, the second assumption required for the equivalence of the four-
and two-compartment models, namely that the concentrations of free IgG in plasma and
endosomes are equal, is unlikely to be valid for feasible parameter values. Having discov-
ered that the reduced model is not a good approximation to the full model, in this section
we investigate whether the two models can nonetheless produce similar predictions, when
the identifiable parameters Vmax and KM are no longer calculated from equations (7-7) and
(7-8), but are estimated from experimental data. In this section IgG responses during mul-
tiple myeloma treatment are compared for the two- and four-compartment models, using
the parameter values estimated in chapters 5 and 6, respectively. The two-compartment
model can no longer be considered as a reduced form of the four-compartment model and
simulated responses will not be identical.
The parameter identification problem was considered for the four-compartment model
in chapter 6. Whilst individual parameter values were difficult to estimate, certain ex-
pressions in terms of the underlying parameters could be estimated (see section 6.4). By
generating certain parameter values randomly and calculating the remaining parameters,
feasible parameter vectors were generated; these are tabulated in tables 6-8–6-11. These
parameter values are used in the simulations in this section.
7.6.1 Models for monoclonal and polyclonal IgG dynamics in
multiple myeloma
In order to simulate monoclonal IgG responses in IgG multiple myeloma, the models of
IgG metabolism need to explicitly account for monoclonal IgG produced by the malignant
plasma cells and polyclonal IgG produced by healthy plasma cells, since both types of IgG
162
Chapter 7. Comparison of two- and four-compartment models
undergo the same processes of recycling and elimination and therefore one is influenced by
the other. For the two-compartment model, the dynamics of monoclonal and polyclonal
IgG in an IgG myeloma patient are described by
x˙1m(t) = −
(
k21 + k31 − Vmax
KM + x1m(t) + x1p(t)
)
x1m(t) + k12x2m(t) + Im(t)
x˙2m(t) = k21x1m(t)− k12x2m(t)
x˙1p(t) = −
(
k21 + k31 − Vmax
KM + x1m(t) + x1p(t)
)
x1p(t) + k12x2p(t) + Ip
x˙2p(t) = k21x1p(t)− k12x2p(t),
(7-28)
where x1m(t) and x2m(t) are the quantities in µmol of monoclonal IgG in plasma and in the
peripheral space, respectively, x1p(t) and x2p(t) are the quantities in µmol of polyclonal
IgG in plasma and in the peripheral space, respectively, Im(t) is the production rate
of monoclonal IgG in µmol day−1, and Ip is the production rate of polyclonal IgG in
µmol day−1, which is assumed to be constant. All other parameters are as defined in
chapter 5. The total quantity of IgG in each compartment is given by
xitot(t) = xim(t) + xip(t), i = 1, . . . , 2. (7-29)
At the beginning of each simulation, the system is assumed to be in steady state. The
initial conditions are thus given by
xim(0) =
Im0
I0
xˆi
xip(0) =
Ip
I0
xˆi,
(7-30)
for i = 1, 2, where xˆ1 and xˆ2 are given by equation (7-10) and I0 = Im0 + Ip.
The monoclonal IgG response, ym(t), is given by
ym(t) =
x1m(t)
x1m(0)
. (7-31)
For the four-compartment model, the dynamics of monoclonal and polyclonal IgG in an
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IgG myeloma patient are described by
x˙1m(t) = −(k21 + k31)x1m(t) + k12x2m(t) + k14x4m(t) + Im(t)
x˙2m(t) = k21x1m(t)− k12x2m(t)
x˙3m(t) = k31x1m(t)− k03x3m(t)− kon
v3
x3m(t)(Rtot − x4m(t)− x4p(t)) + koffx4m(t)
x˙4m(t) =
kon
v3
x3m(t)(Rtot − x4m(t)− x4p(t))− (k14 + koff)x4m(t)
x˙1p(t) = −(k21 + k31)x1p(t) + k12x2p(t) + k14x4p(t) + Ip
x˙2p(t) = k21x1p(t)− k12x2p(t)
x˙3p(t) = k31x1p(t)− k03x3p(t)− kon
v3
x3p(t)(Rtot − x4m(t)− x4p(t)) + koffx4p(t)
x˙4p(t) =
kon
v3
x3p(t)(Rtot − x4m(t)− x4p(t))− (k14 + koff)x4p(t),
(7-32)
where x1m(t) and x1p(t) are the quantities of monoclonal and polyclonal IgG in plasma,
x2m(t) and x2p(t) are the quantities of monoclonal and polyclonal IgG in the peripheral
space, x3m(t) and x3p(t) are the quantities of unbound monoclonal and polyclonal IgG in
endosomes, and x4m(t) and x4p(t) are the quantities of monoclonal and polyclonal IgG
bound to FcRn in endosomes. All quantities have units of µmol. Im(t) is the production
rate of monoclonal IgG in µmol day−1 and Ip is the production rate of polyclonal IgG
in µmol day−1, which is assumed to be constant. All other parameters are as defined in
table 6-1 in chapter 6. The total quantity of IgG in each compartment is given by
xitot(t) = xim(t) + xip(t), i = 1, . . . , 4. (7-33)
At the beginning of each simulation, the system is assumed to be in steady state. The
initial conditions are thus given by
xim(0) =
Im0
I0
xˆi
xip(0) =
Ip
I0
xˆi,
(7-34)
for i = 1, . . . , 4, where xˆi is given by equation (7-2) and I0 = Im0 + Ip.
The monoclonal IgG response, ym(t), is given by
ym(t) =
x1m(t)
x1m(0)
. (7-35)
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Table 7-5 Parameter values for monoclonal and polyclonal IgG production
for the simulations in section 7.6.2
Parameter Units A B C D E F
Im0 µmol day
−1 61 152 116 68 105 53
Im∞ µmol day−1 11.5 5 2.5 0 24 5
kkill day
−1 0.055 0.03 0.07 0.007 0.0065 0.01
Ip µmol day
−1 15 15 15 15 15 15
Table 7-6 Parameter values for the simulations of the two-compartment
model in section 7.6
Parameter Units Value
k21 day
−1 0.441 Estimated for two-compartment model in chapter 5
k31 day
−1 0.159 Estimated for two-compartment model in chapter 5
k12 day
−1 0.422 Estimated for two-compartment model in chapter 5
Vmax µmol day
−1 40.0 Estimated for two-compartment model in chapter 5
KM µmol 272 Estimated for two-compartment model in chapter 5
v1 l 2.9 Value from the literature [6]
v3 l 0.34 Value from the literature [7]
Table 7-7 Parameter values for the simulations of the four-compartment
model in section 7.6
k31 k14 k03 kon/v3 Rtot koff
(day−1) (day−1) (day−1) (µmol−1 day−1) (µmol) (day−1)
A1 0.15419 14.9592 30.8231 751.375 1.71994 167.029
B1 0.15419 1.61346 2.89570 4330.95 15.9465 11164.2
C1 0.15419 1460.34 15.0518 3089.82 0.0176185 72.1920
D1 0.15419 14.5717 4.13855 53.6585 1.765680 82.2232
E1 0.15419 1.74892 0.541327 1607.86 14.7114 22172.6
F1 0.15419 2.17529 590.017 3196.13 11.8279 38.2657
G1 0.15419 0.489903 58.5907 2136.67 52.5185 271.763
Assuming a constant rate of IgG synthesis per plasma cell, the tumour response, yT(t),
is defined as
yT(t) =
Im(t)
Im(0)
. (7-36)
7.6.2 Simulations of responses to a decreasing tumour burden
The simulation in figure 7-6 shows the responses of monoclonal, polyclonal and total
IgG in plasma and the peripheral compartment, respectively, for both the two- and
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Figure 7-6 Monoclonal, polyclonal and total IgG, in compartments 1 and
2, simulated using the two-compartment model (dashed lines) and the four-
compartment model (solid lines). Note the different scales for total and
monoclonal quantities (left axis) and polyclonal quantities (right axis).
four-compartment models. The simulations were produced using equations (7-28) for
the two-compartment model and equations (7-32) for the four-compartment model. The
monoclonal IgG production rate, Im(t), is given by equation (7-27) with parameter values
from column ‘A’ in table 7-5. The system is assumed to be in steady state at time t = 0.
The parameter values for the two-compartment model are those estimated in chapter 5,
summarised here in table 7-6. The values for parameters k21, k12, v1 and v3 are assumed
to be the same for both models. The remaining parameter values used in simulating the
four-compartment model are given by row ‘A1’ in table 7-7. The values in table 7-7 are
taken from tables 6-8 to 6-11 in chapter 6.
The simulation in figure 7-6 shows that the trajectories of a quantity of IgG produced
by the two- and four-compartment models are, as expected, not identical. The two-
compartment model over-estimates all quantities of IgG by 1.7% at the beginning of the
simulated time interval and underestimates them by 1.3% at the end of the time interval.
We note that the quantities of polyclonal IgG are plotted on a different quantity scale as
they represent a small proportion of the total IgG.
Clinicians are most interested in the monoclonal IgG response in terms of the proportional
change during treatment. Figure 7-7 shows the tumour response, given by equation
(7-36), and the monoclonal IgG responses for the two- and four-compartment models,
given by equations (7-31) and (7-35), respectively. The monoclonal IgG response is used
as a surrogate for the tumour response in clinical practice. The simulation shows that,
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Figure 7-7 The monoclonal IgG response to a falling tumour burden,
simulated for both the two-compartment model and the four-compartment
model
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Figure 7-8 Proportional differences between the four-compartment model
and the two-compartment model, for monoclonal, polyclonal and total quan-
tities of IgG and the monoclonal IgG response
for both models, the monoclonal IgG response underestimates the depth of the tumour
response, with a maximum difference of 0.3 between the tumour and monoclonal IgG
responses at time t = 21 days. For the four-compartment model, the underestimation of
the tumour response is slightly greater.
Figure 7-8 shows the proportional differences between the responses produced by the two-
and four-compartment models. Allowing q to represent each of the variables (xitot, xim,
xip and ym, for i = 1, 2), the proportional difference, qdiff, is given by
qdiff =
q(2) − q(4)
q(4)
, (7-37)
where superscripts (2) and (4) denote the two-compartment model and four-compartment
model, respectively. The plot shows that the percentage difference for the quantities in
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Figure 7-9 Proportional differences between the four-compartment model
and the two-compartment model, for monoclonal, polyclonal and total quan-
tities of IgG and the monoclonal IgG response. The four-compartment model
parameter values for each simulation are given by rows (A) B1, (B) C1, (C)
D1, (D) E1, (E) F1, and (F) G1, in table 7-7.
µmol is between −1.3% and 1.9% over the whole simulation. The percentage difference in
the monoclonal IgG response, ym(t), reaches its maximal absolute value of around 2.9% at
t = 200 days, when ym(t) = 0.254 for the four-compartment model and ym(t) = 0.246 for
the two-compartment model. Whilst these differences seem small, they may be important
in future predictions, depending on the scenario that is being investigated.
In chapter 6, it was discovered that a wide range of parameter values for the four-
compartment model produce similar behaviour in the observed model outputs. The
different sets of parameter values in table 7-7 all produce similar behaviour in plasma
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Figure 7-10 Proportional differences between the four-compartment
model and the two-compartment model, for monoclonal, polyclonal and to-
tal quantities of IgG and the monoclonal IgG response. The monoclonal IgG
production parameter values for each simulation are given by columns (A)
B, (B) C, (C) D, (D) E, and (E) F, from table 7-5.
and peripheral IgG (x1(t) and x2(t)), despite having some extremely different individ-
ual values. The simulation of proportional differences, shown in figure 7-8, is therefore
repeated in figure 7-9 for each of the parameter vectors in table 7-7. All other details
of the simulation remain the same. There is some variation between the plots in figures
7-9A to 7-9F; however all of the parameter vectors show a similar pattern in terms of the
differences between the two- and four-compartment model responses.
The differences between the predictions of the two metabolism models are also dependent
on the assumed model for the monoclonal IgG production rate. Figure 7-10 shows the
same simulation of proportional differences between the responses produced by the two-
and four-compartment models, now using parameter values from columns B–F in table
7-5. The four-compartment model parameters are given by row ‘A1’ in table 7-7. Now,
whilst the basic pattern shown remains the same, there is much more variation between
the simulations, for example, we note that the time axis is no longer the same for each
plot, due to the different timescales of the dynamics shown.
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Figure 7-11 (A) The relationship between the total IgG production
rate and the plasma IgG equilibrium point, for both the four- and two-
compartment models. (B) The difference between the plasma IgG equilib-
rium points for the four- and two-compartment models.
In each simulation shown in figures 7-8–7-10, the basic pattern is the same: the percent-
age difference for IgG quantities is between 1% and 2% at t = 0 days, there then is some
positive fluctuation seen, followed by a steady decline then a negative fluctuation, before
reaching a steady state at a negative value for the proportional difference. In this simu-
lation, the system both begins and ends in steady state. Clinicians are most interested
in these ‘final’ responses, which are used to assess what proportion of the tumour has
been killed during therapy. The relationship between the steady states of the two models
therefore is important.
Figure 7-11A shows the relationship between the total IgG production rate and the
plasma IgG equilibrium point, for both the four- and two-compartment models, given
by equations (7-2) and (7-10), respectively. The parameter values used to plot the two-
compartment model equilibrium point are given in table 7-6. The four-compartment
model equilibrium point for x1(t) can be simplified, giving
xˆ1 =
(ψ1 + ψ2 + I0) I0
k31 (ψ1 + I0)
, (7-38)
where
ψ1 =
k03v3 (k14 + koff)
kon
ψ2 = k14Rtot.
(7-39)
The equilibrium point for x2(t) can be similarly simplified; however the equilibrium points
for x3(t) and x4(t) cannot be reduced in this way. Each of the parameter vectors in table
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Table 7-8 Parameter values for monoclonal and polyclonal IgG production
for the simulation of relapse in section 7.6.3
Parameter Units Value
Im1 µmol day
−1 60
Im2 µmol day
−1 5
kkill day
−1 0.028
kgrowth day
−1 0.0118
Ip µmol day
−1 15
7-7 was generated in order to give identical values for the identifiable parameters ψ1 and
ψ2: ψ1 = 7.46556 µmol day
−1 and ψ2 = 25.729 µmol day−1. These parameter values were
used to simulate the equilibrium point in figure 7-11A. Figure 7-11B shows the plasma IgG
equilibrium point for the four-compartment model minus that for the two-compartment
model. Figure 7-11B explains why the two-compartment model tends to overestimate
quantities of plasma IgG at the beginning of the simulated treatment, when the total
IgG production rate is large, and underestimates plasma IgG for the smaller production
rates of around 20–40 µmol day−1 at the end of treatment.
7.6.3 Simulations of responses during relapse
Whilst clinicians are mostly interested in using the monoclonal immunoglobulin (Ig)
response as a surrogate marker for tumour response, plasma monoclonal Ig is also used
to determine the time at which the disease is considered to have relapsed or progressed.
In this section IgG responses in a relapse setting are investigated. Simulations were
produced using equations (7-28) for the two-compartment model and equations (7-32)
for the four-compartment model. The system was assumed to be in steady state at t = 0.
The parameter values used to simulate the two-compartment model are given in table
7-6. The values for parameters k21, k12, v1 and v3 are assumed to be the same for both
models. The remaining parameter values used in simulating the four-compartment model
are given by row ‘A1’ in table 7-7.
The monoclonal IgG production rate, Im(t), is now given by
Im(t) = Im1 exp(−kkillt) + Im2 exp
(
kgrowtht
)
. (7-40)
This model is introduced in chapter 8. The parameter values for monoclonal and poly-
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Figure 7-12 Monoclonal, polyclonal and total IgG, in compartments 1
and 2, simulated using the two-compartment model (dashed lines) and the
four-compartment model (solid lines). The monoclonal IgG production rate
initially falls and then increases during a relapse. Note the different scales for
total and monoclonal quantities (left axis) and polyclonal quantities (right
axis).
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Figure 7-13 (A) The monoclonal IgG response during relapse, simulated
for both the two-compartment model and the four-compartment model. (B)
Proportional differences between the four-compartment model and the two-
compartment model, for monoclonal, polyclonal and total quantities of IgG
and the monoclonal IgG response, during relapse.
clonal IgG production are given in table 7-8.
The simulation shown in figure 7-12 shows the responses of monoclonal, polyclonal and
total IgG in plasma and the peripheral compartment, respectively, for both the two-
and four-compartment models. The two-compartment model now overestimates each
quantity, relative to the four-compartment model, throughout the simulation, peaking at
around 1.9% overestimation.
Figure 7-13A shows the tumour response, given by equation (7-36), the monoclonal IgG
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response for the two-compartment model, given by equation (7-31), and the monoclonal
IgG response for the four-compartment model, given by equation (7-35). Figure 7-13B
shows the proportional differences between the quantities of IgG and monoclonal IgG
responses, for the two models, respectively. The proportional difference between the two
models does not approach a steady state at the end of the simulation. The simulation
was produced by attempting to replicate the trajectory shown by the monoclonal IgG
concentration of a real patient, monitored for approximately 200 days. It is possible that
the two models could diverge at a later time, producing very different predictions. This
was checked by simulating the model over 800 days and finding that the proportional
differences plateau around this time, with none of the proportional differences reaching
an absolute value of more than 5%.
7.7 Conclusions
In this chapter the relationship between the two- and four-compartment models analysed
in chapters 5 and 6, respectively, has been investigated. The assumptions required to
derive the two-compartment model from the four-compartment model were tested using
simulations. The simulations revealed that whilst the QSS assumption is more difficult
to violate than for the classical enzyme reaction model, the assumption of the equality
of the plasma and endosomal concentrations of unbound IgG is not supported by the
four-compartment model in its current form. A possible modification to the model was
briefly mentioned; however this alternative model would require further validation and is
therefore not presented in this thesis.
Whilst the assumption of the equality of the plasma and endosomal concentrations is not
necessarily valid with feasible parameter values, the two models nonetheless produce sim-
ilar predictions, when the parameters Vmax and KM are estimated from experimental data
rather than being derived from the four-compartment model parameters. The simulated
quantities in section 7.6 did not differ by more than 6%; however, when making more
complex predictions it is possible that the models may diverge and this is something to
be aware of.
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8Predicted responses of
immunoglobulins A and G in
multiple myeloma
In this chapter predictions are made of the responses of immunoglobulin A (IgA) and
immunoglobulin G (IgG), in IgA multiple myeloma and IgG multiple myeloma, respec-
tively. The predictions are based on a two-compartment model of IgG metabolism, which
was analysed in chapter 5, and a two-compartment model of IgA metabolism from the
literature, described in section 8.1.1. These models describe the quantities of IgA or IgG
in plasma and in a peripheral compartment. An important component of these models
is the monoclonal immunoglobulin (Ig) production rate, which in multiple myeloma is
time-dependent [1], requiring additional parameters for its description. By coupling the
parameterised metabolic models with parameterised input functions, the models can be
used to predict how plasma monoclonal Igs evolve over time, in response to a changing
tumour burden.
There are a number of hypotheses that can be made relating to the behaviour of mon-
oclonal Igs (particularly IgG) in multiple myeloma patients. In this chapter we inves-
tigate whether these hypotheses are supported by the mathematical models of IgA and
IgG metabolism. This thesis is in large part motivated by the concentration-dependent
metabolism of IgG and how this affects the response of monoclonal IgG to a decreas-
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ing tumour burden during therapy. In particular, does monoclonal IgG respond faster
in patients presenting with large plasma concentrations, due to saturation of recycling
receptors? Another potential issue that may be caused by the long metabolic half-life of
IgG is the persistence of monoclonal IgG in the patient’s system after treatment, when a
maximal proportion of the tumour has been eradicated. At normal concentrations, IgG is
recirculated by the neonatal Fc receptor (FcRn), which may give a falsely high indication
of the proportion of cancerous cells remaining in the bone marrow.
The majority of multiple myeloma patients have IgG- or IgA-producing clones [2]. It
is known that the two proteins are eliminated at very different rates, which implies
that monoclonal IgG responds more slowly than IgA, for a similar tumour response.
Yet, patient responses are assigned in the same way for both IgA and IgG patients. In
this chapter the difference between monoclonal IgA and monoclonal IgG responses is
investigated. Similarly, when a clone of plasma cells is proliferating, the response of the
monoclonal Ig (this time an increase) is likely to be different for IgA and IgG tumours.
However, the recommended criteria for relapse, given in section 2.2 of chapter 2, are
currently the same for all patients regardless of the isotype of the monoclonal Ig.
It must be noted that the number of malignant plasma cells in the body cannot be mea-
sured in practice; it is therefore not possible to validate the predictions made in this
chapter using longitudinal measurements of both the myeloma cell population and the
monoclonal Ig concentration. However, from the outset, the purpose of this work has been
to investigate whether the metabolism of Igs influences their role as prognostic markers.
If we assume that the survival outcomes of patients are driven by the response of their
cancer, that is the proportion of malignant cells that are successfully killed at a clinically
relevant time, then it is possible to qualitatively predict how the effects of Ig metabolism
may influence the association between the monoclonal Ig response and survival. In par-
ticular we wish to ask the question: is it appropriate to interpret monoclonal IgA and
monoclonal IgG responses in the same way, knowing that IgA and IgG are eliminated
from the body at very different rates? This will be the subject of chapter 9, in which
survival analysis is performed using data from the IFM (Intergroupe Francophone du
Mye´lome) 2009/01 clinical trial [3; 4] of newly diagnosed multiple myeloma patients.
In this chapter, serum protein electophoresis (SPEP) data from the IFM 2009/02 clinical
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trial [5] of relapsed and refractory multiple myeloma patients, with IgA or IgG myeloma,
are referred to in order to produce simulations that represent realistic responses. The
IFM 2009/02 dataset is appropriate for this purpose as monoclonal Ig concentrations were
sampled frequently during the initial months following treatment, with measurements
taken at 28-day intervals. The two-compartment model of IgA metabolism described
in section 8.1.1 is based on the description of systemic IgA metabolism provided by
Waldmann et al. [6]; an equivalent model has also been presented by Hattersley et al. [7].
The simulations in this chapter were produced in Mathematica [8] and Berkeley Madonna
[9].
In this chapter tumour responses and monoclonal Ig responses are discussed. Responses
are calculated and plotted as the proportion of the value at the start of treatment, so
for example a patient might have a monoclonal IgA response of 0.25 after 30 days of
treatment and the response at the start of treatment is by definition equal to 1. In practice
however physicians and medical researchers usually talk about responses in terms of the
depth of response, for example the IgA response of 0.25 is referred to as a 75% response.
This chapter is largely about underestimation of the tumour response by the monoclonal
Ig response; in this sense a monoclonal IgA response of 75% underestimates a tumour
response of 80%, for example. Throughout this chapter discussions pertaining to sizes
of responses and under- and overestimations of tumour responses are with regard to the
depth of response; thus a response of 75% (0.25) is considered greater than a response of
60% (0.4). Both definitions of response are used in this chapter but the one being used
should be clear from the context of the discussion.
8.1 Models for the dynamics of IgA and IgG in mul-
tiple myeloma
With the assays currently available (see chapter 2, section 2.4) clinicians are, in theory,
able to monitor total Ig’, monoclonal Ig’, Ig’κ and Ig’λ, where the apostrophe (’) is used to
indicate either A or G, depending on the Ig isotype produced by the clonal plasma cells of
the patient. Model-based predictions need to consider how these quantities interact. The
polyclonal IgG in particular must be accounted for, as the elimination rate of monoclonal
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x1x2
k21
k12
I(t)
k01
Figure 8-1 Schematic of compartmental model of IgA metabolism de-
scribed in section 8.1.1
Table 8-1 States and parameters of model of IgA metabolism
Name Units Value Physiological interpretation
x1 µmol – Quantity of IgA in the central (plasma) compartment
x2 µmol – Quantity of IgA in the peripheral compartment
k01 day
−1 0.25∗ Fraction of IgA in plasma that is catabolised per day
k21 day
−1 0.441† Rate constant of flow of IgA from plasma to peripheral compartment
k12 day
−1 0.422† Rate constant of flow of IgA from peripheral compartment to plasma
∗Strober et al. [10]; †values assumed comparable to values for IgG estimated in chapter 5
IgG depends on the total IgG concentration.
8.1.1 Two-compartment model of IgA metabolism
The metabolism of systemic IgA is not as complex as that of IgG as its catabolic rate
is independent of its concentration in plasma. Like IgG, IgA is known to be distributed
among a central (plasma) compartment and a peripheral compartment. The following
model of IgA metabolism has been presented by Hattersley et al. [7]. The metabolism of
IgA is described by
x˙1(t) = − (k21 + k01)x1(t) + k12x2(t) + I(t)
x˙2(t) = k21x1(t)− k12x2(t),
(8-1)
where x1(t) and x2(t) represent the quantities in µmol of IgA in plasma and the peripheral
compartment, respectively. I(t) represents the synthesis of IgA in plasma in µmol day−1.
The rate constants, kij, represent material flow from compartment j to compartment i.
A schematic of the model is shown in figure 8-1. Table 8-1 summarises the model states
and parameters.
Systemic IgA metabolism has been studied using tracer experiments, although less exten-
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sively than IgG metabolism [6]. The type of data for IgG that were utilised in chapters
5 and 6 have not been found in the literature for IgA; therefore, for the model of IgA
metabolism, parameters are not estimated from experimental data in this thesis, but are
taken from the literature.
Given the similar size of the proteins IgA and IgG (150 kDa), the rate constants of distri-
bution between the central and peripheral compartments, k12 and k21, can be assumed to
be approximately equal for IgA and IgG [7]. This can be additionally justified by consid-
ering the relative quantities in the two compartments at steady state. The intravascular
proportion in steady state is given by k12
k12+k21
and is comparable between IgA and IgG
at approximately 50% [10; 11]. Metabolic studies of IgA have found that the fraction
of plasma IgA catabolised per day (k01 in equations 8-1) is 0.25 day
−1 [10]. This is
markedly greater than that of IgG in normal subjects (0.063 day−1 [6]) and explains the
approximately five-fold greater plasma concentration of IgG compared to IgA in healthy
subjects.
The normal production rate of endogenous IgA, IE (µmol day
−1), is given by IE = k01x1,E,
where x1,E is the quantity of endogenous IgA in plasma in steady state. The IgA pro-
duction rate and the quantity of IgA in plasma were found to be 11 µmol day−1 and 44
µmol, respectively, for a 70 kg individual [10].
8.1.1.1 Stability analysis
When the production rate is constant, I(t) = I0, the system given by equations (8-1) has
a single equilibrium point given by
xˆ1 =
I0
k01
, xˆ2 =
k21
k12
xˆ1. (8-2)
Linearising the system about the equilibrium point givesx˙1(t)
x˙1(t)
 =
− (k21 + k01) k12
k21 −k12

x1(t)
x2(t)
 . (8-3)
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The eigenvalues of the matrix in equation 8-3 are given by
λ1 =
1
2
(
−k01 − k12 − k21 −
√
−4k01k12 + (k01 + k12 + k21)2
)
λ2 =
1
2
(
−k01 − k12 − k21 +
√
−4k01k12 + (k01 + k12 + k21)2
)
.
(8-4)
For a stable equilibrium point, the eigenvalues of the system must have negative real
parts for all permitted parameter values. Firstly it can be shown that the eigenvalues
λ1 and λ2 are always real. The expression within the square root in equation 8-4 can be
rearranged to give
− 4k01k12 + (k01 + k12 + k21)2 = (−k01 + k12 + k21)2 + 4k01k12. (8-5)
The parameters k01, k12 and k21 are all real and positive; therefore the right hand side of
8-5 is always positive and the eigenvalues in equation 8-4 are always real.
All terms in the expression for λ1 are preceded by minus signs, therefore λ1 is always
negative. λ2 is negative provided that the value of the principal square root in equation
8-4 is less than the value of (k01 + k12 + k21). Since
− 4k01k12 + (k01 + k12 + k21)2 > 0 (8-6)
and
− 4k01k12 + (k01 + k12 + k21)2 < (k01 + k12 + k21)2 , (8-7)
then √
−4k01k12 + (k01 + k12 + k21)2 <
√
(k01 + k12 + k21)
2 = k01 + k12 + k21. (8-8)
Therefore λ2 is negative. Both eigenvalues are real and negative for all permitted param-
eter values and therefore the equilibrium point is stable.
8.1.2 Extension of model of IgA dynamics for multiple myeloma
A model is required that describes the dynamics of monoclonal IgA (either IgAκ or IgAλ,
depending on the patient), polyclonal IgAκ and polyclonal IgAλ. The equations for this
model are given by
x˙1Aj(t) = − (k21 + k01)x1Aj(t) + k12x2Aj(t) + IAj(t)
x˙2Aj(t) = k21x1Aj(t)− k12x2A,j(t),
(8-9)
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for j = m, κp, λp.
Here x1Aj is the quantity in µmol in plasma of monoclonal IgA (j = m), polyclonal
IgAκ (j = κp) or polyclonal IgAλ (j = λp). Likewise x2Aj is the quantity in µmol in
the peripheral compartment of monoclonal IgA (j = m), polyclonal IgAκ (j = κp) or
polyclonal IgAλ (j = λp). IAj(t) represents the production rate of each type of IgA in
plasma. The parameter values used are given in table 8-1.
When the production rates are constant (IAj(t) = IAj0) the system has a stable equilib-
rium point given by
xˆ1Aj =
IAj0
k01
, xˆ2Aj =
k21
k12
xˆ1Aj, (8-10)
for j = m, κp, λp.
Clinicians are most interested in the quantity of monoclonal IgA as a proportion of its
initial value at the start of treatment. This is referred to as the monoclonal IgA response
and is given by
yA(t) =
x1Am(t)
x1Am(T0)
, (8-11)
for t > T0, where x1Am(t) is given by equations (8-9) and treatment is assumed to begin
at time t = T0.
8.1.3 Extension of the two-compartment model of IgG dynam-
ics for multiple myeloma
The model presented here is an extension of the two-compartment model of IgG
metabolism studied in chapter 5, now explicitly differentiating between different IgG
types. The equations describing the rates of change of monoclonal IgG, polyclonal IgGκ
and polyclonal IgGλ are given by
x˙1Gj(t) = −
(
k21 + k31 − Vmax
KM + x1Gtot(t)
)
x1Gj(t) + k12x2Gj(t) + IGj(t)
x˙2Gj(t) = k21x1Gj(t)− k12x2Gj(t),
(8-12)
for j = m, κp, λp, with x1Gtot(t) = x1Gm(t) + x1Gκp(t) + x1Gλp(t).
Here x1Gj is the quantity in µmol in plasma of monoclonal IgG (j = m), polyclonal
IgGκ (j = κp) or polyclonal IgGλ (j = λp). Likewise x2Gj is the quantity in µmol in
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Table 8-2 Parameters values for model of IgG dynamics in multiple
myeloma, estimated in chapter 5
Name Units Value
k21 day
−1 0.441
k31 day
−1 0.159
Vmax µmol day
−1 40.0
KM µmol 272
k12 day
−1 0.422
a peripheral compartment of monoclonal IgG (j = m), polyclonal IgGκ (j = κp) or
polyclonal IgGλ (j = λp). IGj(t) represents the production rate of each type of IgG in
plasma. The parameter values used are given in table 8-2.
When the Ig production rates are constant (IGj(t) = IGj0) the system has a stable
equilibrium point (for feasible parameter values; see chapter 5, section 5.2.1) given by
xˆ1Gtot =
−k31KM + IGtot0 + Vmax +
√
4k31KMIGtot0 + (−k31KM + IGtot0 + Vmax)2
2k31
xˆ2Gtot =
k21
k12
xˆ1Gtot,
(8-13)
where x1Gtot and x2Gtot are the total quantities of IgG in plasma and the peripheral
compartment, respectively, and the total production rate of IgG is given by
IGtot0 = IGm0 + IGκp0 + IGλp0. (8-14)
The equilibrium points for the different IgG types are given by
xˆ1Gj =
IGj0
IGtot0
xˆ1Gtot, xˆ2Gj =
IGj0
IGtot0
xˆ2Gtot, (8-15)
for j = m, κp, λp.
The monoclonal IgG response is given by
yG(t) =
x1Gm(t)
x1Gm(T0)
, (8-16)
for t > T0, where x1Gm(t) is given by equations (8-12) and treatment is assumed to begin
at time t = T0.
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8.2 Models for Ig production rates
The models given in section 8.1 can be used to simulate the dynamics of IgA and IgG
in multiple myeloma when coupled with parameterised input functions. When assump-
tions are made about the relationship between the clonal plasma cell population and the
monoclonal Ig production rate, these models can be used to investigate the relationship
between a growing or shrinking plasma cell clone and the monoclonal Ig that it produces.
It is then possible to predict the monoclonal Ig response to a given tumour trajectory
under various conditions including tumour growth, response to therapy and relapse.
The average monoclonal Ig synthesis rate per plasma cell has been reported in the lit-
erature as 1.45× 10−11 g day−1 (9.7× 10−11 µmol day−1) [1] and 1.21× 10−11 g day−1
(8.1× 10−11 µmol day−1) [12]. Sullivan et al. [1] have found that for individual patients
this rate remains constant during the course of the disease. Thus the monoclonal Ig
production rate at time t, denoted by Im(t), can be assumed to be proportional to the
myeloma cell population at time t, denoted by Nm(t). In this section models for the Ig
production rates are provided, assuming proportionality between the plasma cell popu-
lation and the rate of Ig synthesis.
8.2.1 Mono-exponential response to therapy
The simplest approach to modelling the tumour burden in response to therapy is to
assume mono-exponential decay of the myeloma cell population [13; 14]. The evolution
of the myeloma cell population is thus given by
Nm(t) = N0 exp(−kkillt), Nm(0) = N0, (8-17)
where Nm(t) is the myeloma cell population, N0 is the myeloma cell population at time
T0 = 0 days, when treatment is assumed to begin, and kkill (day
−1) is the (positive) rate
constant of tumour kill.
In practice there are a multitude of therapeutic agents and regimens that are used in
the treatment of multiple myeloma. The mono-exponential model is a highly simplistic
representation of the more complex evolution of the tumour burden that is the resultant
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product of the pharmacokinetics, pharmacodynamics and dosing regimen of the therapeu-
tic agent(s) used. Cancer drugs are heterogenous and may operate by killing the existing
cancer cells, inhibiting proliferation or both, often through a number of mechanisms that
are not always clear. Considering a therapy that kills cancer cells and assuming first
order kinetics, the rate at which cancer cells are killed is proportional to the number (or
quantity or concentration) of cells and the concentration of drug; this is known as the
linear log-kill hypothesis [15, p. 21]. Letting c(t) denote the concentration of drug in
µmol l−1, the rate of cell death under this hypothesis is given by
φc(t)Nm(t), (8-18)
where φ (l µmol−1 day−1) is a constant representing the effectiveness of the drug.
The unforced proliferation rate of the cancer cells has previously been modelled by ex-
ponential, Gompertz or logistic growth curves [15, ch. 1]. Taking the simplest of these,
exponential growth, the evolution of the myeloma cell population is now given by
N˙m(t) = rmNm(t)− φc(t)Nm(t), (8-19)
where rm (day
−1) represents the proliferation rate of the cells in the absence of interven-
tion.
The drug concentration at the site of action, c(t), is the realisation of the dosing regimen
and the pharmacokinetic profile of the agent. The simplest approach is to assume that
the drug concentration is constant, c(t) = c0. In reality the concentration is likely to
change in a periodic fashion, increasing with dose administration and decaying in the
interim period. For simplicity, c0 can be considered as the average concentration of drug
over time; then the rate of change of the myeloma cell population is given by
N˙m(t) = (rm − φc0)Nm(t). (8-20)
The tumour cell population now follows mono-exponential decay when the drug has a high
enough concentration and efficacy relative to the proliferation rate of the cells: φc0 > rm.
Assuming a constant Ig production rate per plasma cell, the monoclonal Ig production
rate Im(t) can thus be described by
Im(t) = Im0 exp(−kkillt), (8-21)
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Figure 8-2 Symbol: monoclonal IgG concentration (SPEP) in IgG
myeloma patients undergoing treatment. Line: simulation of monoclonal
IgG concentration in response to a shrinking tumour burden.
Table 8-3 Parameter values used to produce the simulations in figure 8-2
Parameter Units A B C D E F
Im0 µmol day
−1 53 104 152 61 116 68
Im∞ µmol day−1 5 0 5 11.5 2.5 0
kkill day
−1 0.01 0.0037 0.03 0.055 0.07 0.007
with Im(0) = Im0.
The therapy may fail to kill 100% of the clonal cells. In this scenario the myeloma cell
population can be described by
Nm(t) = (N0 −N∞) exp (−kkillt) +N∞, (8-22)
where Nm(t) tends to N∞ for large t. The monoclonal Ig production rate is then given
by
Im(t) = (Im0 − Im∞) exp (−kkillt) + Im∞, (8-23)
with Im(0) = Im0 µmol day
−1 and the quantity Im(t) tending to Im∞ µmol day−1 for large
t. Examples of monoclonal IgG concentrations, measured by SPEP, are shown in figure 8-
2. Superimposed on the data are simulations of the monoclonal IgG concentration when
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the monoclonal IgG production rate is described by equation (8-23). The parameter
values used to produce these simulations are given in table 8-3 and are used to represent
‘reasonable’ parameter values for the simulations in this chapter.
When the goal of therapy is to kill as great a proportion of the cancer cells as possible,
physicians are most interested in the proportion of cancer cells remaining. This is referred
to in this thesis as the tumour response, ym(t), and is given by
ym(t) =
Nm(t)
Nm(T0)
, ym(T0) = 1, (8-24)
for t > T0, where therapy is assumed to begin at T0 days (often with T0 = 0). When
the monoclonal Ig production rate is assumed to be directly proportional to the clonal
plasma cell population, then the tumour response is given by
ym(t) =
Im(t)
Im(T0)
, ym(T0) = 1, (8-25)
for t > T0, again where therapy is assumed to begin at T0 days. Throughout this chapter
it is assumed that Ig synthesis rates are directly proportional to plasma cell populations;
therefore equation (8-25) applies to each of the models presented in this section.
8.2.2 Tumour growth
Growth of myeloma cell populations can be approximated by the Gompertz function [1],
given by
N˙m(t) = rmNm(t) log
(
Km
Nm(t)
)
, (8-26)
where Nm is the population of monoclonal plasma cells, Km is the so-called carrying
capacity, representing the maximal population that can be reached, and rm (day
−1) is a
constant related to the rate of tumour growth. The Gompertz equation has been used
to model multiple myeloma cell population growth in several publications [1; 12; 16–18].
Mechanistically, the Gompertz model represents the effect of competition for resources
in the bone marrow limiting the growth of the clonal cell population.
Sullivan et al. [1] provide parameter values for an alternative parameterisation of the
Gompertz equation for a sample of 11 patients with IgG multiple myeloma, from which
rm and Km can be derived. The calculated values of Km agree with those in Swan et al.
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Figure 8-3 Multiple myeloma growth curves, simulated using equation
(8-26) with parameter values calculated from data in [1]
[18] and Dingli et al. [12]. The predicted growth curves using these parameter values are
shown in figure 8-3. The plot shows the evolution of the myeloma cell population if left
untreated.
Considering a scenario in which the tumour cell population is growing up to the com-
mencement of therapy, which is modelled according to the log-kill hypothesis, the growth
and subsequent decline of the myeloma cell population is given by
N˙m(t) = rmNm(t) log
(
Km
Nm(t)
)
− φc (Nm(t)−Nm1)
Nm(0) = Nm0
φc =

0, t < T0
Φ, t ≥ T0
,
(8-27)
where c (µmol l−1) is the average concentration of drug at the site of action, assumed
constant, φ (l µmol−1 day−1) is a constant expressing the effectiveness of the drug, Nm1
is a constant, representing a population of plasma cells against which the therapy is
ineffective, and T0 (days) is the time at which therapy commences. Since the parameters
φ and c only appear as the product φc, the parameter Φ = φc (day−1) is defined.
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Figure 8-4 Symbol: monoclonal Ig concentration (SPEP) in (A) an IgG
myeloma patient and (B) an IgA myeloma patient. Line: simulation of
monoclonal Ig concentration, responding to a tumour burden that is initially
shrinking and then growing.
8.2.3 Relapse
A simple way to model relapse is to introduce another exponential term in equations
(8-22), this time with a positive exponent, as follows,
Nm(t) = N1 exp (−kkillt) +N2 exp
(
kgrowtht
)
+N∞, Nm(0) = N1 +N2 +N∞, (8-28)
where kgrowth is a positive constant. This model is not derived mechanistically, but
theoretically represents a scenario in which a proportion of the clone is killed (N1), a
proportion continues to grow (N2) and a proportion remains stable (N∞).
The monoclonal Ig production rate, Im(t), is then given by
Im(t) = Im1 exp(−kkillt)+Im2 exp
(
kgrowtht
)
+Im∞, Im(0) = Im1 +Im2 +Im∞. (8-29)
Each of the models given by equations (8-21), (8-23) and (8-29) are constrained cases
of a model based on two exponentials and a constant. Examples of monoclonal IgG
concentrations, measured by SPEP, are shown in figure 8-4. Superimposed on the data
are simulations of the monoclonal IgG concentration when the monoclonal IgG production
rate is described by equation (8-29).
The following, more detailed, model of relapse incorporates tumour growth, tumour kill
during therapy, and relapse due to decreasing effectiveness of therapy. The myeloma cell
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population is described by
N˙m(t) = rmNm(t) log
(
Km
Nm(t)
)
− Φ(t)Nm(t)
Nm(0) = Nm0,
(8-30)
where the effectiveness of therapy, Φ(t), is now assumed to decrease over time and is
given by
Φ(t) =

0, t < T0
φ0 exp
(−kφ(t− T0)) t ≥ T0, (8-31)
where φ0 day
−1 is the initial effectiveness of therapy at time t = T0 and kφ day−1 is a
rate constant describing the rate of loss of effectiveness.
8.2.4 Polyclonal Ig production rate
The simplest approach to modelling the polyclonal Ig production rates is to assume that
they remain at a normal level. The average IgG production rate in normal subjects is
15 µmol day−1 [6]. On average, the proportion of serum IgG that is IgGκ is 64% and
IgGλ 36% [19]. Thus the average normal production rates are IGκp = 9.6 µmol day
−1
and IGλp = 5.4 µmol day
−1, of IgGκ and IgGλ, respectively. Likewise the average IgA
production rate in normal subjects is 11 µmol day−1 [10], with IgAκ representing 55% of
serum IgA [19]. Thus the average normal production rates are IAκp = 6.0 µmol day
−1
and IAλp = 5.0 µmol day
−1, of IgAκ and IgAλ, respectively.
Polyclonal plasma cells in the bone marrow are frequently depleted in multiple myeloma,
causing a corresponding decrease in the overall synthesis rate of normal polyclonal Ig.
There are several complex mechanisms involved, but fundamentally the suppression of
polyclonal cells is believed to be due to competition between monoclonal and polyclonal
cells for survival niches in the bone marrow microenvironment [20–23].
The mechanisms behind the suppression of polyclonal plasma cells in the bone marrow are
not entirely clear; however mechanistic models of competition can frequently be reduced
to commonly applied descriptive models [24, ch. 2]. The most well-known model of
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competition is the Lotka-Volterra competition model [25; 26], given by
N˙1(t) = r1N1(t)
(
K1 −N1(t)− α12N2(t)
)
/K1
N˙2(t) = r2N2(t)
(
K2 −N2(t)− α21N1(t)
)
/K2,
(8-32)
where N1 and N2 are two competing populations, ri is the growth rate of Ni, Ki is the
carrying capacity of Ni and αij is the competition coefficient, representing the negative
action that Nj has onNi (i = 1, 2). The carrying capacity, Ki, is the maximum population
size of Ni, representing the effect of intra-species competition for finite resources. When
only one species is present, the dynamics are of logistic growth form, given by
N˙1(t) = r1N1(t)
(
K1 −N1(t)
)
/K1. (8-33)
In an alternative model the individual populations are assumed to observe Gompertzian
growth in the absence of competition [27]. The model equations are given by
N˙1(t) = r1N1(t) log
(
K1
N1(t) + α12N2(t)
)
N˙2(t) = r2N2(t) log
(
K2
N2(t) + α21N1(t)
)
,
(8-34)
where all variables and parameters are interpreted in the same way as in equation (8-32).
Now the growth of an individual population in the absence of competition is Gompertzian,
given by equation (8-26).
Assuming that growth of the myeloma cell population follows the Gompertz curve, a
model for the populations of malignant and normal polyclonal plasma cells is given by
N˙m(t) = rmNm(t) log
(
Km
Nm(t) + αmpNp(t)
)
N˙p(t) = rpNp(t) log
(
Kp
Np(t) + αpmNm(t)
)
,
(8-35)
where Nm and Np are the numbers of monoclonal and polyclonal plasma cells in the
bone marrow, rm and rp are the proliferation rates of monoclonal and polyclonal plasma
cells, Km and Kp are the carrying capacities of the monoclonal and polyclonal cells, αmp
is the negative effect of competition from Np on Nm, and αpm is the negative effect of
competition from Nm on Np.
Due to the lack of availability of known parameter values, the model can be simplified
by assuming that the polyclonal cells do not have a negative effect on the malignant
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cells, such that αmp = 0. Given the proliferative ability of clonal plasma cells and the
suppression of polyclonal plasma cells seen in myeloma patients, the clonal cells clearly
have a competitive advantage. Then the myeloma cell growth follows the Gompertz
function, as described in section 8.2.2. Now the populations of monoclonal and polyclonal
plasma cells are described by
N˙m(t) = rmNm(t) log
(
Km
Nm(t)
)
N˙p(t) = rpNp(t) log
(
Kp
Np(t) + αpmNm(t)
)
.
(8-36)
The parameter values for the monoclonal cell population can be found in the literature,
as shown in section 8.2.2. The parameters describing the polyclonal plasma cells are rp,
Kp and αpm. At the time of writing the author is unable to find a mathematical model of
long-lived plasma cell homeostasis in the literature; indeed the mechanisms of homeostasis
are still not clear [23; 28]. For the sake of simplicity the parameter rp can be assumed to
be equal to rm. Kp corresponds to the normal population of bone marrow plasma cells.
Again it is difficult to find values for this parameter in the literature, however typical
steady state immunoglobulin production rates in healthy humans are known. Assuming
that long-lived plasma cells in the bone marrow are responsible for the majority of long-
term antibody generation, the polyclonal plasma cell population can be calculated from
the polyclonal immunoglobulin production rate and the synthesis rate per plasma cell.
Taking the average values of normal polyclonal immunoglobulin production of 11 and 15
µmol day−1 for IgA and IgG, respectively, and an average immunoglobulin synthesis rate
per cell of 8× 10−11 µmol day−1 gives Kp = 1.375× 1011 for IgA and Kp = 1.875× 1011
for IgG. The phenomenon of polyclonal plasma cell suppression has not been incorporated
into the simulations presented in this chapter; however, this could be the subject of future
research.
8.3 Comparison of IgA and IgG responses to a de-
creasing tumour burden
In this section, the effect of the different elimination rates of IgA and IgG on their
responses to a shrinking plasma cell clone is investigated. The monoclonal Ig responses
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Table 8-4 Parameters values used in the simulation in section 8.3. Certain
parameter values were adjusted in order that the monoclonal IgG concentra-
tion approximately replicates the patient data shown in figure 8-2D.
Name Units Value Source
Im0 µmol day
−1 61 Adjusted to replicate patient data
Im∞ µmol day−1 11.5 Adjusted to replicate patient data
kkill day
−1 0.055 Adjusted to replicate patient data
IGκp µmol day
−1 9.6 Waldmann et al. [6], Bradwell et al. [19]
IGλp µmol day
−1 5.4 Waldmann et al. [6], Bradwell et al. [19]
of IgA and IgG myeloma patients are compared, assuming that the responses of their
respective tumours to treatment are identical.
A scenario is considered in which two patients, with IgA- and IgG-producing plasma
cell clones, respectively, undergo a course of therapy beginning at time T0 = 0 days.
The monoclonal IgA production rate, IAm(t), and the monoclonal IgG production rate,
IGm(t), are each set equal to Im(t) given by equation (8-23). The parameter values for
the monoclonal Ig production rate are given in table 8-4. The parameter values for the
monoclonal Ig production rate were chosen so that the monoclonal IgG concentration
during treatment approximates the patient data shown in figure 8-2D. The polyclonal
IgG production rates are assumed to be constant and take the average values in normal
subjects, given in table 8-4. It is not necessary to include polyclonal IgA as the system
equations for monoclonal and polyclonal IgA are not coupled.
The dynamics of IgA and IgG are described by equations (8-9) and equations (8-12),
respectively. The parameter values are given in tables 8-1 and table 8-2. At time T0 = 0
days the system is assumed to be in steady state. The initial conditions for the quantities
of IgG and IgA are therefore set to the steady state values given by equations (8-13) and
(8-10), respectively.
Clinicians are most interested in two quantities: the population of myeloma cells as a
proportion of its initial value (tumour response) and the quantity of plasma monoclonal
Ig as a proportion of its initial value (monoclonal Ig response). The tumour response is
given by equation (8-25). The monoclonal Ig responses are given by equations (8-11) and
(8-16), for the IgA myeloma and IgG myeloma patients, respectively, with T0 = 0 days.
Figure 8-5A shows a simulation of the two patients’ monoclonal Ig responses, respectively,
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Figure 8-5 (A) Monoclonal IgA and monoclonal IgG responses for identi-
cal tumour responses. (B) Differences between monoclonal IgA and tumour
responses, monoclonal IgG and tumour responses, and monoclonal IgG and
monoclonal IgA responses. The model used to produce the simulation is
described in section 8.3.
with both patients assumed to have an identical tumour response, as described above. It
can be seen that for the given tumour response, both monoclonal IgA and monoclonal IgG
underestimate the depth of the tumour response, that is, they overestimate the proportion
of cancer cells remaining at time t. Due to its slower rate of catabolism, monoclonal IgG
underestimates the tumour response by a greater margin than monoclonal IgA. Due to
the nonlinear relationship between the steady state of IgG and its production rate (see
equation (8-13)), the monoclonal IgG response does not tend towards the same value as
the tumour response at the end of the simulation.
The degree of underestimation of response is clearly dependent on the time at which
the monoclonal Ig is measured. For these particular conditions, the maximal difference
between the myeloma cell population response and monoclonal IgA response is 0.18 at
t = 13 days. The maximal difference between myeloma response and monoclonal IgG
response is 0.30 at t = 21 days. The differences between the monoclonal IgA response and
the myeloma cell response, the monoclonal IgG response and the myeloma cell response,
and the monoclonal IgG response and the monoclonal IgA response are depicted in figure
8-5B. There is a difference of 0.058 between the monoclonal IgA and IgG responses at
time t = 200 days. If responses were assessed at this time, the IgA patient would be
considered to have had an 81.1% response, whereas the IgG patient would be assigned
a response of 75.3%. The true tumour response is 81.1%. In the clinical setting, 200
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days represents the approximate time at which induction therapy is completed and the
patient is assumed to have achieved a maximal response to treatment. This is therefore
considered the most critical time at which to assess the response. The underestimation
of the tumour response by the monoclonal IgG response at this time suggests that IgG
patients may be given falsely poor prognoses.
8.3.1 Sensitivity of responses to model parameter values
In this section the sensitivity of the responses of monoclonal IgA and monoclonal IgG
to the parameters of the metabolic models is investigated. The sensitivity function of
a variable with respect to a parameter is given by the partial derivative of the variable
with respect to the parameter. For example, the sensitivity function of the monoclonal
IgA response with respect to the parameter k21 is given by
syA,k21(t) =
∂yA
∂k21
(t). (8-37)
Due to the range in size of the parameter values, the sensitivity functions are each scaled
by the size of the respective parameter values. The scaled sensitivity functions are plotted
in figure 8-6, evaluated for the parameter values given in tables 8-1 and 8-2. For example,
the scaled sensitivity function of yA(t) with respect to the parameter k21 is given by
s˜yA,k21(t) = k21
∂yA
∂k21
(t). (8-38)
The scaled sensitivity functions have the same units as yA(t) and are therefore unitless.
The scaled sensitivity functions show the importance of each parameter in determining
the response, relative to the parameter’s size. Figure 8-6A shows that the parameter k01 is
the most important parameter in determining the monoclonal IgA response. Figure 8-6B
shows that the parameter k31 is the most important parameter during the transient phase
of the monoclonal IgG response. The parameter Vmax is the most important parameter
determining the final monoclonal IgG response, with changes in k21 and k12 having no
impact upon the final response.
The simulation shown in figure 8-5 was produced using parameter values that represent
the average parameter values within the population; however there is uncertainty associ-
ated with these parameter values. The standard error as a percentage of the parameter
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Figure 8-6 Scaled sensitivity functions of (A) monoclonal IgA response
and (B) monoclonal IgG response, with respect to the parameters of the
metabolic models
Table 8-5 Relative standard error (RSE %) and 95% confidence intervals
for the parameter values of the metabolic models
Parameter RSE (%) 95% confidence interval
k31 7.0 (0.137, 0.181)
Vmax 26 (19.1, 60.9)
Km 20 (162, 382)
k21 19 (0.278, 0.604)
k12 27 (0.187, 0.657)
k01 – (0.217, 0.288)
estimate, for each parameter of the two-compartment model of IgG metabolism, is given
in table 8-5, along with 95% confidence intervals. The parameter k01 has not been es-
timated in this thesis, but is taken from the literature [10]. Strober et al. [10] provide
estimates for k01 from twelve subjects, with a sample mean of 0.252 day
−1 and sample
standard deviation of 0.0559 day−1. A confidence interval for the population mean was
calculated using
CI =
(
0.252− 2.20× 0.0559√
12
, 0.252 + 2.20× 0.0559√
12
)
, (8-39)
where 2.20 is the critical value for the Student’s T distribution with 12− 1 = 11 degrees
of freedom. This confidence interval is also provided in table 8-5.
In order to take into account the uncertainty in the parameter values, the maximum and
minimum responses of monoclonal IgA and IgG are considered, for the parameter confi-
dence intervals given in table 8-5. According to the local sensitivity functions plotted in
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Figure 8-7 Maximal and minimal monoclonal IgA and IgG responses,
when the parameters k01, k31, Vmax and Km are allowed to vary within
their 95% confidence intervals. The region within the maximal and minimal
responses is shaded, for each of monoclonal IgA and monoclonal IgG.
figure 8-6, an increase in each parameter has the effect of either increasing or decreasing
the value of the monoclonal Ig response over the whole simulated time interval. Whilst
the sensitivity functions are local, the general pattern is the same when the parameters
are varied within the confidence intervals given. It is thus possible to consider a max-
imal/minimal response in monoclonal IgG by maximising/minimising parameters Vmax
and k21 and minimising/maximising parameters k31, KM and k12. Similarly for mono-
clonal IgA, maximising/minimising k21 and minimising/maximising k01 and k12 results
in a maximal/minimal response.
Maximal and minimal monoclonal Ig responses, when the parameters are allowed to vary
within their 95% confidence intervals, are plotted in figure 8-7. Given that the parameters
k21 and k12 are considered equivalent for both models, only the parameters k31, Vmax, KM
and k01 are allowed to vary, whilst k21 and k12 are fixed to the values given in table 8-2.
The region between the minimal and maximal predicted responses is shaded, for both
the monoclonal IgA response and the monoclonal IgG response. The shaded region for
the monoclonal IgG response is significantly larger than that for monoclonal IgA; this
is because there are three parameters allowed to vary for IgG, compared to only one
for IgA. The shaded region for IgG is particularly large because correlations between
the parameter estimates have not been taken into account. For example, the minimal
response is simulated using the lower limit of Vmax = 19.1 µmol day
−1 and the upper limit
of Km = 382 µmol; however these parameter are strongly positively correlated, with a
correlation coefficient of 0.976. The shaded region for monoclonal IgG responses in figure
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Table 8-6 Parameters values used in the simulation in section 8.3.2. The
parameter values were chosen in order that the monoclonal IgG concentration
approximately replicates the patient data shown in figure 8-2D.
Name Units Value Source
rm day
−1 0.01 Sullivan et al. [1]
Km n/a 4× 1012 Sullivan et al. [1]
Nm1 n/a 8.625× 1010 Adjusted to replicate patient data
Nm0 n/a 1
Φ day−1 0.085 Adjusted to replicate patient data
T0 days 300 Adjusted to replicate patient data
ksyn µmol day
−1 8× 10−11 Dingli et al. [12]
IGκp µmol day
−1 9.6 Waldmann et al. [6], Bradwell et al. [19]
IGλp µmol day
−1 5.4 Waldmann et al. [6], Bradwell et al. [19]
8-7 is therefore a conservative representation of the confidence we have in the prediction.
A more accurate prediction interval could be made by considering a confidence region
for the parameters k31, Vmax and KM, that takes into account parameter correlations.
Nevertheless, the value of the minimal monoclonal IgG response is greater than the value
of the maximal monoclonal IgA response, for the entire simulated time interval.
8.3.2 Tumour growth prior to the commencement of therapy
To produce the simulations shown in figure 8-5, it was assumed that the system is in steady
state at time T0 = 0, that is, all production rates including the monoclonal Ig production
rate are constant up to time T0 = 0. It is more realistic to assume that the myeloma
cells are actively proliferating and the monoclonal Ig production rate is increasing when
therapy commences. In this section Gompertzian growth of the myeloma cell population
is assumed prior to the commencement of therapy, at time T0 = 300 days, which is then
modelled according to the log-kill hypothesis. The myeloma cell population is therefore
described by equation (8-27). The parameter values for the myeloma cell population
model and monoclonal Ig production rates are given in table 8-6. The values of the
parameters T0, Φ and Nm1 were adjusted so that the monoclonal IgG concentration
during treatment approximates that shown in figure 8-2D.
Again, two patients are considered – one with an IgA-producing clone and one with an
IgG-producing clone. For both patients, the monoclonal Ig production rate is assumed
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Figure 8-8 (A) Monoclonal Ig production rate up to and during therapy,
as described in section 8.3.2. (B) IgA and IgG response for the same tumour
response, as described in section 8.3.2.
to be directly proportional to the population of malignant cells, with the proportionality
constant ksyn µmol per cell, that is IAm(t) = PGm(t) = ksynNm(t). As before, normal
polyclonal Ig production rates are assumed, given in table 8-6.
The quantities of IgA and IgG are described by equations (8-9) and equations (8-12),
respectively, with the parameter values given in tables 8-1 and 8-2. The purpose of this
simulation is to investigate the responses of monoclonal Igs when the production rate is
increasing at the start of treatment, such that the system is not in steady state when
treatment begins; rather, the system is assumed to be in steady state in the very early
stages of tumour growth, when the growth rate is very slow. Therefore the tumour growth
is simulated with a starting population of Nm0 = 1 at time 0 days. At time 0 days, the
initial conditions of IgA and IgG are given by the steady states in equations (8-10) and
(8-13), respectively. Assuming an average plasma volume of 3 l, the concentrations of
monoclonal IgA and monoclonal IgG at the start of treatment, T0 = 300 days, are given
by 26.0 g l−1 and 14.3 g l−1, respectively.
Figure 8-8A shows a simulation of the monoclonal Ig production rate during clonal cell
population growth and then decay. The dashed line shows the trajectory that would have
been followed if the clone were left untreated. The plot in figure 8-8B shows the response
of the clonal cell population and the monoclonal Ig, for the IgA myeloma patient and
the IgG myeloma patient. As expected, the response in the tumour is underestimated by
the monoclonal Ig, and to a greater extent by monoclonal IgG than monoclonal IgA. For
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Table 8-7 Parameters values used in the simulation in section 8.4
Name Units Value Source
kkill day
−1 0.05 Chosen for reasonable response rate
Im0 (A) µmol day
−1 300 Chosen for a large initial monoclonal IgG concentration
Im∞ (A) µmol day−1 50 Chosen for a reasonable final response
Im0 (B) µmol day
−1 15 Chosen for a small initial monoclonal IgG concentration
Im∞ (B) µmol day−1 2.5 Chosen for a reasonable final response
IGκp µmol day
−1 9.6 Waldmann et al. [6], Bradwell et al. [19]
IGλp µmol day
−1 5.4 Waldmann et al. [6], Bradwell et al. [19]
the parameter values used, the maximal difference between the monoclonal IgA response
and the tumour is 0.273, 11 days after therapy begins. For the IgG myeloma patient, a
maximal difference of 0.425 occurs 18 days after the start of treatment.
Now that the assumption of steady state at the beginning of treatment has been re-
moved, the differences between the two monoclonal Ig responses and the tumour response
are greater. The final tumour response, at t = 500 days, of 84.9% is now slightly un-
derestimated by the monoclonal IgA response of 83.0%. The final tumour response is
underestimated by almost 10% by the final monoclonal IgG response.
8.4 The effect of concentration-dependent elimina-
tion on IgG response
The purpose of this section is to investigate how the concentration-dependent elimination
of IgG, due to recycling by saturable FcRn receptors, influences the response of mono-
clonal IgG in IgG multiple myeloma. Patients with IgG-producing plasma cell clones
are considered. The concentration-dependency of IgG elimination suggests that patients
with larger initial tumour burdens would have faster monoclonal IgG responses than
those with smaller initial tumour burdens, when the tumour response is the same, due
to saturation of FcRn receptors. The size of this effect is investigated in this section.
Two patients (A and B) with IgG-producing clones are considered. It is assumed that
the two patients have identical tumour responses, however the initial monoclonal IgG
production rates are different. The monoclonal IgG production rate for both patients is
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Figure 8-9 (A) Monoclonal IgG responses for identical tumour responses,
with different initial monoclonal IgG production rates. (B) Differences be-
tween monoclonal IgG and tumour responses and the difference between the
two monoclonal IgG responses. The simulation is described in section 8.4.
assumed to be described by equation (8-23). The parameter values for the monoclonal
IgG production rate are given in table 8-7. The initial monoclonal IgG production rate
is much larger for patient A; it is therefore expected that this patient will have a faster
monoclonal IgG response.
The dynamics of IgG are described by equations (8-12), with the parameter values given
in table 8-2. The polyclonal IgG production rates are assumed to be constant and take
the normal values in table 8-7. Assuming that immediately prior to t = 0 days the
system is in steady state, this also means that the initial conditions of IgG are different
for the two patients. The initial conditions for the quantities of IgG are set to the
steady state values given by equation (8-13). Patient A, with an initial monoclonal IgG
production rate of Im0 = 300 µmol day
−1, has an initial quantity of plasma monoclonal
IgG of x1,m(0) = 2100 µmol. Patient B, with Im0 = 15 µmol day
−1, has x1,m(0) = 163
µmol. Assuming a plasma volume of 3 l, these initial conditions can be converted to 105
g l−1 and 8.14 g l−1, respectively, which represent the extremes of the range of baseline
monoclonal IgG concentrations seen in actual patient data (a range of 1.8 to 66.9 g l−1 is
seen in the IFM 2009/02 dataset).
The tumour response and two monoclonal IgG responses are plotted in figure 8-9A. The
simulation illustrates the effect of the concentration dependence of IgG metabolism. A
patient who is observed, via the monoclonal IgG marker, to initially respond faster to
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therapy (patient A in the simulation) may in fact have a faster monoclonal IgG response
because recycling receptors are saturated, and not because the tumour is responding faster
to treatment. Interestingly, by the end of the simulated timecourse, the monoclonal IgG
response for patient B has ‘overtaken’ that of patient A. The patient with the smaller
initial tumour burden has the greater final depth of response; this is because of the
nonlinear relationship between the steady state of plasma IgG and its production rate.
The differences between the two monoclonal IgG responses, respectively, and the tumour
response, are plotted in figure 8-9B, along with the difference between the two monoclonal
IgG responses. The maximal difference between the monoclonal IgG responses of the two
patients is 9% after 37 days of treatment.
8.4.1 Therapy initiated at different stages in the tumour growth
curve
In section 8.4 the effect of the initial monoclonal IgG production rate on the response
rate of monoclonal IgG was considered, with the system assumed to be in steady state at
the start of treatment. Now a more complex, but more realistic, scenario is considered,
in which two IgG-producing clones are treated at different stages in their growth. As in
the simulation at the beginning of section 8.4, the concentration of plasma monoclonal
IgG when treatment begins is 105 g l−1 for the large tumour burden (patient A) and 8.14
g l−1 for the small tumour burden (patient B).
The trajectory of the myeloma cell population, for each of the patients A and B, is
described by equation (8-27). In the current simulation the growth parameters for the
myeloma cell populations, rm and Km, are the same for each tumour, taking the values
in table 8-8. Treatment starts at T0 = 625 days for patient A and T0 = 241.75 days
for patient B, in order to give the same initial plasma concentrations of IgG as in the
previous simulation. The parameters Φ and Nm1 were adjusted to produce a tumour
response that approximates the one in the previous simulation, at the beginning of section
8.4. The monoclonal IgG production rates are assumed to be directly proportional to the
populations of malignant cells, with the proportionality constant ksyn µmol per cell, for
both patients A and B. The polyclonal IgG production rates are assumed to be constant.
All parameter values describing IgG production rates are given in table 8-8.
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Table 8-8 Parameter values used in the simulation in section 8.4.1. Certain
parameter values were adjusted in order that the tumour response approxi-
mately replicates the tumour response simulated in section 8.4.
Name Units Value Source
rm day
−1 0.01 Sullivan et al. [1]
Km n/a 4× 1012 Sullivan et al. [1]
Nm1 (A) n/a 4.125× 1011 Adjusted to approximate the tumour response in sec-
tion 8.4
Nm1 (B) n/a 2.25× 1010 Adjusted to approximate the tumour response in sec-
tion 8.4
Nm0 n/a 1
Φ (A) day−1 0.054 Adjusted to approximate the tumour response in sec-
tion 8.4
Φ (B) day−1 0.08 Adjusted to approximate the tumour response in sec-
tion 8.4
T0 (A) days 625 Chosen for a large initial monoclonal IgG concentra-
tion
T0 (B) days 241.75 Chosen for a small initial monoclonal IgG concentra-
tion
ksyn µmol day
−1 8× 10−11 Dingli et al. [12]
IGκp µmol day
−1 9.6 Waldmann et al. [6], Bradwell et al. [19]
IGλp µmol day
−1 5.4 Waldmann et al. [6], Bradwell et al. [19]
The dynamics of IgG for both patients A and B are described by equations (8-12), with
the parameter values given in table 8-2. At t = 0 the system is assumed to be in steady
state; the initial conditions of IgG for each IgG patient are thus calculated from equations
(8-13).
Figure 8-10A illustrates the scenario in which two tumours, with the same growth pa-
rameters, are treated at different stages of their growth. The blue curve shows a tumour
that is treated at an earlier stage of growth (patient B) and the red curve shows a tumour
that is treated 383.25 days later (patient A), in order to account for the large difference in
the initial monoclonal IgG concentrations. In figure 8-10A the monoclonal IgG produc-
tion rate is plotted, which is proportional to the number of malignant cells. The curves
are plotted on two vertical scales in order to illustrate that the proportional response to
treatment is the same in both cases.
Figure 8-10B shows the effect of beginning treatment at different growth stages on the
monoclonal Ig response. As expected, patient A (large clone) shows a faster monoclonal
IgG response than patient B (small clone). Comparing this result with the simulation
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Figure 8-10 (A) Monoclonal IgG production rates and (B) comparison of
monoclonal IgG responses, for two patients with different plasma monoclonal
IgG concentrations at the beginning of treatment, due to starting treatment
at different stages in the tumour growth curve. Note the two vertical axes
with different scales in panel (A). The simulation is described in section 8.4.1.
shown in figure 8-9, there is now a considerably larger difference between the two mono-
clonal IgG responses and the monoclonal IgG response of patient B no longer ‘overtakes’
that of patient A. The greatest difference between the two monoclonal IgG responses
occurs 30.5 days after the beginning of treatment, around the first monitoring point
for patients who are followed up monthly. At this time the difference between the two
responses is 0.276.
8.5 Tumour responses giving similar monoclonal Ig
responses
Having considered in sections 8.3 and 8.4 scenarios in which two patients having the
same tumour response show different monoclonal Ig responses, it is natural to consider
the reverse problem, in which multiple patients show similar monoclonal Ig responses
resulting from different tumour responses.
8.5.1 Identical monoclonal Ig responses at the end of treatment
In section 8.3, the IgA patient had a final monoclonal IgA response of 81.1% whereas the
IgG patient had a final monoclonal IgG response of 75.3%, despite both patients having
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Figure 8-11 Final tumour response plotted against the initial monoclonal
Ig production rate, for different final monoclonal Ig responses
a final tumour response of 81.1%. In this section we ask, given the final monoclonal Ig
response and the monoclonal Ig isotype (A or G), what is the final tumour response for
the patient? As in sections 8.3 and 8.4, the monoclonal Ig production rate is assumed
to be given by equation (8-23). The final tumour response is calculated from equation
(8-23). The final monoclonal Ig responses are calculated using the steady state values
given by equations (8-10) and (8-13).
Figure 8-11 shows the final tumour response plotted against the initial monoclonal Ig
production rate, for different final monoclonal Ig responses. Each solid line represents
the same final monoclonal IgG response, which may be the result of a range of tumour
responses, depending on the initial monoclonal IgG production rate and hence the sat-
uration level of the recycling receptors. For IgA, there is a linear relationship between
the production rate and the quantity of IgA in plasma; therefore the final monoclonal
IgA response always equals the final tumour response, as represented by the constant
dashed lines in figure 8-11. Figure 8-11 shows that a 50% monoclonal IgG response can
represent a tumour response of up to 57% when the initial monoclonal IgG production
rate is 63 µmol day−1. A 90% monoclonal IgG response can represent a tumour response
of up to 93%, when the initial monoclonal IgG production rate is 163 µmol day−1. The
simulation shown in this figure imply that the underestimation of the tumour response
by the monoclonal IgG response is more important for modest monoclonal IgG responses
between 50% (Partial Response; PR) and 80%. For very good partial response (VGPR;
90%) the underestimation of tumour response is less dramatic. This trend continues as
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even deeper monoclonal Ig responses are considered, such as 95% and 99%. This is to
be expected as the tumour response must be deeper than the monoclonal IgG response;
when the monoclonal IgG response is 99% the tumour response cannot be underestimated
by more than 1%.
8.5.2 Tumour responses resulting in similar transient mono-
clonal IgG responses
As shown in section 8.4, the rate of the monoclonal IgG response depends on the mono-
clonal IgG concentration at the start of treatment as well as the tumour response. In that
section, a patient with an initial monoclonal IgG production rate of Im0 = 15 µmol day
−1
was shown to have a slower monoclonal IgG response (initially) than the patient with an
initial monoclonal IgG production rate of Im0 = 300 µmol day
−1, despite having identical
tumour responses. However, if the patient with the smaller initial tumour burden were to
have a faster tumour response, then the monoclonal IgG of the two patients may respond
at a similar rate. The question then is: at what rate must the smaller tumour respond,
in order for that to be the case?
In this section tumour responses modelled by equation (8-22) are considered. The mon-
oclonal IgG production rates are given by equation (8-23). To simplify the scenario, the
parameter Im∞ is assumed to be zero and different values of the parameters Im0 and kkill
are considered, with the aim of finding contours of Im0 and kkill which produce similar
monoclonal IgG responses. All other features of the simulations are as in section 8.4.
As an example, a patient is considered whose tumour response is parameterised by Im0 =
300 µmol day−1 and kkill = 0.05 day−1 (identical to patient A in section 8.4 but with
Im∞ = 0 µmol day−1). A second patient is considered with a much smaller monoclonal
IgG production rate at the start of treatment, given by Im0 = 5 µmol day
−1, and we
ask what value of kkill is required for this patient in order that the two responses are
closely similar. The ‘most similar’ response is defined here as the response with the
smallest maximal difference, over time, to the response of the first patient. For clarity,
we now refer to the parameters for the first patient (A) as Im01 and kkill1 and those for
the second patient (B) as Im02 and kkill2; therefore Im01 = 300 µmol day
−1, kkill1 = 0.05
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Figure 8-12 The difference between the monoclonal IgG responses of pa-
tients A and B, as described in section 8.5.2
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Figure 8-13 (A) Monoclonal IgG responses for patient A with Im01 = 300
µmol day−1 and kkill1 = 0.05 day−1 and patient B with Im02 = 5 µmol day−1
and kkill2 = 0.087 day
−1. (B) The difference between the monoclonal IgG
responses of patient A and patient B.
day−1, Im02 = 5 µmol day−1 and we are interested in finding values for kkill2.
Figure 8-12 shows the differences between the two patients’ monoclonal IgG responses
for different values of the parameter kkill2, between kkkill2 = 0.06 day
−1 and kkill2 = 0.1
day−1, as the optimal value of kkkill2 is within this range. The difference is given by the
monoclonal IgG response of patient A minus the monoclonal IgG response of patient
B, where the monoclonal IgG response is given by yG(t) in equation (8-16). A negative
value of the difference means that the monoclonal IgG response of patient A is faster.
When kkill2 = 0.06 day
−1, the monoclonal IgG response is much faster for patient A than
patient B; however as the value of kkill2 increases, the difference between the responses
becomes smaller, until eventually patient B has a faster monoclonal IgG response than
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Figure 8-14 (A) A range of tumour responses (blue) yielding very similar
monoclonal IgG responses (red). (B) The difference between each mono-
clonal IgG response plotted in panel (A) and the monoclonal IgG response
of patient A with Im01 = 300 µmol day
−1 and kkill1 = 0.05 day−1.
patient A, when kkill2 = 0.1 day
−1. The difference with the smallest maximum, for the
parameter values shown, is given by kkill2 = 0.09 day
−1. By defining a function that
finds the maximal absolute difference between the two responses, over a range of t = 0 to
t = 500 days, and minimising that function over a range of values of kkill2, the maximal
absolute difference is found to be 5.45× 10−3 when kkill2 = 0.087 day−1. The monoclonal
IgG responses of patients A and B are plotted in figure 8-13A, where kkill2 = 0.087 day
−1.
The difference between the two responses is plotted in figure 8-13B. The two monoclonal
IgG responses are extremely similar, despite the different tumour response rates.
The same approach can then be taken for alternative values of Im02, which will yield
many pairs of values of Im02 and kkill2 which give similar monoclonal IgG responses.
The generated pairs of Im02 and kkill2, along with the original parameters Im01 and kkill1,
give a set of tumour response parameters that yield similar transient monoclonal IgG
responses. Values of kkill2 that minimise the maximal difference between the monoclonal
IgG responses of patients A and B were found for values of Im02 between 5 and 300
µmol day−1. Examples of these monoclonal IgG responses are plotted in figure 8-14A,
along with the corresponding tumour responses, showing a range of tumour responses
that yield very similar monoclonal IgG responses. The differences between each of these
monoclonal IgG responses and the monoclonal IgG response of patient A are plotted in
figure 8-14B.
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Figure 8-15 Parameter contours for tumour responses corresponding to
very similar monoclonal IgG responses. The red line corresponds to the
simulations shown in figure 8-14.
The process can be repeated for different values of kkill1 in order to find similar monoclonal
IgG responses for a range of response rates. This approach was taken in order to find
multiple contours of tumour response parameters which correspond to similar monoclonal
IgG responses; these parameter contours are plotted in figure 8-15. The plot illustrates
that faster monoclonal IgG responses (larger values of kkill) may result from a broader
range of tumour response rates, whereas very slow monoclonal IgG responses only result
from very slow tumour responses. This suggests that clinicians may need to be aware
that very fast monoclonal IgG responses in patients with large initial monoclonal IgG
concentrations may be due to metabolic effects rather than a particularly fast tumour
response. However, the plot suggests that there is little need to be concerned about
fast tumour responses producing particularly slow monoclonal IgG responses in patients
presenting with small monoclonal IgG concentrations. However, this may be of concern in
a trial where particularly fast responses are to be expected. Furthermore, in this section
it has been assumed that the system is in steady state at the beginning of treatment.
Other simulations in this chapter have shown that when a more realistic assumption of
tumour growth at T0 is applied, the effects of Ig metabolism on monoclonal Ig responses
are generally amplified.
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Table 8-9 Parameter values used in the simulation in section 8.6.1. Certain
parameter values were adjusted in order that the monoclonal IgG concentra-
tion approximately replicates the patient data shown in figure 8-4A.
Name Units Value Source
kkill day
−1 0.028 Adjusted to replicate patient data
kgrowth day
−1 0.0118 Adjusted to replicate patient data
Im1 µmol day
−1 60 Adjusted to replicate patient data
Im2 µmol day
−1 5 Adjusted to replicate patient data
IGκp µmol day
−1 9.6 Waldmann et al. [6], Bradwell et al. [19]
IGλp µmol day
−1 5.4 Waldmann et al. [6], Bradwell et al. [19]
8.6 Comparison of IgA and IgG responses during re-
lapse
Another scenario in which the effects of metabolism may be relevant is relapse. In this
section two models of relapse and their corresponding monoclonal Ig responses are consid-
ered. Based on the results of previous simulations, the difference between the monoclonal
IgA and monoclonal IgG responses is investigated. In each example, two patients are con-
sidered, one with an IgA- and one with an IgG-producing clone.
8.6.1 Two-exponential model of relapse
In the following simulation, the myeloma cell population is described by equation (8-28),
with the monoclonal Ig production rate, Im(t), described by equation (8-29). The tumour
response is given by equation (8-25). Whilst the model may seem simplistic and lacking
in mechanistic basis, it adequately reproduces the behaviour seen in patient data, shown
in figure 8-4. Normal polyclonal Ig production rates are assumed. The parameter values
for the Ig production rates are provided in table 8-9. The parameter values were selected
so that the plasma concentration of monoclonal IgG approximately replicates the SPEP
concentration data of a real patient, assuming an average plasma volume of 3 l.
The dynamics of IgA and IgG are described by equations (8-9) and (8-12), respectively,
with the parameter values given in tables 8-1 and 8-2. At time T0 = 0 days the system
is assumed to be in steady state, with the initial conditions of the quantities of IgG and
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Figure 8-16 Monoclonal IgG and IgA responses during tumour kill and
subsequent relapse. Vertical dashed lines are used to indicate the minima of
the curves, at 84, 93 and 105 days, respectively.
IgA set to the steady states given by equations (8-13) and (8-10), respectively.
This scenario is plotted in figure 8-16. The simulation shows the response and subsequent
regrowth of the tumour, as a proportion of its initial size. It also shows the corresponding
responses in plasma monoclonal IgA and IgG, for IgA- and IgG-producing clones, respec-
tively. In each case the proportion of the quantity at time T0 = 0 days is plotted. The
simulation illustrates the delay between the turning point in the cancer cell population
and the turning point in the monoclonal Ig response, for each patient. For the particular
parameter values used in this simulation, there is a delay of 9 days between the turn-
ing point in the myeloma cell response and that in the monoclonal Ig response, for the
IgA-producing clone, and 21 days for the IgG-producing clone.
Figure 8-17 shows how the time delay between the minimal myeloma cell population and
the minimal monoclonal Ig concentration changes, for both IgA and IgG patients, as
selected model parameters vary. The bold portion of each line in figure 8-17 indicates
the 95% confidence interval for that parameter. Figure 8-17A shows that, for an IgA
patient, varying the parameter k01 between 0.4 and 1.6 times its value results in the
greatest change in the relapse delay. However, the relative standard error of the param-
eter k12 is the largest, such that within the 95% confidence intervals of the parameters,
varying the parameter k12 gives the largest range in the relapse delay, between 7.14 and
16.0 days. For the IgG patient, the delay between tumour relapse and monoclonal IgG
relapse appears to be most sensitive to the parameter k31, followed by k12, k21, Vmax and
KM. This suggests that experimental design should focus on improving the precision of
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Figure 8-17 The time delay between the minimal myeloma cell popula-
tion and (A) the minimal monoclonal IgA concentration or (B) the minimal
monoclonal IgG concentration, plotted against the metabolic model parame-
ters. Each parameter is varied between 0.4 and 1.6 times its value. The bold
portion of each line indicates the 95% confidence interval for that parameter.
the parameters with this order of importance. The large relative standard error in the
parameter k12 corresponds to a range of 16.6 to 31.8 days delay between tumour and
monoclonal IgG relapses. In contrast, the parameter KM has relatively little effect on the
relapse delay, with a difference of only one day over the entire range shown.
A significant event is the increase by 25% (or 5 g l−1, whichever is greater) in monoclonal
protein, a criterion for the assignment of progressive disease (PD). The maximal tumour
response is given by 70.5%. The monoclonal IgA reaches approximately the same maximal
response as the myeloma cell population, a decrease of 70%. From this maximal response,
monoclonal IgA increases by 25% on day 136. However, assuming a typical plasma volume
of 3 l, monoclonal IgA does not increase by 5 g l−1 until day 193, an increase of 130%
from its minimal concentration. At the same time, the myeloma cell population has
seen an increase of 156% from its minimum. Due to the slower metabolism of IgG, the
monoclonal protein does not achieve as deep a response as the tumour – 61.6% maximal
response versus 70.5%. From its maximal response, monoclonal IgG increases by 25% on
day 153, but does not see an increase 5 g l−1 until day 172. At this time the myeloma
cells have increased by 101%.
Whilst the two hypothetical patients have the same tumour response, PD can be assigned
to the IgG patient 21 days before the IgA patient. However, with different parameter
values describing the tumour response, a 25% increase in IgA and IgG may be sufficient
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Table 8-10 Results of the simulations in section 8.6.1
IgA IgG
Maximal response in monoclonal protein −70% −61.6%
PD days since t = 0 193 172
Ig increase from maximal response to PD +130% +47%
Myeloma cell increase from maximal response to PD +156% +101%
Table 8-11 Parameters values used in the simulation in section 8.6.2. Cer-
tain parameter values were adjusted in order that the monoclonal IgG con-
centration approximately replicates the patient data shown in figure 8-4A.
Name Units Value Source
rm day
−1 0.01 Sullivan et al. [1]
Km n/a 4× 1012 Sullivan et al. [1]
Nm0 n/a 1 Adjusted to replicate patient data
φ0 day
−1 0.0661 Adjusted to replicate patient data
kφ day
−1 0.0114 Adjusted to replicate patient data
T0 days 303 Adjusted to replicate patient data
ksyn µmol day
−1 8× 10−11 Dingli et al. [12]
IGκp µmol day
−1 9.6 Waldmann et al. [6], Bradwell et al. [19]
IGλp µmol day
−1 5.4 Waldmann et al. [6], Bradwell et al. [19]
for the assignment of PD. In this case PD would occur in the IgA patient before the IgG
patient. Monoclonal IgA responds faster to a relapse in myeloma cells than IgG because
of its faster elimination.
8.6.2 Relapse with Gompertzian growth
The simulation in section 8.6.1 is produced from a highly simplified model that is capable
of describing the behaviour observed in patient data, plotted in figure 8-4. In this section a
more detailed model is considered, which incorporates tumour growth, tumour kill during
therapy, and relapse due to decreasing effectiveness of therapy. Again two patients are
simulated, with IgA- and IgG-producing clones, respectively. The trajectories followed
by their clones are identical; their monoclonal IgA and IgG responses differ due to their
different metabolic properties.
The trajectory of the myeloma cells is described by equation (8-30), with the parameter
values given in table (8-11). The values of all parameters describing therapeutic interven-
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Figure 8-18 (A) Monoclonal Ig production rate for a plasma cell clone that
is initially growing, then shrinks due to treatment, and finally grows due to
decreasing treatment effectiveness. (B) Monoclonal IgG and IgA responses
during tumour kill and subsequent relapse.
tion were chosen so that the trajectory of plasma monoclonal IgG approximately resem-
bles that of a real patient, the data for whom are plotted in figure 8-4A. The monoclonal
Ig production rate is assumed to be directly proportional to the population of malignant
cells, with the proportionality constant ksyn µmol per cell, that is Im(t) = ksynNm(t).
The polyclonal IgG production rates are assumed constant and take the normal values
in table 8-11.
The quantities of IgA and IgG are described by equations (8-9) and (8-12), respectively,
with the parameter values given in tables 8-1 and 8-2. At time 0 days the system is
assumed to be in steady state. The initial conditions for IgA and IgG are thus given by
the steady states in equations (8-10) and (8-13), respectively.
Figure 8-18A shows the monoclonal Ig production rate (directly proportional to the
myeloma cell population) over the course of the disease. The dashed line shows the
trajectory that would be taken without intervention. Figure 8-18B shows the responses
to therapy of the myeloma cell population and monoclonal IgA and IgG, for the IgA-
and IgG-producing clones, respectively. The simulation shows a similar result to the first
relapse simulation in section 8.6.1; the delay between tumour relapse and monoclonal Ig
relapse is 9 days for the IgA patient and 22 days for the IgG patient (cf. 9 and 21 days
when steady state at the start of treatment is assumed).
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8.7 Conclusions
In this chapter a number of simulations were performed in order to investigate whether
mathematical models of IgA and IgG metabolism, based on the known biology of IgA and
IgG, support a number of hypthotheses regarding monoclonal Ig responses to a changing
clonal plasma cell population.
Models for the monoclonal Ig production rates were derived using tumour growth models
from the literature and comparing the resulting trajectories of monoclonal Ig concentra-
tion with SPEP data from a clinical trial. The derived models provide good agreement
with the patient data. Future work could involve deriving more complex models of tu-
mour growth that incorporate the pharmacodynamical effects of therapeutic agents in a
mechanistic way.
In section 8.3 monoclonal Ig responses for an average IgA myeloma patient and an aver-
age IgG myeloma patient were compared for an identical tumour response. Simulations
showed that, with certain assumptions in place, monoclonal IgG underestimates the tu-
mour response significantly more than monoclonal IgA. In addition, the tumour response
is underestimated by monoclonal IgG when the maximal response has been reached,
which in a clinical setting can represent an important assessment point. Whilst the hy-
pothesis that monoclonal IgG underestimates response more than monoclonal IgA has
been shown to have merit, variation within the population in terms of metabolic model
parameters and tumour model parameters has not been incorporated in this study. Pop-
ulation parameters have been estimated in chapter 5 for the parameters k21 and k12; with
further work in order to estimate the other population parameters, or with additional
assumptions, it would be possible to produce simulations of a cohort of patients, incorpo-
rating population-level variability. Whilst in ‘average’ patients, IgG may underestimate
response more than IgA, the effect may lose importance when population-level variability
is taken into account. Furthermore, noise on measurements of plasma concentrations may
reduce the significance of metabolic effects.
In section 8.4 the effect of the initial size of the plasma cell clone on response rates in
IgG myeloma was considered. When the system was assumed to be in steady state at
the beginning of treatment, a patient with a smaller clone showed an initially slower
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response, but a greater maximal response. The parameter values for the monoclonal
IgG production models were chosen in order that the simulation showed the smallest
and largest initial monoclonal IgG concentrations that may be expected in real patients;
even in this extreme scenario, the difference between the monoclonal Ig responses in
the two IgG patients is less significant than the difference between the IgA and IgG
patients compared in section 8.3. However, when more realistic assumptions are made
regarding the tumour growth trajectory at the beginning of therapy, the monoclonal IgG
response for the smaller clone changes significantly, giving a large difference of up to
27.6% between the two monoclonal IgG responses. Again, variability in the population
has not been taken into account; this may be the subject of future research. Variability in
terms of the cellular synthetic rate has also been neglected: it is possible that two patients
may have very different initial monoclonal IgG concentrations due to different cellular
synthesis rates, rather than different clone sizes. In this case the difference between
the two monoclonal IgG responses may be reduced. Future studies must incorporate
these sources of variability in order to assess the magnitude of the metabolic effects at a
population or cohort level.
Simulations of the monoclonal Ig response in an IgA patient and an IgG patient whose
myeloma cell clone initially shrinks and then grows were investigated, showing a differ-
ence between IgA and IgG patients in the time delay between tumour relapse and the
monoclonal Ig relapse. The sensitivity of the time delay to the metabolic model pa-
rameters was investigated, showing certain parameters to be much more important than
others; this information could be fed back into experiment design in order to improve
the precision of estimates of the more important parameters. The relapse scenario was
initially considered with the system assumed to be in steady state and then with the
tumour assumed to be growing, at the beginning of treatment. The two assumptions
yielded similar results in terms of the delay between the tumour relapse and the mon-
oclonal Ig relapse; however, as for the previous simulations, the difference between the
depth of the monoclonal IgA and monoclonal IgG responses is increased. In general,
relaxing the assumption of steady state at the beginning of treatment tends to produce
larger differences between monoclonal IgA and monoclonal IgG responses.
Unfortunately validating the predictions made in this chapter is difficult. The instan-
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taneous production rate of monoclonal Ig and the total number of myeloma cells in the
body are not directly measurable. It is therefore not possible to obtain longitudinal mea-
surements of the tumour burden in order to validate the predictions; however, efforts have
been made to ensure that the simulated models show good qualitative agreement with
the available patient data. This chapter has shown through model simulations the be-
haviour that may arise in monoclonal IgA and IgG responses in multiple myeloma based
on their respective metabolic properties, findings which may have important implications
for patient monitoring and response assessment.
216
Chapter 8. Predicted responses of IgA and IgG in multiple myeloma
References
1. P. W. Sullivan, S. E. Salmon, The Journal of Clinical Investigation 51, 1697–1708
(1972).
2. K. Anderson, Mayo Clinic Proceedings 78, 15–17 (2003).
3. U.S. National Library of Medicine, Study comparing conventional dose combina-
tion RVD to high-dose treatment with ASCT in the initial myeloma up to 65 years
(IFM/DFCI2009), 2010, (2018; https://clinicaltrials.gov/ct2/show/study/
NCT01191060).
4. M. Attal et al., New England Journal of Medicine 376, 1311–1320 (2017).
5. X. Leleu et al., Blood 125, 1411–1417 (2015).
6. T. A. Waldmann, W. Strober, Progress in Allergy 13, 1–110 (1969).
7. J. G. Hattersley et al., Computer Methods and Programs in Biomedicine 109, 126–
133 (2013).
8. Wolfram Research Inc., Mathematica Version 11.1, Champaign, IL, 2017.
9. R. I. Macey, G. F. Oster, Berkeley Madonna 8.3.18, Berkeley, CA, 2009.
10. W. Strober et al., The Journal of Clinical Investigation 47, 1905–1915 (1968).
11. J. M. Woof, J. Mestecky, in Mucosal Immunology, ed. by J. Mestecky et al. (Aca-
demic Press (Elsevier), Amsterdam, ed. 4, 2015), chap. 17, isbn: 9780124159754.
12. D. Dingli et al., Cancer Science 98, 734–739 (2007).
13. A. R. Bradwell, Serum Free Light Chain Analysis (The Binding Site Ltd., Birming-
ham, ed. 6, 2010), isbn: 9780704427969.
14. J. G. Hattersley, PhD thesis, University of Warwick, 2009.
15. H. Scha¨ttler, U. Ledzewicz, Optimal Control for Mathematical Models of Cancer
Therapies (Springer, New York, ed. 1, 2010), isbn: 9781493929726.
16. D. Dingli et al., Cancer Science 98, 1035–1040 (2007).
17. D. Dingli et al., Cancer Gene Therapy 16, 873–882 (2009).
18. G. W. Swan, T. L. Vincent, Bulletin of Mathematical Biology 39, 317–337 (1977).
19. A. Bradwell et al., Leukemia 27, 202–207 (2013).
20. B. Paiva et al., Leukemia 25, 697–706 (2011).
21. M.-C. Kyrtsonis, A. Mouzaki, A. Maniatis, Medical Oncology 16, 73–77 (1999).
22. S. M. Tete, M. Bijl, S. S. Sahota, N. A. Bos, Frontiers in Immunology 5 (2014).
217
Chapter 8. Predicted responses of IgA and IgG in multiple myeloma
23. A. Radbruch et al., Nature Reviews Immunology 6, 741–750 (2006).
24. P. J. Morin, Community Ecology (Wiley-Blackwell, Oxford, ed. 2, 2011), isbn:
9781444341966.
25. A. J. Lotka, Elements of Physical Biology (Williams & Wilkins Company, Philadel-
phia, ed. 1, 1925).
26. V. Volterra, Nature 118, 558–560 (1926).
27. Y. Yu, W. Wang, Z. Lu, Journal of Mathematical Analysis and Applications 334,
333–348 (2007).
28. T. Slocombe et al., Journal of Immunology 191 (2013).
218
9Response assessment in multiple
myeloma
In chapter 8 the behaviour of monoclonal immunoglobulin A (IgA) and monoclonal im-
munoglobulin G (IgG) was investigated in the context of their application as response
markers in multiple myeloma. In that chapter, predictions were performed using sim-
ulations of compartmental models. One of the main findings of chapter 8 was that
the monoclonal immunoglobulin (Ig) response, that is the percentage reduction in blood
monoclonal Ig during treatment, may underestimate the tumour response in IgG patients
compared to IgA patients, due to the different metabolic half-lives of IgA and IgG. This
could have important implications for tumour response assessment in multiple myeloma
using measured responses in monoclonal IgA and IgG.
It is not possible to truly ascertain whether the monoclonal IgG response underestimates
the tumour response; whilst patients’ monoclonal IgA or IgG responses are reported, the
response of the tumour is not measurable in practice. However, the purpose of this work
is to investigate whether the metabolic properties of IgA and IgG are relevant to the use
of monoclonal Ig as a response marker. The drive for improved complete response (CR)
rates in multiple myeloma is based on the fundamental assumption that deeper tumour
responses are correlated with improved survival outcomes [1]. It is suggested here that,
if monoclonal Ig response underestimates tumour response in IgG patients compared to
IgA patients, then monoclonal Ig response will also underestimate survival outcomes in
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Figure 9-1 Illustration of how survival analysis based on monoclonal Ig
responses and Ig metabolism are related
IgG patients, when compared to IgA patients. Equivalently, monoclonal Ig response may
overestimate survival outcomes in IgA patients, when compared to IgG patients.
The aim of the present chapter is to investigate whether IgA and IgG metabolism is
relevant to response assessment in multiple myeloma, by ascertaining whether monoclonal
IgG response underestimates survival outcomes compared to monoclonal IgA response.
In this chapter a dataset from a large-scale clinical trial of newly diagnosed multiple
myeloma patients, including 526 patients with IgA- or IgG-producing clones, is analysed.
The dataset is introduced in section 9.1.
In chapter 8 the relationship between a changing tumour burden and blood monoclonal
Igs was considered. In this chapter the relationship between survival outcomes and mea-
sured serum monoclonal Ig responses, represented by survival models, is analysed. The
relationship between Ig metabolism and the application of the monoclonal Ig response as
a survival marker is depicted simply in figure 9-1. All survival analyses were performed
using the R language and environment for statistical computing version 3.0.1 [2] with the
Survival package version 2.37-4 [3].
9.1 IFM 2009/01 clinical trial data
Data from the IFM (Intergroupe Francophone du Mye´lome) 2009/01 clinical trial [4; 5]
are analysed in this chapter. The data analysed in this chapter were collected in the first
five years of the trial, which is ongoing. The analysed dataset consists of data for 687
newly diagnosed patients under 66 years of age, who were randomised into two protocol
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arms. Patients in both trial arms were treated with induction therapy of lenalidomide,
bortezomib, and dexamethasone (RVD). The patients in one arm were treated with con-
solidation therapy consisting of high-dose melphalan plus autologous stem cell transplan-
tation, whereas those in the other arm were treated with additional cycles of RVD. The
cohort includes patients with intact Ig multiple myeloma (IIMM), light chain multiple
myeloma and oligosecretory disease. Since the investigations in this thesis are centred on
intact Ig behaviour, only the 526 patients with IIMM are eligible to be analysed in this
chapter. These patients’ plasma cell clones produce either monoclonal IgA or IgG.
Baseline, longitudinal, and event time information are reported in the dataset. The
analysis in this chapter is based on the association between monoclonal Ig responses
and survival times; therefore the data that are most important here are longitudinal
measurements of blood Ig concentrations and survival times. Key time points are recorded
for each patient, signifying important phases of monitoring. These are screening, pre-
maintenance and post-maintenance. Screening is the first time point for each patient.
After screening, patients were given induction and consolidation therapy according to
their randomly assigned protocol arm. After consolidation therapy all patients then
received maintenance therapy for one year; the time point labelled ‘pre-maintenance’
marks the beginning of maintenance therapy and ‘post-maintenance’ signifies its end.
After maintenance therapy patients were followed up every two months until the end of
the trial period recorded in the dataset, or until an event occurrence.
9.1.1 Event times
The event times recorded in the dataset are progression-free survival (PFS) and overall
survival (OS) along with associated event indicators, signifying whether an event has
occurred or is right-censored at the given time. Event times are calculated as the time
between two dates: the date at which the event (progression or death) occurred and
another clinically relevant date at which the response to treatment can be evaluated –
here pre-maintenance is used. Thus PFS and OS from pre-maintenance are available to
be analysed. The Kaplan-Meier estimator of the survival function for IIMM patients is
plotted in figure 9-2A for PFS from pre-maintenance and in figure 9-2B for OS from pre-
maintenance. The latest event times recorded in the dataset pertain to events or censoring
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Figure 9-2 (A) Progression-free survival (PFS) and (B) overall survival
(OS) from pre-maintenance in intact immunoglobulin multiple myeloma
(IIMM) patients. Right-censored events are indicated by symbols (+).
in September 2015. PFS was the primary end point for the trial. In the dataset relatively
few deaths are recorded and there is little association between the monoclonal Ig response
and the hazard of death; therefore OS is not considered in the following analyses.
9.1.2 Monoclonal Ig concentrations
Heavy/light chain measurements
In this dataset, patients are primarily monitored using blood Igs measured by the heavy/
light chain (HLC) assay (see section 2.4 in chapter 2). HLC measurements are, in theory,
recorded at every monitoring point: at screening, at pre-maintenance, and then at fre-
quent intervals until the end of patient follow-up, possibly due to a progression or death.
Some HLC data are missing for various reasons – these are outlined in section 9.4.1. Some
patients also have HLC measurements taken between screening and pre-maintenance. In
IgA patients, IgAκ and IgAλ concentrations are reported; in IgG patients, IgGκ and
IgGλ concentrations are reported.
Patient monitoring times are illustrated in figure 9-3. The time at which blood samples
were taken, measured in days since screening, is plotted on the horizontal axis, against
patient number on the vertical axis. All patients in the trial are represented in the plot,
some of whom have light chain or oligosecretory disease. The density of points at 0
days shows that all patients had blood samples taken at screening. The band of points
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Figure 9-3 Monitoring times of all patients in the IFM 2009/01 study.
Each point represents the time in days since screening at which relevant
samples were collected. The points highlighted in pink represent the pre-
maintenance time point.
Table 9-1 The Igs considered as involved and uninvolved for different mon-
oclonal Ig isotypes. The involved and uninvolved Igs are measured by the
HLC assay.
Monoclonal Ig Involved HLC Uninvolved HLC
IgAκ Monoclonal IgAκ + polyclonal IgAκ Polyclonal IgAλ
IgAλ Monoclonal IgAλ + polyclonal IgAλ Polyclonal IgAκ
IgGκ Monoclonal IgGκ + polyclonal IgGκ Polyclonal IgGλ
IgGλ Monoclonal IgGλ + polyclonal IgGλ Polyclonal IgGκ
highlighted in pink shows the clinically relevant pre-maintenance time point, between
around 200 and 300 days since screening.
For IIMM patients, the most important marker is the Ig of the same heavy and light chain
types as the monoclonal Ig. In an IgAλ patient, for example, the IgAλ concentration is
the most important as this is the protein that is produced by their plasma cell clone.
This is referred to as the involved Ig or involved HLC. The HLC measurement of the
same heavy chain type, but alternative light chain type, for example IgAκ in an IgAλ
patient, is referred to as the uninvolved HLC [6]. The uninvolved HLC provides a useful
indicator of the level of polyclonal Ig. The involved and uninvolved HLC quantities for
different monoclonal Ig isotypes are summarised in table 9-1.
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Figure 9-4 Examples of patient data collected in the IFM 2009/01 trial.
Involved HLC is plotted over time for four patients. Screening and pre-
maintenance samples are highlighted. PFS is shown in red where progression
occurs and green where it is censored.
Plots of the involved HLC over time are shown for four patients in figure 9-4. The involved
Ig concentration is elevated at screening and then falls as the clonal plasma cells are killed
by therapy and the production rate of monoclonal protein decreases. PFS is indicated
by a vertical line at the event time, with a red line indicating an event occurrence and a
green line indicating a right-censored event.
Whilst the HLC assay does not discriminate between monoclonal and polyclonal Ig, at
presentation the involved HLC is usually dominated by the monoclonal Ig. However, when
deep responses are achieved following treatment, the monoclonal Ig is greatly reduced
and now the polyclonal component may represent a significant proportion of the involved
HLC. The importance of the polyclonal Ig can be seen by looking at the uninvolved HLC
at pre-maintenance. A histogram of the uninvolved HLC of the same heavy chain type as
the involved HLC (e.g. IgGκ in an IgGλ patient) at pre-maintenance is shown in figure
9-5. Patients with missing data for HLC at screening or pre-maintenance, missing PFS
data or errors in the HLC data (see section 9.4.1) are omitted, leaving 97 IgA patients
and 336 IgG patients. The number of IgA patients in each bin is divided by the total
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Figure 9-5 Histogram of uninvolved HLC at pre-maintenance. Frequen-
cies are normalised by the total number of IgA patients or IgG patients,
respectively.
number of IgA patients, and similarly for IgG, for ease of comparison. The histogram
illustrates the difference in polyclonal IgG and IgA concentration. In normal subjects
the concentration of IgG is five times that of IgA; it is therefore expected that at pre-
maintenance the polyclonal IgG concentration will be greater than the polyclonal IgA
concentration.
The difference between polyclonal IgA and IgG concentrations has implications for the
interpretation of the involved HLC concentration at pre-maintenance and subsequent
monitoring points when the monoclonal Ig concentration is low. Now the polyclonal part
of the involved HLC is significant and, importantly, greater in IgG patients than in IgA
patients. Ideally physicians wish to only monitor the monoclonal Ig that is produced by
the cancer. Whilst the monoclonal and polyclonal parts of the involved HLC are not
truly separable, fortunately the uninvolved HLC concentration provides an indicator of
the polyclonal Ig concentration of the same heavy chain type as the monoclonal Ig.
It is reasonable to assume that the polyclonal part of the involved HLC and polyclonal
uninvolved HLC are strongly correlated. Polyclonal serum IgA and IgG are produced
primarily by long-lived plasma cells in the bone marrow [7; 8]. There is no reason to
believe that κ polyclonal Ig would be any more or less suppressed than λ polyclonal Ig,
and vice versa. If the true ratio of polyclonal IgAκ/IgAλ or IgGκ/IgGλ were known
for each patient, the unknown polyclonal part of the involved HLC could be calculated
using the known concentration of the uninvolved HLC. The true Ig’κ/Ig’λ ratio for each
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individual patient is not known; however since there is no reason to believe that polyclonal
Ig of one light chain type would be more or less suppressed than the other, the median
values of the ratios IgAκ/IgAλ and IgGκ/IgGλ found in normal subject sera are used
here. These values are provided by Bradwell et al. [9]. The median values in normal
subjects of the ratios of IgAκ/IgAλ and IgGκ/IgGλ are denoted by rAκ/Aλ and rGκ/Gλ,
respectively.
The monoclonal Ig concentration is estimated by multiplying the uninvolved Ig concen-
tration by the appropriate normal ratio and subtracting this quantity from the involved
Ig concentration. This quantity is denoted here by mHLC and is calculated it as follows:
mHLCIgAκ = iHLCIgAκ − rAκ/AλuHLCIgAλ
mHLCIgAλ = iHLCIgAλ − 1
rAκ/Aλ
uHLCIgAκ
mHLCIgGκ = iHLCIgGκ − rGκ/GλuHLCIgGλ
mHLCIgGλ = iHLCIgGλ − 1
rGκ/Gλ
uHLCIgGκ.
(9-1)
As the true polyclonal Ig’κ/Ig’λ ratio for each individual patient is not known, in some
cases where the involved HLC is very small, subtracting the estimated involved polyclonal
Ig can result in negative values for the mHLC. Clearly this is not possible and where
negative values occur they are replaced with zero. Where negative values occur this
means that the patient’s polyclonal Ig favours the uninvolved light chain type, compared
with the average normal subject. With no further information available, the only option
is to assume that the monoclonal Ig is in these cases zero.
Serum protein electrophoresis and immunofixation
Also provided in the dataset is the monoclonal Ig concentration measured by serum pro-
tein electrophoresis (SPEP), but only at important monitoring points, including screening
and pre-maintenance. The SPEP assay is less sensitive than the HLC assay (see section
2.4 in chapter 2) and therefore at pre-maintenance the monoclonal Ig is in many patients
not detectable by SPEP. Also provided at key monitoring points is a binary indicator
variable, indicating whether there is a detectable M-spike that can be quantified.
The heavy and light chain types of the monoclonal Ig are provided in the dataset for all
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patients with an intact Ig paraprotein, as confirmed by immunofixation. As with SPEP,
it is also indicated at key monitoring points whether the monoclonal Ig is detectable by
immunofixation.
9.1.3 Monoclonal Ig responses
The monoclonal Ig response at any time tj days, during or after treatment, is defined as
the monoclonal Ig concentration at time tj divided by the the monoclonal Ig concentra-
tion at screening, t0 = 0 days. Alternatively the response may refer to the percentage
reduction in monoclonal Ig, between times t0 = 0 and tj. In this sense, larger reduc-
tions in monoclonal Ig represent ‘deeper’ responses. Both definitions of response are used
in this chapter; it should be clear from the context of the discussion which particular
definition is being used.
Responses need to be compared at the same time between patients. This can be a
clinically relevant time point, such as pre-maintenance, or, if patients are followed up at
regular intervals, responses could be evaluated six months from screening, for example. In
this particular dataset, the most clinically relevant time point at which to assess response
is pre-maintenance. At pre-maintenance, induction and consolidation therapy is complete
and subsequent therapy has the aim of maintaining the previously achieved response [10].
In this chapter therefore we focus on responses evaluated at pre-maintenance.
mHLC responses
The mHLC response at pre-maintenance can be calculated as the mHLC at pre-maintenance
divided by the mHLC at screening. A histogram of mHLC responses is shown for IgA
and IgG patients in figure 9-6. The frequency in each bin is divided by the total number
of IgA or IgG patients, respectively, for ease of comparison, since there are many more
IgG patients than IgA patients. Those patients with missing PFS data or missing or
erroneous data for mHLC at screening or pre-maintenance are excluded, leaving 97 IgA
patients and 336 IgG patients. The histogram shows that, on average, monoclonal IgA
responses are deeper than monoclonal IgG responses.
227
Chapter 9. Response assessment in multiple myeloma
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
0.
0.2
0.4
0.6
0.8
mHLC response
Pr
op
or
tio
n
of
pa
tie
nt
s
IgA
IgG
Figure 9-6 Histogram of mHLC responses at pre-maintenance. Frequen-
cies are normalised by the total number of IgA patients or IgG patients,
respectively. Details are provided in section 9.1.3.
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Figure 9-7 Histogram of SPEP responses at pre-maintenance. Frequen-
cies are normalised by the total number of IgA patients or IgG patients,
respectively. Details are provided in section 9.1.3.
SPEP responses
Similarly, the SPEP response at pre-maintenance can be calculated as SPEP at pre-
maintenance divided by SPEP at screening. A histogram of SPEP responses is shown
for IgA and IgG patients in figure 9-7. The frequency in each bin is divided by the
total number of IgA or IgG patients, respectively, for ease of comparison, since there
are many more IgG patients than IgA patients. Those patients for whom PFS or SPEP
concentration at screening is missing are excluded. Those patients for whom SPEP
concentration is not provided at pre-maintenance, due to a lack of quantifiable M-spike,
are considered as having zero SPEP at pre-maintenance, or a 100% SPEP response.
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Patients for whom SPEP concentration at pre-maintenance is missing for any other reason
are excluded. In total there are 97 IgA patients and 302 IgG patients represented in the
histogram. The histogram shows that, on average, monoclonal IgA responses are deeper
than monoclonal IgG responses.
9.2 Relevant simulations of monoclonal Ig responses
during treatment
In chapter 8, section 8.3, responses of monoclonal IgA and IgG to a decreasing tumour
burden were compared using simulations. It was predicted that, due to the long metabolic
half-life of IgG, monoclonal IgG falls at a slower rate than monoclonal IgA for the same
response in the myeloma cell population. It was predicted that when the monoclonal Ig
settles at a new steady state after treatment, the proportional reduction in monoclonal
IgG underestimates the proportional reduction in myeloma cells, whereas the proportional
reduction in monoclonal IgA does not (assuming that the system is in steady state at the
beginning of treatment).
Figure 9-4 shows the first two IIMM patients, as ordered by patient ID, that have a
progression and the first two for whom the progression event is censored (not including
patients with missing data who were not eligible to be analysed). These plots of the
involved Ig concentration over time show the typical pattern that is seen in the data for
all patients. Samples are taken at infrequent intervals before pre-maintenance. At pre-
maintenance the involved Ig appears to have settled around a low concentration where it
remains until either it increases during relapse, or the study reaches an end. It therefore
appears that a maximal proportion of the cancer cells has been killed and that the system
of Igs is approaching a steady state at pre-maintenance. From conversations with research
collaborators this coincides with their clinical understanding. In some patients, it appears
that at pre-maintenance the involved HLC is still falling, however even for these cases it
is approaching the steady level at which it will eventually settle.
Referring back to the simulations in section 8.3 of chapter 8, the difference between
monoclonal IgA and IgG responses narrows as the cancer cells and Igs approach a steady
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state. The aim of this chapter is to determine whether the difference between measured
monoclonal IgA and monoclonal IgG responses seen in the data is significant enough to
influence their association with survival outcomes.
9.3 Methodology for survival analyses
The aim of this chapter is to ascertain whether the monoclonal Ig response underestimates
survival outcomes in IgG patients compared with IgA patients. Having inspected the
available data, a more specific version of this aim is to ascertain whether monoclonal
IgG response at pre-maintenance underestimates PFS from pre-maintenance, compared
to the monoclonal IgA response.
If the monoclonal IgG response underestimates PFS compared to the monoclonal IgA
response, then when patients are grouped by whether they have achieved a certain mono-
clonal Ig response, or not, the group of ‘responders’ is missing certain IgG patients whose
tumour response was underestimated by their IgG response. Therefore the IgG patients
who were classed as responders, will, on average, have improved survival compared to IgA
responders. Those IgG patients who were wrongly classed as non-responders similarly
will improve the PFS of IgG patients, compared to IgA patients, in the non-responder
category. Ignoring the different metabolic properties of the respective proteins, patients
achieving the same monoclonal Ig response would be expected to have a similar outlook.
In order to analyse the data, patients are grouped according to having achieved, or not, a
certain percentage reduction in their monoclonal Ig at pre-maintenance. As illustrated in
figures 9-6 and 9-7, at pre-maintenance the patients have achieved very deep monoclonal
Ig responses, whether measured by mHLC or SPEP. Therefore we are restricted in the
monoclonal Ig response threshold values that can be used to group the patients. The
response threshold values used in this section are therefore between 90% and 99.5%.
In order to investigate whether the monoclonal IgG response at pre-maintenance under-
estimates PFS compared to the monoclonal IgA response, proportional hazards models
with monoclonal Ig response and monoclonal Ig isotype (IgA or IgG) as explanatory vari-
ables are compared. The monoclonal Ig response is treated as a factor with two levels,
determined by a chosen threshold value, for example a 95% reduction in monoclonal Ig.
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In this way there is an effect associated with having achieved a certain level of response;
let α1 denote this effect. The isotype of the monoclonal Ig, IgA or IgG, can also be
incorporated as a factor in the model. Let βIgG denote the effect associated with having
an IgG paraprotein.
With two explanatory variables there are five possible models to describe the data, which
are here denoted by M1, . . . ,M5 as follows:
M1 : hi(t) = h0(t)
M2 : hi(t) = exp
(
α1xresponse,i
)
h0(t)
M3 : hi(t) = exp
(
βIgGxisotype,i
)
h0(t)
M4 : hi(t) = exp
(
α1xresponse,i + βIgGxisotype,i
)
h0(t)
M5 : hi(t) = exp
(
α1xresponse,i + βIgGxisotype,i + γ1,IgGxresponse,ixisotype,i
)
h0(t).
(9-2)
In equations (9-2),
 hi(t) is the hazard function of individual i in the study;
 h0(t) is the baseline hazard function;
 α1 is the effect associated with having achieved the specified response;
 βIgG is the effect associated with having an IgG paraprotein;
 xresponse,i is the value for patient i of an indicator variable Xresponse that takes the
value 1 for patients who have achieved the specified response and 0 for those who
have not;
 xisotype,i is the value for patient i of an indicator variable Xisotype that takes the
value 1 for IgG patients and 0 for IgA patients;
 the coefficient γ1,IgG represents the effect of an interaction between the response
status and monoclonal Ig isotype.
The models are defined such that the baseline hazard function h0(t) corresponds to the
hazard function of an IgA patient who has not achieved the specified reduction in mon-
oclonal IgA.
M1 is the null model, in which the hazard function depends on neither the monoclonal
Ig response nor the isotype of the monoclonal Ig. In M2 and M3, the hazard of pro-
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gression depends on either the monoclonal Ig response or the isotype of the monoclonal
Ig, respectively. In M4, the hazard function is dependent on both the response and the
isotype. In M5 the hazard function is dependent on both the response and the isotype,
with an interaction term between the two factors. The interaction allows for a difference
in the effect of one factor dependent on the level of the other factor. For example, the
interaction would allow for IgG patients to have improved survival compared to IgA pa-
tients among those who had achieved the specified response, but for IgA patients to have
improved survival among those patients who had not achieved the response.
9.4 Analysis of mHLC response and progression-free
survival from pre-maintenance
In the IFM 2009/01 clinical trial, monoclonal Igs were primarily monitored using the HLC
assay. In this section, the association between the mHLC response at pre-maintenance
and PFS from pre-maintenance is analysed. Proportional hazards models describing PFS
are estimated over a range of mHLC response threshold values. The models, M1, . . . ,M5,
are given by equations (9-2) in section 9.3.
9.4.1 Missing data
PFS from pre-maintenance is missing for 53 IIMM patients, 50 of whom have no recorded
pre-maintenance monitoring point. These patients were omitted from subsequent anal-
yses. A further 29 patients had to be excluded who had missing data for involved or
uninvolved HLC at either screening or pre-maintenance. IgA and IgG patients were af-
fected equally by missing data, with 5% of IgA patients and 7% of IgG patients affected,
respectively. Three IgG patients had to be omitted from analyses because of suspected
antigen excess, or data entry error, in their involved HLC concentration at screening,
giving a falsely low concentration [11]. This issue affected IgA and IgG patients equally;
however some of the affected patients had already been removed due to missing data in
other samples. Seven IgA patients had to be excluded because the involved or uninvolved
HLC concentrations in their pre-maintenance samples were below the sensitivity of the
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assay. One further patient was excluded due to a possible data entry error resulting in an
exceptionally high uninvolved HLC concentration at screening, such that mHLC could
not be accurately calculated. In total, 93 patients were excluded, leaving 433 patients
eligible for analysis – 97 with IgA-producing clones and 336 with IgG-producing clones.
9.4.2 Example: 95% mHLC response threshold
Firstly the models based on a response threshold of a 95% reduction in mHLC are ex-
plained, as an example. Here, patients who have achieved at least a 95% reduction in
mHLC are compared with those who have not, in the models where the variable Xresponse
is included, that is models M2, M4 and M5. The models were fitted using the coxph()
function in the R Survival package [3]. The proportional hazards assumption was tested
for all fitted models using the cox.zph() function. There was no statistically significant
evidence at the 5% level to reject the proportional hazards assumptions for any of the
explanatory variables in any of the fitted models, unless otherwise stated.
For model M2 the maximum likelihood (ML) estimate of the coefficient α1 is given by
αˆ1 = −0.696, such that the estimate of the hazard ratio is given by exp(αˆ1) = 0.499.
The 95% confidence interval estimate of the hazard ratio is given by (0.380, 0.655), which
does not include the value 1. This result shows that patients who achieve at least a 95%
reduction in mHLC have a significantly improved PFS compared to those who do not.
Fitting model M3 gives the ML estimate βˆIgG = −0.0582, such that the point estimate of
the hazard ratio is given by exp
(
βˆIgG
)
= 0.9434. The 95% confidence interval estimate
of the hazard ratio is given by (0.6857, 1.298). The 95% confidence interval is centred
around the value 1, showing that there is little difference in PFS between IgA and IgG
patients.
In model M4 the hazard of progression depends on both the response status and the mon-
oclonal Ig isotype. Now the coefficient estimates are given by αˆ1 = −0.7806 and βˆIgG =
−0.3227. The 95% confidence interval estimate of exp(α1) is given by (0.3430, 0.6119).
The same interval for the coefficient exp
(
βIgG
)
is given by (0.5158, 1.0168). This con-
fidence interval only just includes the value 1, suggesting that in the presence of the
term α1xresponse,i, the term βIgGxisotype,i has an effect on PFS, with IgG patients surviving
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Table 9-2 −2 log Lˆ and AIC for proportional hazards models fitted in sec-
tion 9.4.2
Model −2 log Lˆ AIC
M1 2392.689 2392.689
M2 2368.806 2370.806
M3 2392.563 2394.563
M4 2365.483 2369.483
M5 2365.323 2371.323
longer without progression than IgA patients. Likewise in the presence of βIgGxisotype,i,
the inclusion of α1xresponse,i has a statistically significant effect on PFS, with responders
surviving longer.
Model M5 contains the response status and the monoclonal Ig isotype as explanatory vari-
ables, along with an interaction between the two. The interaction term is not statistically
significant (p = 0.688) and so M5 can be discarded in favour of M4.
Model comparison
Proportional hazards models can be compared formally using the likelihood ratio test
for nested models and the Akaike Information Criterion (AIC) for both nested and non-
nested models, as described in chapter 4 [12]. For the models fitted in this section, the
values of −2 log Lˆ and the AIC are given in table 9-2.
Using a likelihood ratio test it is first checked whether there is strong evidence for an
interaction between the response status and the monoclonal Ig isotype of the patient,
that is, whether the term γ1,IgGxresponse,ixisotype,i should be included in the model in the
presence of the terms α1xresponse,i and βIgGxisotype,i. The test statistic is given by the
difference between the values of −2 log Lˆ for M4 and for M5: −2 log Lˆ4 + 2 log Lˆ5 = 0.16.
A chi-squared test on one degree of freedom is not significant (p = 0.688) and it can
therefore be concluded that there is insufficient evidence to include the interaction term
in the model.
Now Models M2 and M3 are each compared with the null model M1. The comparison
between M1 and M2 is to determine whether there is a significant difference in PFS
between responders and non-responders. The difference in the values of −2 log Lˆ for M1
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and M2 is given by −2 log Lˆ1 + 2 log Lˆ2 = 23.88, which on 1 d.f. is statistically significant
(p<0.001). Thus there is strong evidence that the response status is required in the
model, in the absence of other explanatory variables. This is in line with expectation.
Comparing models M3 and M1 gives a test statistic of −2 log Lˆ1 + 2 log Lˆ3 = 0.127 on 1
d.f. which is not statistically significant (p = 0.72), suggesting that there is not strong
evidence to include the monoclonal Ig isotype in the model, in the absence of any other
explanatory variables. This implies that there is no significant difference in PFS between
IgA and IgG patients.
The inclusion of the isotype of the monoclonal Ig does not offer a statistically significant
improvement over the null model, in which there are no explanatory variables. However, if
it is supposed that monoclonal Ig response underestimates PFS in IgG patients compared
to IgA patients, then in a model associating PFS with response, i.e. M2, the isotype of
the monoclonal Ig now becomes important. This can be evaluated by comparing the
models M4, including both the response status and isotype, and M2, including only the
response status. The difference in −2 log Lˆ between the two models is given by −2 log Lˆ2+
2 log Lˆ4 = 3.32. A chi-squared test on 1 d.f. yields p = 0.068; whilst this is not significant
at the 5% level, there is some evidence that now the inclusion of the monoclonal Ig
isotype improves the fit of the model to the data. Importantly, including the monoclonal
Ig isotype only improves a model in which response status is an explanatory variable.
This is consistent with the hypothesis that the monoclonal IgG response underestimates
PFS compared to the monoclonal IgA response.
9.4.3 Further response thresholds
It is possible that the response in monoclonal IgG underestimates PFS at any chosen
response level. In section 9.4.2 the explanatory variable Xresponse takes the value 1 for
patients whose monoclonal Ig falls by at least 95% and 0 for patients whose monoclonal
Ig falls by less than 95%, between screening and pre-maintenance, with the coefficient
α1 representing the effect on the hazard function of achieving this particular level of
response. The choice of a 95% reduction in monoclonal Ig is arbitrary, however.
The models containing the explanatory variable Xresponse – M2, M4 and M5 – were fitted
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Table 9-3 95% confidence interval estimates for the parameters in models
M2 and M4, for mHLC response at pre-maintenance. Details are provided
in section 9.4.3.
Response threshold
%
M2: exp(αˆ1) 95%
C.I.
M4: exp(αˆ1) 95%
C.I.
M4: exp
(
βˆIgG
)
95%
C.I.
90 (0.3979, 0.724) (0.3782, 0.7006) (0.5908, 1.1403)
91 (0.3649, 0.6482) (0.3408, 0.6192) (0.5588, 1.0853)
92 (0.3604, 0.6333) (0.3336, 0.6014) (0.5450, 1.0620)
93 (0.377, 0.6561) (0.3454, 0.6192) (0.5342, 1.0466)
94 (0.3685, 0.6366) (0.3317, 0.5935) (0.5118, 1.0099)
95 (0.3799, 0.6549) (0.3430, 0.6119) (0.5158, 1.0168)
96 (0.3791, 0.6508) (0.3354, 0.6001) (0.4949, 0.9840)
97 (0.392, 0.6718) (0.3399, 0.6123) (0.4795, 0.9632)
98 (0.4032, 0.6917) (0.3546, 0.6358) (0.4921, 0.9818)
99 (0.3943, 0.6922) (0.3384, 0.6247) (0.4728, 0.9476)
99.5 (0.3556, 0.6409) (0.3188, 0.5926) (0.5021, 0.9831)
to the data over a range of different threshold values for the reduction in mHLC. The
thresholds for response are between 90% reduction and 99.5% reduction in mHLC between
screening and pre-maintenance. For each response threshold, the explanatory variable
Xresponse takes the value 1 for patients achieving at least the specified response, and 0
for those who do not. For each explanatory variable within each model, the proportional
hazards assumption was tested and found not to be violated.
The 95% confidence interval estimates for the parameters in models M2 and M4 are given
in table 9-3. For both M2 and M4, the confidence interval estimate of exp(α1) has its
upper bound less than 1 for all values of the response threshold used. This allows us to
conclude that, for the particular threshold values used, achieving at least the specified
response at pre-maintenance is associated with an improved PFS. Model M4 also includes
the coefficient βIgG, representing the effect of having an IgG paraprotein. Now the interval
estimates of exp
(
βˆIgG
)
have their upper bound less than, or very close to 1, for response
thresholds between 94% and 99.5%, implying that an IgG paraprotein is associated with
an improved PFS, having accounted for the response status of the patient.
For lesser response thresholds, between 90% and 93%, the 95% confidence interval es-
timate of the hazard ratio exp
(
βˆIgG
)
now includes the value 1. This suggests that the
difference in PFS between IgA and IgG patients in not statistically significant, having
taken into account the response status of the patients. The trend however is the same as
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Table 9-4 Comparison of models M2 and M4, for mHLC response at pre-
maintenance. Details are given in section 9.4.3.
Response
threshold %
−2 log Lˆ AIC M4 vs. M2
p-value
M2 M4 M2 M4
90 2377.642 2376.299 2379.642 2380.299 0.246
91 2370.698 2368.599 2372.698 2372.599 0.147
92 2368.481 2366.003 2370.481 2370.003 0.115
93 2369.891 2367.136 2371.891 2371.136 0.097
94 2367.192 2363.728 2369.192 2367.728 0.063
95 2368.806 2365.483 2370.806 2369.483 0.068
96 2367.8 2363.781 2369.8 2367.781 0.045
97 2369.561 2365.061 2371.561 2369.061 0.034
98 2371.22 2367.153 2373.22 2371.153 0.044
99 2371.24 2366.383 2373.24 2370.383 0.028
99.5 2366.42 2362.406 2368.42 2366.406 0.045
for the other response thresholds used, with IgG patients having improved PFS to IgA
patients.
Table 9-4 gives the values of −2 log Lˆ and the AIC for models M2 and M4, estimated for
each response threshold. For each response threshold value the interaction between the
response status and the monoclonal Ig isotype did not significantly improve the model fit
and so the values of −2 log Lˆ and the AIC for M5 are not provided. Also provided in the
table is the p-value of the likelihood ratio test comparing models M2 and M4. The test
evaluates the strength of the evidence for including the term βIgGxisotype,i in the model,
in the presence of the term α1xresponse,i.
The small p-values in table 9-4 suggest that, for values of the response threshold between
94% and 99.5%, there is evidence to support the inclusion of the monoclonal Ig isotype
in the model along with the response status of the patient. This suggests that, having
accounted for the response achieved by the patient, patients with IgG paraproteins have
improved PFS compared to IgA patients.
For smaller values of the mHLC response threshold, between 90% and 93%, the evidence
for including the isotype term weakens. This may be because there are very few IgA
patients who do not achieve the specified response thresholds in these models, such that
grouping patients by a 90% mHLC response, for example, is less meaningful for IgA
patients. Fitting model M2 for IgA patients only shows that IgA responders do not have
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Figure 9-8 Survival plot of PFS stratified by monoclonal immunoglobulin
isotype for the patients analysed in section 9.4. Details are given in section
9.4.3.
significantly improved PFS over non-responders, at the 5% significance level, for response
thresholds between 90% and 92%.
The results can be illustrated with plots of the Kaplan-Meier estimator of the survival
function of PFS, shown in figures 9-8 and 9-9. Figure 9-8 shows a plot of PFS stratified by
the monoclonal Ig isotype, i.e. IgA or IgG. This plot represents model M3 and illustrates
the lack of difference in PFS between IgA and IgG patients.
Figure 9-9 shows plots of PFS now stratified by the mHLC response and the monoclonal
Ig isotype, with different mHLC threshold values defining the response status in each
plot. These plots represent model M4 and illustrate that IgG patients have improved
PFS compared to IgA patients when grouped by mHLC response.
These plots may also help to explain why the difference in PFS between IgA and IgG
patients is less significant for lesser response thresholds, in particular 90% and 92%, shown
in figures 9-9A and 9-9B. At pre-maintenance very deep mHLC responses are achieved
across the cohort, particularly by IgA patients (see figure 9-6), with only five IgA patients
achieving less than a 90% reduction in mHLC, and only eight achieving less than a 95%
reduction, out of a total of 97 IgA patients. Inspecting figure 9-9A, for example, there is
a clear difference in the PFS of IgG responders and IgG non-responders, shown in red and
light red, respectively (p < 0.001). However for IgA patients, very few patients have not
achieved a 90% response. There is not a clear difference in PFS between IgA responders
238
Chapter 9. Response assessment in multiple myeloma
0 500 1000 1500
0.0
0.2
0.4
0.6
0.8
1.0
Time to PFS from pre−maintenance (days)
Su
rv
iva
l p
ro
ba
bi
lity
A
0 500 1000 1500
0.0
0.2
0.4
0.6
0.8
1.0
Time to PFS from pre−maintenance (days)
Su
rv
iva
l p
ro
ba
bi
lity
B
0 500 1000 1500
0.0
0.2
0.4
0.6
0.8
1.0
Time to PFS from pre−maintenance (days)
Su
rv
iva
l p
ro
ba
bi
lity
C
0 500 1000 1500
0.0
0.2
0.4
0.6
0.8
1.0
Time to PFS from pre−maintenance (days)
Su
rv
iva
l p
ro
ba
bi
lity
D
0 500 1000 1500
0.0
0.2
0.4
0.6
0.8
1.0
Time to PFS from pre−maintenance (days)
Su
rv
iva
l p
ro
ba
bi
lity
E
0 500 1000 1500
0.0
0.2
0.4
0.6
0.8
1.0
Time to PFS from pre−maintenance (days)
Su
rv
iva
l p
ro
ba
bi
lity
F
Figure 9-9 Survival plots of PFS by mHLC response and monoclonal Ig
isotype, for six of the response threshold values used: (A) 90%, (B) 92%,
(C) 94%, (D) 96%, (E) 98% and (F) 99.5%. Dark red – IgG responders;
light red – IgG non-responders; dark blue – IgA responders; light blue – IgA
non-responders. Details of the survival models are provided in section 9.4.3.
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and IgA non-responders (p = 0.22). In order to show a clear difference between the PFS
of all four groups, a sufficient number of patients need to be represented in each group.
This is why the analyses were not performed for response thresholds of 50%, for example,
as such a response is not meaningful in this particular sample.
9.5 Analysis based on mHLC response quantiles
The results in section 9.4.3 show that mHLC response significantly underestimates PFS in
IgG patients compared to IgA patients, for mHLC response thresholds between 94% and
99.5%, with the same trend observed for thresholds between 90% and 93%. Considering
the plots in figure 9-9, it can be seen that too few IgG patients have been classed as
responders, or equivalently, too many IgA patients have been classed as responders, for
each of the response thresholds used. It is therefore desirable to move some of the
IgG patients from the non-responders group to the responders group, by using a lesser
response threshold for IgG patients, or alternatively, move some of the IgA patients from
the responders group to the non-responders group, by using a deeper response threshold
for IgA patients. Given the relatively few IgA patients in the non-response category, for
each threshold used, in this section a deeper mHLC response threshold is used for IgA
patients, keeping the same threshold values as before for IgG patients.
The question then is, for an IgG mHLC response threshold of, say, 90%, what is an
appropriate IgA mHLC response threshold, that will result in the same PFS for IgA
patients and IgG patients, having accounted for their response status? A simple approach
is to consider the quantiles of the distributions of mHLC response. Given that there is
no overall difference between the PFS of IgA and IgG patients, it is assumed that the
median mHLC response for IgA patients and the median mHLC response for IgG patients
represent an equivalent tumour response, and so on for other quantiles.
The qth response quantile is defined here as the mHLC response below which q% of mHLC
responses lie, for IgA patients and for IgG patients, respectively. Figure 9-10 shows a
Q-Q plot of the distributions of IgG mHLC response and IgA mHLC response, along
with the line of equality, from 0 to 0.6, that is 100% reduction to 40% reduction in
mHLC. In this plot the mHLC response is defined as mHLC at pre-maintenance divided
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Figure 9-10 IgG mHLC response quantiles plotted against IgA mHLC
response quantiles. Details are provided in section 9.5.
Table 9-5 mHLC response quantiles. The mHLC response is given by the
value of the mHLC at pre-maintenance divided by the value of the mHLC
at screening. Details are provided in section 9.5.
mHLC response quantile
q (%) IgG IgA
74.7 0.1 0.0083
70.5 0.09 0.0056
68.1 0.08 0.005
65.1 0.07 0.004
61.9 0.06 0.0031
60.1 0.05 0.00292
57.2 0.04 0.0022
52.6 0.03 0.002
49.1 0.02 0.0017
37.2 0.01 0.00055
34.2 0.005 0.0004
by mHLC at screening. The plot illustrates the difference between the distributions of
mHLC responses in IgA and IgG patients, respectively.
The mHLC response quantiles were found for both IgA and IgG patients, for values of q
between 35.2 and 74.7. These values were chosen because 35.2% of IgG patients achieved
mHLC responses below 0.005 (greater than 99.5% reduction) and 74.7% achieved mHLC
responses below 0.1 (greater than 90% reduction). These response thresholds correspond
to the minimum and maximum thresholds used for the analysis in section 9.4.3. The
mHLC response quantiles are provided in table 9-5.
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Table 9-6 95% confidence interval estimates for the parameters in models
M2 and M4, with different mHLC response thresholds for IgA and IgG.
Details in section 9.5.
Response
threshold IgG
%
Response
threshold IgA
%
M2: exp(αˆ1)
95% C.I.
M4: exp(αˆ1)
95% C.I.
M4: exp
(
βˆIgG
)
95% C.I.
90 99.17 (0.3866, 0.6816) (0.3867, 0.6817) (0.6880, 1.3026)
91 99.44 (0.3454, 0.5987) (0.3455, 0.5989) (0.6907, 1.3078)
92 99.50 (0.3431, 0.5918) (0.3431, 0.5919) (0.6869, 1.3005)
93 99.60 (0.3622, 0.6221) (0.3621, 0.6219) (0.6811, 1.2895)
94 99.69 (0.3578, 0.6136) (0.3579, 0.6138) (0.6880, 1.3025)
95 99.71 (0.3626, 0.6221) (0.3627, 0.6222) (0.6890, 1.3046)
96 99.78 (0.3587, 0.6168) (0.3587, 0.6168) (0.6852, 1.2973)
97 99.8 (0.3744, 0.6475) (0.3746, 0.6477) (0.6905, 1.3074)
98 99.83 (0.3844, 0.67) (0.3845, 0.6701) (0.6870, 1.3007)
99 99.95 (0.3267, 0.6107) (0.3266, 0.6106) (0.6828, 1.2927)
99.5 99.96 (0.299, 0.5777) (0.2990, 0.5775) (0.6828, 1.2928)
The analyses in section 9.4.3 were then repeated using the mHLC response thresholds
given in table 9-5. The methodology is the same as in section 9.4.3, with the same
group of patients analysed. Models M1 and M3 do not contain the variable Xresponse and
therefore remain unchanged. The results of fitting models M1 (the null model) and M3
are given in section 9.4.2.
The models containing the explanatory variable Xresponse – M2, M4 and M5 – were fitted
to the data with each of the mHLC response quantiles in table 9-5 used for the mHLC
response thresholds. For each response threshold, the explanatory variable Xresponse takes
the value 1 for patients achieving at least the specified mHLC response, now different for
IgA patients and IgG patients, and 0 for those who do not. For each explanatory variable
within each model, the proportional hazards assumption was tested and found not to be
violated.
The 95% confidence interval estimates for the parameters in models M2 and M4 are
given in table 9-6. For both M2 and M4, the confidence interval estimate of exp(α1) has
its upper bound less than 1 for all values of the response thresholds used; therefore it
can be concluded that, for the particular threshold values used, achieving at least the
specified response at pre-maintenance is associated with an improved PFS. Model M4
also includes the coefficient βIgG, representing the effect of having an IgG paraprotein.
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Table 9-7 Comparison of models M2 and M4, with different mHLC re-
sponse thresholds for IgA and IgG. Details are provided in section 9.5.
Response % −2 log Lˆ AIC M4 vs. M2
p-value
IgG IgA M2 M4 M2 M4
90 99.17 2373.128 2373.016 2375.128 2377.016 0.738
91 99.44 2363.311 2363.214 2365.311 2367.214 0.756
92 99.50 2361.693 2361.574 2363.693 2365.574 0.730
93 99.60 2364.7 2364.543 2366.7 2368.543 0.692
94 99.69 2363.049 2362.937 2365.049 2366.937 0.738
95 99.71 2363.854 2363.748 2365.854 2367.748 0.745
96 99.78 2362.835 2362.706 2364.835 2366.706 0.719
97 99.8 2366.386 2366.289 2368.386 2370.289 0.755
98 99.83 2368.898 2368.78 2370.898 2372.78 0.731
99 99.95 2363.991 2363.846 2365.991 2367.846 0.703
99.5 99.96 2360.97 2360.825 2362.97 2364.825 0.703
Now the interval estimates of exp
(
βˆIgG
)
are centred around the value 1, for all response
thresholds used, implying that there is no significant difference in PFS between IgA and
IgG patients, having accounted for the response status of the patients.
Table 9-7 gives the values of −2 log Lˆ and the AIC for models M2 and M4, estimated for
each pair of IgA and IgG response thresholds. Also provided in the table is the p-value
of the likelihood ratio test comparing models M2 and M4, evaluating the evidence for
including the term βIgGxisotype,i in the model, in the presence of the term α1xresponse,i. The
p-values in table 9-7 suggest that there is very little evidence to support the inclusion
of the monoclonal Ig isotype in the model along with the response status of the patient.
This suggests that, having accounted for the mHLC response achieved by the patient,
using the thresholds in table 9-5, there is no significant difference between the PFS of
IgA patients and IgG patients.
Figure 9-11 shows plots of PFS stratified by the response status and the monoclonal Ig
isotype, with the threshold for response indicated for each plot, for IgA and IgG patients
respectively. These plots represent model M4 and illustrate that there is no significant
difference in PFS between IgA and IgG patients when grouped by the response thresholds
indicated.
Now that the assignment of response is based on different thresholds for IgA and IgG
patients, the assignment of response no longer overestimates PFS in IgA patients and
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Figure 9-11 Survival plots of PFS by mHLC response and monoclonal
Ig isotype. Separate mHLC response thresholds are used for IgA and IgG
patients: (A) IgG 90%, IgA 99.17%; (B) IgG 92%, IgA 99.50%; (C) 94%,
IgA 99.69%; (D) IgG 96%, IgA 99.78%; (E) IgG 98%, IgA 99.83%; and
(F) 99.5%, IgA 99.96%. Dark red – IgG responders; light red – IgG non-
responders; dark blue – IgA responders; light blue – IgA non-responders.
Details of the survival models are provided in section 9.5.
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Table 9-8 Comparison of model M2 when the same mHLC response
threshold is used for all patients, and when a deeper mHLC response thresh-
old is used for IgA patients. Details are provided in section 9.5.
Same threshold Different thresholds
Response % Response %
IgG IgA AIC M2 IgG IgA AIC M2 ∆AIC
90 90 2379.642 90 99.17 2375.128 4.514
91 91 2372.698 91 99.44 2365.311 7.387
92 92 2370.481 92 99.50 2363.693 6.788
93 93 2371.891 93 99.60 2366.7 5.191
94 94 2369.192 94 99.69 2365.049 4.143
95 95 2370.806 95 99.71 2365.854 4.952
96 96 2369.8 96 99.78 2364.835 4.965
97 97 2371.561 97 99.8 2368.386 3.175
98 98 2373.22 98 99.83 2370.898 2.322
99 99 2373.24 99 99.95 2365.991 7.249
99.5 99.5 2368.42 99.96 99.98 2362.97 5.45
the ability of model M2 to describe the data is improved. Recall that M2 is the model
that includes the response status of the patient, but not the monoclonal Ig isotype,
as an explanatory variable. In table 9-8, values of the AIC are compared for model
M2 before and after adjusting the mHLC response threshold of IgA patients, according
to the quantiles given in table 9-5. The AIC is always smaller using the deeper IgA
mHLC response threshold, with the size of the difference, ∆AIC, provided in the table.
This result provides further support for the hypothesis that the mHLC response at pre-
maintenance underestimates/overestimates PFS in IgG/IgA patients. It has been shown
that by using a deeper response threshold for IgA patients, there is a stronger association
between the achievement of a response and PFS.
Notably, the improvement is seen for IgG response thresholds between 90% and 93%,
even though the difference in PFS between IgA and IgG patients was not significant for
these thresholds in the analysis in section 9.4.3. This result suggests that in fact mHLC
response does overestimate response in IgA patients for response thresholds between 90%
and 93%, however there were too few IgA patients in the non-response groups to draw
this conclusion from the analysis in section 9.4.3.
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9.5.1 Errors in the data
The mHLC response thresholds used for IgA patients, given in table 9-5, are confined to
a very small range of 0.0004 (99.96%) to 0.0083 (99.17%). All of the response thresholds
used for IgA patients are thus greater than 99% and it seems unlikely that a response of
99.96% represents an improved survival compared to a response of 99.17%.
Measurements of IgAκ and IgAλ concentration using the HLC assay have a coefficient of
variation (CV) of up to 5% [13]. Using standard propagation of error formulas [14], and
assuming that the involved HLC and uninvolved HLC are statistically independent, the
variance of the mHLC can be approximated by
σ2mHLC ≈ σ2iHLC + r2σ2uHLC, (9-3)
where r is a constant, representing the ratio of the median concentration of IgAκ to the
median concentration of IgAλ or vice versa, depending upon the light chain type of the
monoclonal IgA, σ2iHLC is the variance of the involved HLC measurement, and σ
2
uHLC is
the variance of the uninvolved HLC measurement.
Again using propagation of error formulas, the variance of the mHLC response can be
approximated by
σ2response ≈
(
mHLCpreM
mHLCscreen
)2( σ2mHLCpreM
mHLC2preM
+
σ2mHLCscreen
mHLC2screen
)
, (9-4)
where mHLCpreM is the mHLC at pre-maintenance, mHLCscreen is the mHLC at screening,
σ2mHLCpreM is the variance of the mHLC at pre-maintenance, and σ
2
mHLCscreen is the variance
of the mHLC at screening.
The CV of the mHLC response is, by definition, given by
CVresponse =
√
σ2response
mHLCpreM/mHLCscreen
. (9-5)
The CV of measured HLC concentrations tends to decrease for larger concentrations;
however, for simplicity, it is assumed that the CV is the same for each measurement,
denoted by CVHLC. In this way, the CV of the mHLC response can be approximated by
CVresponse ≈√√√√CV2HLC (iHLCpreM + r2uHLCpreM)(
iHLCpreM − ruHLCpreM
)2 + CV2HLC (iHLCscreen + r2uHLCscreen)(iHLCscreen − ruHLCscreen)2 ,
(9-6)
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where iHLCpreM is the involved HLC at pre-maintenance, uHLCpreM is the uninvolved
HLC at pre-maintenance, iHLCscreen is the involved HLC at screening, and uHLCscreen is
the uninvolved HLC at screening.
Substituting into equation (9-6) the average values from the data of iHLCpreM, uHLCpreM,
iHLCscreen and uHLCscreen for IgA patients gives
CVresponse ≈ 2.84CVHLC, (9-7)
for IgAκ, where r = 1.87, and
CVresponse ≈ 1.57CVHLC, (9-8)
for IgAλ, where r = 1/1.87. There is thus an error of up to 15% on calculated values
of the mHLC response in IgA patients. The error in the value of the mHLC response
due to measurement errors alone is relatively small at only 15%; however, that does not
necessarily imply that a measured mHLC response of 0.0004 (99.96%) represents a better
prognosis than a measured mHLC response of 0.0083 (99.17%). There are other sources
of error to account for, apart from measurement errors, such as day-to-day biological
variation.
In figure 9-12A, PFS from pre-maintenance is compared for IgG patients who had an
mHLC response of greater than 99.5%, between 90% and 99.5%, and less than 90%. There
is a large difference between the survival curves for those patients achieving a response of
greater than 99.5% and those achieving a response of between 90% and 99.5%. A similar
plot is shown in figure 9-12B for IgA patients. In figure 9-12, IgA patients are compared
who achieved mHLC responses of greater than 99.96%, between 99.17% and 99.96%, and
less than 99.17%. Perhaps surprisingly, the IgA patients who had an mHLC response
of greater than or equal to 99.96% have significantly fewer events than those achieving
responses of between 99.17% and 99.96%.
Whilst it is not recommended that the mHLC response thresholds given in table 9-5
for IgA patients are used in practice, the analysis in this section shows that the mHLC
response marker has a strong association with PFS, even when very deep responses are
considered. Current guidelines only discriminate between responses of less than 50%,
between 50% and 90%, and greater than 90% [15]. In patients treated with high dose
melphalan and autologous stem cell transplantation, these cut-off values for response
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Figure 9-12 (A) PFS from pre-maintenance in IgG patients; 2 signifies a
response of greater than or equal to 99.5%, 1 signifies a response of greater
than or equal to 90% but less than 99.5%, and 0 signifies a response of
less than 90%. (B) PFS from pre-maintenance in IgA patients; 2 signifies a
response of greater than or equal to 99.96%, 1 signifies a response of greater
than or equal to 99.17% but less than 99.96%, and 0 signifies a response of
less than 99.17%.
become less relevant, particularly for IgA patients. The analysis in this section suggests
that there is potential for deeper cut-off values to be considered.
9.6 Analysis of SPEP response and progression-free
survival from pre-maintenance
In this section, the association between the SPEP response at pre-maintenance and PFS
from pre-maintenance is analysed. The analyses performed are the same as the analyses
of mHLC response and PFS in section 9.4.3, but now using the SPEP response rather
than the mHLC response.
9.6.1 Missing data
As in section 9.4, the 53 IIMM patients with missing PFS from pre-maintenance were
excluded from the analysis. Seven patients with no SPEP concentration recorded at
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Figure 9-13 Survival plot of PFS from pre-maintenance stratified by mon-
oclonal immunoglobulin isotype, for the patients analysed in section 9.6.2
screening were also omitted. Patients with no SPEP concentration recorded at pre-
maintenance, due to a lack of quantifiable M-spike, were considered as having zero SPEP
concentration at pre-maintenance, or a 100% SPEP response. 67 patients for whom
SPEP concentration at pre-maintenance was missing for any other reason were excluded.
In total 127 patients were excluded, leaving 399 patients to be analysed – 97 with IgA-
producing clones and 302 with IgG-producing clones.
9.6.2 Survival analysis
The proportional hazards models estimated in this section are described in section 9.3.
The proportional hazards assumption was tested for all fitted models and found not to
be violated, at the 5% significance level, for any of the explanatory variables in any of
the fitted models.
In this section, a different sample of patients is analysed than in section 9.4, due to pa-
tients having different missing data for SPEP and HLC. Therefore it is first checked that
there is no difference in PFS from pre-maintenance between the IgA and IgG patients,
respectively, who are analysed in this section. Recall that model M3 includes the mono-
clonal Ig isotype, but not the response status of the patient, as an explanatory variable.
Fitting model M3 gives the ML estimate of the coefficient βˆIgG = 0.03662 and the hazard
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Table 9-9 95% confidence interval estimates for the parameters in models
M2 and M4, for monoclonal Ig responses measured by SPEP. Details are
given in section 9.6.2.
Response
threshold %
M2: exp(αˆ1) 95%
C.I.
M4: exp(αˆ1) 95%
C.I.
M4: exp
(
βˆIgG
)
95%
C.I.
90 (0.3397, 0.6193) (0.3226, 0.6027) (0.5981, 1.1988)
91 (0.3325, 0.6013) (0.3130, 0.5817) (0.5829, 1.1726)
92 (0.3325, 0.6013) (0.3130, 0.5817) (0.5829, 1.1726)
93 (0.3755, 0.6676) (0.3440, 0.6375) (0.5551, 1.1358)
94 (0.3755, 0.6676) (0.3440, 0.6375) (0.5551, 1.1358)
95 (0.375, 0.6622) (0.3411, 0.6288) (0.5432, 1.1141)
96 (0.3808, 0.6718) (0.3419, 0.6334) (0.5305, 1.0960)
97 (0.3451, 0.6095) (0.3046, 0.5656) (0.5029, 1.0404)
98 (0.349, 0.6166) (0.3067, 0.5709) (0.4999, 1.0369)
99 (0.3404, 0.602) (0.2964, 0.5537) (0.4894, 1.0176)
99.5 (0.3404, 0.602) (0.2964, 0.5537) (0.4894, 1.0176)
ratio exp
(
βˆIgG
)
= 1.037. The 95% confidence interval estimate of the hazard ratio is
given by (0.7428, 1.449), which contains the value 1; it can be concluded that there is no
statistically significant difference in PFS between IgA and IgG patients, as illustrated by
the survival plot in figure 9-13.
The 95% confidence interval estimates for the parameters in models M2 and M4 are given
in table 9-9. For both M2 and M4, the confidence interval estimate of exp(α1) has its
upper bound less than 1 for all values of the response threshold used. It can therefore be
concluded that, for the particular threshold values used, achieving at least the specified
response at pre-maintenance is associated with an improved PFS. Model M4 also includes
the coefficient βIgG, representing the effect of having an IgG paraprotein. The interval
estimates of exp
(
βˆIgG
)
include the value 1 for all of the SPEP response thresholds used.
For SPEP response threshold values between 97% and 99.5%, the interval estimates of
exp
(
βˆIgG
)
have their upper bounds close to 1. Note that grouping the patients by SPEP
response thresholds of 99% and 99.5% results in the same groups of patients and therefore
models M2 and M4 for both of these thresholds, respectively, are equivalent.
Table 9-10 gives the values of −2 log Lˆ and the AIC for models M2 and M4, estimated for
each SPEP response threshold. Also provided in the table is the p-value of the likelihood
ratio test comparing models M2 and M4, evaluating the evidence in favour of including
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Table 9-10 Comparison of models M2 and M4, for SPEP responses. De-
tails are provided in section 9.6.2.
Response
threshold %
−2 log Lˆ AIC M4 vs. M2
p-value
M2 M4 M2 M4
90 2110.544 2109.685 2112.544 2113.685 0.354
91 2108.152 2107.044 2110.152 2111.044 0.293
92 2110.066 2108.681 2112.066 2112.681 0.239
93 2112.965 2111.415 2114.965 2115.415 0.213
94 2114.277 2112.737 2116.277 2116.737 0.215
95 2111.726 2109.906 2113.726 2113.906 0.177
96 2112.37 2110.293 2114.37 2114.293 0.150
97 2105.34 2102.407 2107.34 2106.407 0.087
98 2106.123 2103.127 2108.123 2107.127 0.083
99 2104.306 2100.962 2106.306 2104.962 0.067
99.5 2104.306 2100.962 2106.306 2104.962 0.067
the term βIgGxisotype,i in the model, in the presence of the term α1xresponse,i.
The p-values in table 9-10, for the analysis based on SPEP responses, are notably larger
than the p-values in table 9-4, for the analysis based on mHLC responses. When SPEP
responses are used, there is not sufficient evidence to support the inclusion of the mono-
clonal Ig isotype in the model along with the response status of the patient. The same
general trend as before however is observed and can be demonstrated by Kaplan-Meier
survival plots.
Figure 9-14 shows Kaplan-Meier survival plots of PFS stratified by the SPEP response and
the monoclonal Ig isotype, with different response threshold values defining the SPEP
response in each plot. These plots represent model M4. Whilst the results of fitting
proportional hazards models do not support the inclusion of the monoclonal Ig isotype
in a model describing PFS, the survival plots show the same general trend as the same
plots produced for mHLC responses, depicted in figure 9-9.
The less significant improvement of M4 compared with M2, for SPEP rather than mHLC,
may be partially explained by the larger proportion of data that were missing for SPEP,
compared to HLC. The SPEP responses of only 399 patients were analysed, whereas
the mHLC responses of 433 patients were analysed. This could contribute to the larger
p-values seen in table 9-10.
Another problem with the SPEP responses is that 87 out of the 97 IgA patients analysed
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Figure 9-14 Survival plots of PFS by SPEP response and monoclonal Ig
isotype, for six of the response threshold values used: (A) 90%, (B) 92%,
(C) 94%, (D) 96%, (E) 98% and (F) 99.5%. Dark red – IgG responders;
light red – IgG non-responders; dark blue – IgA responders; light blue – IgA
non-responders. Details of the survival models are provided in section 9.6.2.
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have no quantifiable M-spike. Only 10 of the IgA patients analysed therefore have an
SPEP response less than 100%. Therefore, there is little difference between the response
thresholds used, where IgA patients are concerned. In fact, six, seven, eight, nine and ten
IgA patients have SPEP responses less than 90%, 93%, 94%, 96% and 97%, respectively.
Therefore the groupings of IgA patients by SPEP response are largely the same for each
of the response thresholds used. This can be seen by inspecting the survival curves of IgA
patients (in blue) in figure 9-14. In contrast to IgA patients, 87, 116, 120, 138, and 147
IgG patients have SPEP responses less than 90%, 93%, 94%, 96% and 97%, respectively.
Therefore the groupings of IgG patients by SPEP response result in quite different groups
when different response thresholds are used.
9.7 Discussion
The analyses in this chapter suggest that mHLC and SPEP responses underestimate/over-
estimate PFS in IgG/IgA patients; however it is not possible to attribute this effect en-
tirely to the metabolic properties of the respective Igs. Figure 9-1, in the introduction
to this chapter, illustrates how monoclonal Ig metabolism may influence the association
between the monoclonal Ig response and survival. However, it is not possible, based on
the analyses here, to isolate the effect of Ig metabolism from the effect of the laboratory
tests used to measure the monoclonal Ig response in practice. For example, measurements
of the involved HLC at pre-maintenance include a significant proportion of polyclonal Ig.
In this chapter efforts have been made to subtract the polyclonal part of the involved
HLC by calculating the mHLC, as described in section 9.1.2; however, this method only
results in an estimate of the monoclonal Ig concentration.
SPEP responses are also on average deeper in IgA patients than in IgG patients, as illus-
trated in figure 9-7. 87 out of 97, or 90%, of IgA patients have no SPEP concentration
recorded at pre-maintenance due to an unquantifiable M-spike. By comparison, only 49%
of IgG patients have an unquantifiable M-spike at pre-maintenance. This may be due to
the recirculation of monoclonal IgG by neonatal Fc receptors, resulting in larger mono-
clonal Ig concentrations at pre-maintenance in IgG patients. However, it is also known
that IgA migrates in the β-region of the gel (see section 2.4 in chapter 2), which could also
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offer an explanation for the high proportion of IgA patients with unquantifiable M-spikes
at pre-maintenance, and hence the deeper responses seen in IgA patients compared to
IgG patients.
In section 8.3 of chapter 8, it was shown that, for the parameter values estimated in chap-
ter 5, monoclonal IgG responds more slowly than monoclonal IgA when tumour responses
are comparable. However, the difference between monoclonal IgA and IgG responses de-
pends upon the rate and depth of the tumour response, whether the system is assumed
to be in steady state at the beginning of treatment, and the values of the parameters of
the metabolism models. In chapter 8, hypotheses pertaining to monoclonal Ig responses
were investigated assuming fixed parameter values for the metabolism models, in order
to represent average or typical responses. However, in reality, patients will have a range
of different parameter values. In order to investigate the importance of the parameter
values to the analyses in this chapter, it is necessary to perform the simulations from
section 8.3 for a sample of patients, incorporating variability in their parameter values
and tumour response rates. This is recommended for future work.
The Ig data analysed in this chapter have been confined to the monoclonal Ig response at
pre-maintenance, as pre-maintenance is considered the most clinically relevant time point
at which to assess the success of the treatment in killing the cancer. In future work it may
be possible to take additional Ig measurements into account by fitting dynamic models to
the patient data. Parameterised models for the plasma cell population may be assumed,
such as the model used to produce the simulations in sections 8.3 and 8.4 in chapter 8.
This approach would also require analysis of the structural and practical identifiability
of the parameters to be estimated. Fitting models to the data could provide a more
accurate estimate of the ‘true’ unobserved monoclonal Ig response, not contaminated
with measurement errors. It would also be possible to obtain a fitted tumour response,
which is assumed to drive patient survival, rather than the monoclonal Ig response. It
would then be possible to compare proportional hazards models using monoclonal Ig
responses and using tumour responses. In theory the tumour response should have a
stronger association with PFS and there should be no difference in PFS between IgA and
IgG patients, within responder and non-responder groups, respectively.
Multiple data points could also be used to fit joint models for longitudinal and time-to-
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event data. This approach involves estimating the joint distribution of the event time
outcomes, such as PFS, and longitudinal outcomes, such as the monoclonal Ig response
at multiple monitoring points. In joint models, a time-varying hazard function at time t
is assumed to be associated with the level of a time-varying covariate at time t. For the
dataset analysed in this chapter, a joint model would be based upon the assumption that
the hazard of a disease progression occurring at time t is associated with the monoclonal
Ig response at time t.
Using standard proportional hazards models, it is assumed that the hazard function is
constant and the same for all patients who have or have not achieved a certain response
by pre-maintenance. All subjects who have had a disease progression or died before
pre-maintenance are excluded. Using joint models, it would be possible to analyse PFS
since screening and include patients in the analysis who did not respond well to in-
duction therapy. Similarly, in the analyses in this chapter, information about response
markers acquired after pre-maintenance is not considered. If joint models were used,
it would be possible to analyse the association between the hazard of progression after
pre-maintenance and the level of the response at any time after pre-maintenance. Such a
model could be used to make individualised predictions of PFS, that could be updated at
each monitoring point [16, p. 11]. Other information could be included, such as the stage
of the disease at screening and the age of the patient; all of this information including
accumulated biomarker levels could be used for prediction and decision making on an
individual basis [17].
Joint modelling has seen many developments in recent years; however most joint models
still tend to be based upon linear sub-models for the longitudinal data, i.e. marker re-
sponses [17–19]. When longitudinal data are markedly nonlinear, such as the mHLC and
SPEP responses seen in multiple myeloma, their trajectories are usually modelled using
splines. In the widely used R package for joint modelling, JM, linear and spline models
are available [20]. Estimating the joint distribution of the longitudinal biomarker and
event time outcomes whilst simultaneously fitting an underlying dynamic model would
require some significant software development. However, even without accounting for
differences between monoclonal IgA and IgG responses, joint models are likely to provide
much more predictive power and flexibility than classifying patients into response groups
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at a single time point.
9.8 Conclusions
In this chapter it has been shown that deeper monoclonal Ig responses are achieved
by IgA patients compared to IgG patients at pre-maintenance, however this does not
translate into an improvement in PFS for IgA patients. This suggests that monoclonal Ig
responses overestimate PFS in IgA patients, or equivalently underestimate PFS in IgG
patients. It was found that when patients are grouped by their monoclonal Ig response,
IgG responders have improved PFS over IgA responders; similarly IgG non-responders
have improved PFS over IgA non-responders. For mHLC responses and certain response
thresholds, this finding was statistically significant at the 5% level.
Further support for the hypothesis that the monoclonal IgA response overestimates PFS
was provided by repeating survival analyses using a deeper response threshold for IgA
patients, compared to IgG patients. The response thresholds used were based on the
quantiles of the distributions of mHLC responses. With this approach, there was no
longer any difference in PFS between IgA and IgG patients, after they had been grouped
by having achieved or having not achieved the specified mHLC response. The ability of a
proportional hazards model, based only on the response status of the patient, to describe
the variation in PFS was significantly improved.
The aim of this chapter was to investigate whether the monoclonal Ig response under-
estimates survival outcomes in IgG patients compared to IgA patients, based on the
simulations of monoclonal Ig responses in chapter 8. It has been shown that the mono-
clonal Ig response at pre-maintenance, quantified by mHLC, underestimates PFS in IgG
patients. However, it is not known whether the difference in mHLC and SPEP responses
between IgA and IgG patients is solely due to the metabolic differences between the Igs;
there are also possible differences between measured monoclonal IgA and IgG responses
related to the particular laboratory assay used.
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10
Conclusions
The aim of this project was to investigate the possible effects of immunoglobulin (Ig)
metabolism on plasma monoclonal Ig responses in immunoglobulin A (IgA) and im-
munoglobulin G (IgG) myeloma and to determine which, if any, of these effects are likely
to influence the prognostic utility of monoclonal Igs as response markers. Simple models
of IgG metabolism, which were deemed suitable for parameter estimation using data from
human studies, were selected from the literature. The two models were compared under
the conditions of multiple myeloma and were shown to produce very similar, although
not identical, responses. Two-compartment models of IgG and IgA metabolism were
then used to produce simulations showing the effects of Ig metabolism on monoclonal
Ig responses in multiple myeloma. Based on these simulations it was determined that
the difference between IgA and IgG responses could mean that IgG patients are assigned
falsely modest responses. This effect was studied using proportional hazards survival
models in a large dataset of newly diagnosed IgA and IgG myeloma patients. Evidence
for an underestimation of progression-free survival using the monoclonal IgG marker was
found in this dataset.
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10.1 A two-compartment model describing IgG
metabolism
In chapter 5, population parameters were estimated for a two-compartment model of IgG
metabolism, using timecourse data from tracer studies found in the literature. Two model
outputs were considered: the proportion of the tracer dose remaining in plasma (y1(t)) and
the proportion of the tracer dose remaining in the body (y2(t)). The errors resulting from
the data generating process were considered and expressions for the relationship between
the variance and mean of each model output were derived. The second output, y2(t), was
found to have a non-standard relationship between its error variance and its mean, which
is not amenable to standard error models available in mixed effects modelling software
packages, such as Monolix. Given other issues identified, including systematic errors
in both outputs and autocorrelation in measurements of y2(t), parameter estimation
methods assuming two simple error models were compared using synthetic data. The
variability of the parameter estimates was similar for both methods but showed large
differences between samples of subjects, suggesting that the small sample size largely
contributed to the variability.
A recommendation for future work is to perform an additional simulation study using (i)
additional subjects and (ii) the raw radioactivity measurements (rather than quantities
calculated from radioactivity measurements) in order to determine which strategy for
experiment design would offer the most improvement in parameter accuracy or precision.
It is presumed by the author that increasing the number of subjects would offer the
greater improvement. The estimated population parameters tend to be close to the
medians of the true individual parameters, rather than the true population parameter,
when these values are compared for synthetic data. For the data simulated in chapter 5,
the sample medians of the individual parameters can be significantly different from the
true population parameters, since the sample size is small. It has been verified by the
author that the raw radioactivity measurements (the plasma radioactivity concentration,
the radioactivity of the tracer dose and the radioactivity in urine collections) can be fitted
in Monolix using the models described in section 5.5 of chapter 5. If it were possible
to take repeated samples and measurements, it may be possible to verify the assumed
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error models. If systematic errors in the data were found to have a large effect on the
parameter estimates, then this would be a simple way in which to improve parameter
accuracy and/or precision without increasing the number of subjects involved and the
associated costs.
The source of systematic error in the timecourse data is the division by a measurement at
time zero in order to obtain all observations in terms of the proportion of the radioactivity
dose. The model outputs fitted to the data (y1(t) and y2(t)) are therefore by definition
equal to 1 at time 0 days. This may cause bias in the parameter estimates, similar to
fitting a linear regression model without an intercept. Adding an additional intercept
term may improve the accuracy of the parameter estimates. This has not been analysed
in this thesis but could form a part of additional simulation studies in any future work.
Another recommendation for future work is to perform a sensitivity analysis with respect
to the parameter identification problem, using the generalised sensitivity functions (GSFs)
of Thomaseth et al. [1], recently adapted for multiple observations by Kappel et al.
[2]. Such analyses can reveal time subintervals on which measurements have the most
influence over the parameter estimates. This information can be used to design future
experiments in which measurements are taken at certain times in order to maximise the
information obtained on the parameters, minimise the number of measurements taken, or
minimise the duration of sampling, to improve the comfort of subjects and reduce costs.
Methods for analysing the structural identifiability of mixed effects models, recently de-
veloped by Janze´n et al. [3], were applied. The application of a population approach
in chapter 5 could also benefit from techniques to analyse the sensitivity of population
parameter estimates, akin to the GSFs. To the author’s knowledge, such a methodology
does not yet exist; however it could be used to determine whether the number of individ-
ual subjects is sufficient, in a similar way to how GSFs can be used to determine whether
the sampling rate is sufficient, in order to accurately estimate the parameter values.
The remaining two-compartment model parameters were estimated from fractional catabolic
rate (FCR) and half-life data, using a naive pooled approach. A recommendation for fu-
ture work is to calculate the FCR and half-life from simulated radioactivity measurements
and consider the form taken by the resulting errors. The parameters could then be es-
timated from the synthetic FCR and half-life data using different assumed error models
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and the variability of the parameter estimates compared.
A final recommendation for analysing the two-compartment model is to consider whether
an alternative radioactivity dosing schedule could be used to expose the nonlinear be-
haviour in the timecourse responses, such that all model parameters could be estimated
from the same dataset, rather than using separate observations. It might then be possible
to obtain population parameter estimates for all model parameters; however, the ethical
implications of the effect of the dosing schedule on the subject might not permit this
approach.
10.2 A four-compartment model describing IgG
metabolism
In chapter 6 a four-compartment model of IgG metabolism was studied. Individual (not
population) parameter values were estimated for linearised timecourse outputs using dif-
ferential evolution. Differential evolution is a stochastic global minimisation algorithm;
however, despite trying many different values for the crossover probability and scaling
factor, the algorithm yielded many different parameter estimates whose fits to the data
were similarly excellent. The structural identifiability of the parameters of the linearised
model had been verified; it appeared however that the parameter estimates were insuf-
ficiently sensitive to the true parameter values. For four of the subjects, several runs of
the differential evolution algorithm gave estimates of zero for one of the model parame-
ters, suggesting that the model is over-parameterised with respect to the available data.
A population approach to parameter estimation was not considered due to the ability
of the model to produce very similar outputs for very different parameter vectors. The
parameters were estimated by unweighted least squares. Alternative, more appropriate
error models were not considered; however it is likely that the same problems regarding
sensitivity would emerge, were the correct error model used. In chapter 5 errors in the
timecourse data were considered and found to be complex.
From the point of view of experiment design, the model could be further studied us-
ing sensitivity analysis, by looking at GSFs and the Fisher information matrix, whilst
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assuming the true parameter vectors are known. Some preliminary results using GSFs
for some of the estimated parameter vectors suggest that refining the sampling grid to
every 0.1 days may decrease the correlations between certain parameters, but still the
Fisher information matrix has a large condition number for many parameter vectors.
This analysis also assumes that the true parameter vectors are known, whereas we have
little confidence that the true global minimum has been found for our data.
An expression was derived for the FCR of the endogenous IgG, which is denoted by FCRE.
A re-parameterisation of this expression was used in order to estimate the parameters
k31, ψ1 and ψ2 from the FCRT (FCR of the tracer) data. The parameters k31 and ψ2
are physiologically meaningful and their estimates are close to previously published pa-
rameter values. Parameter vectors for the four-compartment model were generated using
the constraints provided by fixing k31, ψ1 and ψ2 to their estimated values, with certain
parameters randomly generated. The FCRT and FCRE were then compared for these
parameter vectors and in some cases large differences were seen. It would be interesting,
in future work, to produce simulations of the timecourses of tracer in all four model com-
partments and compare them for each of the generated parameter vectors. Preliminary
simulations not included in this thesis show that parameter vectors estimated from the
FCRT data result in similar behaviour in plasma and peripheral radiolabelled IgG but
different behaviour in the endosomal compartments. The actions of parameters determin-
ing recycling, degradation, association and dissociation can approximately balance each
other out with respect to the dynamics in the plasma compartment, even though the en-
dosome compartments may be greatly affected by different individual parameter values.
It would also be interesting to see which dynamical responses in the model correspond to
large differences between FCRT and FCRE. Future work could involve investigating the
possibility of a model reduction using the parameters k31, ψ1 and ψ2.
10.3 Comparison of models of IgG metabolism
The two models of IgG metabolism from the literature were compared using simulations in
chapter 7. A derivation of the two-compartment model from the four-compartment model
by Hattersley [4] was investigated using simulations. The equivalence of the two models
263
Chapter 10. Conclusions
depends upon two assumptions: a quasi-steady state assumption for the bound IgG in
endosomes and equal concentrations of unbound IgG in plasma and endosomes. It was
found that the quasi-steady state assumption was valid for all simulations of IgG responses
in multiple myeloma, when parameter vectors which give reasonable responses were used
and steady state initial conditions were assumed. In order to find conditions in which this
assumption was violated, the model was compared with the classical Michaelis-Menten
enzyme reaction. The assumption could be violated by reducing the amount of IgG
available to bind to neonatal Fc receptors, either by decreasing the value of the parameter
k31, decreasing the initial condition x1(0), or increasing the value of the parameter k03 (in
addition to setting the synthesis rate of IgG to zero). These extreme conditions however
result in extreme behaviour in plasma IgG, for example maintenance of a large quantity
of plasma IgG over a period of tens of years, in spite of zero IgG synthesis.
The second assumption, namely that the concentrations of unbound IgG in endosomes
and plasma are equal, is based on knowledge of the process of pinocytosis, whereby IgG is
internalised into endosomes at random (i.e. not surface-receptor mediated) within pockets
of the extracellular fluid. However, this assumption has not previously been linked with
conditions on certain parameter values and it is found that with feasible parameter values
the two concentrations are not equal. It is possible to modify the four-compartment
model such that the concentrations of unbound IgG in plasma and endosomes are equal,
by changing the volume of the endosomes containing IgG into a variable. This model
indeed produces equivalent responses to the reduced two-compartment model; however
it is not included in this thesis as justification for the changing volume of endosomes
would require further analysis, perhaps requiring individual endosomes to be considered
as separate entities.
The responses of the four-compartment and two-compartment models were compared
for the parameter values estimated in chapters 5 and 6, that is, the two-compartment
model parameter values were not derived from the four-compartment model parameter
values. IgG responses during multiple myeloma treatment and relapse were compared.
The responses were shown to be very similar; however the final monoclonal IgG response
could be underestimated by up to 6% by the four-compartment model. However, the
larger differences of up to 6% were seen when the absolute final response is very large, up
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to 100%. This simulation study also showed the remakarbly similar responses given by
randomly generated parameter vectors obeying the constraints provided by setting the
parameters k31, ψ1 and ψ2 to the values estimated in chapter 6.
Comparing the four-compartment and two-compartment models of IgG metabolism from
the literature showed that the two-compartment model is not a valid reduction of the
four-compartment model, for feasible parameter values. However, it is possible to derive
alternative two-compartment models from the four-compartment model. Future work
may involve investigating alternative two-compartment models derived from the four-
compartment model.
10.4 Predicted responses in multiple myeloma
In chapter 8 the effects of Ig metabolism on blood monoclonal Ig responses in multiple
myeloma were investigated. Three main scenarios were investigated: the difference be-
tween monoclonal IgA and IgG responses during treatment, the difference in the rate of
monoclonal IgG response between patients with different initial plasma IgG concentra-
tions, and the difference between monoclonal IgA and IgG responses during relapse. The
simulations produced in this chapter map extremely well onto the available real data.
These detailed simulations allow for investigation of monoclonal Ig responses under vari-
ous clinical conditions, including response to treatment and relapse. They also allow for
investigation of hypotheses regarding Ig metabolism which may have real impact in a
practical sense.
Sensitivity analysis was performed with respect to the difference between the average
monoclonal IgA and monoclonal IgG responses, showing that certain parameters are much
more important than others in determining the difference between the two responses. The
sensitivity of the delay between tumour relapse and monoclonal Ig relapse to the model
parameters was also analysed, again showing certain parameters to be much more relevant
than others. This information could be fed back into the design of future experiments
for parameter estimation.
The difference between the monoclonal Ig responses of IgA and IgG patients, for identical
tumour responses, was investigated with simulations. As well as considering the differ-
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ences in responses of patients whose tumour responses are the same, the reverse problem
was considered, in which a range of tumour responses result in identical or similar mono-
clonal Ig responses. This analysis showed that identical final monoclonal Ig responses may
correspond to a range of final tumour responses. For modest monoclonal IgG responses
of between 50% and 80%, the final tumour response may be underestimated by between
5% and 7%. Such responses are common in patients who are considered to old or frail for
regimens incorporating autologous stem cell transplantation. The large underestimation
of tumour response by monoclonal IgG for these levels of response may have a significant
impact upon the association between the marker response and survival; this could be
studied in future work. The analysis also showed that very similar transient monoclonal
Ig responses may result from a range of tumour response rates, particularly when the
tumour response rate is fast. In general, it was found that assessments of response are
more uncertain during the initial, transient part of the response; clinicians may need to
consider that early assessments using monoclonal Igs may not reflect the true quality of
the response.
The simulation results in chapter 8 are subject to errors in the models of Ig metabolism,
errors in the models of tumour growth, errors in the parameter values for the metabolism
models, and oversimplified assumptions, for example assuming the system is in steady
state at the beginning of treatment. In chapter 7 the two-compartment model of IgG
metabolism was shown to over-estimate the depth of the monoclonal IgG response, when
compared to the four-compartment model. If the four-compartment model is a more
accurate representation of the biological system, then the level of underestimation of the
tumour response by the monoclonal IgG response could be underestimated by the two-
compartment model. Simulations in which the clonal plasma cell population is assumed
to be growing when treatment begins also show a greater difference between the tumour
response and the monoclonal Ig response.
All of the simulations in chapter 8 are intended to represent a typical IgA or IgG patient.
Future studies should take into account variability in the population, in terms of the
tumour responses, the cellular rate of synthesis of Igs, and the parameter values for IgG
and IgA metabolism. Measurement errors should also be considered in order to simulate
the data of a cohort of patients and compare it with data from a real clinical trial.
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10.5 Response assessment and prognosis in multiple
myeloma
In chapter 9 evidence was found for the underestimation of progression-free survival
(PFS) by the mHLC (defined in chapter 9) response in IgG patients or, equivalently,
overestimation of PFS by the mHLC response in IgA patients. However, the deeper
mHLC responses and serum protein electrophoresis (SPEP) responses seen in IgA patients
could be due to IgA patients achieving deeper tumour responses (although there is no
improved survival seen in IgA patients) or systematic differences in how IgA and IgG
are quantified by laboratory tests. In order to assess the relative contributions of the
effects of metabolism and systematic errors in quantification of monoclonal Ig responses,
a population simulation is required. A recommendation for future work is to simulate a
cohort of patients, designed to replicate the data from a clinical trial. Using a population
simulation it could be shown whether the metabolic differences between IgA and IgG are
significant enough to account for the difference seen in mHLC responses between IgA and
IgG patients.
The clinical implication of the results presented in chapter 9 is that IgA and IgG patients
may be assigned incorrect responses. According to the International Myeloma Work-
ing Group (IMWG) response criteria, a reduction of at least 90% in serum monoclonal
Ig represents a very good partial response (VGPR). 75% of IgG patients in the IFM
(Intergroupe Francophone du Mye´lome) 2009/01 trial [5; 6] were assigned VGPR at pre-
maintenance, compared with 95% of IgA patients. Achieving VGPR is therefore found
not to be meaningful for IgA patients, whereas for IgG patients there is a very significant
difference in PFS between those patients who were assigned VGPR or better and those
who were assigned partial response (PR). IgA patients assigned VGPR on the other hand
have a very similar survival curve to patients who were assigned PR. It was shown in
section 9.5 that, in terms of PFS, an mHLC response of at least 90% in IgG patients
is comparable to a response of approximately 99% in IgA patients. The implication of
this is that IgA patients may receive falsely optimistic information about their prognosis
whilst IgG patients may receive falsely pessimistic information.
Using a population simulation it would be possible to investigate alternative response
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markers such as the heavy/light chain (HLC) ratio, that is the ratio of IgGκ to IgGλ in IgG
patients and the ratio of IgAκ to IgAλ in IgA patients, both of which are measured by the
HLC assay. The HLC ratio (normal vs. abnormal) has been shown to correlate strongly
with survival [7] and has been considered as a criterion for the assignment of complete
response (CR), showing a strong association with PFS compared to current methods.
At the beginning of treatment, patients typically have an abnormal HLC ratio due to
the elevated involved HLC. As treatment progresses the involved HLC concentration
decreases and the HLC ratio normalises. Using a population simulation it would be
possible to analyse whether there is a discrepancy between IgA and IgG patients in
terms of the proportion of patients whose HLC ratio enters the normal range at pre-
maintenance.
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AExample code for survival analysis
in R
Survival curves, given by the Kaplan-Meier estimator and stratified by patient response,
are plotted using:
survivalCurve<-survfit(Surv(PFStime,PFSevent)~response,data=ifmData)
plot(survivalCurve)
The corresponding proportional hazards model, with response as an explanatory variable,
and the null model are estimated using:
modelResponse<-coxph(Surv(PFStime,PFSevent)~response,data=ifmData)
nullModel<-coxph(Surv(PFStime,PFSevent)~1,data=ifmData)
The models are compared by calculating −2 log Lˆ for each and performing a chi-squared
test on the difference:
dNull<-nullModel$loglik*-2
dResponse<-modelResponse$loglik[2]*-2
1-pchisq(dNull-dResponse,1)
1
BMathematica code for structural
identifiability analysis of mixed
effects model
The structural identifiability analysis of the mixed effects model is performed in Mathe-
matica using the following script.
Firstly we define the A, B and C matrices of the system. Parameters are prefixed by θ
to represent the fixed component of the parameter.
(a = {{-\[Theta]k21 - \[Theta]k01, \[Theta]k12}, {\[Theta]k21, -\
\[Theta]k12}}) // MatrixForm
(c = {{1, 0}, {1, 1}}) // MatrixForm
(b = {{1, 0}, {0, 0}}) // MatrixForm
(x = {{x1}, {x2}}) // MatrixForm
The following calculates the transfer functions:
gmat = Simplify[((c.(Inverse[((s*IdentityMatrix[2]) - a)])).b)]
Extract the numerators and denominators of the transfer functions:
n1 = Numerator[gmat[[1, 1]]]
n2 = Numerator[gmat[[2, 1]]]
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d1 = Denominator[gmat[[1, 1]]]
d2 = Denominator[gmat[[2, 1]]]
Extract the deterministic moment invariants from the transfer functions:
\[Phi]s =
DeleteDuplicates[{Coefficient[n1, s, 0], Coefficient[n2, s, 0],
Coefficient[d1, s, 0], Coefficient[d1, s, 1],
Coefficient[d2, s, 0], Coefficient[d2, s, 1]}]
Compute the random variable moment invariants:
zs = \[Phi]s /. {\[Theta]k01 -> \[Theta]k01*
Exp[\[Eta]k01], \[Theta]k12 -> \[Theta]k12*
Exp[\[Eta]k12], \[Theta]k21 -> \[Theta]k21*Exp[\[Eta]k21]}
z1 = zs[[1]]; z2 = zs[[2]]; z3 = zs[[3]]; z4 = zs[[4]];
Define the variance-covariance matrix of the random effects:
(\[CapitalOmega]\[Rho] = {{\[Sigma]k01^2, \[Rho]k01k12*\[Sigma]k01*\
\[Sigma]k12, \[Rho]k01k21*\[Sigma]k01*\[Sigma]k21}, {\[Rho]k01k12*\
\[Sigma]k01*\[Sigma]k12, \[Sigma]k12^2, \[Rho]k12k21*\[Sigma]k12*\
\[Sigma]k21}, {\[Rho]k01k21*\[Sigma]k01*\[Sigma]k21, \[Rho]k12k21*\
\[Sigma]k12*\[Sigma]k21, \[Sigma]k21^2}}) // MatrixForm
Compute the first order statistical moments of the random variable moment invariants:
\[Lambda]1 =
Expectation[
z1, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
\[Lambda]2 =
Expectation[
z2, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
\[Lambda]3 =
Expectation[
3
Appendix B. Mathematica code for structural identifiability analysis of mixed effects
model
z3, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
\[Lambda]4 =
Expectation[
z4, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
Solve simultaneous equations for first order moments (already known that pop parameters
are identifiable):
Assuming[{ \[Sigma]k12bar > 0},
Simplify[Solve[\[Lambda]1 == (\[Lambda]1 /. {\[Sigma]k12 -> \
\[Sigma]k12bar}), \[Sigma]k12, Reals]]]
Assuming[{\[Sigma]k21 > 0, \[Sigma]k21bar > 0},
Simplify[Solve[\[Lambda]2 == (\[Lambda]2 /. {\[Sigma]k21 -> \
\[Sigma]k21bar}), \[Sigma]k21, Reals]]]
Assuming[{\[Sigma]k01 > 0, \[Sigma]k01bar > 0},
Simplify[Solve[\[Lambda]4 == (\[Lambda]4 /. {\[Sigma]k01 -> \
\[Sigma]k01bar}), \[Sigma]k01, Reals]]]
Solve[\[Lambda]3 == (\[Lambda]3 /. {\[Rho]k01k12 -> \
\[Rho]k01k12bar}), \[Rho]k01k12, Reals]
Generate second order statistical moments:
\[Lambda]12 =
Expectation[
z1^2, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
\[Lambda]22 =
Expectation[
z2^2, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
\[Lambda]32 =
Expectation[
z3^2, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
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\[Lambda]42 =
Expectation[
z4^2, {\[Eta]k01, \[Eta]k12, \[Eta]k21} \[Distributed]
MultinormalDistribution[{0, 0, 0}, \[CapitalOmega]\[Rho]]]
Solve simultaneous equations in second order moments to find that ρk12k21 and ρk21k01 are
identifiable:
Solve[\[Lambda]22 == (\[Lambda]22 /. {\[Rho]k12k21 -> \
\[Rho]k12k21bar}), \[Rho]k12k21, Reals]
Solve[\[Lambda]42 == (\[Lambda]42 /. {\[Rho]k01k21 -> \
\[Rho]k01k21bar}), \[Rho]k01k21, Reals]
5
CSimulation of tracer experiment data
(*solve system ODEs to get solutions for x1(t) and x2(t) *)
x1exp=DSolveValue[{x1’[t]==-(k01+k21)*x1[t]+k12*x2[t],
x2’[t]==k21*x1[t]-k12*x2[t],x1[0]==d\[Mu]mol,x2[0]==0},x1[t],t];
x2exp=DSolveValue[{x1’[t]==-(k01+k21)*x1[t]+k12*x2[t],
x2’[t]==k21*x1[t]-k12*x2[t],x1[0]==d\[Mu]mol,x2[0]==0},x2[t],t];
(*y1(t) and y2(t) are given by*)
y1=x1exp/d\[Mu]mol;
y2=(x1exp+x2exp)/d\[Mu]mol;
(*Parameters are rate constants k01, k12 and k21, and the dose of labelled
IgG in \[Mu]mol*)
Variables[x1exp];
(*population parameters*)
\[Theta]mu={k12pop->0.422,k21pop->0.441,k01pop->0.0778};
\[Theta]sd={k12sd->0.713,k21sd->0.498,k01sd->0.685};
\[Theta]corr={\[Rho]k12k21->0.739,\[Rho]k21k01->0.608,
\[Rho]k01k12->0.872};
\[Theta]pop=Join[\[Theta]mu,\[Theta]sd,\[Theta]corr];
(*experimental parameters: dose in micromoles, alpha and plasma volume*)
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\[Theta]experiment={d\[Mu]mol->0.005,\[Alpha]->9000,plasmaVol->3};
Draw individual parameters from lognormal distribution
(*Parameters of lognormal distribution*)
\[Mu]=Log[{k01pop,k12pop,k21pop}];
(\[CapitalSigma]={{k01sd^2,k01sd*k12sd*\[Rho]k01k12,
k01sd*k21sd*\[Rho]k21k01},{k01sd*k12sd*\[Rho]k01k12,
k12sd^2,k12sd*k21sd*\[Rho]k12k21},{k01sd*k21sd*\[Rho]k21k01,
k12sd*k21sd*\[Rho]k12k21,k21sd^2}})//MatrixForm;
\[Theta]dist=LogMultinormalDistribution[\[Mu],\[CapitalSigma]]
/.\[Theta]pop;
(*number of individual parameter vectors*)
n=7;
(*number of times to simulate the data with new errors*)
lmax=100;
(*Draw n individuals from the distribution*)
\[Theta]indsVals=Table[RandomVariate[\[Theta]dist],{j,n}];
(*replacement rules with individual parameter vectors and experimental
parameters*)
\[Theta]inds=Table[Join[{k01->\[Theta]indsVals[[j,1]],
k12->\[Theta]indsVals[[j,2]],k21->\[Theta]indsVals[[j,3]]},
\[Theta]experiment],{j,n}];
(*Set cv values here-------------------------------------------------*)
(*cv for plasma measurements and dose measurement*)
cv=0.07;
(*cv for urine measurements*)
cvu=0.3;
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(*Simulate y1(t) data----------------------------------------------*)
(*radioactivity concentration in plasma, i.e. measured variable from which we
calculate y1(t) *)
plasmaRadConc=x1exp*\[Alpha]/plasmaVol;
(*Plot the true value of the radiation concentration in plasma, for the first
set of individuals*)
Plot[Evaluate[Table[plasmaRadConc/.\[Theta]inds[[k]],{k,n}]],{t,0,25},
PlotRange->All];
(*plot plasmaRadConc(t)/plasmaRadConc(0)*)
Plot[Evaluate[Table[(plasmaRadConc/(plasmaRadConc/.t->0))
/.\[Theta]inds[[k]],{k,n}]],{t,0,25},PlotRange->All];
(*measurement timepoints. The time over which we measure depends upon how
fast are the dynamics of the individual. *)
Do[
tmax[k]=Max[Ceiling[-70*\[Theta]indsVals[[k,1]]+24],7]
,{k,n}
]
(*Assume that measurements are taken daily*)
Do[
timepoints[k]=Table[j,{j,0,tmax[k]}]
,{k,n}
]
(*For our 7 parameter vectors, generate lmax datasets for plasmaRadConc
[uCi/ml], assuming that this measurement has constant cv *)
Do[
plasmaRadConcTable[l]=Table[Table[(plasmaRadConc/.\[Theta]inds[[j]])
+RandomVariate[NormalDistribution[0,(cv*plasmaRadConc)
/.\[Theta]inds[[j]]]],{t,timepoints[j]}],{j,n}]
,
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{l,lmax}]
(*plot one example of noisy measurements of plasmaRadConc(t)*)
Show[ListPlot[Table[Transpose[{timepoints[k],plasmaRadConcTable[1][[k]]}]
,{k,n}],Joined->False,PlotRange->All],Table[Plot[Evaluate[plasmaRadConc
/.\[Theta]inds[[k]]],{t,0,tmax[k]},PlotRange->All,
PlotStyle->ColorData[97,k]],{k,n}]];
(*calculate y1(t) measurements*)
Do[
y1Table[l]=Table[plasmaRadConcTable[l][[j]]/plasmaRadConcTable[l][[j,1]]
,{j,n}]
,
{l,lmax}
]
(*plot one example of noisy measurements of y1(t)*)
y1plot=Show[ListPlot[Table[Transpose[{timepoints[k],y1Table[1][[k]]}]
,{k,n}],Joined->False,PlotRange->All],Table[Plot[Evaluate[y1
/.\[Theta]inds[[k]]],{t,0,tmax[k]},PlotRange->All,PlotStyle->
ColorData[97,k]],{k,n}]];
(*Simulate y2(t) data----------------------------------------------*)
(*The radiation in urine is given by*)
radUrine=Simplify[\[Alpha]*(d\[Mu]mol-x1exp-x2exp)];
Plot[Evaluate[Table[radUrine/.\[Theta]inds[[k]],{k,n}]],{t,0,25}
,PlotRange->All,AxesLabel->{"time (days)","radUrine (\[Mu]Ci)"}];
(*The amount of radioactivity in the urine collected at each time point*)
dailyRadUrine=Simplify[radUrine-(radUrine/.t->(t-1))];
(*Plot the amount of radioactivity in the urine each day*)
dailyRadUrinePlot=Show[Table[Plot[Evaluate[dailyRadUrine
/.\[Theta]inds[[k]]],{t,1,tmax[k]},PlotRange->All,PlotStyle->
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ColorData[97,k]],{k,n}]];
(*Calculate the radioactivity in urine collections with a constant CV
(proportional error model)*)
Do[
dailyRadUrineTable[l]=Table[Table[((dailyRadUrine/.\[Theta]inds[[j]])
/.t->Drop[timepoints[j],1])[[k]]+RandomVariate[NormalDistribution[0,
cvu*(((dailyRadUrine/.\[Theta]inds[[j]])/.t->Drop[timepoints[j],1])[[k]])]]
,{k,tmax[j]}],{j,n}]
,
{l,lmax}
]
(*These are the noisy measurements of the radioactivity in each day’s urine
collection*)
Show[dailyRadUrinePlot,ListPlot[Table[dailyRadUrineTable[1][[k]],{k,n}]]];
(*The calculated cumulative urine radioactivity is given by*)
Do[
radUrineTable[l]=Table[Prepend[Accumulate[dailyRadUrineTable[l][[k]]],0]
,{k,n}]
,
{l,lmax}
]
(*plot of the cumulative radioactivity in urine*)
Show[ListPlot[Table[Transpose[{timepoints[k],radUrineTable[1][[k]]}]
,{k,n}]],Table[Plot[Evaluate[radUrine/.\[Theta]inds[[k]]],{t,0,tmax[k]}
,PlotRange->All,PlotStyle->ColorData[97,k]],{k,n}],PlotRange->All];
(*the radioactivity in the dose is given by radDose = alpha*d\[Mu]mol*)
radDose=\[Alpha]*d\[Mu]mol;
(*Simulate measurements of the radioactivity measured in the tracer dose for
the seven subjects and repeat lmax times*)
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Do[
radDoseTable[l]=Table[(radDose/.\[Theta]experiment)
+RandomVariate[NormalDistribution[0,cv*(radDose/.\[Theta]experiment)]]
,{k,n}]
,
{l,lmax}
]
(*Calculate y2(t) *)
Do[
y2Table [l]=Table[1-(radUrineTable[l][[k]]/radDoseTable[l][[k]]),{k,n}]
,
{l,lmax}
]
(*plot one example of noisy measurements of y2(t)*)
y2plot=Show[ListPlot[Table[Transpose[{timepoints[k],y2Table[1][[k]]}]
,{k,n}]],Table[Plot[Evaluate[y2/.\[Theta]inds[[k]]],{t,0,tmax[k]},
PlotRange->All,PlotStyle->ColorData[97,k]],{k,n}]];
(*y1(t) and y2(t) plotted together*)
Show[y1plot,y2plot];
(*Combine 100 simulated datasets for each parameter vector so they can be
plotted together*)
Do[y1plotTable[k]=Show[ListPlot[Table[Transpose[{timepoints[k],
y1Table[l][[k]]}],{l,lmax}],Joined->False,PlotStyle->ColorData[97,k],
PlotRange->All],Plot[Evaluate[y1/.\[Theta]inds[[k]]],{t,0,tmax[k]},
PlotRange->All,PlotStyle->ColorData[97,k]]]
,
{k,n}
]
Do[
y2plotTable[k]=Show[ListPlot[Table[Transpose[{timepoints[k],
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y2Table[l][[k]]}],{l,lmax}],PlotStyle->ColorData[97,k]],
Plot[Evaluate[y2/.\[Theta]inds[[k]]],{t,0,tmax[k]},PlotRange->All,
PlotStyle->ColorData[97,k]]]
,
{k,n}
]
(*Plot the 100 simulated datasets for each parameter vector*)
Table[Show[y1plotTable[k],y2plotTable[k]],{k,n}];
12
DMathematica code for generating
expressions for λ4, A14 and A34
(*ODEs for the linear model of tracer kinetics*)
dt1 = -(k21 + k31)*t1[t] + k12*t2[t] + k14*t4[t];
dt2 = k21*t1[t] - k12*t2[t];
dt3 = k31*t1[t] - k03*t3[t] - k43*t3[t] + k34*t4[t];
dt4 = -(k14 + k34)*t4[t] + k43*t3[t];
(*ODEs and initial conditions put into one list to be used by DSolve*)
odes = {t1’[t] == dt1, t2’[t] == dt2, t3’[t] == dt3, t4’[t] == dt4};
ics = {t1[0] == d, t2[0] == 0, t3[0] == 0, t4[0] == 0};
eqns = Join[odes, ics];
(*Solve the system of ODEs for t1, t2, t3 and t4*)
odeSol = DSolve[eqns, {t1[t], t2[t], t3[t], t4[t]}, t];
(*We define parameter values from the literature so that we can \
simulate the model and check it looks correct*)
litParams1 = {d -> 1, k21 -> 0.51, k31 -> 0.18, k12 -> 0.41, k14 -> 5,
k03 -> 3, kon -> 1000, v3 -> 0.34, konv3 -> 1000/0.34, Rtot -> 14,
koff -> 100, Ie -> 15, k34 -> 100};
k43value = (k03 (k14 + koff) kon Rtot)/(Ie kon +
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k03 (k14 + koff) v3) /. litParams1;
(*parameter vector from literature*)
litParams = Join[litParams1, {k43 -> k43value}];
(*Simulate the model to check*)
Plot[{Evaluate[t1[t] /. odeSol /. litParams],
Evaluate[t2[t] /. odeSol /. litParams],
Evaluate[t3[t] /. odeSol /. litParams],
Evaluate[t4[t] /. odeSol /. litParams]}, {t, 0, 25}]
(*Calculate the A-matrix of the system*)
(aMat = {{-(k21 + k31), k12, 0, k14}, {k21, -k12, 0, 0}, {k31,
0, -k03 - k43, k34}, {0, 0, k43, -(k14 + k34)}}) // MatrixForm
(*We want A14 and A34, which are the coefficients of \
exp(\[Lambda]4*t) in equation (6-26). \[Lambda]4 is given by: *)
\[Lambda]4 = Eigenvalues[aMat][[4]];
(*expression for t1(t)*)
t1sol = DSolveValue[eqns, {t1[t], t2[t], t3[t], t4[t]}, t][[1]];
(*check with parameter values*)
t1sol /. litParams
(*expression for t3(t)*)
t3sol = DSolveValue[eqns, {t1[t], t2[t], t3[t], t4[t]}, t][[3]];
(*check with parameter values*)t3sol /. litParams
(*Find A14. Evaluate for parameter values and check it’s correct \
against t1sol*)
a14 = Coefficient[Normal[t1sol], Exp[t*\[Lambda]4]];
a14 /. litParams
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(*Find A34. Evaluate for parameter values and check it’s correct \
against t3sol*)
a34 = Coefficient[Normal[t3sol], Exp[t*\[Lambda]4]];
a34 /. litParams
(*If we want to look at A14 and A34 in full, without Root objects*)
a14Full =
Replace[a14, {Root[x_, y_] :> ToRadicals[Root[x, y]]}, Infinity];
a34Full =
Replace[a34, {Root[x_, y_] :> ToRadicals[Root[x, y]]}, Infinity];
(*lambda4 in full*)
\[Lambda]4Full =
Eigenvalues[aMat, Cubics -> True, Quartics -> True][[4]];
(*Export symbolic expressions to text files*)
SetDirectory[NotebookDirectory[]];
Export["A14.txt", a14Full];
Export["A34.txt", a34Full];
Export["lambda4.txt", \[Lambda]4Full];
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